Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 1
Stanley Fahn, M.D.
Neurological Institute, Columbia University Medical Center, 710 W 168th St, New York, NY 10032, U.S.A. Telephone: (1-212) 305-3716; Fax: (1-212) 305-3530 E-Mail: [email protected]; Website: http://columbianeurology.org/profile/sfahn Educator: http://columbianeurology.org/education-and-training/fellowship-programs/movement-disorders Date of last update: April 18, 2019
STANLEY FAHN, M.D...... 1 DATE AND PLACE OF BIRTH ...... 2 MARITAL STATUS ...... 2 EDUCATION ...... 2 CHRONOLOGY OF PROFESSIONAL EMPLOYMENT ...... 2 MILITARY SERVICE ...... 3 FIELDS OF INTEREST ...... 3 BOARD CERTIFICATION ...... 4 MEDICAL LICENSES ...... 4 HONORS ...... 4 TITLED LECTURES ...... 7 SOCIETIES ...... 9 NATIONAL OFFICES HELD ...... 10 INTERNATIONAL OFFICES HELD ...... 10 NATIONAL COMMITTEE MEMBERSHIPS ...... 11 INTERNATIONAL COMMITTEE MEMBERSHIPS ...... 12 NATIONAL AND INTERNATIONAL FOUNDATIONS ...... 14 EDITORIAL BOARDS ...... 16 SPECIAL SERVICE ...... 17 OTHER SPECIAL RECOGNITION AND INTERNATIONAL LECTURER ...... 25 VISITING LECTURES AND VISITING PROFESSOR ...... 46 UNIVERSITY AND HOSPITAL COMMITTEES ...... 52 UNIVERSITY TEACHING ...... 52 POSTDOCTORAL FELLOWS ...... 54 MEDICAL STUDENT RESEARCH IN THE LABORATORY ...... 60 PAPERS PUBLISHED ...... 61 BOOKS PUBLISHED ...... 95 CHAPTERS AND REVIEWS PUBLISHED ...... 97 ABSTRACTS, LETTERS, REPORTS AND COMMENTARIES PUBLISHED ...... 112
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 2
DATE AND PLACE OF BIRTH November 6, 1933, Sacramento, California
MARITAL STATUS Married, two children
EDUCATION Sept. 1948 - June 1951 C.K. McClatchy High School (Sacramento, CA)
Sept. 1951 - June 1954 University of California (Berkeley), B.A. in Medical Science (1955)
Sept. 1954 - June 1958 University of California School of Medicine, San Francisco. M.D. (1958)
Summer 1955 Biochemical research training under Dr. Eugene Roberts, City of Hope (Duarte, CA)
Summer 1957 Fellowship in Cellular Physiology Course Marine Biological Laboratory (Woods Hole, MA)
July 1958 - June 1959 Rotating internship. Philadelphia General Hospital
July 1959 - June 1962 Residency in Neurology, Neurological Institute of New York Columbia-Presbyterian Medical Center, New York City
Sept 1960 - June 1961 Evening course in biochemistry, Columbia University
July 1962 - June 1965 Training in neurochemistry under tutelage of Dr. R.W. Albers, Chief, Section of Enzyme Chemistry, Laboratory of Neurochemistry, NINDB, NIH, Bethesda, Maryland
Sept 1962 - June 1965 Courses given by the graduate school at NIH, in comparative biochemistry, neurochemistry, theory of organic chemistry, and neurophysiology
CHRONOLOGY OF PROFESSIONAL EMPLOYMENT 1957 - June 1958 Externe, Kaiser Foundation, San Francisco
July 1958 - June 1959 Rotating Intern, Philadelphia General Hospital
July 1959 - June 1962 Neurology Resident, Neurological Institute of New York
July 1962 - June 1965 Research Associate, Section of Enzyme Chemistry, Laboratory of Neurochemistry, NINDB, NIH, Bethesda.
July 1965 - June 1967 Research Associate, Department of Neurology, Columbia University, College of Physicians & Surgeons, New York City
July 1965 - June 1967 Assistant Neurologist, Presbyterian Hospital and Neurological Institute of New York.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 3
July 1967 - July 1968 Assistant Professor, Department of Neurology, Columbia University College of Physicians & Surgeons.
Assistant Attending Neurologist, Presbyterian Hospital and Neurological Institute of New York.
Aug. 1968 - June 1969 Assistant Professor, Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia.
Aug. 1968 - Aug. 1973 Chief, Laboratory of Neurochemistry and Basal Ganglia Disease, University of Pennsylvania School of Medicine
July 1969 - Aug. 1973 Associate Professor, Department of Neurology, University of Pennsylvania School of Medicine.
Sept.1973 - July 1978 Professor, Department of Neurology, Columbia University, College of Physicians & Surgeons.
Sept.1973 - Present Attending Neurologist, Presbyterian Hospital (now New York Presybterian Hosptial)
Sept.1973 – June 2013 Director, Parkinsonism and Movement Disorder Division, Department of Neurology, Columbia University College of Physicians & Surgeons. Attending Neurologist and Chief, Movement Disorder Clinic, Presbyterian Hospital and Neurological Institute of New York.
Sept.1975 - Aug. 1976 Visiting Scientist, Groupe de Neuropharmacologie Biochimique, Laboratoire de Biologie Moleculaire, College de France, Paris, France.
July 1978 - Present H. Houston Merritt Professor of Neurology, Columbia University, College of Physicians & Surgeons.
July.1981 - Mar. 1998 Director, Dystonia Clinical Research Center, Columbia University, College of Physicians & Surgeons.
July 1994 – June 2013 Director, Center for Parkinson's Disease and Other Movement Disorders, Columbia-Presbyterian Medical Center
Sept 1999 – Aug 2003 Founder and Director, Morris K. Udall Parkinson's Disease Research Center of Excellence at Columbia University, supported by NIH
July 2013 – Present Directo Emerituxr, Center for Parkinson's Disease and Other Movement Disorders, Columbia-Presbyterian Medical Center
MILITARY SERVICE July 1962 - June 1965 Three years active duty with U.S. Public Health Service.
FIELDS OF INTEREST Movement disorders; clinical & experimental aspects of neuropharmacology, neurochemistry, clinical neurology, and experimental therapeutics, basal ganglia, neurotransmitters
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 4
BOARD CERTIFICATION Diplomate of the American Board of Psychiatry and Neurology in Neurology, 1968, Certificate 9849
MEDICAL LICENSES Medical licenses for California (A18703; expires 11/30/2019) and New York (084994-1; expires 10/31/2018)
HONORS Societies: Phi Beta Kappa, Sigma Xi, Alpha Omega Alpha
Awards: Honorary scholar, University of California, 1951-1952
First prize for research in medical school, 1955
Fogarty Fellowship, National Institutes of Health, 1976-1977
Moses Prize in Clinical Neurology, Columbia University, 1977
Robert Wartenberg Award for Outstanding Clinical Research, American Academy of Neurology, 1986
Eric Sundblad Memorial Award Lectureship, Scandinavian Congress of Neurology, 1986
First Soriano Award Lectureship, American Neurological Association, October 1988
A.B.Baker Award for Excellence in Neurological Education, American Academy of Neurology, March 25, 1996
Neurologist of the Year Award, Association of Indian Neurologists in America, April 25, 1997
First Movement Disorder Award, American Academy of Neurology, April 25, 1997
Masterpiece of Parkinson’s Disease Research Award, German Parkinson Society, 2001
Lifetime Achievement Award, Madras Institute of Neurology, Chennai, India, 2002
Elected Member, Institute of Medicine, U, S. National Academies, 2002
Named one of the most highly cited authors, Institute of Scientific Information, 2002
Elected Honorary Member, Movement Disorder Society, 2002
Elected Honorary Member, American Academy of Neurology, 2003
Selected Chairman, 2004, First World Parkinson Congress, Washington, DC, in February 2006
President’s Distinguished Service Award, Movement Disorder Society, March 2005
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 5
Annemarie Opprecht Foundation Parkinson Award, co-winner for the best scientific paper on Parkinson’s disease published in the years 2002-2004, October 2005
Elected Honorary Member, American Neurological Association, 2006
Selected Co-chairman, 2006, Second World Parkinson Congress, Glasgow, SCOTLAND, in Sept- Oct 2010
Selected Co-chairman, 2010, Third World Parkinson Congress, Montreal, CANADA, in October 2013
Keynote Speaker, Second International Congress on Treatment of Dystonia, Hannover, GERMANY, May 2013
Jay Van Andel Award for Outstanding Achievement in Parkinson's Disease Research, Van Andel Research Institute, September 2016
Recogntition Award and Honoree, American Society for Experimental Therapeutics (ASENT) annual meeting, March 17, 2017
Alfred Markowitz Service Award, Society of Practitioners, Columbia University Medical Center, May 2017.
Honorary Foreign Society Memberships: Associacion Colombiana de Neurologia (Colombian Neurological Association), 1986
Sociedad Español de Neurologia (Spanish Neurological Society), 1987
Société Française de Neurologie (French Neurological Society), “Membre d’honneur à titre étranger” (Foreign Honorary Member), 2002
Sociedad Neurologica Argentina (Argentinian Neurological Society), 2004
La Academia Mexicana de Neurologia (Mexican Academy of Neurology), 2008
Polish Society of Parkinson’s Disease and Other Movement Disorders, 2015
Japanese Society of Neurology, 2016
Foundation Honors: Inducted into Blepharospasm Research Foundation's Hall of Fame, August 8, 1992
Appointed Honorary Lifetime Member of the Board of Directors of the Dystonia Medical Research Foundation, 1998
Fred Springer Award, American Parkinson's Disease Association, 1998
Guthrie Family Humanitarian Award, Huntington Disease Society of America, 2003
The Page and William Black Lifetime Achievement Award, Parkinson’s Disease Foundation, 2006
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 6
James Parkinson Medal, Parkinson’s Disease Foundation, 2007
Distinguished Service Award, Dystonia Medical Research Foundation, 2011
Donald Calne Award, Parkinson Society Canada, 2011
Honoree, American Society of Experimental Neurotherapeutics (ASENT)
Bruce Ochsman Lifetime Achievement Award, Tourette Association of America, 2016 Jay Van Andel Award for Outstanding Parkinson’s Disease Research, Van Andel Institute, 2016 Alfred M. Markowitz Award for Clinical Service (Practitioner of the Year), Society of Practitioners, Columbia University Medical Center, May 2017 Melvin D. Yahr Lecturer, XXII World Congress of Parkinson Disease and Related Disorders, Ho Chi Minh City, Vietnam, November 2017
Honored with Named International Lectureship and Awards: The Stanley Fahn Lecture was established by the Movement Disorder Society to be presented by a designated honoree at the Biannual (later Annual) International Congresses of Parkinson's Disease and Movement Disorders.
Honorees to date:
1994, Stanley Prusiner (San Francisco, CA) 1996, Oleh Hornykiewicz (Vienna, Austria) 1998, Anders Bjorklund (Lund, Sweden) 2000, Anne B.Young (Boston, MA) 2002, David J. Brooks (London, England) 2004, Huda Zoghbi (Houston, TX) 2005, Heiko Braak (Frankfurt, Germany) 2006, Ira Shoulson (Rochester, NY) 2007, Pierre Pollak (Grenoble, France) 2008, Susan Bressman (New York, NY) 2009, Christopher Goetz (Chicago, IL) 2010, Gerald Stern (London, England) 2011, Anthony E. Lang (Toronto, ON, Canada) 2012, Andrew E. Lees (London, England) 2013, Philip Thompson (Adelaide, Australia) 2014, Joseph Jankovic (Houston, Texas) 2015, Guenter Deuschl (Kiel, Germany) 2016, Eduardo Tolosa (Barcelona, Spain) 2017, Ali Rajput (Saskatoon, Saskatchawan, Canada) 2018, Marie Vidailhet (Paris, France)
The Stanley Fahn Fellowship was established by the Dystonia Medical Research Foundation in 1998.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 7
The Stanley Fahn Award was established in 2003 by the Dystonia Medical Research Foundation to provide $100,000 per year funding for 3 years to honor and support research to an individual who has made an outstanding contribution to the understanding and treatment of dystonia. Winners of the 3-year Award 2006-2009: William Dauer 2012-2014: Pedro Gonzalez-Alegre and Antonio Pisani
The Stanley Fahn Travel Grant was established by the World Parkinson Coalition in 2013
The Stanley Fahn Transition Faculty Award was established by the Parkinson’s Disease Foundation in 2015 to provide 3 years of support with $100,000 per year for an outstanding junior faculty person to help attain independent funding.
Honorees to date: 2016 Dr. James Dahlman (Georgia Institute of Technology) Dr. Ignacio Fernandez-Mata (University of Washington) Dr. Alexandria Nelson (UCSF)
The Stanley Fahn Junior Investigator Award was established by the World Parkinson Coalition in 2016 to honor the best poster presentation at its triennial World Parkinson Congress.
Honorees to date: WPC2016 - Morten Gersel Stokholm (Denmark) – Neuroinflammation in prediagnostic Parkinson’s disease: a multitracer PET study of idiopathic REM sleep behavior disorder patients.
Article regarding my contributions to movement disorders by Jankovic J, Bressman S, Dauer W, Kang UJ. Clinical and scientific perspectives on movement disorders: Stanley Fahn's contributions. Mov Disord. 2015 Dec;30(14):1862-9. doi: 10.1002/mds.26445. PMID: 26477883.
Medical School Honor: Inducted into the inaugural class of Columbia University’s Academy of Clinical Excellence, 2017.
TITLED LECTURES 1. 3rd Irwin Levy Lecturer, Washington University School of Medicine, 1981
2. Second Greenberg Lecturer in the Neurological Sciences, University of Oklahoma School of Medicine, 1981
3. Silver Anniversary Lecturer, Class of 1958, University of California School of Medicine, San Francisco, 1983
4. First André Barbeau Lecturer, Quebec Society of Clinical Neurology, Montreal, 1984
5. The 1985 Neuroscience Guest Lecturer, Louisiana State University Medical Center, New Orleans
6. Crous Visiting Fellow and Lecturer, Witswatersrand University School of Medicine, Johannesburg, South Africa, 1985
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 8
7. Second Druker Lecturer, Harvard Medical School, 1985.
8. Jesse Barber Orator, National Medical Association, 1986
9. Utterback Memorial Lecturer, University of Tennessee School of Medicine, Memphis, 1986
10. First Annual Oschin Lecturer, Cedars-Sinai Medical Center, Los Angeles, 1986
11. Ben Boshes Lecturer at the Golden Anniversary, Department of Neurology, Hebrew University School of Medicine, Hadassah Medical Center, Jerusalem, Israel, 1988
12. The 1989 Neurology Residents' Visiting Professor, Mayo Clinic, Rochester, MN
13. Second Hassel Foundation Lecturer, University of Pennsylvania School of Medicine, 1990
14. J. Norman Allen Lecturer, Ohio State University, Columbus, Ohio, November 1992
15. The 1992 Distinguished Visiting Professor, University of California at Irvine, November 1992
16. The A.B. Baker Lecturer, University of Minnesota, Minneapolis, November 3, 1994
17. The William S. Fields Lecturer, University of Texas, Houston, November 17, 1994
18. The Richard W. Graves Lecturer, Albany Medical College, May 8, 1995
19. The Charles Aring Lecturer, University of Cincinnati, June 8, 1995
20. The 22nd Joseph J. Gitt Lecturer, Washington University School of Medicine, St. Louis, Missouri, November 7, 1995
21. G. Milton Shy Visiting Professor at the National Institutes of Health, University of Pennsylvania, and Columbia University, 1997
22. First Druker Memorial Lecturer, Beth Israel Deaconess Hospital, Boston, May 1998
23. The First Distinguished Neurology Professor Lecturer, Uniformed Services University of the Health Sciences, Bethesda, MD, November 5, 1998
24. Harold Klawans Memorial Lecturer, Rush-Presbyterian-St.Lukes Medical Center, Chicago, February 18, 1999
25. Bernard Alpers Memorial Lecturer, Hahnemann Medical School, Philadelphia, May 6, 1999
26. Richmond S. Paine Memorial Lecturer, George Washington School of Medicine, Washington, D.C., March 2, 2000
27. First C. David Marsden Memorial Lecturer, Institute of Neurology, Queens Square, London, England, June 19, 2000
28. Keynote Speaker, 2nd Congress of the German Parkinson Society, Bochum, Germany, March, 2001
29. C. David Marsden Memorial Lecturer, World Congress of Neurology, London, England, June, 2001
30. Public Health Policy Lecturer, American Neurological Association, 2001
31. T.S.Srinivasan Memorial Lecturer, T.S.Srinivasan Endowment Trust, Chennai, India, February 2002
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 9
32. Neurodegeneration Special Lecturer, National Institute of Neurological Diseases and Stroke, N.I.H., Bethesda, MD, September 23, 2002
33. Landa Memorial Lecturer, University of Utah, Salt Lake City, October 24, 2002
34. Morris Bender Memorial Lecturer, Mount Sinai School of Medicine, New York, April 21, 2003
35. Keynote Speaker, Italian League Against Parkinson and Extrapyramidal Diseases (LIMPE), Montesilvano, Italy, November 18, 2003
36. Guy Williams Lecturer, Cleveland Clinic Foundation, Cleveland, June 2, 2004
37. George C. Cotzias Lecturer, Foundation for Biomedical Research of the Academy of Athens, Athens, Greece, September 10, 2004
38. J. Stephen Fink Memorial Lecturer, Adenosine 2A Antagonist Symposium, MassGeneral Institute for Neurodegenerative Disease, Boston, May 19, 2006
39. J. Stephen Fink Memorial Lecturer, Parkinson’s Disease: State of the Art, Boston University, Boston, November 30, 2006
40. 6th Gilberto Gamez Memorial Lecturer, Evolution of Parkinson’s Disease: From Clinical Discovery to Genetic Recognition, Philippines Neurological Association, November 21, 2008
41. First Wayne Hening Memorial Lecturer, Sleep Problems in Parkinson Disease, World Association of Sleep Medicine, Sao Paolo, BRAZIL, November 10, 2009
42. Cotzias Lecturer, Spanish Movement Disorders Group, Barcelona, SPAIN, November 17, 2010
43. Luis Barraquer Ferré Lecturer, Spanish Neurological Society, Barcelona, SPAIN, November 18, 2010
44. Donald Calne Lecturer, Parkinson Society Canada, Toronto, CANADA, June 7, 2011
45. R.M. Varma Oration at M.S.Ramaiah Institute Of Neurosciences in Bangalore, INDIA, Nov. 19, 2012
46. James W. Stephens Memorial Lecturer, Univ. of Colorado School of Medicine, Denver, May 7, 2014
47. Melvin Yahr Lecturer, XXII Congress of the International Association of Parkinsonism and Related Disorders (IAPRD) in Ho Chi Minh City, VIETNAM. Nov. 12, 2017
48. James J. and Joan A. Gardner Endowed Lecturer, University of Cincinnati School of Medicine, Feb. 21, 2018
49. Jerome Joseph Landa Endowed Lecture, Western Intermountain Neurological Organizatiion, Salt Lake City, Utah, March 23, 2018
50. 11th Annual Robert W. Hervey Distinguished Lecturer on Parkinson’s Disease, Houston Methodist Hospital, April 13, 2018.
51. The Donald and Marcia Pellar Lecturer, Mayo Clinic Florida, Jacksonville, FL, April 1-2, 2019.
SOCIETIES Professional: American Neurological Association American Academy of Neurology
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 10
Movement Disorder Society Society for Neuroscience American Society for Neurochemistry American Association for the Advancement of Science Association for Research in Nervous and Mental Disease New York Academy of Science The Harvey Society International Brain Research Organization International Basal Ganglia Society International Society of Neurochemistry Honorary Member, Sociedad Español de Neurologia American Society for Experimental NeuroTherapeutics
Founder, 1975: Basal Ganglia Club of Greater New York Founder, 1985: Movement Disorder Society Co-Founder, 1986: Parkinson Study Group (PSG) Co-Chairman, 1986-2006: Parkinson Study Group (PSG) Founder, 2005: World Parkinson Coalition President, World Parkinson Coalition, 2005-2013 Founder, 2012: Movement Disorders Fellowship Match Network Founder and Main Organizer, 2012-2017: Movement Disorders Fellowship Match Network
NATIONAL OFFICES HELD Councilor, American Neurological Association, 1984-87 Second Vice President, American Neurological Association, 1987-88 Vice President, American Academy of Neurology, 1993-97 Co-Chairman, Parkinson Study Group, 1986-1996 Co-Chairman, Parkinson Study Group, 1996-2006 Member, Board of Directors, American Society of Experimental NeuroTherapeutics, 1999-2001 President-Elect, American Academy of Neurology, 1999-2001 President, American Academy of Neurology, 2001-2003 Immediate Past-President, American Academy of Neurology, 2003-2005
INTERNATIONAL OFFICES HELD Chairman, Steering Committee, Movement Disorder Society, 1985-1988 First President, Movement Disorder Society, 1988-1991 Immediate Past-President, Movement Disorder Society, 1991-1994 First President, World Parkinson Coalition, 2005-2013
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 11
NATIONAL COMMITTEE MEMBERSHIPS 1978-1987 Member, Scientific Program Committee American Academy of Neurology
1982 Member, Folch-Pi Memorial Award Committee, American Society for Neurochemistry
1983-1986 Member, Continuing Education Committee, American Academy of Neurology
1986-1998 Member, Neuropharmacology Section, American Academy of Neurology
1986-1991 Member, Neuropharmacology Fellowship Selection Committee, American Academy of Neurology
1986-1994 Member, Audiovisual Subcommittee, Education Committee, American Academy of Neurology
1987-1993 Chairman, Education Committee, American Academy of Neurology
1987-1993 Member, Convention Management Committee, American Academy of Neurology
1987-1993 Member, By-laws Committee, American Academy of Neurology
1987-1993 Member, Ad Hoc Committee on Neuronet, American Academy of Neurology
1988-1993 Consultant, Task Force of DSM IV on Tourette's Syndrome and Tic Disorders, American Psychiatric Association
1988 Member, Task Force of International Diagnostic Classification of Neurological Disorders, American Neurological Association
1994-1996 Chairman, Annals of Neurology Oversight Committee, American Neurological Association
1999-2002 Chairman, Publication Committee, American Society for Experimental NeuroTherapeutics
1999-2001 Chairman, Committee on Sections, American Academy of Neurology
1999-2003 Member, Executive Committee, American Academy of Neurology
1999-2003 Member, Strategic Planning Committee, American Academy of Neurology
1999-2005 Member, Finance Committee, American Academy of Neurology
1999-2009 Member, Meeting Management Committee, American Academy of Neurology
1999-2003 Member, Leadership Council of Neurological Societies
1999-2000 Member, Ad Hoc Committee on For-Profit Subsidiary, American Academy of Neurology
1999-2005 Member, Board of Directors, American Academy of Neurology Foundation
2001 Member, Nominating Committee for A. B. Baker Award, American Academy of Neurology
2001 Member, Nominating Committee for American Academy of Neurology Foundation Board of Directors
2001-2002 Member, Organizing Committee for New York Academy of Science Conference: Life Cycle of the Dopamine Neuron, Princeton, NJ, September 18-20, 2002
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 12
2001-2002 Member, History Committee, American Neurological Association
2002-2003 Member, Investment Committee, American Academy of Neurology
2002-2003 Member, Investment Committee, American Neurological Association
2003-2005 Chair, Publications Oversight Committee, American Society of Experimental NeuroTherapeutics
2003-2009 Member, Meeting Membership Committee, American Academy of Neurology
2005 Member, Task Force on the Relationship of the AAN and the AAN Foundation
2005-2012 Member, AAN Foundation Science Council
2006-2007 Chair, Nominations Committee, American Academy of Neurology
2007-2012 Member, Jon Stolk Award Committee, American Academy of Neurology
2009-2013 Chair, Meeting Management Committee, American Academy of Neurology
2009-2013 Member, Environmental Planning Committee, American Academy of Neurology
2009-2011 Member, Annual Meeting Logistics Task Force, Ameican Academy of Neurology
2011 Chair, Nominations Committee, American Academy of Neurology Foundation
2011 Member, Nominations Committee, Parkinson Study Group
2012-2015 Member, Research Committee, American Brain Foundation
2013-2015 Member, Journal Arbitration Committee, American Academy of Neurology
INTERNATIONAL COMMITTEE MEMBERSHIPS 1976-1998 World Federation of Neurology, Research Group on Huntington's Disease
1984-Present World Federation of Neurology, Research Group on Extrapyramidal Diseases
1985-1988 Founder, Movement Disorder Society, Chair of Steering Committee
1985-2005 Parkinson Study Group, co-founder, co-chair and member of Executive Committee
1985-Present Member, Parkinson Study Group
1987-1988 Member, International Advisory Board to the 9th International Symposium on Parkinson's Disease, Jerusalem, Israel, June, 1988
1988-1990 Member, Organizing Committee, First International Congress on Movement Disorders, Washington, D.C., April 1990
1988-1991 First President, Movement Disorder Society
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 13
1989-1990 Member, International Advisory Board of the Rome European Conference on Parkinson's Disease, Rome, Italy, July, 1990
1989-1991 Member, International Advisory Board to the 10th International Symposium on Parkinson's Disease, Kyoto, Japan, October, 1991
1990-1992 Member, Organizing Committee, Second International Congress of Movement Disorders, Munich, Germany, May 1992
1991-1994 Member, International Advisory Board to the 11th International Symposium on Parkinson's Disease, Rome, Italy, March, 1994
1992-1994 Member, Organizing Committee, Third International Congress of Movement Disorders, Orlando, Florida, Nov 1994
1992-1999 Member, Education Committee, Movement Disorder Society
1992-1999 Member, Strategy and Planning Committee, Movement Disorder Society
1993-1994 Member, International Advisory Board to the Symposium entitled Focus on Dystonia, Italy, March, 1994
1994 Member, Nominating Committee, Movement Disorder Society
1994-1998 Chairman, Constitution and By-laws Committee, Movement Disorder Society
1994-1996 Member, Organizing Committee, Fourth International Congress of Movement Disorders, Vienna, June 1996
1995-2000 Chairman, Journal Oversight Committee, Movement Disorder Society
1995-1997 Member, International Advisory Board to the 12th International Symposium on Parkinson's Disease, London, England, March 1997
1996-1998 Chairman, Organizing Committee, Fifth International Congress of Movement Disorders, held in New York City, October 1998
1997-1998 Chairman, Nominating Committee, Movement Disorder Society
1997-1999 Member, International Advisory Board to the 13th International Symposium on Parkinson's Disease, Vancouver, BC, Canada, July 1999
1997-2000 Member, International Advisory Board to the 6th International Congress of Parkinson’s Disease and Movement Disorders, Barcelona, Spain, June 2000
1999-2001 Member, International Advisory Board to the 14th International Symposium on Parkinson's Disease, Helsinki, Finland, July 2001
1999-2001t Member, Scientific Advisory Board, Musicians with Dystonia, a subset of the Dystonia Medical Research Foundation
2000-2002 Member, International Advisory Board to the 7th International Congress of Parkinson’s Disease and Movement Disorders, Miami, Florida, November 2002
2001-2003 Member, Organizing Committee, International Workshop on Psychogenic Movement disorders, Atlanta, November 2003
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 14
2002 Member, Search Committee for Editors-in-Chief of Movement Disorders Movement Disorder Society
2002-2003 Member, International Advisory Board to the 15th International Symposium on Parkinson's Disease, Beijing, China, May-June 2003
2003-2004 Member, Nominating Committee, Movement Disorder Society
2005-2008 Member, Archives Committee, Movement Disorder Society
2005-2009 Chairperson, Awards Committee, Movement Disorder Society
2008-2010 Member, Nominating Committee, Movement Disorder Society
2010 Member, Advisory Committee on Conflict of Interests, Movement Disorder Society
NATIONAL AND INTERNATIONAL FOUNDATIONS 1972-1985 Member, National Science Council, Huntington's Disease Foundation of America (nee: Committee to Combat Huntington's Disease)
1974-1981 Chairman, National Science Council, Committee to Combat Huntington's Disease
1974-1984 Member, Medical Advisory Board, The Dystonia Foundation
1979-2016` Scientific Director and Member, Board of Directors, Parkinson's Disease Foundation
1980-1981 Member, Scientific Advisory Board, Amyotrophic Lateral Sclerosis Society of America
1982-1989 Member, Medical Advisory Board, Benign Essential Blepharospasm Research Foundation
1982-2004 Member, Medical Advisory Board, Myoclonus Research Foundation
1983-1987 Member, Scientific Advisory Board, Dystonia Medical Research Foundation
1984-1996 Member, Scientific Advisory Board, American Parkinson's Disease Association
1984-1985 Member, External Advisory Board, National Parkinson Foundation
1985-2000 Honorary Medical Consultant, National Spasmodic Torticollis Association
1985-1988 Member, Scientific Advisory Council, Amyotrophic Lateral Sclerosis Association
1986 Co-organizer, Second International Dystonia Symposium, Dystonia Medical Research Foundation, Arden House, Harriman, New York, 1986
1988-1990 Member, Scientific Advisory Board, Birkmayer-Institut fur Parkinsontherapie, Vienna, Austria
1989-1995 Member, Scientific Advisory Board, Dystonia Medical Research Foundation
1989-1998 Member, Board of Directors, International Tremor Foundation
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 15
1990-2000 Senior Consultant, Benign Essential Blepharospasm Research Foundation
1991 Member, Steering Committee, Parkinson's Disease Society of America
1991-1995 Member, Medical Advisory Board, Society for Progressive upranuclear Palsy
1992 Member, Scientific Advisory Board, Associazione Italiana pe la Ricerca sulla Distonia (Italian Association for Research on Dystonia), Rome, Italy
1993 Honorary Member, Scientific Committee, Associazione Italiana Parkinsoniani, (Italian Association of Parkinsonians), Milano, Italy
1995-1996 Co-organizer, Third International Dystonia Symposium, Dystonia Medical Research Foundation, Miami, Florida, October 1996
1999-2001 Co-organizer, Fourth International Symposium on Dystonia, Dystonia Medical Research Foundation, Chicago, IL, September 26-28, 2001
1999-2005 Member, Board of Directors, American Academy of Neurology Foundation
2003-2010 Member, Research Council, American Academy of Neurology Foundation
2003-2005 Appointed Chairperson, Scientific Community Council, Michael J. Fox Foundation
2003-present Lifetime Honorary Member, Board of Directors, Dystonia Medical Research Foundation,
2004-2013 President, World Parkinson Coalition
2004-2006 Chairman and Chief Organizer, First World Parkinson Congress held Feb. 22-26, 2006
2006-2010 Chairman and Chief Organizer, Second World Parkinson Congress held Sept. 28-Oct. 1, 2010, Glasgow, SCOTLAND
2010-2015 Member, Medical Advisory Board, Tourette Syndrome Association
2010-2013 Co-Chairman and Organizer, Third World Parkinson Congress, Oct. 1-4, 2013, Montreal, Quebec, CANADA
2010- 2017 Member, Executive Committee: Dystonia Coalition, supported by NIH
2011- present Member, Fellowship Committee: Dystonia Medical Research Foundation
2012 Invited Keynote speaker, Gathering of Dystonia Medical Research Foundation Dystonia Fellows, New York City, Sept. 27, 2012
2012-2015 Member, Research Council, American Brain Foundation
2013 Invited speaker, Board of Trustees of Dystonia Medical Research Foundation Dystonia, Scottsdale, AZ, Feb. 22, 2013
2013 Chair, Curriculum Committee. Movement Disorder Section, American Academy of Neurology
2014- 2018 Member, Scientific Advisory Committee, Centre for Brain Research, India Institute of Science, Bangaluru, INDIA
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 16
2015 Invited Keynote Speaker at Opening Ceremony, “History of Dystonia as a Disease Entity,” Polish Neurological Association, Warsaw, POLAND, Oct. 8, 2015
2016 - present Member, Board of Directors, Parkinson's Foundation
2019 Keynote Speaker, History of botulinum toxin as therapy for neurologic disorders,” training program for use in treating migraine, Dallas, TX, March 22, 2019
EDITORIAL BOARDS 1975-1985 Member, Editorial Board, BIOMEDICINE
1976 -1986 Associate Editor, NEUROLOGY
1980 - 2000 Member, Editorial Board, ADVANCES IN NEUROLOGY
1981-1988 Editorial Board, WEEKLY UPDATE, NEUROLOGY AND NEUROSURGERY
1980-1984 Editorial Board, Butterworth's International Medical Reviews for Neurology
1985-1995 Founder and Co-Chief Editor, MOVEMENT DISORDERS
1987-1991 Member, Editorial Board, MUSCLE AND NERVE
1987-1989 Section Editor, CURRENT OPINION IN NEUROLOGY AND NEUROSURGERY
1987-1989 Member, Editorial Board, NEURODEGENERATION
1993-2001 Member, Editorial Board, NEUROLOGY REVIEWS
1993-1997 Member, Editorial Board, CONTINUUM, American Academy of Neurology
1997-2003 Member, Editorial Board, EXPERIMENTAL NEUROLOGY
1999-2003 Member, Editorial Board, NEUROLOGY ALERT
2000-Present Founding Co-editor, CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS
2010-Present Founding Member, Editorial Board, JOURNAL OF PARKINSON’S DISEASE
2013-Present Founding Member, Editorial Board, Movement Disorders Clinical Practice
2014-Present Founder and Advisory Editor, npj Parkinson’s Disease
Reviewer: Annals of Neurology; Archives of Neurology; Brain; Brain Research; Biochemical Pharmacology; Canadian Journal of Neurological Science; Clinical Neuropharmacology; Journal of Neurochemistry; Journal of Neurological Sciences; Journal of Neurology, Neurosurgery and Psychiatry; Life Sciences; Mayo Clinic Proceedings; Movement Disorders; Neurology; Neuroscience Letters; Neurosurgery; New England Journal of Medicine; New York State Journal of Medicine; Proceedings of the National Academy of Science U.S.; Science
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 17
SPECIAL SERVICE 1971, 72, 74, 75, 78 Examiner, American Board of Psychiatry and Neurology
1975 Co-Chairman and Co-Organizer, International Conference on Dystonia, New York
1977 Member, Clinical Care Subcommittee, Congressional Commission for the Control of Huntington's Disease and Its Consequences, Washington, D.C.
1978 Co-Chairman and Co-Organizer, International Workshop on Cerebral Hypoxia and its Consequences, Sterling Forest, NY
1978-1979 Member Advisory Committee, Division of Neuropharmacological Drug Products, Bureau of Drugs, U.S. Food and Drug Administration
1979 Chairman and Organizer, Special Symposium on Controversies in the Therapy of Movement Disorders, American Neurological Association
1979, 1980 Consultant, External Review Committee, Department of Neurology, Albert Einstein College of Medicine, Bronx, NY
1980 Ad Hoc Member, Board of Scientific Counselors of the National Institute of Neurological and Communicative Disorders and Stroke
1981 Organizer and Chairman, International Symposium on Experimental Therapeutics of Movement Disorders, New York City
1981 Member, Organizing and Program Committee, First International Symposium Tourette Syndrome, New York City
1981 External referee for NIH grants
1981-2000 Organizer and Chairman, Annual Dinner and After-Dinner Seminars on Unusual Movement Disorders, American Academy of Neurology
1982 Organizer and Chairman, workshop on the Management of Parkinson's Disease, New York Academy of Science
1983 Organizer and Chairman, International Workshop on Myoclonus, Arden House, NY
1983 Co-organizer and Co-chairman, Symposium on Parkinson's Disease and Dementia, Scottsdale, AZ
1983-1985 External Reviewer, Huntington's Disease Project, University of Rochester School of Medicine, Rochester, NY
1984-1992 Primary Reviewer, Orphan Products Development, Food and Drug Administration
1984 Co-organizer and Co-chairman, Symposium on Current Topics in Parkinson's Disease, Bermuda
1984 Organizer, Workshop on Developing a Unified Rating Scale for Parkinsonism, Bermuda
1985 Organizer, Course on Unusual Movement Disorders, International Congress of Neurology, Hamburg, West Germany
1985 Representative, American Academy of Neurology on APA Task Force on Tardive Dyskinesia
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 18
1985-1987 Appointed member, Advisory Committee on Peripheral and Central Nervous System Drugs, Food and Drug Administration
1986-1990 Organizer and Chairman, Course on Movement Disorders, American Academy of Neurology
1986 Co-organizer and Chairman, Second International Symposium on Torsion Dystonia, Arden House, New York
1987 Co-organizer, International Symposium Honoring the 30th Anniversary of the Parkinson's Disease Foundation, New York City
1987 Co-organizer, International Symposium on Early Dopamine Agonist Therapy in Parkinson's Disease, New York City
1987 Co-organizer, International Symposium on Abnormal Muscle Tone, Lake Louise, Alberta, Canada
1987 Co-organizer, International Symposium on Parkinson's disease, Maui, Hawaii
1987 Organizer, International Workshop on Myoclonus, Arden House, New York
1987 Co-organizer, International Symposium on Pathogenesis of Parkinson's Disease, Movement Disorder Society, San Francisco, October 1987
1987-1989 Chairman, Advisory Committee on Peripheral and Central Nervous System Drugs, Food and Drug Administration
1988-1992 Organizer and Chairman, Workshop on the Definition and Quantitation of Tourette's Syndrome, Tourette Syndrome Association, New York City
1988 Co-organizer, International Symposium on High Technology on Quantitation of Movement Disorders, Movement Disorder Society, Jerusalem, Israel, June 1988
1988 Organizer and Chairman, Session on Unusual Movement Disorders, IXth International Symposium on Parkinson's Disease, Jerusalem, Israel
1988 Co-organizer, International Symposium on Pathogenesis of Parkinson's Disease, Movement Disorder Society, Philadelphia, October 1988
1988 Chairman, Ad Hoc Committee of the American Academy of Neurology to select the First Springer Award on Parkinson's Disease
1989 Consultant, Advisory Committee on Pulmonary and Allergic Drugs, Food and Drug Administration
1989 Member, Task Force to develop assessment of neurologists for continued certification, American Academy of Neurology
1989 Consultant, Technology Subcommittee, American Academy of Neurology
1989 Consultant, Roche Pharmaceuticals
1989 Member, Planning Committee, NIH-sponsored Consensus Conference on the Clinical Use of Botulinum Toxin, Bethesda, MD
1990 Co-Organizer, Workshop on Myoclonus, Washington, D.C.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 19
1990 Co-Organizer, First International Congress of Movement Disorders, Washington, D.C.
1990 Consultant, Essential Tremor in the Aging Nervous System, National Institute on Aging
1990 Member, International Program Committee, Second International Symposium on Tourette Syndrome
1991 Organizer and Lecturer, 4-day course "Movement Disorders for the Clinical Practitioner", Aspen, CO
1991 Moderator, Program "New Strategies in the Management of Parkinson's Disease", New York City
1991-1996 Chairman, Advisory Committee on Peripheral and Central Nervous System Drugs, Food and Drug Administration
1992 Appointed Member, Organizing Committee for an International Symposium on Parkinson's Disease to be held in Rome, Italy, in 1994
1992 Organizer and Lecturer, 4-day course "Movement Disorders for the Clinical Practitioner", Aspen, CO
1992-1993 Co-Organizer, Special Session on Parkinson's Disease and Other Movement Disorders, World Congress of Neurology, Vancouver, British Columbia, Canada
1992 Appointed Member, Diagnostic and Therapeutic Technology Assessment Program of the American Medical Association
1993 Appointed Member, special NIH committee to advise the Federal Government on Fetal Tissue Banks
1993 Organizer and Lecturer, 4-day course "Movement Disorders for the Clinical Practitioner", Aspen, CO
1993 Moderator and Lecturer, Review Course on Movement Disorders, sponsored by the University of Kansas
1993 Consultant, PET scanning program project, University of Michigan, Ann Arbor
1994 Co-Organizer and Co-Chairman, International Conference on the Management of the Parkinsonian Patient, Paris, January 1994
1994 Invited Speaker, Dystonia Medical Research Foundation's course for physicians, Houston, March 1994
1994 Invited Speaker, Dystonia Medical Research Foundation's meeting for patients, Houston, March 1994
1994 Co-Chairman, European Conference on the Long Range Planning of Studies on Selegiline for Parkinsonism, Rome, March 1994
1994 Chairman, Task Force for Continuum's booklet and videotape on Movement Disorders, American Academy of Neurology
1994 Moderator and Lecturer, Symposium: Matching treatment strategies to maximize patient functionality in Parkinson's disease, Washington, May 1994
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 20
1994 Consultant, The Salk Institute Biotechnology/Industrial Associates
1994 Organizer and Lecturer, 4-day course "Movement Disorders for the Clinical Practitioner", Aspen, CO, August 1994
1994 Member, Data Monitoring Board for the Dept. of Veterans Affairs Cooperative Studies on Vitamin E Treatment of Tardive Dyskinesia
1994 Consultant, Genta Pharmaceuticals
1995 Invited Participant, Workshop organized by the Benign Essential Blepharospasm Foundation, Bethesda, MD, February 1995
1995 Answerer of Patient Questions, Dystonia Dialogue
1995 Reviewer for National Institute of Aging, Program Project on Guamaian disease
1995 Consultant, Teva Pharmaceuticals
1995 Organizer and Lecturer, 4-day course "Movement Disorders for the Clinical Practitioner", Aspen, CO, August 1995
1995-1999 Medical Advisory Board, SmithKline Beecham Pharmaceuticals
1995-1998 Medical Advisory Board, Pharmacia-Upjohn Pharmaceuticals
1995-2001 Consultant, Diacrin Pharmaceuticals
1995 Appointed Member, International Advisory Panel for the XIIth International Symposium on Parkinson's Disease to be held in London, UK, in 1997
1996 Consultant, Somerset Pharmaceuticals
1996 Invited Speaker, Symposium on Gene Therapy of Parkinson's Disease, Washington, DC, April 1996
1996 Invited Speaker, Dystonia Medical Research Foundation's Symposium for Patients, New York City, May 1996
1996 Organizer and Lecturer, 4-day course "Movement Disorders for the Clinical Practitioner", Aspen, CO, August 1996
1996 Co-organizer and Lecturer, Third International Dystonia Symposium, Miami, Florida
1996-1998 Medical Advisory Board, DuPont Pharma
1996-1997 Medical Advisory Board, Sandoz Pharmaceuticals
1996-1999 Medical Advisory Board, Roche Pharmaceuticals
1997 Invited Speaker, Patient Symposium, International Tremor Foundation, Ohio State University, Columbus
1997 Invited Speaker, Physician Symposium, Movement Disorders: An Update and Case Presentations, International Tremor Foundation, New York City
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 21
1997-1999 Appointed Member, International Advisory Panel for the XIIIth International Symposium on Parkinson's Disease to be held in Vancouver, B.C., Canada, in 1999
1997 Organizer and Lecturer, 4-day course "Movement Disorders for the Clinical Practitioner", Aspen, CO, July 1997
1997-2000 Medical Advisory Board, Novartis Pharmaceuticals
1998 Co-organizer and speaker, International Workshop on Neurodegenerative Mechanisms and Neuroprotective Interventions in Parkinson's Disease, Phoenix, AZ.
1998 Organizer and Lecturer, 4-day course "Movement Disorders for the Clinical Practitioner", Aspen, CO, July 1998
1998-1999 Medical Advisory Board, Kyowa Pharmaceuticals
1998 Neurological Advisory Board, Amgen, Inc.
1998 Consultant, Zeneca Pharmaceuticals, Inc.
1998-2000 Member, Safety Monitoring Committee, NIH-sponsored CARE-HD Clinical Trial, investigating new medications for Huntington’s disease
1998-1999 Co-organizer, Workshop on Animal Models of Myoclonus, Washington, Dc, March 21-22, 1999
1999 Speaker, Dystonia Medical Research Foundation International Symposium
1999 Appointed Member, International Advisory Board for the 5th International Conference on Alzheimer's and Parkinson's Disease to be held in Kyoto, Japan, April 1-5, 2001
1999 Consultant, Quintiles, Inc.
1999 Consultant, AstraZeneca Pharmaceuticals, Inc.
1999-2001 Appointed Member, International Advisory Panel for the XIVth International Symposium on Parkinson's Disease to be held in Helsinki, Finland, in 2001
1998-2000 Co-organizer and speaker, International Symposium on Myoclonus and Paroxysmal Movement Disorders, Atlanta, GA, October 2000
1999-2001 Co-organizer and speaker, Fourth International Symposium on Dystonia, Chicago, IL, September 26-28, 2001
1999-2001 Appointed Member, International Symposium on Mental and Behavioral Dysfunctions in Movement Disorders, Montreal, Canada, October 10-14, 2001
2000 Invited participant to NIH Advisory Committee on future research on Parkinson’s disease, Bethesda, MD, Jan 4-6, 2000
2000-2003 Member, Independent Advisory Committee, PHAROS study to determine onset of Huntington’s disease in a population at risk
2000 Consultant, Schwarz Pharma, Inc.
2000 Consultant, Sankyo Pharma, Inc
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 22
2000 Consultant, EMD Pharma, Inc
2001 Consultant, Novartis Pharmaceuticals
2001 Consultant, Bayer Pharmaceuticals
2001-2013 Invited Member, Oversight Committee, NINDS Clinical Trials on Neuroprotective Therapy for Parkinson's Disease
2002 Invited participant to NIH Advisory Committee on future research on Parkinson’s disease, Bethesda, MD, Jan 9-10, 2002
2002 Consultant, NeuroSearch Inc.
2002-2003 Member, International Advisory Panel for the XVth International Symposium on Parkinson's Disease to be held in Beijing, China, in 2003
2002-2003 Consultant, Teva Pharmaceuticals.
2002-2003 Invited Reviewer, Michael J. Fox Foundation
2002 Consultant, Eli Lilly Pharmaceuticals.
2002 Consultant, UCB Pharmaceuticals.
2002-2004 Invited participant, Annual Bachmann-Strauss Dystonia and Parkinson Foundation workshops on TorsinA
2002-2004 Invited member, Task Force to develop Treating Guidelines for Parkinson disease, American Academy of Neurology
2003 Consultant, Prestwick Pharmaceuticals.
2003 Consultant, Novartis Pharmaceuticals
2003 Consultant, Teva Neuroscience
2003 Consultant, Kyowa Pharmaceuticals
2003 Invited Speaker, North Carolina Parkinson Society
2004 Invited member of Organizing Committee of an NINDS sponsored public meeting on “Genetic Testing in PD.” March 2004
2004 Consultant, Novartis Neuroscience Global Strategic Advisory Board
2004 Consultant, Teva Neuroscience, meeting with FDA, April 2004
2004-2006 Selected Chairman, Steering Committee, First World Parkinson Congress, to be held in Washington, DC, February 23-26, 2006
2004 Invited Speaker, Parkinson’s Disease Scientific Advisory Meeting on rasagiline, New York Academy of Sciences, October 2004
2004 Consultant, Boerhinger-Ingelheim and Pfizer Pharmaceuticals
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 23
2004 Chairperson and Program Developer, Winter Regioal Courses, American Academy of Neurology, San Diego, CA, February 2005
2005 Consultant, Scientific Advisory Board for Disease Modification Trial, Teva Pharmaceuticals, January 2005
2005 Consultant, Teva Pharmaceuticals, meeting with Canadian regulators, Ottawa, Canada, March 2005
2005 Consultant, Eisai Pharmaceuticals, April 2005
2005-2006 Clinical Advisory Board, Cita NeuroPharmaceuticals
2005 Clinical Advisory Board, Valeant Pharmaceuticals
2005 Consultant, Food and Drug Administration, August 4, 2005
2005-2006 Consultant, Eisai Medical Research, Inc., October 22, 2005
2005 Consultant, Cita NeuroPharmaceuticals meeting with the FDA., October 24, 2005
2006-2010 Member, Data and Safety Monitoring Board, Botulinum toxin studies for blepharospasm and cervical dystonia, Merz Pharmaceuticals, 2006-2010
2005 Consultant, Boerhinger-Igelheim meeting on Augmentation in Resless Legs Syndrome, Rome, Italy, March 16 2006. 2006 Member, Advisory Board, IMPAX Pharmaceuticals, San Francisco, January 27, 2006.
2006 Consultant, Novartis Advisory meeting on Parkinson’s Disease Dementia, March 23, 2006.
2006 Consultant, IMPAX Pharmaceuticals, Food & Drug Administration, July 17, 2006.
2006 Invited speaker, Dystonia Study Group and Dystonia Medical Research Foundation Dystonia Rating Scale Workshop, October 7, 2006
2006 Invited Speaker, Workshop on Parkinsond disease, Boerhinger-Ingelheim Pharmaceuticals, Miami, FL, December 2006
2007 Consultant, Boerhinger-Igelheim Advisory Board, Vienna Australia, March 2007.
2007 Consultant, Eisai Medical Research, Inc., May 2007
2007 Consultant, IMPAX Pharmaceuticals, Food & Drug Administration, July 10, 2007.
2007 Reviewer of Parkinson disease grants, RJG Foundation, Boston, August 2007
2007 Member, Advisory Board, IMPAX Pharmaceuticals, Chicago, September 20, 2007.
2007 Consultant, EMD-Serono Pharmaceuticals, Boston MA, November 2007
2007 Invited Speaker, Workshop on Parkinson’s disease, Boerhinger-Ingelheim Pharmaceuticals, Miami, FL, December 2007
2008 Consultant and Advisory Board member, Teva Pharmaceuticals, Paris, France
2008 Consultant, INTEC Pharma, New York
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 24
2008 Consultant, Antares Pharma, Zurich, Switzerland
2008 Consultant, Genzyme Pharmaceuticals, Boston
2008-2010 Reviewer of Parkinson disease grants, RJG Foundation
2008 Dedication Ceremony speaker, Dublin Neurological Institute, Dublin Ireland, Sept. 19, 2008
2008 Consultant and Advisory Board member, IMPAX Pharmaceuticals, San Francisco
2009 Invited Speaker: “Putting Research Into Practice. What Treatment for Parkinson Disease Will Look Like in the Next Decade – 2020 Vision.” National Webcast to U.S. neurologists, March 31, 2009
2009 Consultant, INTEC Pharma, Paris
2009 Consultant, Oxford Biomedica, Frankfurt, Germany
2009-2012 Member, NINDS Committee on Common Data Elements for Parkinson Disease
2009-2017 Member, Executive Committee, Dystonia Coalition
2010 Moderator and Jurist, NeuroFilm Festival, Annual Meeting of the American Academy of Neurology, Toronto, Canada, April 2010
2010 Moderator, Videotaped Panel Discussion on Neuroprotection Therapy of Parkinson’s Disease, Annual Meeting of the American Academy of Neurology, Toronto, Canada, April 2010
2010 Member, Advisory Committee for Impax Pharmaceuticals
2010-2015 Member, Tourette Syndrome Association Medical Advisory Board
2010 Co-chair, Xenazine Advisory Board Meeting, Buenos Aires, Argentina, June 12, 2010
2010 Jurist: Second World Parkinson Congress Film Festival, Glasgow, SCOTLAND,
2010 Speaker: Opening Ceremony, Second World Parkinson Congress, Glasgow, SCOTLAND, Sept 2010
2011 Consultant, INTEC Pharma, New York
2011 Member, Clinical Advisory Committee for Teva to select promising compounds for PD
2011 Consultant, Oxford Biomedica to develop gene therapy for Parkinson disease
2011-2015 Member, SynAgile Advisory Board to develop new therapy for Parkinson disease
2011-2015 Member, Data and Safety Monitoring Board, Botulinum toxin studies for spasticity, Merz Pharmaceuticals
2011 Consultant, AstraZeneca Pharmaceuticals, October 2011
2011-2012 Advisor, Green Cross Corporation
2011-2014 Advisor, Genervon Pharmaceuticals
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 25
2012-2018 Founder and Organizer, Movement Disorder Fellowship Match Network in North America
2015-2018 Advisory Board member, ADAMAS Pharmaceuticals
2015-2016 Consultant, Lifemax Laboratories
2016 Invited Member, Psychopharmacology Advisory Committee, Food and Drug Administration, March 29, 2016
2016 Consultant, Pridopidine Advisory Board meeting, Teva Pharmaceuticals, Tel Aviv, ISRAEL, Dec. 13, 2016
2017 Consultant, Advisory Board meeting, PhotoPharmics, Vancouver, BC, CANADA, June 7, 2017
2017-2018 Consultant, Advisory Board meeting, Sun Pharma Research (SPARC), Princeton, NJ, July 13, 2017
2017 Consultant, Advisory Board meeting, Kashiv Pharma, New York, NY, July 20, 2017
2017 Speaker, Sparks of Life, a support group for Orthodox patients with PD, Young Israel of Midwood Synagogue, Brooklyn, NY, Nov 30, 2017.
2018 Speaker, Parkinson Voice Project, Dallas, Texas, April 14, 2018
2018 Consultant, Inventram, Istanbul, Turkey
2018 Speaker, Sparks of Life, a support group for Orthodox patients with PD, Crown Plaza Hotel, Suffern, NY, October 14, 2018.
2019 Consultant, Advisory Board meeting, Sun Pharma Research (SPARC), Princeton, NJ, April 5, 2019
2019 Consultant, Kashiv Pharma, Philadelphia, PA, May 10, 2019
2019 Consultant, Stopparkinson LLC
OTHER SPECIAL RECOGNITION AND INTERNATIONAL LECTURER 1970 Chairman and Lecturer, Special Course on Parkinsonism, American Academy of Neurology
1970 Lecturer, Special Course in Neurochemistry, American Academy of Neurology
1970-1973 Principal Investigator, NIH grant
1974-1977 Principal Investigator, NIH grant
1975 Lecturer, Special Course on Medical Therapy, American Academy of Neurology
1975-1976 Fogarty Senior International Fellow, USPHS
1978 Lecturer, Special Course on Medical Therapy, American Academy of Neurology
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 26
1978 Invited participant, International Conference on Bromocriptine, Stockholm, Sweden
1979 Lecturer, Special Course on Medical Therapy, American Academy of Neurology
1979 Elected as Fellow, American Academy of Neurology
1980-1982 Principal Investigator, NIH grant
1980 Lecturer, Special Course on Clinical Chemistry, American Academy of Neurology
1980 Lecturer, Special Course on Neuropharmacology, American Academy of Neurology
1980 Special Course in Neurology, American College of Physicians
1981 Visiting Professor, Hadassah Medical Center, Jerusalem and Sachler School of Medicine in Tel Aviv, Israel
1981 Lecturer, Special Course on Therapy in Neurology, American Academy of Neurology
1981 Chairman and Lecturer, Unusual Movement Disorders Seminar, American Academy of Neurology
1981 Invited Lecturer, 1st International Tourette Syndrome, New York City
1981 Invited Speaker, Neuropharmacology Symposium, XIIth World Congress of Neurology, Kyoto, Japan
1981 Invited speaker, Argentine Society of Neurology, Rosario, Argentina
1982 Consultant on tardive dyskinesia, McNeil Laboratories
1982 Lecturer, Special Course on Neurology of Aging, American Academy of Neurology
1982 Lecturer, Course on Clinical Neurochemistry, American Academy of Neurology
1982 Lecturer, Course on Neuropharmacology, American Academy of Neurology
1982 Lecturer, Course on Therapy in Neurology, American Academy of Neurology
1982 Chairman and Lecturer, Unusual Movement Disorders Seminar, American Academy of Neurology
1982 Invited Speaker, New Jersey Academy of Medicine, Section on Neurology
1982 Consultant on tardive dyskinesia, Smith, Kline and French Laboratories
1982 Invited Speaker, 23rd Annual Meeting of the Japanese Society of Neurology, Tokyo
1982 Invited Speaker, Tokyo Metropolitan Institute for Neurosciences
1982 Visiting Professor, Neurological Institute of New York, Kyushu University, Fukuoka, Japan
1982 Visiting Professor, Brain Research Institute, Niigata University, Niigata, Japan
1982 Visiting Professor, Brain Research Institute, Shinshu University School of Medicine, Matsumoto, Japan
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 27
1982 Visiting Professor, Tianjin Medical College, Tianjin, People's Republic of China
1982 Visiting Lecturer, Chinese Academy of Medical Science and Capital Hospital, Beijing, People's Republic of China
1982 Visiting Lecturer, 4th Military Medical University and Xian Medical College Hospital, Xian, People's Republic of China
1982 Visiting Professor, Traditional Medical College of Anhwei, Hefei, People's Republic of China
1982 Visiting Professor, Department of Neurology, Hadassah Medical Center, Jerusalem, Israel
1982 Invited Speaker, International Symposium on Parkinson's Disease, Frankfurt, West Germany
1982 Invited Speaker, International Symposium on Tremor, Marbella, Spain
1983 Lecturer, Special Course on Therapy in Neurology, American Academy of Neurology
1983 Chairman and Lecturer, Unusual Movement Disorders Seminar, American Academy of Neurology
1983 Invited Discussant, Symposium on Tardive Dyskinesia, American Psychiatric Association, Los Angeles
1983 Invited Speaker, Symposium on Dystonia, International Society for Neurochemistry, Vancouver, B.C., Canada
1983 Invited Speaker, International Symposium on Methods of Clinical Drug Trials in Neurology, Aix-en-Provence, France
1983 North Pacific Society of Neurology and Psychiatry, Portland, Oregon
1983 Invited Speaker, Canadian Symposium on Controversies in Parkinson's Disease, Montebello, Ontario.
1983 Invited Speaker, 6th Asian and Oceanian Congress of Neurology, Taipei, Taiwan
1983 Invited Speaker, Symposium on Neurotransmitters and Neuropeptides, Taipei, Taiwan
1984 Chairman and Lecturer, Unusual Movement Disorders Seminar, American Academy of Neurology
1984 Invited Speaker, Symposium on Tardive Dyskinesia, American Psychiatric Association Meeting, Los Angeles
1984 Invited Speaker, Second International Symposium on Essential Blepharospasm, Iowa City
1984 Invited Speaker, Indiana Neurological Society
1985 Visiting Professor, Witswatersrand University School of Medicine, Johannesburg, South Africa
1985 Visiting Professor, University of Orange Free State, Bloemfontein, South Africa
1985 Visiting Professor, University of Cape Town, Cape Town, South Africa
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 28
1985 Visiting Professor, University of Natal, Durban, South Africa
1985 Visiting Professor, Pretoria University, Pretoria, South Africa
1985 Invited Speaker, Boston Neurological Society
1985 Lecturer, Special Course on Neurology of Aging, American Academy of Neurology
1985 Chairman and Lecturer, Unusual Movement Disorders Seminar, American Academy of Neurology
1985 Visiting Professor, Clinica Universitaria, Pamplona, Spain
1985 Invited Speaker, International Symposium on Basal Ganglia Diseases, Marbella, Spain
1985 Visiting Professor, University of Barcelona, Barcelona, Spain
1985 Invited Speaker, International Symposium on Parkinson's Disease, New York City
1985 Invited Organizer and Chairman, Symposium on Parkinsonism in Aging, International Congress of Gerontology, New York City
1985 Invited Speaker, Symposium on Movement Disorders, XIIIth World Congress of Neurology, Hamburg, West Germany
1985 Visiting Professor, Salpetriere Hospital, Paris, France
1985 Visiting Professor, University of Warsaw, Poland
1985 Invited Speaker, International Symposium on Tourette Syndrome, New York City
1985 Invited Speaker, Third International Meeting of the Benign Essential Blepharospasm Research Foundation, Houston
1986 Invited Speaker, Associacion Colombiana de Neurologia, Bogota, Colombia
1986 Invited Speaker, Philadelphia Neurological Society
1986 Lecturer, Special Course on Neurology of Aging, American Academy of Neurology
1986 Chairman and Lecturer, Course on Movement Disorders, American Academy of Neurology
1986 Chairman and Lecturer, Unusual Movement Disorders Seminar, American Academy of Neurology
1986 Invited Speaker, First Congress of the International Medical Society of Motor Disturbances, Lausanne, Switzerland
1986 Invited Speaker, Fourth International Meeting of the Benign Essential Blepharospasm Research Foundation, Barcelona, Spain
1986 Invited Speaker, International Symposium on Movement Disorders, Barcelona, Spain
1986 Invited Speaker, Workshop on Continuous Dopaminergic Stimulation in Parkinson's Disease, Alicante, Spain
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 29
1986 Chairman and Organizer of Session on Movement Disorders, and Invited Speaker, International Workshop on Neurologic Quantitation, Talloires, France
1986-1988 Principal Investigator, FDA grant evaluating botulinum toxin for spasmodic torticollis
1987 Invited Speaker, International Symposium on Abnormal Muscle Tone, Lake Louise, Alberta, Canada
1987 Speaker, International Symposium on Parkinson's disease, Maui, Hawaii
1987 Invited Speaker, Western Neurological Association Meeting, Del Coronado, California
1987-1992 Co-Principal Investigator, NIH grant, Multicenter clnical trial evaluating deprenyl and tocopherol anti-oxidant therapy in Parkinson's disease
1987 Lecturer, Special Course on Neurology of Aging, American Academy of Neurology
1987 Chairman and Lecturer, Course on Movement Disorders, American Academy of Neurology
1987 Chairman and Lecturer, Unusual Movement Disorders Seminar, American Academy of Neurology
1987 Invited Speaker, Annual Meeting of North American Society of Neuroradiology, New York City
1987 Invited Speaker, 6th International Catecholamine Symposium, Jerusalem, Israel
1987 Invited Speaker, Pan American Neurological Congress, San Juan, Puerto Rico
1987 Invited Speaker, Spanish Neurological Society, Barcelona, Spain
1988 Chairman and Lecturer, Course on Movement Disorders, American Academy of Neurology
1988 Chairman and Lecturer, Unusual Movement Disorders Seminar, American Academy of Neurology
1988-1990 Principal Investigator, NIH grant evaluating quantitative accelerometric recordings in parkinsonism
1988 Invited Speaker, Kingman Foundation Symposium on Parkinson's Disease, San Antonio, Texas
1988 Invited Speaker, Sociedad Neurologica Argentina, International Symposium on Movement Disorders, Buenos Aires, Argentina
1988 Invited Speaker, International Symposium on Neural Mechanisms in Disorders of Movement, Manchester, England
1988 Invited Speaker, 50th Anniversary of the Department of Neurology, Hadassah Medical Center, Jerusalem, Israel
1988 Invited Speaker, New Orleans Neurological Society
1988 Invited Speaker, Second Congress of the International Medical Society of Motor Disturbances, Rome, Italy
1988 Invited Speaker, IXth International Symposium on Parkinson's Disease, Jerusalem, Israel
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 30
1988 Invited Speaker, International Symposium on Torsion Dystonia, Jerusalem, Israel
1988 Invited Speaker, International Symposium on Vitamin E: Biochemistry and Health Implications, New York Academy of Sciences, New York City
1988-1991 Principal Investigator, NIH grant evaluating genetic linkage anaylsis for idiopathic torsion dystonia
1989 Chairman and Lecturer, Course on Movement Disorders, American Academy of Neurology
1989 Chairman and Lecturer, Unusual Movement Disorders Seminar, American Academy of Neurology
1989 Invited Speaker, Annual meeting of the Sociedade Portuguesa de Neurologia (Portugese Neurological Society), Coimbra, Portugal
1989 Invited Speaker, University of Naples, Naples, Italy
1989 Invited Speaker, Triennual meeting of the International Basal Ganglia Society, Caglieri, Sardinia, Italy
1989 Invited Speaker, Nobel Symposium on Cholinergic Mechanisms, Stockholm, Sweden
1989 Invited Speaker, Annual Courses of the Medical Society of New York
1989 Invited Speaker, International Conference on Antioxidant Vitamins and Beta-Carotene in Disease Prevention, London, England
1989 Co-chairman, Symposium on Parkinson's disease, World Congress of Neurology, New Delhi, India
1989 Invited Speaker, Special Course, World Congress of Neurology, New Delhi, India
1989 Chairman and Speaker, Course on Current Concepts on the Treatment of Parkinson's disease and Other Movement Disorders, Greenwich, Connecticut
1989 Chairman and Speaker, Course on Parkinson's disease Update, 1989, New York City
1990 Invited Speaker, First International Congress of Movement Disorders, Washington, D.C.
1990 Chairman and Lecturer, Course on Movement Disorders, American Academy of Neurology
1990 Chairman and Lecturer, Unusual Movement Disorders Seminar, American Academy of Neurology
1990 Invited Speaker, International Symposium on Inherited Disorders of the Jewish People, Neve Ilan, Israel
1990 Invited Speaker, European Conference on Parkinson's Disease and Extrapyramidal Disorders, Rome, Italy
1990 Invited Speaker, Academia Brasileira de Neurologia, Rio de Janeiro, Brazil
1990 Invited Speaker, NIH-sponsored Consensus Conference on the Clinical Use of Botulinum Toxin, Bethesda, MD
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 31
1991 Invited Speaker, International Workshop on Parkinson's Disease from Basic Research to Long-term Treatment, Berlin, Germany
1991 Invited Speaker, ARIEN (Association Research International Neuroscience, Crans-sur-Sierre, Switzerland
1991 Invited Speaker, Course on Movement Disorders, American Academy of Neurology
1991 Invited Speaker, Course on Therapy in Neurology, American Academy of Neurology
1991 Chairman and Lecturer, Unusual Movement Disorders Seminar, American Academy of Neurology
1991 Invited Speaker, Symposium on Clinical Horizons - An Update on Movement Disorders, Boston
1991 Invited Speaker, Swedish Neurological Association, Umea, Sweden
1991 Invited Moderator and Speaker, Frontiers in Dystonia: Untwisting Chronic Muscle Contractions, American Medical Association, New York City
1991 Invited Speaker, Fulton Society, Seattle, WA
1991 Invited Speaker, Pan American Neurological Congress, Montevideo, Uruguay
1991 Invited Speaker, University of New South Wales, Sydney, Australia
1991 Invited Speaker, Xth International Symposium on Parkinson's Disease, Tokyo, Japan
1991 Invited Speaker and Moderator, Symposium: Role of Dopamine Agonists in the Treatment of Parkinson's Disease, Tokyo, Japan
1991 Invited Speaker, Panel Session on Extrapyramidal Disorders, 30th Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico
1991 Invited Discussant, Workshop: Neurosurgical Horizons in Parkinson's Disease, Chicago
1992 Moderator and Speaker: Symposium on Strategies on Managing Movement Disorders, San Diego
1992 Invited Speaker, Course on Movement Disorders, American Academy of Neurology
1992 Chairman and Lecturer, Unusual Movement Disorders Seminar, American Academy of Neurology
1992 Invited Lecturer, Universite Libre de Bruxelles, Brussels, Belgium
1992 Invited Speaker, Quantitation and Rating Scales in Movement Disorders, Prien, Chiemsee, Germany
1992 Invited Speaker, Symposium on Dopamine Agonists in Parkinsonism, Munich, Germany
1992 Invited Speaker, Second International Congress of Movement Disorders, Munich, Germany
1992 Invited Speaker, Symposium on Controversial Issues in Therapy of Parkinson's Disease, Munich, Germany
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 32
1992 Invited Speaker, Symposium on Dystonia and Torticollis, Munich, Germany
1992-1995 Principal Investigator, NIH grant evaluating genetic linkage anaylsis for idiopathic torsion dystonia
1992 Invited Speaker, Symposium on Neurologic Complications of Pregnancy, New York City
1993 Invited Speaker, Course on Parkinson's Disease, Mahidol University, Bangkok, Thailand, Jan. 1993
1993 Invited Speaker, Course on Neuroimaging, Society for Neuroimaging, Orlando, FL, Feb. 1993
1993 Invited Member, N.I.H. Committee to advise the federal government on Fetal Tissue Banks, Feb. 8, 1993
1993 Invited Speaker, National Parkinson Foundation's First Annual Parkinson's Disease Symposium in Los Angeles, Feb. 13, 1993
1993 Invited Speaker, Course on Movement Disorders, American Academy of Neurology
1993 Chairman and Lecturer, Unusual Movement Disorders Seminar, American Academy of Neurology
1993 Invited Speaker, International Symposium on Current Aspects in Clinical Neuropharmacolog, Cappadocia, Turkey, May 13-15,
1993 Invited Speaker, 2nd International Bakirkoy Days, Istanbul, Turkey, May 22-23, 1993
1993 Invited Speaker, N.I.H. Workshop on Torsion Dystonia, Bethesda
1993 Invited Chairperson for Clinical Session, Biannual meeting of the Research Group on Huntington's Disease, Boston, September 1993
1993 Invited Speaker on Controversies in the Treatment of Parkinson's Disease, World Congress of Neurology, Vancouver, Sept. 1993
1993 Invited Speaker on Update of Dystonia, World Congress of Neurology, Vancouver, September 1993
1993 Invited Speaker, American Neurological Association's Symposium on Neurological Therapeutics on "Therapy of Parkinson's Disease", Boston, October 1993
1993 Univ. of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, October 1993
1993 Invited Speaker, Spanish Neurological Society Annual Meeting "Antioxidant Therapy of Parkinson's Disease", Barcelona, Spain, December 1993
1994 Consultant, Abbott Laboratories, Treatment of Parkinson's Disease, Chicago, January 1994
1994 Invited Speaker, Patient Symposium on Torsion Dystonia, Houston, March 1994
1994 Invited Speaker, International Symposium on Torsion Dystonia on "Clinical Presentations of Dystonia", Rome, Italy, March 1994
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 33
1994 Invited Speaker, 11th International Symposium on Parkinson's Disease on "Controversies in the Therapy of Parkinson's Disease", Rome, Italy, March 1994
1994 Invited Speaker, Course on Movement Disorders, American Academy of Neurology, May 1994
1994 Chairman and Lecturer, Unusual Movement Disorders Seminar, American Academy of Neurology, May 1994
1994 Invited Speaker, Oleh Hornykiewicz Festschrift, Quebec City, Canada, July 1994
1994 Univ. of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, October 1994
1994 Invited Speaker, 18th Annual Meeting of the Academia Mexicana de Neurologia, Villahermosa, Tabasco, Mexico, October 1994
1994 Invited Speaker, Course on Movement Disorders, University of Nueva Leon, Monterrey, Nueva, Mexico, November 1994
1994 Consultant, Abbott Laboratories, Treatment of Parkinson's Disease, Orlando, November 1994
1994-2003 Co-Principal Investigator, NIH grant evaluating embryonic tissue transplantation for Parkinson’s disease
1995 Invited Speaker, New York Academy of Sciences, Neuroscience Section, April 1995
1995 Invited Speaker, Sociedad Neurologica Argentina, Simposio Internacional Sobre Enfermedades Extrapiramidales, Buenos Aires, Argentina, April 1995
1995 Consultant, Otsuka America Pharmaceutical, Rockville, April 1995
1995 Consultant, CytoTherapeutics, April 1995
1995 Consultant, Teva Pharmaceuticals, Treatment of Parkinson's Disease, Seattle, May 1995
1995 Consultant, Abbott Laboratories, Treatment of Parkinson's Disease, Seattle, May 1995
1995 Invited Speaker, Course on Movement Disorders, American Academy of Neurology, May 1995
1995 Chairman and Lecturer, Unusual Movement Disorders Seminar, American Academy of Neurology, May 1995
1995 Asan Medical Center, Seoul, South Korea, May 1995
1995 Testified, U.S. House of Representatives Commerce Committee hearing on Neurology research, July 1995
1995 Invited Participant, National Institute of Neurological Disorders and Stroke Research Planning Workshop on Parkinson's Disease, Washington, D.C., August 1995
1995 Invited Participant, Conference on Cellular and Molecular Treatments of Neurological Disease, Cambridge, MA, Sept., 1995
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 34
1995 Invited Speaker, Neuroscience Conference, Tan Tock Seng Hospital, Singapore, October 1995
1995 Asan Medical Center, Seoul, South Korea, October 1996
1996 Chairman and Lecturer, Unusual Movement Disorders Seminar, American Academy of Neurology
1996 Invited Speaker, Course on Controversies in Neurology, American Academy of Neurology
1996 Invited Speaker, Course on Psychiatry in Neurology, American Academy of Neurology
1996 Invited Speaker, Course on Therapy in Neurology, American Academy of Neurology
1996 Invited Speaker, Course on Movement Disorders, American Academy of Neurology
1996 Organizer and Moderator, Therapeutic Program on Neurosurgery for Parkinson's Disease, American Academy of Neurology
1996 Consultant, Teva Pharmaceuticals, Treatment of Parkinson's Disease, San Francisco, March 1996
1996 Invited Participant, Conference on Gene Therapy for Parkinson's Disease, Washington, DC, April 1996
1996 Invited Speaker, Massachusetts Neurological Society, April 1996
1996 Invited Speaker, 70th Anniversary Celebration, Neurological Institute of New York of Uruguay, Montevideo, Uruguay, May 1996
1996 Asan Medical Center, Seoul, South Korea, May 1996
1996 Invited Speaker, Symposium on Monoamine Oxidase Inhibitors, Haifa, Israel, June 1996
1996 Invited Speaker, Genetics of Dystonia, 4th International Congress of Movement Disorders, Vienna, Austria, June 1996
1996 Invited Chairman, Videotapes of Unusual Movement Disorders, 4th International Congress of Movement Disorders, Vienna, Austria, June 1996
1996 Invited Speaker, New Classification of Dystonia, Advances in Clinical Neurosciences: A four Neurological Institute of New York Debate, Milano, Italy, December 1996
1997 Invited Speaker, Festschrift honor Professor Oleh Hornykiewicz, discoverer of dopamine deficiency in Parkinson's disease. Vienna, January 1997
1997 Invited Speaker, National Institute of Mental Health and Neuroscience of India. Bangalore, India, January-February 1997, lecturing on Parkinson's disease, dystonia, tardive dyskinesia, and psychogenic movement disorders.
1997 Chairman and Lecturer, Unusual Movement Disorders Seminar, American Academy of Neurology
1997 Organizer and Lecturer, Course on Innovative Neurosurgical Procedures for Movement Disorders, American Academy of Neurology
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 35
1997 Invited Speaker, Course on Parkinson's Disease and Other Movement Disorders, 32nd Meeting of the Canadian Congress of Neurological Sciences, Saskatoon, Saskatchewan, Canada, June 1997
1997 Invited Speaker and Co-chairman, Symposium on Movement Disorders Other than Parkinson's Disease, World Congress of Neurology, Buenos Aires, Argentina, September 1997. Lecture on genetics of dystonia.
1997 Invited Speaker, 35th Congresso Societa Italiana di neurologia (Italian Association of Neurologists), Palermo, Sicily, October 1997. Lecture on treatment of Parkinson's disease.
1997 Invited Speaker, Symposium on Parkinson's Disease, Tokyo, Japan, Lecture on treatment of Parkinson's disease. Nov. 1997.
1997 Juntendo University School of Medicine, Tokyo, Japan, Nov. 1997
1998 Invited Participant, Workshop on "Levodopa: Where Do We Stand?", Paris, France, January 1998
1998 Co-Organizer and Speaker, International Workshop on "Neuroprotection for Parkinson's disease," Phoenix, AZ, February, 1998
1998 Chairman and Lecturer, Unusual Movement Disorders Seminar, American Academy of Neurology
1998 Organizer and Lecturer, Course on Innovative Neurosurgical Procedures for Movement Disorders, American Academy of Neurology
1998 Invited Participant, Workshop on "Deep brain stimulation for Parkinson's disease," Monaco, August, 1998
1998 Invited Participant, Workshop on "Levodopa-dopa induced dyskinesias," Bermuda, November, 1998
1998-2003 Principal Investigator, NIH grant for evaluating earlier vs. later levodopa therapy for Parkinson’s disease
1999 Visiting Professor, Universita'degli Studi di Roma "La Sapienza," Dipartimento di Scienze neurolgiche, Roma, Italy, March-April, 1999
1999 Course on Parkinson's disease, Instituto per la Malattia de Parkinson, Milano, Italy, April 8-9, 1999
1999 Chairman and Lecturer, Unusual Movement Disorders Seminar, American Academy of Neurology
1999 Organizer and Lecturer, Course on Innovative Neurosurgical Procedures for Movement Disorders, American Academy of Neurology
1999 Keynote Speaker, Parkinson Society of New South Wales, Australia, Sidney, Australia, August 1999
1999 Invited Speaker, International Symposium on Muscle Stiffness, Port Douglas, Australia, August 1999
1999 Invited Speaker, International Symposium on Gait Disorders, Prague, Czech Republic, September 1999
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 36
1999-2004 Director, Morris K. Udall Center of Excellence for Parkinson's Disease Research, awarded by the National Institutes of Health
1999 Invited Speaker, New York Discussion Group of Parkinson’s Disease and Other Movement Disorders, November 1999
2000 Invited Speaker, California Association of Neurologists and Neurosurgeons, San Francisco, January 23, 2000
2000 Invited Speaker, Symposium on Parkinson’s disease, Rush-Presbyterian-St. Luke’s Medical Center, Chicago, March 2000
2000 Chairman and Lecturer, Unusual Movement Disorders Seminar, American Academy of Neurology
2000 Invited Speaker, When to start levodopa therapy, Therapeutics Course on Parkinson’s Disease, American Academy of Neurology
2000 Invited Speaker, Neurosurgical therapy, Therapeutics Course on Parkinson’s Disease, American Academy of Neurology
2000 Invited Organizer and Lecturer, Meet the Professor Luncheon, American Academy of Neurology
2000 Organizer and Lecturer, Course on Innovative Neurosurgical Procedures for Movement Disorders, American Academy of Neurology
2000 Invited Speaker, Symposium on Cervical Dystonia, National Spasmodic Torticollis Association, San Diego, May 2000
2000 Invited Speaker, Society of Biological Psychiatry, Chicago, May 13, 2000
2000 Invited Speaker on Diagnostic Dilemmas in Parkinsonism, The Italian Neurological Society at the International Congress of Parkinson’s Disease and Movement Disorders, Barcelona, Spain, June 2000
2000 Invited Speaker, The ELLDOPA Study, International Congress of Parkinson’s Disease and Movement Disorders, Barcelona, Spain, June 2000
2000 Invited Speaker, Fetal Tissue Transplantation in Parkinson’s Disease, International Congress of Parkinson’s Disease and Movement Disorders, Barcelona, Spain, June 2000
2000 Invited Speaker, Institute of Neurology, Queen Square, London, England, June 19, 2000
2000 Invited Speaker, International Symposium on Myoclonus and Paroxysmal Dyskinesias, Atlanta, Georgia, October 26-28, 2000
2000 Invited Speaker, Society for Neuroscience, Annual Meeting, New Orleans, November 4, 2000.
2000 Visiting Professor, Chinese University of Hong Kong, Hong Kong, November 17, 2000.
2000 Invited Speaker, Hong Kong Neurological Society, Hong Kong, November 19, 2000.
2001 Invited Speaker, Workshop on Neurosonology in Parkinson’s Disease, Wűrzburg University, Wűrzburg, Germany, March 6, 2001.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 37
2001 Invited Keynote Speaker, German Parkinson Society Congress, Bochum, Germany, March 7, 2001.
2001 Chairman and Lecturer, Unusual Movement Disorders Seminar, American Academy of Neurology
2001 Invited Speaker, Update on dystonia, Movement Disorder Update Course, American Academy of Neurology
2001 Invited Speaker, Movement Disorderd Emergency Course, American Academy of Neurology
2001 Invited Speaker, European Pediatric Neurology Society Congress, Baden-Baden, Germany, September 2001.
2001 Invited Speaker on Public Health Policy at the annual meeting of the American Neurological Association, October 2001.
2001 Opening Speaker, International Symposium on Mental and Behavioral Dysfunctions in Movement Disorders, Montreal, Canada, October 10-14, 2001
2001 Invited Speaker, Cajal Club, Society for Neuroscience, November 13, 2001
2002 Invited Speaker, Association of California Neurologists, San Francisco, January 19
2002 Visiting Professor, Sri Ramachandra Medical College, Chennai, India, February 16
2001 Invited Speaker, The Place Of Placebos/Sham Surgery In Clinical Trials, Annual Meeting of the American Society of Experimental Neurotherapeutics, Washington, DC, March 15
2002 Invited Speaker, Teachers College of Columbia University, April 6
2002 Invited Speaker, Update on dystonia, Movement Disorder Update Course, American Academy of Neurology
2002 Invited Speaker, Movement Disorderd Emergency Course, American Academy of Neurology
2002 Invited Speaker, International Symposium on the Life Cycle of the Dopamine Neuron, sponsored by the New York Academy of Sciences, Princeton, NJ, September 18
2002 Invited Speaker, 7th International Congress on Parkinson’s Disease and Movement Disorders, Miami Beach, November 10 and 14
2002 Speaker and co-organizer, Symposium on Movement Disorders, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
2003 Invited Speaker, University of Miami Neurology Update Course, Miami, Florida
2003 Invited Speaker, Winter Neurology Update Course, American Academy of Neurology, Las Vegas, Nevada
2003 Keynote Speaker, Polish Movement Disorder Society, Szczyrk, Poland
2003 Invited Speaker, Update on dystonia, Movement Disorder Update Course, American Academy of Neurology
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 38
2003 Invited Speaker, Movement Disorderd Emergency Course, American Academy of Neurology
2003 Invited Speaker on Parkinson Disease, Instituto Juan March de Estudios e Investigaciones, Centre for International Meetings on Biology, Madrid, Spain
2003 Invited Speaker on Parkinson Disease, Meeting of Spanish Neurologists, Cordoba, Spain
2003 Invited Speaker, Parkinson Disease Symposium, Kobe, Japan, Sept. 27, 2003
2003 Co-organizer and Invited Speaker, Pyschogenic Movement Disorders, an international worksop, Aberdeen Woods, Georgia, Oct. 10-13, 2003.
2003 Invited Speaker, National Parkinson Foundation International Sympsoium, New Orleans, LA, October 8, 2003
2003 Invited Participant, Bachmann-Strauss Foundation International Workshop on Torsion Dystonia, New York, NY, November 14-15, 2003
2003 Keynote Speaker, Italian League Against Parkinson and Extrapyramidal Diseases (LIMPE), Montesilvano, Italy, November 18, 2003
2004-2006 Founding Member, Organizing Committee, World Parkinson Congress to be held in Washington, DC, February 2006
2004 Selected Chairman, Steering Committee, World Parkinson Congress to be held in Washington, DC, February 2006
2004 Invited Speaker, Update on dystonia, Movement Disorder Update Course, American Academy of Neurology
2004 Invited Speaker, Movement Disorderd Emergency Course, American Academy of Neurology
2004 Invited Speaker, Treatment of early Parkinson Disease, Movement Disorders Course, American Academy of Neurology
2004 Invited Organizer and Speaker, Therapeutics of Parkinson Disease Course, American Academy of Neurology
2004 Invited Speaker, Course on the new Unified Parkinson Disease Rating Scale, International Congress of Parkinson Disease and Movement Disorders, Movement Disorder Society, Rome, Italy, June 15, 2004
2004 Invited Chairman, Plenary Session on Dyskinesias, International Congress of Parkinson Disease and Movement Disorders, Movement Disorder Society, Rome, Italy, June 17, 2004
2004 Invited Speaker, Celebration of the Opening of the Hertie-Institute for Clinical Brain Research, Tubingen, Germany, June 18, 2004
2004 Invited Speaker, Academy of Athens, Athens, Greece, September 2004
2004 Invited Speaker, First Aegean Meeting on Neurological Therapeutics, Heraklion, Crete, September 2004
2004 Invited Speaker, Parkinson’s Disease Symposium, Buenos Aires, Argentina, October 2004
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 39
2004 Invited Speaker, Brazilian Neurological Congress, Brasilia, Brazil, October 2004
2004 Invited Speaker, Parkinson Disease Symposium, Tokyo, Japan, November 2004
2004-2005 Invited Organizer, Winter Course of the American Academy of Neurology, San Diego, February 2005
2004-2006 Selected as Chairman and Organizer, First World Parkinson Congrsess to be held in Washington, DC. February 22-26, 2006
2005 Invited Speaker, Medical Therapy of dystonia, Dystonia Medical Research Foundation Confernece on Rehabilitation, Atlanta, GA, January 8-9, 2005
2005 Invited Speaker, Is levodopa toxic. 9th International Congress of Parkinson’s Disease and Movement Disorder, New Orleans, March 2005
2005 Invited Speaker, Update on dystonia, 9th International Congress of Parkinson’s Disease and Movement Disorder, New Orleans, March 2005
2005 Invited Speaker, Update on dystonia, Movement Disorder Update Course, American Academy of Neurology
2005 Invited Speaker, Does levodopa hasten or slow Parkinson disease?, Ukraine Neurological Society, Lviv, Ukraine, May 26, 2005
2005 Invited Speaker, A new look at an old drug – levodopa, 16th International Symposium on Parkinson Disease, Berlin, Germany, June 2005
2005 Invited Speaker, Treatment of early Parkinson’s disease, 12th Congress of Central American Neurologists, San Salvador, El Salvador, September 2, 2005
2005 Invited Speaker, Selecting patients for deep brain stimulation in advanced Parkinson’s disease, 12th Congress of Central American Neurologists, San Salvador, El Salvador, September 2, 2005
2005 Invited Speaker, Treatment of dystonia, 12th Congress of Central American Neurologists, San Salvador, El Salvador, September 2, 2005
2005 Invited Speaker, Description of patients with dystonia and their needs, Dystona Medical Research Foundation Rehabilitation Workshop, Atlanta, Georgia, September 10, 2005
2005 Invited Discussant. Therapy of essential tremor. International Symposium on Essential Tremor, Washington, DC, October 20-21, 2005
2005 Visiting Professor, Prince of Wales Hospital, University of Hong Kong, Hong Kong, November 2, 2005
2005 Invited Chairman, Course on Parkisnon’s disease, World Congress of Neurology, Sydney, Australia, November 5, 2005.
2005 Invited Speaker, Evidence of Neuroprotection in Parkinson’s Disease, World Congress of Neurology, Sydney, Australia, November 5, 2005.
2005 Invited Speaker, Tics, World Congress of Neurology, Sydney, Australia, November 5, 2005.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 40
2005 Invited Speaker, Clinical Assessment and Recognizing Subtypes of Parkinson’s Disease, World Congress of Neurology, Sydney, Australia, November 9, 2005.
2005 Invited Speaker, Clinical Skills on Dystonia, World Congress of Neurology, Sydney, Australia, November 10, 2005.
2006 Visiting Professor, Seoul National University Hospital, Seoul, Korea, March 10
2006 Invited Speaker: Evidence of Neuroprotection in Parkinson’s Disease, Intenational Symposium, Seoul National University Hospital, Seoul, Korea, March 11, 2006.
2006 Invited Speaker” Clinical Significance of dyskinesias in Parkinson’s disease, 10th Intenational Congress of of Parkinson’s Disease and Movement Disorders, Kyoto, Japan, Octobert 30, 2006.
2006 Invited Speaker: Lessons my patients have taught me, 10th International Congress of of Parkinson’s Disease and Movement Disorders, Kyoto, Japan, Octobert 31, 2006.
2006 Invited Speaker: History of Levodopa Therapy, 10th International Congress of of Parkinson’s Disease and Movement Disorders, Kyoto, Japan, November 1, 2006.
2006 Invited Speaker: Diagnosis and treatment of dystonia, 10th International Congress of of Parkinson’s Disease and Movement Disorders, Kyoto, Japan, November 1, 2006.
2007 Invited Debater: Should MAO-B inhibitors be used as the initial treatment of Parkinson disease, International Symposium on Parkinson Disease and Restless Legs Syndrome, Vienna, Austria, March 29, 2007.
2007 Invited Speaker: Clinical Assessment of Parkinson Disease, with video demonstration, International Symposium on Parkinson Disease and Restless Legs Syndrome, Vienna, Austria, March 29, 2007.
2007 Invited Speaker: Symposium on Parkinson’s Disease and Restless Legs Syndrome, Vienna, Austria, March 2007.
2007 Invited Speaker: Update on Parkinson’s Disease, Intenational Symposium to celebrate the 70th anniversary of the Dept. of Neurology, Hadassah Medical Center, Jerusalem, Israel, June 4, 2007.
2006-2007 Organizer and Speaker: Progress on Parkinson’s Disease in the last 10 years, International Symposium to celebrate the 50th anniversary of the Parkinson’s Disease Foundation, New York City, NY, October 11-12, 2007.
2007 Organizer and Speaker: Movement Disorders Update Course, American Academy of Neurology Fall Course, Las Vegas, NV, November 3, 2007.
2007 Invited Speaker: Update on Parkinson’s Disease, Hong Kong Neurological Society Symposium on Movement Disorders, Hong Kong, CHINA, November 11, 2007.
2007 Keynote Speaker: History of The Movement Disorder Society, Inauguration of the Hong Kong Movement Disorder Society, Hong Kong, CHINA, November 11, 2007.
2007 Invited Speaker, Evaluation of Movement Disorders, Hong Kong Neurological Society, Hong Kong, CHINA, November 12, 2007.
2007 Invited Speaker: International Parkinson’s Disease Symposium, Amsterdam, The Netherland, December, 2007.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 41
2008 Organizer and Lecturer: A Comprehensive Review of Movement Disorders for the Clinical Practitioner, Ootacamund, INDIA, January 17-20, 2008
2008 Member, Planning Committee for Second International Symposium on Psychogenic Movement Disorders to be held April 2009.
2008 Invited Speaker and Visiting Professor, Warsaw, POLAND, April 2008.
2008 Invited Speaker, FDA sponsored symposium on clinical trial designs for neuroprotection in Parkinson disease, Arlington, VA, April 2008
2008 Invited Speaker: Course on UPDRS, 12th International Congress of of Parkinson’s Disease and Movement Disorders, Chicago, IL, June 25, 2008.
2008 Moderator, Program on mentoring young investigators, sponsored by the Parkinson Study Group, during the 12th International Congress of of Parkinson’s Disease and Movement Disorders, Chicaqgo, IL, June 24, 2008.
2008 Invited Debater: DBS for Parkinson disease will be passé in 10-15 years, 12th International Congress of of Parkinson’s Disease and Movement Disorders, Chicaqo, IL, June 26, 2008.
2008 Organizer and Lecturer: A Comprehensive Review of Movement Disorders for the Clinical Practitioner, Goa, INDIA, September 11-14, 2008
2008 Invited Speaker: Annual UK Movement disorder meeting, Chester, UK, October 10–11, 2008.
2008 Invited Speaker: Annual meeting of the Mexican Academy of Neurology, Puerto Vallarta, MEXICO, October 30 – November 1, 2008.
2008 Invited Speaker: Annual meeting of the Philippines Neurological Association, Manila, PHILIPPINES, November 22 – 24, 2008.
2009 Invited Speaker: AAN sponsored video program for patients on Parkinson disease. January 2009
2009 Invited Speaker: AAN special meeting on sections and subspecialties in neurology, Phoenix, AZ, February 26, 2009
2009 Movement Disorder Society Visiting Professorship in Beijing and Shanghai, CHINA and in Bangkok, THAILAND, on different topics on Parkinson disease, March 18-28, 2009
2009 Invited Speaker: Webcast to U.S. neurologists on Putting Research into Practice, what treatment of PD will look like in 2020. New York City, March 31, 2009
2009 Director and Organizer, Therapy in Neurology Course, American Academy of Neurology meeting, Seattle, WA, April 27, 2009
2009 Speaker, Therapy of Parkinson’s Disease in Therapy in Neurology Course, American Academy of Neurology meeting, Seattle, WA, April 27, 2009
2009 Invited Speaker: Early Management of Parkinson disease, 13th International Congress of of Parkinson’s Disease and Movement Disorders, Paris, FRANCE, June 7, 2009.
2009 Organizer and Lecturer: A Comprehensive Review of Movement Disorders
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 42
for the Clinical Practitioner, Faridabad, INDIA, September 3-6, 2009
2009 Invited Speaker: Centennial Celebration Symposium honoring the Neurological Institute of New York, September 25, 2009.
2009 Invited Speaker: Annual meeting of the Korean Neurological Association, Killen, SOUTH KOREA, October 9 – 10, 2009.
2009 Invited Speaker, Course on Hyperkinetic Movement Disorders, World Congress of Neurology, Bangkok, THAILAND, October 24, 2009
2009 Invited Speaker, Course on Movement Disorders, World Congress of Neurology, Bangkok, THAILAND, October 25, 2009
2009 Invited Speaker, Course on Neurological Therapeutics, World Congress of Neurology, Bangkok, THAILAND, October 25, 2009
2009 Invited Speaker: International Parkinson’s Disease Symposium, Miami, December 2009.
2010 Invited Discussant, International Workshop on Freezing of Gait in Parkinson’s Disease, Washington, DC York, Feb. 24-25, 2010
2010 Invited Speaker, Symposium on Parkinson’s Disease: Past, Present and Future, Mount Sinai Medical Center, New York, March 5, 2010
2010 Director, Organizer and Speaker, Therapy in Neurology Course, American Academy of Neurology meeting, Toronto, ON, CANADA, April 12, 2010
2010 Invited Speaker, 25th Annual Parkinson’s Summer Forum of the Grand Traverse Parkinson’s Support Group, Traverse City, MI, June 3, 2010
2010 Invited Speaker: Unusual Movement Disorders, 14th International Congress of Parkinson’s Disease and Movement Disorders, Buenos Aires, ARGENTINA, June 13, 2010.
2010 Invited Panelist, N.I.H. Workshop on Sham Surgery in Parkinson’s Disease, Bethesda, MD York, June 29-30, 2010
2010 Organizer and Lecturer: Couse on Fundamentals of Parkinson’s Disease, Second World Parkinson Congress, Glasgow, SCOTLAND, September 28, 2010
2010 Speaker: Opening Ceremony, Second World Parkinson Congress, Glasgow, SCOTLAND, Sept 28, 2010
2010 Invited Speaker: Nuts and Bolts of Parkinson’s Disease Progression, Second World Parkinson Congress, Glasgow, SCOTLAND, September 30, 2010
2010 Invited Chair and Speaker: Neuroprotection of Parkinson’s Disease, Second World Parkinson Congress, Glasgow, SCOTLAND, October 1, 2010
2010 Organizer and Lecturer: A Comprehensive Review of Movement Disorders for the Clinical Practitioner, Bhubaneshwar, INDIA, October 7-10, 2010
2010 Invited Speaker: Annual UK Movement disorder meeting, London, UK, October 15–16, 2010.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 43
2011 Invited Speaker: Course on Treatment of Parkinsonism and Hyperkinesias, Houston, TX, January 2011
2011 Director, Organizer and Speaker, Therapy in Neurology Course, American Academy of Neurology meeting, Honolulu, Hawaii, April 10, 2011
2011-2012 Invited Member: Workshop on Classification of Dystonia, Rome, ITALY, May 23- 24, 2011
2011 Invited Guided Poster Tour Leader, 15th International Congress of Parkinson’s Disease and Movement Disorders, Toronto, ON, CANADA, June 6, 2011.
2011 Invited Speaker: Unusual Movement Disorders, 15th International Congress of Parkinson’s Disease and Movement Disorders, Toronto, ON, CANADA, June 6, 2011.
2011 Invited Session Chair and Panellist: 5th International Dystonia Symposium, Barcelona, SPAIN, October 20-22, 2011
2011 Organizer and Lecturer: A Comprehensive Review of Movement Disorders for the Clinical Practitioner, Agra, INDIA, November 3-6, 2011
2012 Invited Keynote Speaker: “The Natural History of Parkinson’s Disease” at the International Symposium of Genetics in Parkinson’s Disease, Focus in Ashkenazi Jews, Tel Aviv, ISRAEL, February 16, 2012.
2012 Keynote speaker: Bachmann-Strauss Foundation symposium on dystonia, New York, Feb. 28, 2012
2012 Invited speaker: Mount Sinai Symposium on Advances in Movement Disorders, New York, March 25, 2012
2012 Director, Organizer and Speaker, Therapy in Neurology Course, American Academy of Neurology meeting, New Orleans, LA, April 22, 2012
2012 Invited Chair of Opening Ceremony: 8th International Congress on Mental Dysfunction & Other Non-Motor Features in Parkinson’s Disease and Related Disorders - MDPD 2012, Berlin, GERMANY, May 3, 2012.
2012 Invited Speaker: Diagnostic Criteria for Parkinson Disease, 8th International Congress on Mental Dysfunction & Other Non-Motor Features in Parkinson’s Disease and Related Disorders - MDPD 2012, Berlin, GERMANY, May 4, 2012.
2012 Opening speaker: Parkinson Association of Ireland, Dublin, IRELAND, June 17, 2012.
2012 Invited Chair of a scientific session: 16th International Congress of Parkinson’s Disease and Movement Disorders, Dublin, IRELAND, June 18, 2012.
2012 Invited speaker, “Psychogenic Movement Disorders,” Oregon Health Sciences University, Portland, OR, Sept. 22, 2012
2012 Invited speaker, “Parkinson disease: Past, Present and Future.” Andalusian Neurological Society, Granada, SPAIN, Oct. 20, 2012
2012 Invited speaker, Italian League Against Parkinson and Extrapyramidal Diseases (LIMPE), Pisa, ITALY, November 19, 2012
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 44
2012 Organizer and Lecturer: A Comprehensive Review of Movement Disorders for the Clinical Practitioner, Trivandrum, INDIA, November 15-18, 2012
2013 Invited Speaker, “Overview of Parkinson Disease Pathophysiology,” Integrated Neuroscience Session, American Academy of Neurology meeting, San Diego, CA, March 17, 2013
2013 Invited Speaker, “Movement Disorders Update,” Neurology Update II Course, American Academy of Neurology meeting, San Diego, CA, March 22, 2013
2013 Invited Speaker, Kuwait North American Conference on Neurology, Sponsored by Kuwaiti Ministry of Health, Kuwait City, KUWAIT, April 29, 2013
2013 Keynote Speaker: “History of Dystonia,” Workshop on Treatment of Dystonia, Hannover, GERMANY, May 10, 2013
2013 Invited Chair of a Plenary Session: 17th International Congress of Parkinson’s Disease and Movement Disorders, Sydney, AUSTRALIA, June 17, 2013.
2013 Invited Speaker: “History of Dystonia,” Symposium on the History of Movement Disorders, Sydney, AUSTRALIA, June 21, 2013
2013 Keynote Speaker: “FXTAS in the Realm of Movement Disorders,” International Symposium on Premutation Disorders, Perugia, ITALY, June 26, 2013
2013 Invited Speaker: Annual meeting of the Mexican Academy of Neurology, Merida, MEXICO, November 3, 2013. “Psychogenic Movement Disorders” and “Paroxysmal Dyskinesias”.
2014 Invited Speaker: Parkinson’s Disease Foundation Conference for patients, New York City, February 18, 2014. ”Understanding PD: Key to the Cure.”
2014 Invited Speaker: Global Community Conference on Parkinson’s Disease, Keystone, Colorado, March 2-4, 2014. “Lab to Life.”
2014 Co-organizer and Speaker: 50th Anniversary Symposium on Levodopa Therapy for Parkinson Disease, International Parkinson’s Disease and Movement Disorder Society, Miami, FL, March 20, 2014.
2014 Co-organizer and Speaker: Course on Therapy for Parkinson Disease, International Parkinson’s Disease and Movement Disorder Society, Miami, FL, March 21- 22, 2014.
2014 Visiting Professor: University of Colorado, Denver, CO, May 2014.
2014 Invited Speaker: “Controlled Clinical Trials on Fetal Tissue Transplant Studies for Parkinson Disease, 18th International Congress of Parkinson’s Disease and Movement Disorders, Stockholm, SWEDEN, June 2014.
2014 Invited Speaker: Annual meeting of the Mexican Academy of Neurology, Cancun, MEXICO, November 1 and 2, 2014. “Treatment of Motor Complications in PD” and “Approaches to Myoclonus”.
2014 Invited Speaker, Kuwait North American Conference on Neurology, Sponsored by Kuwaiti Ministry of Health, Kuwait City, KUWAIT, December 13, 2014
2015 Visiting Professor, Barrow Neurological Institute, Phoenix, AZ, February 2015
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 45
2015 Keynote Speaker, Course on Movement Disorders for Young Neurologists, International Parkinson’s Disease and Movement Disorder Society, Atlanta, GA, February 2015
2015 Invited Speaker, Course for young investigators on Parkinson disease: Fostering New Directions in Parkinson’s Research, International Parkinson’s Disease and Movement Disorder Society, held May 4-9, 2015 at the Burke Medical Research Institute in White Plains, NY, USA.
2015 Invited Panelist: “How to evaluate patients”, Grand Rounds at 19th International Congress of Parkinson’s Disease and Movement Disorders, San Diego, CA, June 2015.
2015 Organizer and Moderator of debate at First World Congress on Tourette and Tic Disorders, London, England, June 26, 2015
2015 Keynote Speaker, “History of Dystonia as a Disease Entity,” Polish Neurological Association, Movement Disorder Annual Meeting, Warsaw, Poland, October 8, 2015
2015 Invited Speaker, “History of Development of Levodopa for Parkinson Disease,” Polish Neurological Association, Movement Disorder Annual Meeting Warsaw, Poland, October 9, 2015
2015 Invited Participant: Milken Institute Retreat on State of Science in Parkinson Disease, New York City, November 4-5, 2015
2015 Invited Speaker, “Some aspects on the pathogenesis and progression of Parkinson disease,” Conference on Neurodegenerative Diseases: Pathogenesis to Therapy, Centre for Brain Research, Bengaluru, India, November 18, 2015
2016 Keynote Speaker, “50 Years of L-dopa as a Treatment for Parkinson Disease,” Centricity Series: Parkinson’s disease – Evaluating the gold standard treatment. Feinstein Institute for Medical Research, Northwell Health, Manhasset, NY, February 25, 2016
2016 Invited Speaker, C.David Marsden. In Session: Pioneers in Neurology.at the Annual meeting of the American Acedemy of Neurology, Vancouver, BC, Canada. April 19, 2016
2016 Keynote Speaker, Myths and Mistakes made by patients and doctors regarding Parkinson disease, Annual Parkinson Disease Educational Symposium for Patients, Caregivers and Healthcare Providers, University of Florida, Gainesville, Florida, May 7, 2016
2016 Invited Speaker, Development of the Concept of Dystonia as a Disease, a Syndrome and a Movement Phenomenology, Annual meeting of the Japanese Neurological Society, Kobe, Japan, May 18, 2016
2016 Invited Speaker, How to treat people who have just been diagnosed with Parkinson disease, Annual meeting of the Japanese Neurological Society, Kobe, Japan, May 19, 2016
2016 Invited Lecturer, Continuing Medical Education course, Movement Disorders for the Clinical Practitioner, Movement Disorder Society, July 30-Aug 4, 2016, Aspen, CO; five lectures
2016 Invited Speaker, Brazil MovDisord Meeting, Nov 4-6, 2016, Natal, Brazil, three lectures
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 46
2017 Keynote Speaker, First Pan-American Congress of Movement Disorders, Feb 24, 2017, Miami, Florida
2017 Co-Chair, Skilled Workshop, How to become a successful movement disorder specialist, 21st Annual Congress of Parkinson’s Disease and Movement Disorders, June 7, 2017, Vancouver, BC, CANADA
2017 Invited Lecturer, Continuing Medical Education course, Movement Disorders for the Clinical Practitioner, J Movement Disorder Society, August 1-4, 2017, Aspen, CO; Three lectures
2017 Inaugural Lecturer, International Symposium on Alpha-Synuclein, Sept 7, 2017, Athens, GREECE "50 years of dopamine supplementation therapy in Parkinson’s Disease and Related Disorders".
2017 Invited Lecturer, 1ST Middle East School on Movement Disorders for Young Neurologists, Kuwait City, KUWAIT, Oct. 2-3, 2017; Five lectures
2017 Invited Lecturer, 3rd Middle East Camp on Movement Disorders, Dubai, UNITED ARAB EMIRATES, Oct. 5-5, 2017; Six lectures
2017 Invited Lecturer, Psychogenic Movement Disorders, XXII Congress of the International Association of Parkinsonism and Related Disorders (IAPRD) in Ho Chi Minh City, VIETNAM. Nov. 14, 2017
2017 Invited Lecturer, Meet the Professor, XXII Congress of the International Association of Parkinsonism and Related Disorders (IAPRD) in Ho Chi Minh City, VIETNAM. Nov. 14, 2017
2018 Plenary Lecturer, Colombian Association of Neurology, Barranquilla, Colo9mbia, March 16, 2018
2018 Opening Lecturer, First International Tremor Conference, New York City, May 11, 2018
2018 Invited Lecturer, Continuing Medical Education course, Movement Disorders for the Clinical Practitioner, J Movement Disorder Society, July 29 –August 2, 2018, Aspen, CO; Three lectures
2018 Invited Speaker, Skilled Workshop, How to become a successful movement disorder specialist, 22st Annual Congress of Parkinson’s Disease and Movement Disorders, October 8,, 2018, Hong Kong
2018 Invited Speaker, Philadelphia Neurological Society, Dec. 12, 2018
2019 Keynote Speaker, The early history in the development of botulinum toxin as a treatment of neurologic disorders. The 30th Anniersary of FDA approval of botulinum toxin.,March 22, 2019, Dallas, TX
2019 Invited Member, Oversight Committee, NINDS Common Data Elements
VISITING LECTURES AND VISITING PROFESSOR 1974 University of Pennsylvania School of Medicine S.U.N.Y. - Downstate Medical Center Cornell University Medical College Albert Einstein College of Medicine
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 47
1975 Hershey Medical School Montefiore Hospital and Medical Center Bird S. Coler Hospital
1976 University of Pennsylvania School of Medicine Brooklyn V.A. Hospital Tarbox Symposium on Parkinsonism
1977 Brookdale Hospital and Medical Center Montefiore Hospital and Medical Center Cabrini Health Care Center Cornell University College of Medicine Eastern Maine Medical Center
1978 Temple University School of Medicine New York Medical College Wenner-Gren Institute, Stockholm University of California School of Medicine George Washington University School of Medicine White Plains Hospital Medical Center
1979 Mt. Sinai School of Medicine University of Tennessee School of Medicine St. Vincent's Medical Center, New York City Tufts University School of Medicine New York University School of Medicine Carrier Clinic and Foundation, Princeton University of Rochester School of Medicine Nassau Hospital Yale University School of Medicine
1980 North Shore University Hospital New Jersey College of Medicine and Dentistry Baylor College of Medicine Montefiore Medical Center
1980 University of Florida School of Medicine Central Islip State Hospital University of Kansas Medical Center Nassau County Medical Center Bronx V.A. Hospital Temple University School of Medicine New York University School of Medicine Albany Medical College St. Vincent's Medical Center Riverside Methodist Hospital, Columbus
1981 Long Island Jewish-Hillside Medical Center Washington University School of Medicine Hadassah Medical Center, Jerusalem Sachler School of Medicine, Tel Aviv Vanderbilt University School of Medicine Walter Reed Army Medical Center University of South Carolina School of Medicine Case-Western Reserve University School of Medicine University of Oklahoma School of Medicine Cleveland Clinic
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 48
1982 Northwestern University School of Medicine St. Barnabas Hospital, Livingston New Jersey College of Medicine New Jersey Academy of Medicine Lyons V.A. Hospital St. Joseph's Medical Center, Yonkers University of Massachusetts School of Medicine University of California School of Medicine Rutgers University College of Medicine State University of New York at Buffalo Coney Island Hospital Albert Einstein College of Medicine University of Connecticut School of Medicine Tufts University School of Medicine Emory University School of Medicine Mayo Clinic Harvard Medical School University of Cincinnati School of Medicine Brooklyn Neurological Society
1983 Southern California Permanente Medical Group, Los Angeles Naval Medical Center, Bethesda University of Miami School of Medicine Albany Medical College University of Colorado School of Medicine Vail Clinical Brain Conference University of Oregon School of Medicine Massachusetts General Hospital University of California School of Medicine, San Francisco University of Ottawa School of Medicine Cornell Medical College-New York Hospital Bryn Mawr Hospital Rutgers Medical School Harvard Medical School University of Pennsylvania School of Medicine
1984 Southwestern Medical School, Dallas White Plains Hospital University of Iowa School of Medicine Massachusetts General Hospital University of Indiana School of Medicine
1985 Beth Israel Hospital, Boston Brigham and Women's Hospital, Boston University of Warsaw, Poland University of South Carolina School of Medicine Emory University School of Medicine, Atlanta Medical College of Georgia, Augusta University of Pittsburgh School of Medicine Baylor College of Medicine, Houston University of Pennsylvania School of Medicine
1986 UCLA School of Medicine University of Tennessee School of Medicine Cedars-Sinai Medical Center, Los Angeles Memphis Neurological Society
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 49
1987 Toronto Western Hospital, Toronto Columbia Hospital, Milwaukee University of Trondheim Medical School, Trondheim, Norway Albert Einstein College of Medicine Walter Reed Army Medical Center
1988 State University of New York, Stony Brook University of California at San Francisco Stanford University University of Texas at San Antonio Robert Wood Johnson Medical School, New Brunswick
1989 Mayo Clinic University of Vermont Downstate Medical Center, Brooklyn Robert Wood Johnson Medical School, New Brunswick University of Pennsylvania School of Medicine
1990 North Shore University Hospital New York University Graduate Hospital, Philadelphia National Institute of Neurological Diseases and Stroke
1991 Case-Western Reserve School of Medicine Cleveland Neurological Society Emory University School of Medicine Harvard Medical School University of Indiana School of Medicine Indianapolis Neurological Society Barrow Neurological Institute of New York University of New South Wales, Sydney, Australia University of South Florida, Tampa, Florida
1992 Medical College of Georgia, Augusta, GA Universite Libre de Bruxelles, Brussels, Belgium University of Connecticut, Hartford, CT Brown University, Providence, RI University of California, Irvine, CA Cornell Medical College, New York City Long Island Jewish-Hillside Medical Center, New York University of California, Irvine Ohio State University, Columbus
1993 Cedars-Sinai Medical Center, Los Angeles Case-Western Reserve School of Medicine New York University School of Medicine
1994 University of California, San Francisco Baylor College of Medicine, Houston, TX Johns Hopkins University School of Medicine Mount Sinai Medical Center, New York City University of Minnesota School of Medicine University of Maryland School of Medicine University of Texas, Houston
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 50
University of California, Los Angeles
1995 University of Pennsylvania Robert Wood Johnson School of Medicine, New Brunswick University of Massachusetts School of Medicine, Worcester Albany Medical College Washington University School of Medicine, St. Louis
1996 Asan Medical Center, Seoul, South Korea, May 1996 University of Arkansas School of Medicine, May 1996 Carmel Medical Center, Haifa, Israel, June 1996
1997 National Institute of Mental Health and NeuroScience, Bangalore, India New York University Juntendo University School of Medicine, Tokyo, Japan University of Pennsylvania University of California, San Francisco
1998 Albert Einstein School of Medicine Mount Sinai Medical Center National Institutes of Health Mayo Clinic, Rochester, MN Beth Israel and Deaconess Hospital, Boston Massachusetts General Hospital, Boston Uniformed Services University of the Health Sciences, Bethesda, MD Baylor College of Medicine, Houston, TX
1999 University of Chicago Pritzker School of Medicine Rush-Presbyterian-St. Luke’s Medical Center, Chicago Jefferson Medical College, Philadelphia University of Massachusetts Medical Center, Worcester New York University School of Medicine Beth Israel Medical Center, New York City
2000 George Washington University School of Medicine, Washington, DC Rush-Presbyterian-St. Luke’s Medical Center, Chicago Institute of Neurology, Queens Square, London, England Chinese University of Hong Kong, Hong Kong, China Yale University School of Medicine, New Haven, CT
2001 Cornell University School of Medicine, New York, NY Mayo Clinic, Scottsdale, Arizona
2002 Sri Ramachandra Medical College, Chennai, India, February 16 University of Utah, Salt Lake City New York University, New York City Harvard Medical School, Boston University of Utah School of Medicine, Salt Lake City Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
2003 University of Miami School of Medicine, Miami, Florida New York University School of Medicine, New York City Mount Sinai School of Medicine, New York City Harvard Medical School, Boston, MA Institute for Neurodegenerative Diseases, New Haven, CT
2004 Cornell University School of Medicine, New York, NY
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 51
Johns Hopkins School of Medicine, Baltimore, MD University of Mississippi, Jackson, MS Lennox Hill Hospital, New York, NY Cleveland Clinic, Cleveland, OH Jefferson Medical College, Philadelphia, PA
2005 Jefferson Medical College, Philadelphia, PA University of Southern California, Los Angeles University of Arkansas, Little Rock Prince of Wales Hospital, University of Hong Kong, Hong Kong
2006 Seoul National University Hospital, Seoul, Korea
2007 SUNY Downstate Medical School, Brooklyn, NY SUNY Stony Brook Medical School, Stony Brook, NY Pennsylvania State University School of Medicine, Hershey, PA University of Pittsburgh Medical Center, Pittsburgh, PA Drexel Allegheny Hospital, Pittsburgh, PA Baylor College of Medicine, Houston, TX Hong Kong University Medical School, Hong Kong, China Philadelphia Neurological Society
2008 Johns Hopkins Medical Center, Baltimore, MD University of Alabama at Birmingham Medical School, Birmingham, AL Cleveland Clinic, Cleveland, OH Wayne State University School of Medicine, Detroit, MI
2009 Peking Union Medical College Hospital, Beijing, CHINA Shanghai Jiaotong University School of Medicine, Shanghai, CHINA Chulalongkorn University Medical School, Bangkok, THAILAND
2013 Emory University Medical School, Atlanta, GA
2014 University of Colorado School of Medicine,
2015 Barrow Neurological Institute, Phoenix, AZ Mayo Clinic Scottsdale, Scottsdale, AZ University of Texas Southwestern, Dallas, TX Sept 8,9, 2015
2016 New York State Psychiatric Institute, NYC, Jan 10, 2016 New York Methodist Hospital, Brooklyn, NY, Feb 29, 2016 University of Florida School of Medicine, Gainesville, FL, May 6, 2016
2017 Lenox Hill Hospital, New York City, February 14, 2017 Weill-Cornell Medical Center, New York City, March 1, 2017 University of Chicago School of Medicine, Chicago, IL, March 23, 2017 University of California San Diego. San Diego, CA, May 24, 2017
2018 University of Cincinnati Medical Center, Cincinnati, OH, Feb. 21, 2018 University of,Utah Medical Center, Salt Lake City, UT, March 23, 2018 New York Methodist Hospital, Brooklyn, NY, April 17, 2018 New York University, New York,NY, June 12, 2018 University of Pennsylvania, Philadelphia, PA, Dec. 12, 2018
2019 Mayo Clinic Florida, Jacksonvile, FL. April 1-2, 2019
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 52
UNIVERSITY AND HOSPITAL COMMITTEES 1972-1973 Member, Social Service Committee, Hospital of the University of Pennsylvania 1973 Member, Review and Search Committee for the Department of Neurology, University of Pennsylvania School of Medicine 1973 Member, Committee on Studies Involving Man, University of Pennsylvania 1973-2014 Member, Department Executive Committee
1973-Present Member, Department Committee on Appointments and Promotions 1973-1998 Member, Department Graduate Training Committee 1975 Member, Dean's Task Force on Clinical Pharmacology, Columbia University 1975 Member, Advisory Committee of the General Clinical Research Center 1976-1982 Chairman, Departmental Research Committee 1977 Member, Search Committee for Chief of Division of Pediatric Neurology 1977-1983 Member, Neurobiology Training Program 1978-1985 Chairman, Departmental Committee on Human Investigation 1978-1982 Faculty Advisor, Class of 1982 1978-1979 Member, Committee for the Review of the Department of Rehabilitation Medicine 1980-1982 Member, Departmental Committee on Positron Emission Tomography 1981-1982 Member, Committee for the Review of the Department of Pediatrics 1985-1986 Member, Committee for the Review of the Department of Neurosurgery 1991 Member, Ad Hoc Tenure Committee, Columbia University 1991-1993 Secretary, Medical Board of Presbyterian Hospital 1994 Member, Imaging Committee, CPMC 1995 Member, Ad Hoc Tenure Committee, Columbia University 1995 Member, Liason Committee for Search for Chairman of Neurology Department 1996 Chairman, Ad Hoc Tenure Committee, Columbia University 1996-2004 Member, Lippard Lecture Selection Committee 2004-present Member, Ad Hoc Tenure Committee, Columbia University
UNIVERSITY TEACHING 1973-1975 Preceptor, Introduction to the Patient, Neurology 1973-1977 Lecturer, Postgraduate Course for Psychiatrists 1973-2013 Director, Movement Disorder Program 1973-1999t Attending Rounds, Neurological Institute of New York 1973-1983 Neurobiology Seminars 1973-1981 Lecturer, Concepts of Neurological Diseases course 1973-Present Lecturer to house staff and medical students on movement disorders and neurotransmitters 1976-1980 Preceptor, Neural Science Course
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 53
1977 Preceptor, Student Elective in Clinical Neurology 1977-Present weekly Movement Disorder Rounds 1977-1980 Lecturer, Neural Science Course 1978-1985 Lecturer, Department of Psychiatry 1979 Lecturer, Pharmacology graduate students 1984-Present Weekly Movement Disorder Video Rounds 1990 Course Director and Lecturer, Continuing Medical Education course, The Treatment of Dystonia Including the Use of Botulinum Toxin, June 30, 1990 1990 Lecturer, Continuing Medical Education course, Hypnosis in Psychotherapy and Behavioral Medicine, October 7, 1990 1990 Course Director and Lecturer, Continuing Medical Education course, The Use of Botulinum Toxin in the Treatment of Focal Dystonia, October 27, 1990 1991 Course Director and Lecturer, Continuing Medical Education course, Movement Disorders for the Clinical Practitioner, August 4-7, 1991, Aspen, CO 1991 Course Moderator, Continuing Medical Education course, New Strategies in the Management of Parkinson's Disease, September 5, 1991 1992 Course Director and Lecturer, Continuing Medical Education course, Movement Disorders for the Clinical Practitioner, August 3-6, 1992, Aspen, CO 1992 Course Director and Lecturer, Continuing Medical Education course, Therapy of Movement Disorders as Practiced by the Movement Disorder Group at Columbia-Presbyterian Medical Center, Nov. 13-14, 1992 1993 Course Director and Lecturer, Continuing Medical Education course, Movement Disorders for the Clinical Practitioner, August 3-6, 1993, Aspen, CO 1994 Course Director and Lecturer, Continuing Medical Education course, Movement Disorders for the Clinical Practitioner, August 1-4, 1994, Aspen, CO 1995 Course Director and Lecturer, Continuing Medical Education course, Movement Disorders for the Clinical Practitioner, August 1-4, 1995, Aspen, CO 1995 Lecturer, Continuing Medical Education course, Psychiatry Update October 14, 1995 1996 Course Director and Lecturer, Continuing Medical Education course, Movement Disorders for the Clinical Practitioner, August 1-4, 1996, Aspen, CO 1997 Course Director and Lecturer, Continuing Medical Education course, Movement Disorders for the Clinical Practitioner, July 28-31, 1997, Aspen, CO 1997 Course Director and Lecturer, Continuing Medical Education course, Movement Disorders for the Clinical Practitioner, July 28-31, 1997, Aspen, CO 1997 G. Milton Shy Lecturer, December 3, 1997, Genetics and the new classification of dystonia, Grand Rounds, Neurological Institute of New York 1998 Course Director and Lecturer, Continuing Medical Education course, Movement Disorders for the Clinical Practitioner, July 28-31, 1998, Aspen, CO 1999 Course Director and Lecturer, Continuing Medical Education course, Movement Disorders for the Clinical Practitioner, July 30 - August 2, 1999, Aspen, CO 2000 Course Director and Lecturer, Continuing Medical Education course, Movement Disorders for the Clinical Practitioner, July 28-31, 2000, Aspen, CO 2001 Course Director and Lecturer, Continuing Medical Education course, Movement Disorders for the Clinical Practitioner, August 3-6, 2001, Aspen, CO 2002 Course Director and Lecturer, Continuing Medical Education course, Movement Disorders for
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 54
the Clinical Practitioner, August 1-4, 2002, Aspen, CO 2003 Speaker, Lou Gehrig Birthday Centennial Course on Clinical Trials in Amyotrophic Lateral Sclerosis 2003 Course Director and Lecturer, Continuing Medical Education course, Movement Disorders for the Clinical Practitioner, August 1-4, 2003, Aspen, CO 2004 Course Director and Lecturer, Continuing Medical Education course, Movement Disorders for the Clinical Practitioner, July 30-August 2, 2004, Aspen, CO 2005 Course Director and Lecturer, Continuing Medical Education course, Movement Disorders for the Clinical Practitioner, July 29-August 1, 2005, Aspen, CO 2006 Course Director and Lecturer, Continuing Medical Education course, Movement Disorders for the Clinical Practitioner, July 28-31, 2006, Aspen, CO 2007 Course Director and Lecturer, Continuing Medical Education course, Movement Disorders for the Clinical Practitioner, July 30-August 2, 2007, Aspen, CO 2008 Course Director and Lecturer, Continuing Medical Education course, Movement Disorders for the Clinical Practitioner, July 28-31, 2008, Aspen, CO 2009 Course Director and Lecturer, Continuing Medical Education course, Movement Disorders for the Clinical Practitioner, July 27-30, 2009, Aspen, CO 2010 Course Director and Lecturer, Continuing Medical Education course, Movement Disorders for the Clinical Practitioner, July 26-29, 2010, Aspen, CO 2011 Course Director and Lecturer, Continuing Medical Education course, Movement Disorders for the Clinical Practitioner, July 25-28, 2011, Aspen, CO 2012 Course Director and Lecturer, Continuing Medical Education course, Movement Disorders for the Clinical Practitioner, July 30-August 2, 2012, Aspen, CO 2013 Course Director and Lecturer, Continuing Medical Education course, Movement Disorders for the Clinical Practitioner, July 28-August 1, 2013, Aspen, CO 2014 Course Co-Director and Lecturer, Continuing Medical Education course, . Somatization at the Neurology-Psychiatry Interface: Differential Diagnosis & Treatment Considerations, June 27, 2014, New York, NY 2014 Course Director and Lecturer, Continuing Medical Education course, Movement Disorders for the Clinical Practitioner, July 27-31, 2014, Aspen, CO 2015 Course Director and Lecturer, Continuing Medical Education course, Movement Disorders for the Clinical Practitioner, July 26-30, 2015, Aspen, CO 2016 Lecturer, Continuing Medical Education course, 2nd Columbia Psychosomatic Conference, The Neurologist’s Aproach: Making the Dx and engaging the patient in a multidisciplinary Rx, Jan 10, 2016, NYC
POSTDOCTORAL FELLOWS 1980-1982 De-Hua Jiang Tianjin School of Medicine, People's Republic of China 1980-1983 Avinoam Reches Hadassah Medical Center, Jerusalem, Israel 1980-1982 Robert E. Burke Neurological Institute of New York 1980-1981 Stephen Gollomp Boston University 1980-1982 Joyce Ilson Neurological Institute of New York 1981-1983 Mohammed N. Hassan University of Ottawa
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 55
1981-1983 Susan B. Bressman Neurological Institute of New York 1982-1984 Wayne Hening Neurological Institute of New York 1982-1984 Arthur Walters SUNY, Downstate Medical Center 1983-1984 Michael Traub University of London, England 1983-1986 Mitchell Brin Neurological Institute of New York 1984-1985 Andrzej Friedman Medical University of Warsaw, Warsaw, Poland 1984-1985 Lee Voulters University of Western Ontario, London, Ontario, Canada 1985-1987 Heidi Shale Washington University, St. Louis 1985-1988 Paul E. Greene Albert Einstein Medical School 1985-1987 Daniel D. Truong University of South Carolina 1985-1987 Justo Garcia de Yebenes University of Madrid, Spain 1986-1987 Marie St.-Hillaire Montreal Neurological Institute 1986-1988 Un Jung Kang Neurological Institute of New York 1986-1987 Maria-Angeles Mena University of Madrid, Spain 1986-1989 Torbjoern Nygaard Rutgers University School of Medicine 1986-1987 Gianni Pezzoli University of Milano, Italy 1987 Douglas Hobson, observer University of Manitoba, Winnepeg, Canada 1987 Jean Lud Cadet National Institutes of Health 1987-1988 Zygmunt Jamrozic University of Warsaw, Warsaw, Poland 1987-1989 Enrico Fazzini Boston University School of Medicine 1987-1989 Kristina Dahl Duke University School of Medicine 1988 Jane Chan, observer Albert Einstein College of Medicine 1988 Charles Adler University of Pennsylvania 1988-1990 Rolando Diaz-Olivo University of Puerto Rico 1989-1991 Serge Przedborski University of Brussels, Belgium 1989 David Besser, observer State University of New York, Brooklyn 1989-1991 Mark F. Gordon State University of New York, Stony Brook 1989-1991 Ann Hunt University of Arizona, Tucson 1989-1991 Nir Giladi Technion University, Haifa, Israel 1989-1990 Takashi Kujirai Yamagata University, Japan 1989-1991 Kayoko Kujirai Yamagata University, Japan 1989-1990 Vladimir Kostic University of Belgrade, Yugoslavia 1989 Kersti Bruining, observer Albert Einstein College of Medicine 1990 Samson Mebrahtu, observer Downstate Medical Center, Brooklyn 1990-1991 Richard Trosch Yale University 1991-1992 John Rogers Neurological Institute of New York 1991-1993 Beom Jeon University of Minnesota 1991-1992 Iliana Bahena, observer University of Nueva Leon, Monterrey, Mexico
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 56
1991-1993 Hong Jiang Tianjin School of Medicine, People's Republic of China 1991-1993 Uday Muthane University of Bangalore, Bangalore, India 1992-1994 Blair Ford Montreal Neurological Institute of New York 1992-1994 Efrain Perez Syracuse University 1992 Zoe Katsarou, observer Thessaloniki, Greece 1992 Sevasti Bostantjopoulou, observer Thessaloniki, Greece 1992-1993 Bulent Elibol, observer Hacettepe University, Ankara, Turkey 1993 Anna Rita Bentovoglio, observer Catholic University, Rome, Italy 1993 Blanca de la Barera, observer University of Mexico, Mexico City 1993-1995 Timothy Lynch Neurological Institute of New York 1993-1995 Daniel Togasaki Neurological Institute of New York 1993-1995 Elan Louis Neurological Institute of New York 1993-1995 Giselle Petzinger Yale University 1994-1995 Miran Salgado SUNY, Downstate Medical Center 1994-1995 Joanne Wesley SUNY, Stony Brook Medical Center 1994-1995 Adrian Tan National University of Singapore 1995-1997 Alice Rusk Cornell-New York Medical Center 1995-1997 Pushp Raj Kapoor SUNY, Buffalo Medical Center 1995-1997 Sylvain Chouinard University of Montreal 1996-1997 Arif Dalvi University of Cincinnati 1996-1997 Dominic Thyagarajan University of Melbourne, Australia 1996-1997 Rachel Saunders-Pullman Neurological Institute of New York 1996-1998 Danna Jennings Boston University 1996-1999 William Dauer Neurological Institute of New York 1997-1999 Steven Frucht Cornell-New York Medical Center 1997-1999 Helen Chang Neurological Institute of New York 1997-1999 Samer Tabbal University of Arkansas 1998-2001 Maria Sangiorgio University of Rochester 1998-2000 Leonardo Fugoso SUNY, Downstate Medical Center 1998-1999 Melicio Diaz, observer University of Zulia, Maracaibo, Venezuela 1999 Samie Badarny, observer Technion University, Haifa, Israel 1999-2001 Pietro Mazzoni Neurological Institute of New York 1999-2000 Paul Gordon Neurological Institute of New York 1999-2001 Cathy Chuang Neurological Institute of New York 1999-2001 Scott Cooper Neurological Institute of New York 1999-2000 Joo-Hyuk Im, observer Assan Medical Center, Seoul, South Korea 2000 Vincent Mok, observer Prince of Wales Hospital, Hong Kong 2000-2001 Roser Pons Neurological Institute of New York
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 57
2000-2001 Katherine Widnell Johns Hopkins Medical Center 2000-2002 Oren Cohen Hadassah Medical Center, Jerusalem, Israel 2000-2002 Anne Constantino Cornell Medical Center 2000-2003 Judy McDonald Massachusetts General Hospital 2000-2001 Aurelio Hernandez Lain, observer Avalon, Spain 2000-2001 Pablo Mir, observer University of Sevilla, Spain 2001 Carlos Juri, observer Santiago, Chile 2001 Hansjoerg Baezner, observer Mannheim University Hospital, Germany 2001 Mandy Au Yeung, observer Chinese University of Hong Kong 2001-2004 Carlos Portera-Cailleau Massachusetts General Hospital 2001-2003 Daryl Victor Albert Einstein College of Medicine 2001-2003 Panida Piboolnurak Cornell University College of Medicine 2001-2003 Anjan Chatterjee Long Island Jewish Medical Center 2001-2003 Claire Henchcliffe Neurological Institute of New York 2002 Nelson Cheung, observer Queen Elizabeth Hospital, Hong Kong 2002-2003 Pinky Agarwal New Jersey School of Medicine 2002-2005 David Hardesty New Mexico School of Medicine 2002-2005 Melissa Nirenberg University of California San Francisco 2003-2004 Yvette Bordelon Massachusetts General Hospital, Boston 2003-2004 David Jaeger Yale University School of Medicine, New Haven 2003-2005 Michael Pourfar Mount Sinai School of Medicine, New York 2003-2004 Stacy Wu Neurological Institute of New York 2003 Anotonella Caria, observer Università degli studi di Cagliari, Sardinia, Italy 2004-2005 Amrit Grewal University of Virginia, Charlottesville, VA 2004-2006 Samay Jain Cleveland Clinic, Cleveland 2004-2006 Julie Leegwater-Kim Massachusetts General Hospital, Boston 2004-2006 Steven Lo University of Chicago 2004-2006 Lawrence Severt Neurological Institute of New York 2005-2008 Monica Kurtis Madrid University Hospital, Madrid, Spain 2005-2006 Naomi Lubarr Neurological Institute of New York 2005-2007 Shu-Chin (Gene) Hu University of Washington 2005-2007 Anna Conti Washington University in St. Louis 2006-2008 Nina Browner Cleveland Clinic, Cleveland 2006-2008 Victoria Chang Brown University, Providence 2006-2008 Abigail Collins University of California San Francisco 2006-2008 Martin Niethammer Neurological Institute of New York 2006-2008 Kathleen Poston University of California San Francisco 2007-2009 Jonas Yeung, observer Prince of Wales Hospital, Chinese University of Hong Kong.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 58
2007-2010 Roy Alcalay Massachusetts General Hospital, Boston 2007-2009 Rebecca Wolf Gilbert Neurological Institute of New York 2007-2010 Oren Levy Cornell Medical Center 2007-2010 Toni Pearson Neurological Institute of New York 2007-2010 Michael Rotstein Hadassah Medical Center Jerusalem, Israel 2008 Jin Whan Cho, observer Seoul National University Hospital, Seoul, South Korea 2008-2010 Elizaberth Haberfeld Neurological Institute of New York 2008-2010 Nancy Diaz State University of New York, Stony Brook 2008-2009 Leila Maybodi University of Cincinnatti, Cincinnatti, Ohio 2009-2010 Hee-Jin Kim, observer Seoul National University Hospital, Seoul, South Korea 2009-2011 Era Hanspal Thomas Jefferson University, Philadelphia 2009-2011 Sheng-Han Kuo Baylor College of Medicine, Houston 2009-2011 Markos Poulopoulos University of Connecticut 2009-2011 Daniel Schneider University of Massachusetts 2009-2010 Tao Xie Emory University, Atlanta 2010 Anne Chan, observer Prince of Wales Hospital, University of Hong Kong 2010 Christopher Min Neurological Institute of New York 2010-2012 Christopher Hess Neurological Institute of New York 2010-2012 Mary Ann Thenganatt Neurological Institute of New York 2010-2012 Alexander Shtilbans Mount Sinai School of Medicine 2010 Juan Pablo Romero, observer Madrid, Spain 2010 María Azahara Marcos, observer Madrid, Spain 2010 Elvira Garcia, observer Madrid, Spain 2010 Juan García Caldentey, observer Madrid, Spain 2010-2011 Lidia Gomez, observer Madrid, Spain 2010-2011 Francesca Di Biasio, observer Rome, Italy 2011-2012 Liu Wei-Guo, observer NanJing, China 2011 Wang Ming-wei, observer Hebei, China 2011-2013 Tuhin Virmani Washington Univ. St. Louis 2011-2013 Sirinan Tazen University of West Virginia 2011-2013 David Arkadir Hadassah Medical Center, Jerusalem, Israel 2012 Jesus Perez, observer Barcelona, SPAIN 2012 Surat Singmaneesakulchai observer Chulalongkorn University, Bangkok, Thailand 2012 Daniel Prefasi, observer Madrid, SPAIN 2012-2014 Madeleine Sharp University of British Columbia, Vancouver, Canada 2012-2014 Brenton Wright Neurological Institute of New York 2012-2014 Rubén Martinez Mexico City, Mexico 2013 Sonia Benitez, observer Seville, SPAIN
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 59
2013 Harsh Gupta, observer University of Arkansas 2013-2014 David Rydz University of British Columbia, Vancouver, Canada 2013-2015 Daphne Robakis Boston University, Boston, MA 2013-2015 Meir Kestenbaum Tel Aviv University Medical Center, Tel Aviv, Israel 2013-2015 Hiral Shah Neurological Institute of New York 2013-2015 Husain Shaath King Faisal Specialist Hospital, Riyadh,Saudia Arabia 2013 Jihyung Park, observer SOUTH KOREA 2013 Esther Blanco Vicente, observer Madrid, SPAIN 2014 María Pardo Parrado, observer Santiago, SPAIN 2014-2015 Angel Vinuela University of Puerto Rico 2014-2017 Miriam Sklerov Neurological Institute of New York 2014 Margi Patel, observer Gujarat University, INDIA 2014 Carina Franca, observer University of São Paulo, BRAZIL 2014 Adel Mahmoud, observer King Saud bin Abdul Aziz University, Riyadh, SAUDI ARABIA 2014 Vikash Rambhujun, observer Mauritius, AFRICA 2014 Lais Olivera, observer São Paulo University Medical School, BRAZIL 2015 Jui-Tsen Yu, observer National Taiwan University, TAIWAN 2015 Lui-En Lee, observer National Taiwan University, TAIWAN 2015 Mariana Pontalti, observer Hospital Mãe de Deus, Porto Alegre, Brazil 2015 David Jalda, observer Hospital Universitario Puerto de Hierro, Madrid, Spain 2015 Salvador Delis Gomez, observer 12 de Octubre University Hospital, Madrid, Spain 2015 Lei Luo, visiting professor Traditional Chinese Medical Hospital of Zhuji, Zhuji, CHINA 2015-2016 Giulietta Riboldi, observer University of Milan, Fondazione IRCCS “Cà Granda” Ospedale Maggiore Policlinico 2015-2016 Shabbir Merchant Drexel University, Philadelphia 2015-2017 Lan Luo Baylor College of Medicine, Houston 2016 Diego Pinheiro, observer University of Sao Paolo, Sao Paolo, Brazil 2016 Sven Redko, observer Minsk, Belarus 2016 Aijun Ma, observer Qingdao University, Qingdao, China 2016-2018 Sarah O’Shea University of Iowa Medical Center 2016-2018 Christine Kim Neurological Institute of New York 2016-2018 Devin Hall Western University, London, ON, Canada 2016-2018 Deepak Gupta Cleveland Clinic 2016 Christian Perez Lohman Instituto Mexicano del Seguro Social, Mexico City 2016-2017 Massimo Marano, observer Università Campus Bio-Medico di Roma, Rome, Italy 2017 Junfeng Su, Visiting Professor Jingzhou Central Hospital, Jingzhou, China 2017-2018 Krithi Irmady Yale New Haven Hospital, New Haven, CT
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 60
2017 Victor Blanco, observer 12 de Octubre University Hospital, Madrid, Spain 2017 Goun Je, observer Kyung Hee University School of Medicine, Seoul, Korea 2017 Lingjing Jin, visiting professor Shanghai Tongji Hospital, Shanghai, China 2017 Mohamed Elkasaby, observer Paracelsus Klinik, Osnabrueck., Germany 2017 Chih-chun Lin, visiting resident Methodist Hospital, Houston, TX., 2018 Tamara Gonzalez-Fernandez, observer Hospital Universitario de Canarias, Spaun., 2018 Ali H Abusrair, observer King Faisal Specialist Hospital & Research Centre, Riyadh, SAUDI ARABISA 2018 Marcelo Duarte Dias Mendonça de Sousa, observ Centro Hospitalar de Lisboa Ocidental, Lisbon, PORTUGAL 2018-2020 Lynda Nwabuobi NYU 2018-2020 Kimberly Kwei Mount Sinai Medical Center 2018-2020 Leila Montaser-Kouhsari Mount Sinai Medical Center 2018 Nadia Gandarilla, observer National Institute of Neurology and Neurosurgery, Mexico City, Mexico 2018 Yun Jik Park, observer Asam Medical Center, Seoul, South Korea
MEDICAL STUDENT RESEARCH IN THE LABORATORY
1974 Harvey Makadon Columbia University College of Physicians and Surgeons Edward Lane Columbia University College of Physicians and Surgeons
1975 Cheryl Hutt Columbia University College of Physicians and Surgeons Bruce Stein Columbia University College of Physicians and Surgeons
1976 David Sahar Columbia University College of Physicians and Surgeons Judith Glassgold Harvard University Kenneth Tellerman Johns Hopkins University
1977 Richard Comi Harvard University Alan Astrow Yale University
1978 Emile Heisiger New York Medical College Eric Wasserman Swarthmore College Syma Suriff Barnard College
1979 Ronald Strobel Columbia University College of Physicians and Surgeons Loretta Cody Barnard College
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 61
BIBLIOGRAPHY OF STANLEY FAHN, MD
PAPERS PUBLISHED
1. Rowland LP, Fahn S, Schotland DL. McArdle’s disease: Hereditary myopathy due to absence of muscle phosphorylase. Arch Neurol 1963;9:325-342.
2. Albers RW, Fahn S, Koval GJ. The role of sodium ions in the activation of Electrophorus electric organ adenosine triphosphatase. Proc Natl Acad Sci 1963;50:474-481.
3. Rowland LP, Fahn S, Hirschberg E, Harter DH. Myoglobinuria. Arch Neurol 1964;10:537-562.
4. Fahn S, Albers RW, Koval GJ. Electrophorus adenosine triphosphatase: Appearance of a sodium-activated exchange after N-ethyl maleimide. Science 1964;145:283-284.
5. Fahn S, Albers RW, Koval GJ. Thin-layer chromatography for the separation of nucleotides. Anal Biochem . 1965;10:468-471.
6. Fahn S, Koval GJ, Albers RW. Sodium-potassium-activated adenosine triphosphatase in Electrophorus electric organ. I. An associated sodium-activated transphosphorylation. J Biol Chem 1966;241:1882-1889.
7. Fahn S, Hurley ME, Koval GJ, Albers RW. Sodium-potassium-activated adenosine triphosphatase in Electrophorus electric organ. II. Effects of N-ethyl maleimide and other sulphydryl reagents. J Biol Chem 1966;241:1890-1895.
8. Fahn S, Cote LJ. Regional distribution of gamma-aminobutyric acid (GABA) in the brain of the Rhesus monkey. J Neurochem 1968;15:209-213.
9. Fahn S, Cote LJ. Regional distribution of choline acetylase in the brain of the Rhesus monkey. Brain Res 1968;7:323-325.
10. Fahn S, Koval GJ, Albers RW. Sodium-potassium-activated adenosine triphosphatase in Electrophorus electric organ. V. Phosphorylation by AT32P. J Biol Chem 1968;243:1993-2002.
11. Fahn S, Cote LJ. Regional distribution of sodium-potassium-activated adenosine triphosphatase in the brain of the Rhesus monkey. J Neurochem 1968;15:433-436.
12. Fahn S. Correlation of sodium-potassium-activated adenosine triphosphatase with acetyl cholinesterase of the Electrophorus electric organ. Experientia 1968;24:544-545.
13. Cote LJ, Fahn S. Some aspects of the biochemistry of the substantia nigra of the Rhesus. In Barbeau A. Brunette J-R. eds. Progress in Neuro-Genetics. Amsterdam, Excerpta Medica Foundation, International Congress Series No. 175, 1969;311-317.
14. Fahn S, Rodman JS, Cote LJ. Association of tyrosine hydroxylase with synaptic vesicles in bovine caudate nucleus. J Neurochem 1969;16:1293-1300.
15. Schwarz GA, Fahn S: Newer medical treatment in parkinsonism. Med Clin No Am 1970;54:773-785.
16. O'Brien CP, DiGiacomo JN, Fahn S, Schwarz GA: Mental effects of high dosage L-dopa. Arch Genl Psychiat 1971;24:61-64.
17. DiGiacomo JN, Fahn S, Glass JB, Westlake RJ. A case with Gilles de la Tourette’s syndrome : Recurrent refractoriness to haloperidol and unsuccessful treatment with L-dopa. J Nerv Ment Dis 1971 ;152 :115-117.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 62
18. Fahn S, Craddock G, Kumin G. Acute toxic psychosis from suicidal overdosage of amantadine. Arch Neurol 1971;25:45-48.
19. Fahn S, Libsch LR, Cutler RW: Monoamines in the human neostriatum: Topographic distribution in normals and in Parkinson's disease and their role in akinesia, rigidity, chorea, and tremor. J Neurol Sci 1971;14:427-455.
20. Fahn S, Prasad ALN, Delesie R. A reliable and simple method for the simultaneous determination of dopa and 3-O-methyldopa in plasma and brain. Anal Biochem 1972;46:557-575.
21. Fahn S: Differential diagnosis of tremors. Med Clin No Am 1972;56:1363-1375.
22. Fahn S: Treatment of choreic movements with perphenazine. Dis Nerv Syst 1972;33:653-658.
23. Fahn S, Greenberg J. Striatonigral degeneration. Trans Am Neurol Assoc 1972;97:275-277.
24. Fahn S, David E. Oral-facial-lingual dyskinesia due to anticholinergic medication. Trans Am Neurol Assoc 1972;97:277-279.
25. Fahn S, Mishkin MM, Hoffman RR. Pharmacologic and radiologic investigation in Huntington’s chorea. Adv Neurol 1973;1:581-597.
26. Brait K, Fahn S, Schwarz GA. Sporadic and familial parkinsonism and motor neuron disease. Neurology 1973;23:990-1002.
27. Prasad ALN, Fahn S. Fluormetric determination of homovanillic acid in the presence of other acid metabolites of catecholamines. J Neurochem 1973;21:1551-1554.
28. Cook DG, Fahn S, Brait KA. Chronic manganese toxicity. Arch Neurol 1974;30:59-64.
29. Prasad ALN, Fahn S. 3-O-Methyl metabolites of catecholamines: automated fluormetric assay and their plasma levels in patients receiving levodopa and carbidopa. Biochem Med 1974;9:136-147.
30. Fahn S. "On-off" phenomenon with levodopa therapy in parkinsonism: Clinical and pharmacologic correlations and the effect of intramuscular pyridoxine. Neurology 1974;24:431-441.
31. Earnest MP, Fahn S, Karp JH, Rowland LP: Normal pressure hydrocephalus and hypertensive cerebrovascular disease. Arch Neurol 1974; 31:262-266.
32. Prockop L, Fahn S, Barbour P. Homovanillic acid: entry rate kinetics for transfer from plasma to cerebrospinal fluid. Brain Res 1974;80:435-442.
33. Fahn S, Isgreen WP: Long-term evaluation of amantadine and levodopa combination in parkinsonism by double-blind crossover analyses. Neurology 1975;25:695-700.
34. Fahn S, Snider SR, Prasad ALN, Lane E, Makadon H. Normalization of brain serotonin by L-tryptophan in levodopa-treated rats. Neurology 1975;25:861-865
35. Snider SR, Hutt C, Stein B, Fahn S. Increase in brain serotonin produced by bromocriptine. Neurosci Lett 1975;1:237-241
36. Prasad ALN, Fahn S, Isgreen WP: Dopamine: A sensitive automated assay and examples of levodopa therapy. Biochem Med 1975; 13: 24-32.
37. Isgreen WP, Fahn S. Treatment of Parkinson’s disease. In Conn HF, ed. Current Therapy 1976. Philadelphia, Saunders, 1976;718-722.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 63
38. Snider SR, Hutt C, Stein B, Prasad ALN, Fahn S. Correlation of behavioral inhibition or excitation produced by bromocriptine with changes in brain catecholamine turnover. J Pharm Pharmac 1976;28:563-566.
39. Fahn S, Cote JL. Stability of enzymes in post-mortem rat brain. J Neurochem 1976;26:1039-1042.
40. Snider SR, Fahn S, Isgreen WP, Cote LJ. Primary sensory symptoms in parkinsonism. Neurology 1976;26:423-429
41. Fahn S, Eldridge R. Definition of dystonia and classification of the dystonic states. In Dystonia. Adv Neurol Vol.14:. New York, Raven Press, 1976;1-5.
42. Isgreen WP, Fahn S, Barrett RE, Snider SR, Chutorian AM. Carbamazepine in torsion dystonia. Adv Neurol 1976;14:411-416.
43. Fahn S. Medical treatment of movement disorders. In Davis FA, ed: Neurological Reviews 1976. Minneapolis; American Academy of Neurology, 1976:72-106.
44. Isgreen WP, Chutorian AM, Fahn S. Sequential parkinsonism and chorea following 'mild' influenza. Trans Am Neurol Assoc 1976;101:56-60.
45. Snider SR, Miller C, Prasad ALN, Jackson V, Fahn S. Is dopamine a neurohormone of the adrenal medulla? Studies with morphine stimulation. Naunyn-Schmiedeberg’s Arch Pharmacol 1977;297:17-22. .
46. Snider SR, Sahar D, Prasad ALN, Fahn S. Changes in adrenal dopamine concentration after metyrapone or ACTH administration: implications for the in vivo regulation of dopamine beta-hydroxylase by glucocorticoids. Life Sciences 1977;20:1077-1086.
47. Hutt C, Snider SR, Fahn S. Interaction of bromocriptine and levodopa. Biochemical basis for an improved treatment of parkinsonism. Neurology 1977;27:505-510.
48. Johnson WG, Fahn S: Treatment of vascular hemiballism and hemichorea. Neurology 1977;27:631-636.
49. Fahn S. New approaches in the management of hyperkinetic movement disorders. Adv Exp Med Biol 1977;90:157-173.
50. Shoulson I, Calne E, Fahn S, Kobayashi R, Koknen E, Sax D, Weingartner H, Wexler N. Clinical care of the patient and family with Huntington’s disease. In Report of the Commission for Control of Huntington’s Disease and Its Consequences. DHEW (NIH) Publication, Vol 2, U.S. Govt Printing Office, 1977;424-456.
51. Fahn S, Calne DB: Considerations in the management of parkinsonism. Neurology 1978;28:5-7.
52. Lesser RP, Fahn S: Dystonia: A disorder often misdiagnosed as a conversion reaction. Am J Psychiat 1978;153:349-452,
53. Mayeux R, Fahn S. Strokes and ulcerative colitis. Neurology 1978;28:5-7.
54. Shoulson I, Fahn S. Huntington disease: Clinical care and evaluation. Neurology 1979;29:1-3.
55. Fahn S, Comi R, Snider SR, Prasad ALN: Effect of a catechol-O-methyl transferase inhibitor, U-0521, with levodopa administration. Biochem Pharmacol 1979;28:1221-1225.
56. Fahn S, Cote LJ, Snider SR, Barrett RE, Isgreen WP: Role of bromocriptine in the treatment of parkinsonism. Neurology 1979;29:1077-1083.
57. Lesser RP, Fahn S, Snider SR, Cote LJ, Isgreen WP, Barrett RE: Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology 1979;29:1253-1260.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 64
58. Fahn S, Barrett RB: Increase of parkinsonian symptoms as a manifestation of levodopa toxicity. Adv Neurol 1979;24:451-459.
59. Sharma JN, Snider SR, Fahn S, Heisiger E. Anoxic myoclonus in the rat. In Fahn S, Davis JN, Rowland LP, eds. Cerebral Hypoxia and Its Consequences. Adv Neurol 1979;26:181-189. New York, Raven Press.
60. Tellerman K, Astrow A, Fahn S, Snider S, Snider R, Glassgold J: Cerebellar control of catecholaminergic activities. Implications for drug therapy of movement disorders. Int J Neurol 13: 135-155, 1979.
61. Fahn S, Barbeau A, Calne D, Markham C, Paulson G. Therapeutic controversies in movement disorders. Trans Am Neurol Assoc 1980;104:31-51.
62. Fahn S, Mayeux R. Unilateral Parkinson's disease and contralateral tardive dyskinesia: A unique case with successful therapy that may explain the pathophysiology of these two disorders. J Neural Transm Suppl 16:179-185, 1980.
63. Fahn S, Cote LJ, Barrett RE, Snider SR: Further experiences with low doses of bromocriptine in Parkinson's disease. In: Ergot Compounds and Brain Function. Advances in Biochemical Psychopharmacology, Vol 23, Goldstein M, Calne DB, Lieberman A, Thorner MO, eds: New York, Raven Press, 1980, pp 255-260.
64. Jankovic J, Fahn S: Physiologic and pathologic tremors: Diagnosis, mechanism and management. Ann Int Med 93: 460-465, 1980.
65. Prasad ALN, Fahn S: GABA levels in CSF of neurological patients by high performance liquid chromatography. Brain Res Bull 5:Suppl 2: 737-740, 1980.
66. Burke RE, Fahn S, Gold AP: Delayed-onset dystonia in patients with 'static' encephalopathy. J Neurol Neurosurg Psychiat 43: 789-797, 1980.
67. Fahn S: Tics, tremors and other common movement disorders: When to use drugs. Drug Therapy 10: 47-56, 1980.
68. Floud A, Fahn S: L-DOPA uptake by human red blood cells. Biochim Biophys Acta 645:165-169, 1981.
69. Burke RE, Fahn S, Mayeux R, Weinberg H, Louis K, Willner J. Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with HD. Neurology 1981;31:1022-1026.
70. Reches A, Jiang D, Fahn S: Use of a catechol O-methyltransferase inhibitor to enhance central action of L-dopa. In: Function and Regulation of Monoamine Enzymes: Basic and Clinical Aspects. Usdin E, Weiner N, Youdim MBH: eds, 1982, pp 683-689.
71. Matison R, Mayeux R, Rosen J, Fahn S: 'Tip-of-the-tongue' phenomenon in Parkinson disease. Neurology 32: 567-570, 1982.
72. Reches A, Wagner HR, Jiang D, Jackson V, Fahn S: The effect of chronic L-DOPA administration on supersensitive pre- and postsynaptic dopaminergic receptors in rat brain. Life Sci 31: 37-44, 1982.
73. Prasad ALN, Fahn S: A semiautomated method for the rapid determination of dopa: Comparison of plasma and erythrocyte dopa con centration in levodopa-treated patients. Biochem Med 27: 297- 304, 1982.
74. Fahn S: Dystonia: Recognizing the neurologic signs. Consultant 22: No. 7: 99-111, 1982.
75. Reches A, Mielke LR, Fahn S: 3-O-Methyldopa inhibits rotations induced by levodopa in rats after unilateral destruction of the nigrostriatal pathway. Neurology 32: 887-888, 1982.
76. Reches A, Jiang D, Fahn S: Catechol-O-methyltransferase inhibition by U-0521 increases striatal
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 65
utilization of levodopa. Naunyn-Schmiedeberg's Arch Pharmacol 320: 34-37, 1982.
77. Reches A, Fahn S: 3-O-Methyldopa blocks dopa metabolism in rat corpus striatum. Ann Neurol 12: 267-271, 1982.
78. Mayeux R, Fahn S: Paroxysmal dystonia choreoathetosis in a patient with familial ataxia. Neurology 32: 1184-1186, 1982.
79. Fahn S: The clinical spectrum of motor tics. Adv Neurol 35:341-344, 1982.
80. Fahn S: A case of post-traumatic tic syndrome. Adv Neurol 35:349-350, 1982.
81. Reches A, Jiang D-H, Fahn S: Effect of 3',4'-dihydroxy-2-methyl-propriophenone (U-0521) on catechol-O-methyltransferase activity and on DOPA accumulation in rat red blood cells and corpus striatum. Biochem Pharmacol 31:3415-3418, 1982.
82. Reches A, Wagner H, Jackson V, Fahn S: Chronic lithium administration has no effect on haloperidol-induced supersensitivity of pre- and postsynaptic dopamine receptors in rat brain. Brain Res 246: 172-177, 1982.
83. Burke RE, Fahn S, Wagner HR, Smeal M: Chlorpromazine methiodide-induced barrel rotation: an antimuscarinic effect. Brain Res 250: 133-142, 1982.
84. Burke RE, Fahn S, Jankovic J, Marsden CD, Lang AE, Gollomp S, Ilson J: Tardive dystonia. Late-onset and persistent dystonia caused by antipsychotic drugs. Neurology 1982;32:1335-1346.
85. Fahn S: Torsion dystonia: Clinical spectrum and treatment. Seminars in Neurology 2:316-323, 1982.
86. Fahn S: Pathophysiological mechanisms of adverse effects from levodopa therapy. Rinsho Shinkeigaku (Clinical Neurology) 22:1088-1091, 1982.
87. Ilson J, Fahn S, Mayeux R, Cote L: Pergolide treatment in parkinsonism. In: Calne DB, Horowski R, McDonald RJ, Wuttke W, eds: Lisuride and other dopamine agonists. New York, Raven Press, 1983, pp 443-451.
88. Ilson J, Fahn S, Mayeux R, Cote LJ, Snider SR: Pergolide treatment in parkinsonism. Adv Neurol 37: 85-94, 1983.
89. Burke RE, Fahn S: Double-blind evaluation of trihexyphenidyl in dystonia. Adv Neurol 37: 189-192, 1983.
90. Gollomp SM, Fahn S, Burke RE, Reches A, Ilson J. Therapeutic trials in Meige syndrome. Adv Neurol 1983;37:207-213
91. Fahn S: Long-term treatment of tardive dyskinesia with presynaptically acting dopamine-depleting agents. Adv Neurol 37:267- 276, 1983.
92. Burke RE, Fahn S: Electroencephalographic studies of chlorpromazine methiodide and somatostatin-induced barrel rotation in rats. Exp Neurol 79:704-713, 1983.
93. Reches A, Burke RE, Jiang D-H, Wagner HR, Fahn S: Neurotensin interacts with dopaminergic neurons in rat brain. Peptides 4:43-48, 1983.
94. Fahn S: Treatment of tardive dyskinesia: Use of dopamine-depleting agents. Clin Neuropharm 6: 151-158, 1983.
95. Jiang D-H, Reches A, Fahn S: Normal erythrocyte uptake of L- DOPA in Parkinson's, Huntington's, and related diseases. Neurology 33: 793796, 1983.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 66
96. Reches A, Hassan MN, Jackson V, Fahn S: Lithium attenuates dopamine depleting effects of reserpine and tetrabenazine but not that of alpha methyl-p-tyrosine. Life Sci 33:157-160, 1983.
97. Reches A, Hassan MN, Jackson V, Fahn S: Lithium interferes with reserpine-induced dopamine depletion. Ann Neurol 13: 671- 673, 1983.
98. Reches A, Burke RE, Kuhn CM, Hassan MN, Jackson VR, Fahn S: Tetrabenazine, an amine-depleting drug, also blocks dopamine receptors in rat brain. J Pharmacol Exp Ther 225: 515-521, 1983.
99. Reches A, Wagner HR, Jackson V, Yablonskaya-Alter E, Fahn S: Dopamine receptors in the denervated striatum: further supersensitvity by chronic haloperidol treatment. Brain Res 275: 183-185, 1983.
100. Fahn S: High dosage anticholinergic therapy in dystonia. Neurology 33: 1255-1261,1983.
101. Ilson J, Bressman S, Fahn S: Current concepts in Parkinson's disease. Hospital Medicine 19:33-56, 1983.
102. Burke RE, Fahn S: Studies of somatostatin-induced barrel rotation in rats. Regulatory Peptides 7: 207-220, 1983.
103. Burke RE, Fahn S: Chlorpromazine methiodide acts at the vestibular nuclear complex to induce barrel rotation in the rat. Brain Research 288: 273-281, 1983.
104. Antunes JL, Fahn S, Cote L: Normal pressure hydrocephalus and Parkinson's disease. J Neural Transm Suppl 19: 225-231, 1983.
105. Reches A, Fahn S: Catechol-O-methyl transferase and Parkinson's disease. Adv Neurol 40:171-179, 1984.
106. Ilson J, Fahn S, Cote L: Painful dystonic spasms in Parkinson's disease. Adv Neurol 40:395-398, 1984.
107. Stern Y, Mayeux R, Ilson J, Fahn S, Cote L: Pergolide therapy for Parkinson's disease: Neurobehavioral changes. Neurology 34: 201-204, 1984.
108. Fahn S, Bressman SB: Should levodopa therapy for parkinsonism be started early or late? Evidence against early treatment. Canad J Neurol Sci 11: 200-206, 1984.
109. Jiang D-H, Reches A, Wagner HR, Fahn S: Biochemical and behavioral evaluation of pergolide as a dopamine agonist in the rat brain. Neuropharmacology 23: 295-301, 1984.
110. Reches A, Jackson-Lewis V, Fahn S: Lithium does not interact with haloperidol in the dopaminergic pathways of the rat brain. Psychopharmacology 82: 330-334, 1984.
111. Bodnar RJ, Kordower JH, Reches A, Wallace MM, Fahn S: Reductions in pain thresholds and morphine analgesia following intracerebroventricular parachlorophenylalanine. Pharmacol Biochem Behav 21: 79-84 , 1984.
112. Reches A, Wagner HR, Barkai AI, Jackson V, Yablonskaya-Alter E, Fahn S: Electroconvulsive treatment and haloperidol: effects on pre- and postsynaptic dopamine receptors in rat brain. Psychopharmacology 83: 155-158, 1984.
113. Fahn S: The varied clinical expressions of dystonia. Neurologic Clinics. 2: 541-554, 1984.
114. Fahn S, Jankovic J: Practical management of dystonia. Neurologic Clinics. 2: 555-569, 1984.
115. Reches A, Wagner HR, Jackson-Lewis V, Yablonskaya-Alter E, Fahn S: Chronic levodopa or pergolide administration induces down- regulation of dopamine receptors in the denervated striatum. Neurology 34: 1208-1212, 1984.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 67
116. Walters A, Jackson-Lewis V, Sadik A, Fahn S: Failure to produce chronic parkinsonism with MPTP in rodents. Biogenic Amines 1: 297-302, 1984.
117. Walters A, Jackson-Lewis V, Fahn S: Little effect of dimethyl sulfoxide on blood-brain barrier to dopamine. Experientia 40: 859-861, 1984.
118. Bressman SB, Fahn S, Falk C, Allen FH Jr, Suciu-Foca N: Genetic linkage analysis in primary torsion dystonia. Neurology 34: 1490-1493, 1984.
119. Fahn S: Clinical features and diagnosis of Huntington's disease, tardive dyskinesia and dystonias. In: Teychenne PF, ed: Neurotransmitters and Neuropeptides, Excerpta Medica Asia Pacific Congress Series No. 32: 34-40, 1984.
120. Fahn S: Cerebellar tremor: clinical aspects. In: Findley LJ, Capiledeo R, eds: Movement Disorders: Tremor., New York, Oxford University Press, 1984; 355-363.
121. Fahn S: Atypical tremors, rare tremors, and unclassified tremors. In: Findley LJ, Capiledeo R, eds: Movement Disorders: Tremor., New York, Oxford University Press, 1984; 431-443.
122. Crider AM, Hemdi TF, Hassan MN, Fahn S: Synthesis and dopaminergic activity of 3-(3,4-dihydroxy)phenyl-1-n-propylpyrrolidine hydrobromide. J Med Chem 73: 1585-1587, 1984.
123. Burke RE, Fahn S, Marsden CD, Bressman SB, Moskowitz C, Friedman J. Validity and reliability of a rating scale for the primary torsion dystonias. Neurology 1985;35:73-77.
124. Maltese WA, Bressman S, Fahn S, DeVivo DC: Acetylcholinesterase activity in patients with torsion dystonia. Measurement in erythrocyte membranes. Arch Neurol 42: 154-155, 1985.
125. Burke RE, Fahn S: Choline acetyltransferase activity of the principal vestibular nuclei of rat, studied by micropunch technique. Brain Res 328:196-199, 1985.
126. Fahn S: A therapeutic approach to tardive dyskinesia. J Clin Psychiat 46: 19-24, 1985.
127. Burke RE, Reches A, Traub MM, Ilson J, Swash M, Fahn S: Tetrabenazine induces acute dystonic reactions. Ann Neurol 1985;17:200-202.
128. Burke RE, Fahn S: Serum trihexyphenidyl levels in the treatment of torsion dystonia. Neurology 35:1066-1069, 1985.
129. Barkai AI, Kowalik S, Reches A, Cooper TB, Fahn S: Attenuation by electroshock treatment of the haloperidol-induced rise in the binding of 3H-imipramine to rat brain membranes. Psychopharmacolgy 86:400:403, 1985
130. Reches A, Liu KP, Karpiak SE, Fahn S, Cooper TB, Suckow R, Jackson V, Tamir H: Serotonin depletion induced by reserpine is attenuated by prophylactic administration of lithium. Eur J Pharmacol 113:225-231, 1985.
131. Burke RE, Fahn S: Pharmacokinetics of trihexyphenidyl after short-term and long-term administration to dystonic patients. Ann Neurol 18:35-40, 1985.
132. Wagner RH, Reches A, Fahn S: Clonazepam-induced up-regulation of serotonin-1 binding sites in frontal cortex of rat. Neuropharmacology 24:953-956, 1985.
133. Reches A, Wagner HR, Jackson-Lewis V, Fahn S: Presynaptic inhibition of dopamine synthesis in rat striatum: effects of chronic dopamine depletion and receptor blockade. Brain Research 347:346-349, 1985.
134. Traub M, Wagner HR, Hassan M, Jackson-Lewis V, Fahn S: The effects of chronic bromocriptine
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 68
treatment on behavior and dopamine receptor binding in the rat striatum. Eur J Pharmacol 118:147-154, 1985.
135. Fahn S: Blepharospasm: a focal dystonia. Advances in Ophthalmic Plastic Reconstructive Surgery. 1985;4:87-91.
136. Fahn S: Rating scales for blepharospasm. Advances in Ophthalmic Plastic Reconstructive Surgery. 1985;4:97-101.
137. Fahn S, Hening WA, Bressman S, Burke R, Ilson J, Walters A: Long-term usefulness of baclofen in the treatment of essential blepharospasm. Advances in Ophthalmic Plastic Reconstructive Surgery. 1985;4:219-226.
138. Reches A, Jackson-Lewis V, Fahn S: DL-Threo-DOPS as a precursor of norepinephrine. Naunyn-Schmiedeberg's Arch Pharmacol 331:202-208,1985.
139. Burke RE, Fahn S: The effect of selective lesions on vestibular nuclear complex choline acetyltransferase in the rat. Brain Res 360:172-182, 1985.
140. Blitzer A, Lovelace RE, Brin MF, Fahn S, Fink ME: Electromyographic findings in focal laryngeal dystonia (spastic dysphonia). Ann Oto Rhino Laryngol 94:591-594, 1985.
141. Traub M, Wagner HR, Hassan M, Jackson-Lewis V, Fahn S: Effects of chronic bromocriptine treatment on behavior and on dopamine receptor binding in the rat striatum. In Fahn S, Marsden CD, Jenner P, Teychenne P, eds: Recent Developments in Parkinson's Disease. New York, Raven Press, 1986. pp 205-214.
142. Reches A, Traub M, Wagner HR, Jackson-Lewis V, Fahn S: Plasticity of rat striatal dopamine receptor. In Fahn S, Marsden CD, Jenner P, Teychenne P, eds: Recent Developments in Parkinson's Disease. New York, Raven Press, 1986. pp 229-238.
143. Bressman S, Fahn S, Eisenberg M, Brin M, Maltese W: Biotin-responsive encephalopathy with myoclonus, ataxia, and seizures. In: Fahn S, Marsden CD, Van Woert MH, eds: Myoclonus. Adv Neurol, vol. 43, New York, Raven Press, 1986. 119-125.
144. Fahn S: Newer drugs for posthypoxic action myoclonus: Observations from a well-studied case. In: Fahn S, Marsden CD, Van Woert MH, eds: Myoclonus. Adv Neurol, vol. 43, New York, Raven Press, 1986. pp 197-199.
145. Bressman S, Fahn S: Essential myoclonus. In: Fahn S, Marsden CD, Van Woert MH, eds: Myoclonus. Adv Neurol, vol. 43, New York, Raven Press, 1986. pp 287-294.
146. Walters A, Hening W, Cote L, Fahn S: Dominantly inherited restless legs with myoclonus and periodic movements of sleep: a syndrome related to the endogenous opiates? In: Fahn S, Marsden CD, Van Woert MH, eds: Myoclonus. Adv Neurol, vol. 43, New York, Raven Press, 1986. pp 309-319.
147. Wagner RH, Yablonskaya E, Reches A, Fahn S: Clonazepam-induced up-regulation of serotonin-1 and serotonin-2 binding sites in rat frontal cortex. In Fahn S, Marsden CD, Van Woert MH, eds: Myoclonus. Adv Neurol, vol. 43, New York, Raven Press, 1986. pp 645-651.
148. Burke RE, Fahn S, Marsden CD. Torsion dystonia: A double-blind, prospective trial of high-dosage trihexyphenidyl. Neurology 1986;36:160-164.
149. Hassan MN, Reches A, Kuhn C, Higgins D, Fahn S: Pharmacologic evaluation of dopaminergic receptor blockade by metoclopramide. Clin Neuropharmacol 9:71-78, 1986.
150. Friedman A, Fahn S: Spontaneous remissions in spasmodic torticollis. Neurology 36:398-400, 1986.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 69
151. Shale H, Fahn S, Mayeux R: Tics in a patient with Parkinson's disease. Movement Disorders 1:79-83, 1986.
152. Breakefield XO, Bressman SB, Kramer PL, Ozelius L, Moskowitz C, Tanzi R, Brin MF, Hobbs W, Kaufman D, Tobin A, Kidd KK, Fahn S, Gusella JF: Linkage analysis in a family with dominantly-inherited torsion dystonia: Exclusion of the pro-opiomelanocortin and glutamic acid decarboxylase genes and other chromosomal regions using DNA polymorphisms. J Neurogenetics 3:159-175, 1986.
153. Hassan MN, Higgins D, Traub M, Fahn S: Chronic treatment with bromocriptine induces behavioral supersensitivity in rats. Life Sci 19:513-518, 1986.
154. Walters A, Hening W, Chokroverty S, Fahn S: Opioid responsiveness in patients with neuroleptic-induced akathisia. Mov Disord 1:119-127, 1986.
155. Hening W, Walters A, Kavey N, Gidro-Frank S, Cote LJ, Fahn S. Dyskinesias while awake and periodic movements in sleep in restless legs syndrome: Treatment with opioids. Neurology 1986;36:1363-1366.
156. Mayeux R, Stern Y, Herman A, Greenbaum L, Fahn S: Correlates of early disability in Huntington's disease. Ann Neurol 20:727-731, 1986.
157. Burke RE, Brin MF, Fahn S, Bressman SB, Moskowitz C: An analysis of the clinical course of non-Jewish autosomal dominant torsion dystonia. Mov Disord 1:163-178, 1986.
158. Kang UJ, Burke RE, Fahn S: Natural history and treatment of tardive dystonia. Movement Disorders 1:193-208, 1986.
159. Traub M, Reches A, Wagner HR, Fahn S: Reserpine-induced up-regulation of dopamine D2 receptors in the rat striatum is enhanced by denervation but not by chronic receptor blockade. Neurosci Lett 70:245-249, 1986.
160. Fahn S: Generalized dystonia: concept and treatment. Clin Neuropharmacol 9:(Suppl 2):S37-S48, 1986.
161. Fahn S, Lee RG. What Is It? Case 1, 1986. A young man with tremor. Mov Disord 1986;1:275-280.
162. Fahn S, Calne DB. What Is It? Case 2, 1986. A young woman with seizures, myoclonus, and ataxia. Mov Disord 1986;1:281-287.
163. Fahn S, Lang AE, Jankovic J. What Is It? Case 3, 1986. A man complaining of chronic hiccups. Mov Disord 1986;1:289-297.
164. Fahn S, Koller WC, Hallett M. What Is It? Case 4, 1986. A woman with right arm movements. Mov Disord 1986;1:299-308.
165. Fahn S, Jankovic J, Lang AE. What Is It? Case 5, 1986. A man with oral-buccal-lingual dyskinesia. Mov Disord 1986;1:309-318.
166. Shale HM, Fahn S: Management of fluctuations in Parkinson's disease. Internal Medicine for the Specialist 8:127-134, 1987.
167. Tschappat KD, Crider AM, Hassan MN, Fahn S: Synthesis and dopaminergic activity of trans-4-methyl-3-phenylpyrrolidines. J Heterocyclic Chem 24:673-676, 1987.
168. Rutledge JN, Hilal SK, Silver AJ, Defendini R, Fahn S: Study of movement disorders and brain iron by MR. Am J Neuroradiol 8:397-411, 1987.
169. de Yebenes JG, Fahn S, Lovelle S, Jackson-Lewis V, Jorge P, Mena MA, Reiriz J, Bustos JC, Magarinos C, Martinez A. Continuous intracerebroventricular infusion of dopamine and dopamine agonists through a
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 70
totally implanted drug delivery system in animal models of Parkinson's disease. Mov Disord 2:143-158, 1987.
170. Lange DJ, Brin MF, Warner CL, Fahn S, Lovelace RE. Distant effects of local injection of botulinum toxin. Muscle Nerve 1987;10:552-555,
171. Gollomp SM, Fahn S: Transient dystonia as a complication of varicella. J Neurol Neurosurg Psychiatry 50:1228-1229, 1987.
172. de Yebenes JG, Fahn S: Nuevas alternativas terapeuticas en la enfermedad de Parkinson. Neurologia 2:199-201, 1987.
173. Kramer PL, Ozelius L, Gusella JF, Fahn S, Kidd KK, Breakefield XO. Exclusion of autosomal dominant dystonia gene from large regions of chromosomes 11p, 13q and 21q by multi-point linkage analysis. Genetic Epidemiology 4:377-386, 1987.
174. Brin MF, Fahn S, Moskowitz C, Friedman A, Shale HM, Greene PE, Blitzer A, List T, Lange D, Lovelace RE, McMahon D: Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord 2:237-254, 1987.
175. de Yebenes JG, Fahn S, Jackson-Lewis V, Mena M. The effect of intracerebroventricular infusion of (+)-4-propyl-9-hydroxynaphthoxacine (PHNO) through a totally implanted drug delivery system in rats with dopamine deficiency. Mov Disord 2:291-299, 1987.
176. Shale HM, Fahn S, Koller WC, Lang AE. What is it? Case 1, 1987: Unusual tremors, bradykinesia, and cerebral lucencies. Mov Disord 2:321- 338, 1987.
177. Cadet JL, Kuyatt B, Fahn S, De Souza EB. Differential changes in [125-I]- LSD labeled 5-HT-2 serotonin receptors in discrete regions of brain in the rat model of persistent dyskinesias induced by iminodipropionitrile (IDPN): evidence from autoradiographic studies. Brain Res 437:383-386, 1987.
178. Rutledge JN, Hilal SK, Schallert T, Silver AJ, Defendini RD, Fahn S. Magnetic resonance imaging of parkinsonism. In Fahn S, Marsden CD, Calne DB, Goldstein M, eds: Recent Developments in Parkinson's Disease, Vol. 2. Florham Park, NJ: Macmillan Healthcare Information, 1987. pp 123-133.
179. Fahn S, Elton RL, Members of the UPDRS Development Committee. The Unified Parkinson's Disease Rating Scale. In Fahn S, Marsden CD, Calne DB, Goldstein M, eds: Recent Developments in Parkinson's Disease, Vol. 2. Florham Park, NJ: Macmillan Healthcare Information, 1987. pp. 153-163, 293-304.
180. Fahn S. Blepharospasm: A form of focal dystonia. In Facial Dyskinesias. Adv Neurol 1988;49:125-133.
181. Bressman SB, de Leon D, Brin MF, Risch N, Shale H, Burke RE, Greene PE, Fahn S. Inheritance of idiopathic torsion dystonia among Ashkenazi Jews. Dystonia 2. Adv Neurol 1988;50:45-56.
182. Kramer PL, Ozelius LO, Brin MF, Bressman SB, Moskowitz CB, Fahn S, Kidd KK, Gusella J, Breakefield XO. Molecular genetics of an autosomal dominant form of torsion dystonia. Dystonia 2. Adv Neurol 1988;50:57-66.
183. Falk CT, Bressman SB, Allen FH Jr, Moskowitz C, Fahn S, Brin M. Linkage studies in families with dystonia: Linkage analysis as a tool to locate and characterize the gene(s) for dystonia. Dystonia 2. Adv Neurol 1988;50:67-72.
184. de Yebenes JG, Moskowitz C, Fahn S, Saint-Hilaire MH. Long-term treatment with levodopa in a family with autosomal dominant torsion dystonia. Dystonia 2. Adv Neurol 1988;50:101-111.
185. Ruberg M, Villageois A, Bonnet A-M, Rieger F, Agid Y, Fahn S. Acetylcholinesterase and butyrylcholinesterase in cerebrospinal fluid from patients with dystonia. Dystonia 2. Adv Neurol 1988;50:211-213.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 71
186. Brin MF, Moskowitz C, Fahn S. Dystonia Clinical Research Center Tissue Resource Facility: Investigations on collected tissue. Dystonia 2. Adv Neurol 1988;50:215-229.
187. Rutledge JN, Hilal SK, Silver AJ, Defendini R, Fahn S. Magnetic resonance imaging of dystonic states. Dystonia 2. Adv Neurol 1988;50:265-275.
188. Burke RE, Fahn S. An evaluation of sustained postural abnormalities in rats induced by intracerebro-ventricular injection of chlorpromazine methiodide or somatostatin as models of dystonia. Dystonia 2. Adv Neurol 1988;50:335- 342.
189. Bressman SB, Fahn S, Burke RE. Paroxysmal non-kinesigenic dystonia. Dystonia 2. Adv Neurol 1988;50:403-413.
190. Kang UJ, Burke RE, Fahn S. Tardive dystonia. Dystonia 2. Adv Neurol 1988;50:415-429.
191. Fahn S, Williams DT. Psychogenic dystonia. Dystonia 2. Adv Neurol 1988;50:431-455.
192. Tolosa E, Kulisevsky J, Fahn S. Meige syndrome: Primary and secondary Forms. Dystonia 2. Adv Neurol 1988;50:509-515.
193. Greene P, Shale H, Fahn S. Experience with high dosages of anticholinergic and other drugs in the treatment of torsion dystonia. Dystonia 2. Adv Neurol 1988;50:547-556.
194. Brin MF, Fahn S, Moskowitz C, Friedman A, Shale HM, Greene PE, Blitzer A, List T, Lange D, Lovelace RE, McMahon D. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Dystonia 2. Adv Neurol 1988;50:599-608.
195. Lange DJ, Brin MF, Fahn S, Lovelace RE. Distant effects of locally injected botulinum toxin: Incidence and course. Dystonia 2. Adv Neurol 1988;50:609- 613.
196. Truong DD, Fahn S. An early description of dystonia: Translation of Schwalbe's thesis and information on his life. Dystonia 2. Adv Neurol 1988;50:651-664.
197. Greene P, Shale H, Fahn S. Analysis of open-label trials in torsion dystonia using high dosages of anticholinergics and other drugs. Mov Disord 1988;3:46-60.
198. Truong DD, De Yebenes JG, Pezzoli G, Jackson-Lewis V, Fahn S. Glycine involvement in DDT-induced myoclonus. Mov Disord 1988;3:77-87.
199. Blitzer A, Brin MF, Fahn S, Lovelace RE. The use of botulinum toxin for the treatment of focal laryngeal dystonia (spastic dysphonia). Laryngoscope 1988;98:193-197.
200. Mayeux R, Stern Y, Rosenstein R, Marder K, Hauser A, Cote L, Fahn S. An estimate of the prevalence of dementia in idiopathic Parkinson's disease. Arch Neurol 1988;45:260-262.
201. Truong DD, Sczesni B, Fahn S, Gross J, Donovan K, van Bakel A, Wiley MK. Das neuroleptische maligne Syndrome (dopaminabhangige maligne Hyperthermie): Vier differente Falle. [Neuroleptic malignant syndrome (dopamine dependent malignant hyperthermia): four cases.] Der Nervenarzt 1988;59:103-109.
202. Vatassery GT, Brin MF, Fahn S, Kayden HJ, Traber MG. Effect of high doses of dietary vitamin E on the concentrations of vitamin E in several brain regions, plasma, liver, and adipose tissue of rats. J Neurochem 1988;51:621-623.
203. Truong DD, Fahn S. Therapeutic trial with glycine in myoclonus. Mov Disord 1988;3:222-232.
204. Fahn S, Tolosa E, Marin C. Clinical rating scale for tremor. In Jankovic J, Tolosa E, eds: Parkinson's Disease and Movement Disorders. Urban and Schwarzenberg, Baltimore; 1988:225-234.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 72
205. Cadet JL, Jackson-Lewis V, Fahn S. The iminodipropionitrile (IDPN) model of persistent spasmodic dyskinesias: Regional serotonin metabolism in rat brain. Brain Res 1988;456:371-374.
206. Cadet JL, Clark CR, Fahn S. Regional effects of alpha-benzyl-N-methylphenethylamine, a methamphetamine analog: Inhibition by ketanserin and para-chlorophenylalanine (PCPA). Pharmacol Biochem Behav 1988;29:125-128.
207. Pezzoli G, Fahn S, Dwork A, Truong DD, de Yebenes JG, Jackson-Lewis V, Cadet JL, Herbert J. Non-chromaffin tissue plus nerve growth factor reduces experimental parkinsonism in aged rats. Brain Res 1988;459:398-403.
208. Truong DD, Bressman S, Shale H, Fahn S. Clonazepam, haloperidol and clonidine in tic disorders. Southern Medical Journal 1988;81:1103-1105.
209. de Yebenes JG, Fahn S, Jackson-Lewis V, Jorge P, Mena MA, Reiriz J. Intracerebroventricular administration of dopamine and dopamine agonists to animal models of Parkinson's disease. J Neural Transm 1988;suppl 27:141-161.
210. de Yebenes JG, Brin M, Mena MA, de Felipe C, Del Rio RM, Bazan E, Martinez A, Fahn S, Del Rio J, Vazquez A, Varela de Seijas E. Neurochemical findings in neuroacanthocytosis. Mov Disord 1988;3:300-312.
211. Shale H, Fahn S, Calne DB. What Is It? Case 1, 1988. Head tilt in a young girl associated with neck pain and limitation of neck movement. Mov Disord 1988;3:347-351.
212. Shale H, Fahn S, Sternlieb I, Scheinberg IH. Follow-up of "What Is It?" Case 1, 1987. Mov Disord 1988;3:370.
213. de Yebenes JG, Fahn S, Mena Ma, Pardo B, Casarejos MJ. Intracerebroventricular infusion of dopamine and its agonists in rodents and primates. An experimental approach to the treatment of Parkinson's disease. ASAIO Transactions 1988;34:951-957.
214. Blitzer AB, Brin MF, Fahn S, Lovelace RE. Clinical and laboratory characteristics of laryngeal dystonia: A study of 110 cases. Laryngoscope 1988; 98:636-640.
215. Cadet JL, Katz M, Jackson-Lewis V, Fahn S. Vitamin E attenuates the toxic effects of intrastriatal injection of 6-hydroxydopamine (6-OHDA) in rats: behavioral and biochemical evidence. Brain Res 1989;476:10-15.
216. Blitzer A, Brin MF, Greene PE, Fahn S. Botulinum toxin injection for the treatment of oromandibular dystonia. Ann Otol Rhinol Laryngol 1989;98:93-97.
217. Thomas J, Jackson-Lewis V, Fahn S, Cadet JL. Methylprednisolone treatments alter apomorphine-induced circling in the rat model of 6-hydroxydopamine-induced striatal denervation. Int J Neurosci 1989;44:149-154.
218. Truong DD, Diamond B, Pezzoli G, Mena MA, Fahn S. Monoamine oxidase inhibitory properties of milacemide in rats. Life Sci 1989;44:1059-1066.
219. BLR L, Kramer PL, Moskowitz CB, Kwiatkowski DJ, Brin MF, Schuback DE, Falk CT, Haines J, Bressman SB, DeLeon D, Burke RE, Gusella JF, Fahn S, Breakefield XO. Human gene for torsion dystonia located on chromosome 9q32-34. Neuron 1989;2:1427-1434.
220. Burke RE, Kang UJ, Jankovic J, Miller LG, Fahn S. Tardive akathisia: An analysis of clinical features and response to open therapeutic trials. Mov Disord 1989;4:157-175.
221. Mena MA, de Yebenes JG, Dwork A, Latov N, Fahn S, Herbert J. Biochemical properties of monoamine-rich human neuroblastoma cell lines. Brain Res 1989;486:286-296.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 73
222. Fahn S. Clinical variants of idiopathic torsion dystonia. J Neurol Neurosurg Psychiatry Special Supplement 1989;96-100.
223. Stennett R, Katz M, Jackson-Lewis V, Fahn S, Cadet JL. The protein synthesis inhibitor, anisomycin, causes exacerbation of the iminodipropionitrile-induced spasmodic dyskinetic syndrome in rats. Pharmacol Biochem Behav 1989;32:1003-1008.
224. Truong DD, Galloway MP, Pezzoli G, Jamrozik Z, Fahn S. Milacemide increases 5-hydroxytryptamine and dopamine levels in rat brain. Possible mechanisms of milacemide antimyoclonic property in the p,p'-DDT-induced myoclonus. Pharmacol Biochem Behav 1989;32:993-1001.
225. Bressman SB, de Leon D, Brin MF, Risch N, Burke RE, Greene PE, Shale H, Fahn S. Idiopathic torsion dystonia among Ashkenazi Jews: Evidence for autosomal dominant inheritance. Ann Neurol 1989;26:612-620.
226. Parkinson Study Group. DATATOP: A multicenter controlled clinical trial in early Parkinson's disease. Arch Neurol 1989;46:1052-1060.
227. Shoulson I, Parkinson Study Group. Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism (DATATOP). Acta Neurol Scand 1989;80(S126):171-175.
228. Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989;321:1364-1371.
229. Brin MF, Blitzer A, Fahn S, Gould W, Lovelace RE. Adductor laryngeal dystonia (spastic dysphonia): Treatment with local injections of Botulinum toxin (Botox). Mov Disord 1989;4:287-296.
230. Kang UJ, Fahn S, Schwarz H, Shoulson I, Vallejos H, Goldman J. What Is It? Case 1, 1989. Juvenile-onset parkinsonism, dystonia, and pyramidal tract signs. Mov Disord 1989;4:363-370.
231. Perumal AS, Tordzro W, Katz M, Jackson-Lewis V, Cooper TB, Fahn S, Cadet JL. Regional effects of 6-hydroxydopamine (6-OHDA) on free radical scavengers in rat brain. Brain Res 1989;504:139-141.
232. Przedborski S, Wright M, Fahn S, Cadet JL. Regional changes in brain 5-HT-1A serotonin receptors in the rat model of persistent spasmodic dyskinesias induced by iminodipropionitrile. Brain Res 1989;504:311-314.
233. Przedborski S, Wright M, Fahn S, Cadet JL. Autoradiographic evidence of [3H]neurotensin binding changes in discrete regions of brain in the rat model of persistent spasmodic dyskinesia induced by iminodipropionitrile. Neurosci Lett 1989;107:335-340.
234. Fahn S. The endogenous toxin hypothesis of the etiology of Parkinson's disease and a pilot trial of high dosage antioxidants in an attempt to slow the progression of the illness. Ann NY Acad Sci 1989;570:186-196.
235. Brin MF, Fahn S, Loftus S, McMahon D, Flaster E. Relationship between dose of vitamin E administered and blood level. Ann NY Acad Sci 1989;570:421-424.
236. Nygaard TG, Trugman JM, de Yebenes JG, Fahn S. Dopa-responsive dystonia: The spectrum of clinical manifestations in a large North American family. Neurology 1990;40:66-69.
237. Kramer PL, Ozelius L, de Leon D, Risch N, Brin MF, Bressman SB, Burke RE, Kwiatkowski DJ, Schuback DE, Shale H, Gusella JF, Breakefield XO, Fahn S. Dystonia gene in Ashkenazi Jewish population located on chromosome 9q32-34. Ann Neurol 1990;27:114-120.
238. Risch N, Bressman SB, deLeon D, Brin MF, Burke RE, Greene PE, Shale H, Claus EB, Cupples LA, and Fahn S. Segregation analysis of idiopathic torsion dystonia in Ashkenazi Jews suggests autosomal dominant inheritance. Am J Hum Genet 1990;46:533-538.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 74
239. Przedborski S, Wright M, Fahn S, Cadet JL. Quantitative autoradiographic changes in 4-[3H]HT-labeled 5-HT1 serotonin receptors in discrete regions of brain in the rat model of persistent spasmodic dyskinesias induced by iminodipropionitrile (IDPN). Neurosci Lett 1990;116:51-57.
240. Greene P, Kang U, Fahn S, Brin MF, Moskowitz C, Flaster E. Double-blind, placebo controlled trial of botulinum toxin injection for the treatment of spasmodic torticollis. Neurology 1990;40:1213-1218.
241. Eidelberg D, Moeller JR, Dhawan V, Sidtis JJ, Ginos JZ, Strother SC, Cedarbaum J, Greene P, Fahn S, Rottenberg DA. The metabolic anatomy of Parkinson's disease: Complementary [F-18]fluorodeoxyglucose and [F-18]fluorodopa positron emission tomographic studies. Mov Disord 1990;5:203-213.
242. Park DH, Kang UJ, Moskowitz CB, Burke RE, Joh TH, Fahn S. Dopamine beta-hydroxylase activity in cerebrospinal fluid in idiopathic torsion dystonia. Neurology 1990;40:1500-1503.
243. Giladi N, Burke RE, Kostic V, Przedborski S, Gordon M, Hunt A, Fahn S. Hemiparkinsonism-hemiatrophy syndrome: clinical and neuroradiological features. Neurology 1990;40:1731-1734.
244. Greene PE, Fahn S, Lang AE, Watts RL, Eidelberg D, Powers JM. What Is It? Case 1, 1990: Progressive unilateral rigidity, bradykinesia, tremulousness, and apraxia, leading to fixed postural deformity of the involved limb. Mov Disord 1990;5:341-351.
245. Kujirai K, Przedborski S, Kostic V, Jackson-Lewis, Fahn S, Cadet JL. Autoradiography of dopamine receptors and dopamine uptake sites in the spontaneously hypertensive rat. Brain Res Bull 1990;25:703-709.
246. Fahn S. An open trial of high-dosage antioxidants in early parkinson's disease. Am J Clin Nutr 1990;53:380S-382S.
247. Kwiatkowski DJ, Nygaard TG, Schuback DE, Perman S, Trugman JM, Bressman SB, Burke RE, Brin MF, Ozelius L, Breakefield XO, Fahn S, Kramer PL. Identification of a highly polymorphic microsatellite VNTR within the argininosuccinate synthetase locus: exclusion of the dystonia gene on 9q32-34 as the cause of dopa-responsive dystonia in a large kindred. Am J Hum Genetics 1991;48:121-128.
248. Jackson-Lewis, Przedborski S, Kostic V, Suber F, Fahn S, Cadet JL. Partial attenuation of chronic fluphenazine-induced changes in regional monoamine metabolism by D-alpha-tocopherol in rat brain. Brain Res Bull 1991;26:251-258.
249. Nygaard TG, Marsden CD, Fahn S. Dopa-responsive dystonia: long-term treatment response and prognosis. Neurology 1991;41:174-181.
250. Saint-Hilaire M-H, Burke RE, Bressman SB, Brin MF, Fahn S. Delayed-onset dystonia due to perinatal or early childhood asphyxia. Neurology 1991;41:216-222.
251. Wilhelmsen KC, Weeks DE, Nygaard TG, Moskowitz CB, Rosales RL, dela Paz DC, Sobrevega EE, Fahn S, Gilliam TC. Genetic mapping of "lubag" (X-linked dystonia-parkinsonism) in a Filipino kindred to the pericentromeric region of the X chromosome. Ann Neurol 1991;29:124-131.
252. Chan J, Brin MF, Fahn S. Idiopathic cervical dystonia: clinical characteristics. Mov Disord 1991;6:119-126.
253. Fahn S, Sjaastad O. Hereditary essential myoclonus in a large Norwegian family. Mov Disord 1991;6:237-247.
254. Przedborski S, Levivier M, Kostic V, Jackson-Lewis V, Dollison A, Gash DM, Fahn S, Cadet JL. Sham transplantation protects against 6-hydroxydopamine-induced dopaminergic toxicity in rats: behavioral and morphological evidence. Brain Res 1991;550:231-238.
255. Fahn S, Parkinson Study Group. DATATOP and Clinical Neuromythology IX. Neurology 1991;41:771-773.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 75
256. Lange DJ, Rubin M, Greene PE, Kang UJ, Moskowitz CB, Brin MF, Lovelace RE, Fahn S. Distant effects of locally injected botulinum toxin: a double-blind study of single fiber EMG changes. Muscle Nerve 1991;14:672-675.
257. Schuback DE, Kramer PL, Ozelius L, Holmgren G, Kyllerman M, Wahlstrom J, Forsgren L, Kyllerman M, Wahlstrom J, Craft CM, Nygaard T, Brin M, DeLeon D, Bressman S, Moskowitz CB, Burke RE, Sanner G, Drugge U, Gusella JF, Fahn S, Breakefield XO. Dopamine beta-hydroxylase gene excluded in four subtypes of hereditary dystonia. Hum Genet 1991;87:311-316.
258. Fazzini E, Dwork AJ, Blum C, Burke R, Cote L, Goodman RR, Jacobs TP, Naini AB, Pezzoli G, Pullman S, Solomon RA, Truong D, Weber CJ, Fahn S: Stereotaxic implantation of autologous adrenal medulla into caudate nucleus in four patients with parkinsonism: One-year follow-up. Arch Neurol 1991;48:813-820.
259. Kwiatkowski DJ, Ozelius L, Kramer P, Perman S, Schuback DE, Gusella JF, Fahn S, Breakefield XO. Torsion dystonia genes in two populations defined to a small region on chromosome 9q32-34. Am J Hum Genet 1991;49:366-371.
260. Kujirai K, Fahn S, Cadet JL. Receptor autoradiography of mu-opioid and delta-opioid peptide receptors in spontaneously hypertensive rats. Peptides 1991;12:779-785.
261. Goetz CG, Stebbins GT, Klawans HL, Koller WC, Grossman RG, Bakay RAE, Penn RD, United Parkinson Foundation Neural Transplantation Registry. United Parkinson Foundation Neurotransplantation Registry on adrenal medullary transplants: Presurgical, and 1- and 2-year follow-up. Neurology 1991;41:1719-1722.
262. Pezzoli G, Zecchinelli A, Ricciardi S, Burke RE, Fahn S, Scarlato G, Carenzi A. Intraventricular infusion of epidermal growth factor restores dopaminergic pathway in hemiparkinsonian rats. Mov Disord 1991;6:281-287.
263. Vecht CJ, Meerwaldt JD, Lees AJ, Marsden CD, Fahn S. What Is It? Case 2, 1991: Unusual tremor, myoclonus, and a limping gait. Mov Disord 1991;6:371-375.
264. Micheli F, Fernandez Pardal M, Giannaula R, Fahn S. What Is It? Case 3, 1991: Moaning in a man with parkinsonian signs. Mov Disord 1991;6:376-378.
265. Przedborski S, Jackson-Lewis V, Popilskis S, Kostic V, Levivier M, Fahn S, Cadet JL. Unilateral MPTP-induced parkinsonism in monkeys: a quantitative autoradiographic study of dopamine D1 and D2 receptors and re-uptake sites. Neurochirugie 1991;37:377-382.
266. Eidelberg D, Dhawan V, Moeller JR, Sidtis JJ, Ginos JZ, Strother SC, Cederbaum J, Greene P, Fahn S, Powers JM, Rottenberg DA. The metabolic landscape of cortico-basal ganglionic degeneration: regional asymmetries studied with positron emission tomography. J Neurol Neurosurg Psychiatry 1991;54:856-862.
267. Langston JW, Widner H, Goetz CG, Brooks D, Fahn S, Freeman T, Watts R. Core assessment program for intracerebral transplantations (CAPIT). Mov Disord 1992;7:2-13.
268. Mena MA, Pardo B, Casarejos MJ, Fahn S, de Yebenes JG. Neurotoxicity of levodopa on catecholamine-rich neurons. Mov Disord 1992;7:23-31.
269. Greene PE, Fahn S. Baclofen in the treatment of idiopathic dystonia in children. Mov Disord 1992;7:48-52.
270. Giladi N, McMahon D, Przedborski S, Flaster E, Guillory S, Kostic V, Fahn S. Motor blocks in Parkinson's disease. Neurology 1992;42:333-339.
271. Ozelius LJ, Kramer PL, de Leon D, Risch N, Bressman SB, Schuback DE, Brin MF, Kwiatkowski DJ, Burke RE, Gusella JF, Fahn S, Breakefield XO. Strong allelic association between the torsion dystonia gene (DYT1) and loci on chromosome 9q34 in Ashkenazi Jews. Am J Hum Genet 1992;50:619-628.
272. Blitzer A, Brin MF, Stewart C, Aviv JE, Fahn S. Abductor laryngeal dystonia: A series treated with
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 76
botulinum toxin. Laryngoscope 1992;102:163-167.
273. Fazzini E, Fleming J, Fahn S. Cerebrospinal fluid antibodies to coronavirus in patients with Parkinson's disease. Mov Disord 1992;7:153-158.
274. Lieberman A, Fahn S, Olanow CW, Tetrud JW, Koller WC, Calne D, Fazzini EA, Muenter MD. Does selegiline provide a symptomatic or a neuroprotective effect? Neurology 1992;42 (Suppl 4):41-48.
275. Przedborski S, Kostic V, Jackson-Lewis V, Naini AB, Simonetti S, Fahn S, Carlson E, Epstein CJ, Cadet JL. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. J Neurosci 1992;12:1658-1667.
276. Zhu SM, Kujirai K, Dollison A, Angulo J, Fahn S, Cadet JL. Implantation of genetically modified mesencephalic fetal cells into the rat striatum. Brain Res Bull 1992;29:81-93.
277. Fahn S. A pilot trial of high-dose alpha-tocopherol and ascorbate in early Parkinson's disease. Ann Neurol 1992;32:S128-S132.
278. Russman BS, Lang AE, Fahn S, Greene P, Grunnet ML. WHAT IS IT? Case 1, 1992. Progressive gait deterioration, peripheral neuropathy, optic atrophy, bradykinesia, and dystonia in a young girl. Mov Disord 1992;7:373-379.
279. Giladi N, Fahn S. Hemiparkinsonism-hemiatrophy syndrome may mimic early-stage cortical basal ganglionic degeneration. Mov Disord 1992;7:384-385.
280. Nygaard TG, Takahashi H, Heiman GA, Snow BJ, Fahn S, Calne DB. Long-term treatment response and fluorodopa positron emission tomographic scanning of parkinsonism in a family with dopa-responsive dystonia. Ann Neurol 1992;32:603-608.
281. LeWitt PA, Galloway MP, Matson W, Milbury P, McDermott M, Srivastava DK, Oakes D, Parkinson Study Group. Markers of dopamine metabolism in Parkinson's disease. Neurology 1992;42:2111-2117.
282. Shoulson I, Parkinson Study Group. An interim report of the effect of selegiline (L-deprenyl) on the progression of disability in early Parkinson's disease. Eur Neurol 1992;32:46-53.
283. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early parkinson's disease. N Engl J Med 1993;328:176-183.
284. Przedborski S, Goldman S, Giladi N, Dhawan V, Takikawa S, Hildebrand J, Fahn S, Eidelberg D. Positron emission tomography in hemiparkinson-hemiatrophy syndrome. Adv Neurol 1993;60:501-505.
285. Greene P, Cote L, Fahn S. Treatment of drug-induced psychosis in Parkinson's disease with clozapine. Adv Neurol 1993;60:703-706.
286. Dwork AJ, Balmaceda C, Fazzini EA, MacCollin M, Cote L, Fahn S. Dominantly inherited, early-onset parkinsonism: Neuropathology of a new form. Neurology 1993;43:69-74.
287. Fahn S, Tolosa E, Marin C. Clinical rating scale for tremor. In Jankovic J, Tolosa E, eds: Parkinson's Disease and Movement Disorders. Baltimore, Williams and Wilkins;1993:271-280.
288. Parkinson Study Group. A controlled trial of lazabemide (RO19-6327) in untreated Parkinson's disease. Ann Neurol 1993;33:350-356.
289. Eidelberg D, Takikawa S, Moeller JR, Dhawan V, Redington K, Chaly T, Robeson W, Dahl JR, Margouleff D, Fazzini E, Przedborski S, Fahn S. Striatal hypometabolism distinguishes striatonigral degeneration from Parkinson's disease. Ann Neurol 1993;33:518-527.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 77
290. Pardo B, Mena MA, Fahn S, De Yebenes JG. Ascorbic acid protects against levodopa-induced neurotoxicity on a catecholamine-rich human neuroblastoma cell line. Mov Disord 1993;8:278-284.
291. Waters CH, Faust PL, Powers J, Vinters H, Moskowitz C, Nygaard T, Hunt AL, Fahn S. Neuropathology of Lubag (X-linked dystonia parkinsonism). Mov Disord 1993;8:387-390.
292. Eidelberg D, Takikawa S, Wilhelmsen K, Dhawan V, Chaly T, Robeson W, Dahl R, Margouleff D, Greene P, Hunt A, Przedborski S, Fahn S. Positron emission tomographic findings in Filipino X-linked dystonia-parkinsonism. Ann Neurol 1993;34:185-191.
293. Waters CH, Takahashi H, Wilhelmsen KC, Shubin R, Snow BJ, Nygaard TG, Moskowitz CB, Fahn S, Calne DB. Phenotypic expression of X-linked dystonia-parkinsonism (lubag) in two women. Neurology 1993;43:1555-1558.
294. Eidelberg D, Takikawa S, Dhawan V, Chaly T, Robeson W, Dahl R, Margouleff D, Moeller JR, Patlak CS, Fahn S. Striatal [18]F-dopa uptake: absence of an aging effect. J Cereb Blood Flow Metab 1993;13:881-888.
295. Shults CW, Parkinson Study Group . Effect of selegiline (deprenyl) on the progression of disability in early Parkinson's disease. Acta Neurol Scand 1993;87:36-42.
296. Greene PE, Fahn S. Use of botulinum toxin type-F injections to treat torticollis in patients with immunity to botulinum toxin type-A. Mov Disord 1993;8:479-483.
297. Gordon MF, Diaz-Olivo R, Hunt AL, Fahn S. Therapeutic trial of milacemide in patients with myoclonus and other intractable movement disorders. Mov Disord 1993;8:484-488.
298. Przedborski S, Jackson-Lewis V, Muthane U, Jiang H, Ferreira M, Naini AB, Fahn S. Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity. Ann Neurol 1993;34:715-723.
299. Nygaard TG, Wilhelmsen KC, Risch NJ, Brown DL, Trugman JM, Gilliam TC, Fahn S, Weeks DE. Linkage mapping of dopa-responsive dystonia (DRD) to chromosome 14q. Nature Genetics 1993;5:386-391.
300. Giladi N, Sutton M, Lo B, Przedborski S, Fahn S, Cadet JL. Toxicity of the specific antimuscarinic agent methoctramine and other non-specific anticholinergic drugs in human neuroblastoma cell lines in vitro. Toxicol In Vitro 1993;7:595-603.
301. Olanow CW, Fahn S, Muenter M, Klawans H, Hurtig H, Stern M, Shoulson I, Kurlan R, Grimes JD, Jankovic J, Hoehn M, Markham CH, Duvoisin R, Reinmuth O, Leonard HA, Ahlskog E, Feldman R, Hershey L, Yahr MD. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet(R) in Parkinson's disease. Mov Disord 1994;9:40-47.
302. Bressman SB, Heiman GA, Nygaard TG, Ozelius LJ, Hunt AL, Brin MF, Gordon MF, Moskowitz CB, de Leon D, Burke RE, Fahn S, Risch NJ, Breakefield XO, Kramer PL. A study of idiopathic torsion dystonia in a non-Jewish family: Evidence for genetic heterogeneity. Neurology 1994;44:283-287.
303. Parkinson Study Group. A controlled trial of lazabemide (RO19-6327) in levodopa-treated Parkinson's disease. Arch Neurol 1994;51:342-347.
304. Lew MF, Shindo M, Moskowitz CB, Wilhelmsen KC, Fahn S, Waters CH. Adductor laryngeal breathing dystonia in a patient with Lubag (X-linked dystonia-parkinsonism syndrome). Mov Disord 1994;9:318-320.
305. Wahlström J, Ozelius L, Kramer P, Kyllerman M, Schuback D, Forsgren L, Holmgren G, Drugge U, Sanner G, Fahn S, Breakefield XO. The gene for familial dystonia with myoclonic jerks responsive to alcohol is not located on the distal end of 9q. Clin Genet 1994;45:88-92.
306. Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord 1994;9:213-217.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 78
307. Eidelberg D, Moeller JR, Dhawan V, Spetsieris P, Takikawa S, Ishikawa T, Chaly T, Robeson T, Margouleff D, Przedborski S, Fahn S. The metabolic topography of parkinsonism. J Cereb Blood Flow Metab 1994;14:783-801.
308. Kramer PL, Heiman GA, Gasser T, Ozelius LJ, de Leon D, Brin MF, Burke RE, Hewett J, Hunt AL, Moskowitz C, Nygaard TG, Wilhelmsen KC, Fahn S, Breakefield XO, Risch NJ, Bressman SB. The DYTI gene on 9q34 is responsible for most cases of early limb-onset idiopathic torsion dystonia in non-Jews. Am J Hum Genet 1994;55:468-475.
309. Przedborski S, Giladi N, Takikawa S, Ishikawa T, Dhawan V, Spetsieris P, Chaly T, Fahn S, Eidelberg D. The metabolic topography of the hemiparkinsonism-hemiatrophy syndrome. Neurology 1994;44:1622-1628.
310. Pullman SL, Elibol B, Fahn S. Modulation of Parkinsonian tremor by radial nerve palsy. Neurology 1994;44:1861-1864.
311. Lynch T, Sano M, Marder KS, Bell KL, Foster NL, Defendini RF, Sima AAF, Keohane C, Nygaard TG, Fahn S, Mayeux R, Rowland LP, Wilhelmsen KC. Clinical characteristics of a family with chromosome 17-linked disinhibition dementia parkinsonism amyotrophy complex. Neurology 1994;44:1878-1884.
312. Kieburtz K, McDermott M, Como P, Growdon J, Brady J, Carter J, Huber S, Kanigan B, Landow E, Rudolph A, Saint Cyr J, Stern Y, Tennis M, Thelen J, Shoulson I, Parkinson Study Group. The effect of deprenyl and tocopherol on cognitive performance in early untreated Parkinson's disease. Neurology 1994;44:1756-1759.
313. Bressman SB, de Leon D, Kramer PL, Ozelius LJ, Brin MF, Greene PE, Fahn S, Breakefield XO, Risch NJ. Dystonia in Ashkenazi Jews: Clinical characterization of a founder mutation. Ann Neurol 1994;36:771-777.
314. Ford B, Greene P, Fahn S. Oral and genital tardive pain syndromes. Neurology 1994;44:2115-2119.
315. Bressman SB, Hunt AL, Heiman GA, Brin MF, Burke RE, Fahn S, Trugman JM, De Leon D, Kramer PL, Wilhelmsen KC, Nygaard TG. Exclusion of the DYT1 locus in a non-Jewish family with early-onset dystonia. Mov Disord 1994;9:626-632.
316. Anderson RL, Blitzer A, Brin M, Carruthers A, Comella C, Consky E, Dubinsky R, Fahn S, Frueh BR, Hallett M, Jankovic J, Koman A, Kraft SP, Lang A, Ludlow C, Namerow NS, Rhew K, Simpson LL, Tsui J, Waters C, Woodson G. Training guidelines for the use of botulinum toxin for the treatment of neurologic disorders. Neurology 1994;44:2401-2403.
317. Greene P, Kang UJ, Fahn S. Spread of symptoms in idiopathic torsion dystonia. Mov Disord 1995;10:143-152.
318. Louis ED, Goldman JE, Powers JM, Fahn S. Parkinsonian features of eight pathologically diagnosed cases of diffuse Lewy body disease. Mov Disord 1995;10:188-194.
319. Risch N, De Leon D, Ozelius L, Kramer P, Almasy L, Singer B, Fahn S, Breakefield X, Bressman S. Genetic analysis of idiopathic torsion dystonia in Ashkenazi Jews and their recent descent from a small founder population. Nat Genet 1995;9:152-159.
320. Fahn S, Shoulson I, Oakes D, Odoroff C, Lang A, Langston JW, LeWitt P, Olanow CW, Penney JB, Tanner C, Kieburtz K, Rudolph A, Pelusio RM, Koller W, Rodnitzky R, Fink JS, Growdon JH, Paulson G, Kurlan R, Friedman JH, Gancher S, Nutt J, Rajput AH, Bennett JB, Wooten GF, Goetz C, Shannon K, Brin MF, Bressman SB, Weiner MJ, Sanchez-Ramos J, Jankovic J, Hoehn M, Tetrud J, Grimes JD, Pfeiffer R, Shults C, Thal L, Gauthier S, Golbe LI, Perlmutter JS, Moses H, Reich SG, Hurtig HI, Stern M. Cerebrospinal fluid homovanillic acid in the DATATOP study on Parkinson's disease. Arch Neurol 1995;52:237-245.
321. Goetz CG, Stebbins GT, Chmura TA, Fahn S, Klawans HL, Marsden CD. Teaching tape for the motor
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 79
section of the Unified Parkinson's Disease Rating Scale. Mov Disord 1995;10:263-266.
322. Przedborski S, Jackson-Lewis V, Fahn S. Antiparkinsonian therapies and brain mitochondrial complex I activity. Mov Disord 1995;10:312-317.
323. McDermott MP, Jankovic J, Carter J, Fahn S, Gauthier S, Goetz CG, Golbe LI, Koller W, Lang AE, Olanow CW, Shoulson I, Stern MB, Tanner CM, Weiner WJ, Parkinson Study Group. Factors predictive of the need for levodopa therapy in early, untreated Parkinson's disease. Arch Neurol 1995;52:565-570.
324. Gordon MF, Bressman S, Brin MF, De Leon D, Warburton D, Yeboa K, Fahn S. Dystonia in a patient with deletion of 18q. Mov Disord 1995;10:496-499.
325. Ford B, Fahn S, Pullman SL. Peripherally induced electromyographic silent periods: normal physiology and disorders of motor control. Adv Neurol 1995;67:321-328.
326. Lang AE, Koller WC, Fahn S. Psychogenic parkinsonism. Arch Neurol 1995;52:802-810.
327. Holmgren G, Ozelius L, Forsgren L, Almay BGL, Holmberg M, Kramer P, Fahn S, Breakefield XO. Adult onset idiopathic torsion dystonia is excluded from the DYT 1 region (9q34) in a Swedish family. J Neurol Neurosurg Psychiatry 1995;59:178-181.
328. Stewart C, Winfield L, Hunt A, Bressman SB, Fahn S, Blitzer A, Brin MF. Speech dysfunction in early Parkinson's disease. Mov Disord 1995;10:562-565.
329. Eidelberg D, Moeller JR, Ishikawa T, Dhawan V, Spetsieris P, Chaly T, Belakhlef A, Mandel F, Przedborski S, Fahn S. Early differential diagnosis of Parkinson's disease with F-18-fluorodeoxyglucose and positron emission tomography. Neurology 1995;45:1995-2004.
330. Louis ED, Lynch T, Cargan AL, Fahn S. Generalized chorea in an infant with semilobar holoprosencephaly. Pediat Neurol 1995;13:355-357.
331. Eidelberg D, Moeller JR, Ishikawa T, Dhawan V, Spetsieris P, Przedborski S, Fahn S. The metabolic topography of idiopathic torsion dystonia. Brain 1995;118:1473-1484.
332. Shoulson I, Fahn S, Oakes D, et al. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Ann Neurol 1996;39:29-36.
333. Penney JB, Oakes D, Shoulson I, Fahn S, et al. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Ann Neurol 1996;39:37-45.
334. Louis ED, Fahn S. Pathologically diagnosed diffuse Lewy body disease and Parkinson's disease - Do the parkinsonian features differ? Adv Neurol 1996;69:311-314.
335. Pullman SL, Ford B, Elibol B, Uncini A, Su PC, Fahn S. Cutaneous electromyographic silent period findings in brachial dystonia. Neurology 1996;46:503-508.
336. Greene PE, Fahn S. Response to botulinum toxin F in seronegative botulinum toxin A-resistant patients. Mov Disord 1996;11:181-184.
337. Louis ED, Lynch T, Marder K, Fahn S. Reliability of patient completion of the historical section of the Unified Parkinson's Disease Rating Scale. Mov Disord 1996;11:185-192.
338. Tan A, Salgado M, Fahn S. Rapid eye movement sleep behavior disorder preceding Parkinson's disease with therapeutic response to levodopa. Mov Disord 1996;11:214-216.
339. Fahn S, Brin MF, Dwork AJ, Weiner WJ, Goetz CG, Rajput AH. Case 1, 1996: Rapidly progressive parkinsonism, incontinence, impotency, and levodopa-induced moaning in a patient with multiple myeloma.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 80
Mov Disord 1996;11:298-310.
340. Louis ED, Lynch T, Ford B, Greene P, Bressman SB, Fahn S. Delayed-onset cerebellar syndrome. Arch Neurol 1996;53:450-454.
341. Ford B, Louis ED, Greene P, Fahn S. Oral and genital pain syndromes in Parkinson's disease. Mov Disord 1996;11:421-426.
342. Pullman SL, Greene P, Fahn S, Pedersen SF. Approach to the treatment of limb disorders with botulinum toxin A: Experience with 187 patients. Arch Neurol 1996;53:617-624.
343. Parkinson Study Group. Effect of lazabemide on the progression of disability in early Parkinson's disease. Ann Neurol 1996;40:99-107.
344. Louis ED, Lynch T, Kaufmann P, Fahn S, Odel J. Diagnostic guidelines in central nervous system Whipple's disease. Ann Neurol 1996;40:561-568.
345. Bressman SB, Warner TT, Almasy L, Uitti RJ, Green PE, Heiman GA, Raymond D, Ford B, De Leon D, Fahn S, Kramer PL, Risch NJ, Maraganore DM, Nygaard TG, Harding AE. Exclusion of the DYT1 locus in familial torticollis. Ann Neurol 1996;40:681-684.
346. Ford B, Greene P, Louis ED, Petzinger G, Bressman SB, Goodman R, Brin MF, Sadiq S, Fahn S. Use of intrathecal baclofen in the treatment of patients with dystonia. Arch Neurol 1996;53:1241-1246.
347. Olanow CW, Fahn S, Langston JW, Godbold J. Selegiline and mortality in Parkinson's disease. Ann Neurol 1996;40:841-845.
348. Louis ED, Lynch T, Kaufmann P, Fahn S, Odel J. Three cases of central nervous system Whipple's disease. Rev Series Dementia 1996;2:21-23.
349. Tan A, Salgado M, Fahn S. The characterization and outcome of stereotypic movements in nonautistic children. Mov Disord 1997;12:47-52.
350. Louis ED, Klatka LA, Liu Y, Fahn S. Comparison of extrapyramidal features in 31 pathologically confirmed cases of diffuse Lewy body disease and 34 pathologically confirmed cases of Parkinson's disease. Neurology 1997;48:376-380.
351. Kurlan R, Brin MF, Fahn S. Movement disorder in reflex sympathetic dystrophy: A case proven to be psychogenic by surveillance video monitoring. Mov Disord 1997;12:243-245.
352. Ozelius LJ, Hewett J, Kramer P, Bressman SB, Shalish C, de Leon D, Rutter M, Risch N, Brin MF, Markova ED, Limborska SA, Ivanova-Smolenskaya IA, McCormick MK, Fahn S, Buckler AJ, Gusella JF, Breakefield XO. Fine localization of the torsion dystonia gene (DYT1) on human chromosome 9q34: YAC map and linkage disequilibrium. Genome Res 1997;7:483-494.
353. Louis ED, Ottman R, Ford B, Pullman S, Martinez M, Fahn S, Hauser WA. The Washington Heights-Inwood Genetic Study of Essential Tremor: Methodologic issues in essential-tremor research. Neuroepidemiology 1997;16:124-133.
354. Giladi N, Kao R, Fahn S. Freezing phenomenon in patients with parkinsonian syndromes. Mov Disord 1997;12:302-305.
355. Fahn S. Third International Dystonia Symposium - Miami, Florida, USA -October 9-11, 1996 - Introduction. Mov Disord 1997;12:A1-A2.
356. Bressman SB, de Leon D, Raymond D, Greene PE, Brin MF, Fahn S, Ozelius LJ, Breakefield XO, Kramer PL, Risch NJ. Secondary dystonia and the DYTI gene. Neurology 1997;48:1571-1577.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 81
357. Kieburtz K, Shoulson I, McDermott M, Fahn S, Lang A, et al. Parkinson Study Group. Safety and efficacy of pramipexole in early Parkinson disease: A randomized dose-ranging study. JAMA 1997;278:125-130.
358. Lynch T, Odel J, Fredericks DN, Louis ED, Forman S, Rotterdam H, Fahn S, Relman DA. Polymerase chain reaction-based detection of Tropheryma whippelii in central nervous system Whipple's disease. Ann Neurol 1997;42:120-124.
359. Ozelius LJ, Hewett JW, Page CE, Bressman SB, Kramer PL, Shalish C, de Leon D, Brin MF, Raymond D, Corey DP, Fahn S, Risch NJ, Buckler AJ, Gusella JF, Breakefield XO. The early-onset torsion dystonia gene (DYT1) encodes an ATP binding protein. Nat Genet 1997;17:40-48.
360. Almasy L, Bressman SB, Raymond D, Kramer PL, Greene PE, Heiman GA, Ford B, Yount J, de Leon D, Chouinard S, Saunders-Pullman R, Brin MF, Kapoor RP, Jones AC, Shen H, Fahn S, Risch NJ, Nygaard TG. Idiopathic torsion dystonia linked to chromosome 8 in two Mennonite families. Ann Neurol 1997;42:670-673.
361. Kieburtz K, Shoulson I, Fahn S, et al. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol 1997;42:747-755.
362. Chouinard S, Louis ED, Fahn S. Agreement among movement disorder specialists on the clinical diagnosis of essential tremor. Mov Disord 1997;12:973-976.
363. Shoulson I, Oakes D, Fahn S, Lang A, Langston JW, LeWitt P, Olanow CW, Penney JB, Tanner C, Kieburtz K, Koller W, Rodnitzky R, Fink JS, Growdon JH, Paulson G, Kurlan R, Friedman JH, Gancher S, Nutt J, Rajput AH, Bennett JB, Wooten GF, Goetz C, Shannon K, Suchowersky O, Brin MF, Bressman SB, Weiner WJ, Sanchez-Ramos J, Jankovic J, Tetrud J, Grimes JD, Pfeiffer R, Shults C, Thal L, Gauthier S, Golbe LI, Perlmutter JS, Moses H, Reich SG, Hurtig HI, Stern M, Barter R, Vetere-Overfield B, Gauger L, Malapira T, Dobson J, Atamian S, Tennis M, et al. Mortality in DATATOP: A multicenter trial in early Parkinson's disease. Ann Neurol 1998;43:318-325.
364. Fahn S, Chouinard S. Experience with tranylcypromine in early Parkinson's disease. J Neural Transmission 1998;[Suppl] 52:49-61.
365. Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, Pickering-Brown S, Chakraverty S, Isaacs A, Grover A, Hackett J, Adamson J, Lincoln S, Dickson D, Davies P, Petersen RC, Stevens M, Degraaff E, Wauters E, Vanbaren J, Hillebrand M, Joosse M, Kwon JM, Nowotny P, Che LK, Norton J, Morris JC, Reed LA, Trojanowski J, Basun H, Lannfelt L, Neystat M, Fahn S, Dark F, Tannenberg T, Dodd PR, Hayward N, Kwok JBJ, Schofield PR, Andreadis A, Snowden J, Craufurd D, Neary D, Owen F, Oostra BA, Hardy J, Goate A, Vanswieten J, Mann D, et al. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998;393:702-705.
366. Vatassery GT, Fahn S, Kuskowski MA, Parkinson Study Group. Alpha tocopherol in CSF of subjects taking high-dose vitamin E in the DATATOP study. Neurology 1998;50:1900-1902.
367. Dalvi A, Fahn S, Ford B. Intrathecal baclofen in the treatment of dystonic storm. Mov Disord 1998;13:611-612.
368. Lieberman A, Olanow CW, Sethi K, Swanson P, Waters CH, Fahn S, Hurtig H, Yahr M. A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Neurology 1998;51:1057-1062.
369. Eidelberg D, Moeller JR, Antonini A, Kazumata K, Nakamura T, Dhawan V, Spetsieris P, de Leon D, Bressman SB, Fahn S. Functional brain networks in DYT1 dystonia. Ann Neurol 1998;44:303-312.
370. Ford B, Louis ED, Greene P, Fahn S. Outcome of selective ramisectomy for botulinum toxin resistant torticollis. J Neurol Neurosurg Psychiatry 1998;65:472-478.
371. Fahn S, Bressman SB, Marsden CD. Classification of dystonia. In: Fahn S, Marsden CD, DeLong MR, eds. Dystonia 3. Adv Neurol 1998;78:1-10. Philadelphia;Lippincott-Raven Pub.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 82
372. Ozelius LJ, Hewitt JW, Page CE, Bressman SB, Kramer PL, Shallish C, de Leon D, Brin MF, Raymond D, Jacoby D, Penney J, Risch NJ, Fahn S, Gusella JF, Breakefield XO. The gene (DYT1) for early-onset torsion dystonia encodes a novel protein related to the clp protease/heat shock family. In: Fahn S, Marsden CD, DeLong MR, eds. Dystonia 3. Adv Neurol 1998;78:93-105. Philadelphia;Lippincott-Raven Pub.
373. Bressman SB, de Leon D, Raymond D, Greene PE, Brin MF, Fahn S, Ozelius LJ, Breakefield XO, Kramer PL, Risch NJ. The role of the DYT1 gene in secondary dystonia. In: Fahn S, Marsden CD, DeLong MR, eds. Dystonia 3. Adv Neurol 1998;78:107-115. Philadelphia;Lippincott-Raven Pub.
374. Ford B, Greene PE, de Leon D, Louis ED, Bressman SB, Goodman RR, Brin MF, Sadiq S, Fahn S. Intrathecal baclofen in the treatment of dystonia. In: Fahn S, Marsden CD, DeLong MR, eds. Dystonia 3. Adv Neurol 1998;78:199-210. Philadelphia;Lippincott-Raven Pub.
375. Wilhelmsen KC, Moskowitz CB, Weeks DE, Neystat M, Nygaard TG, Clark L, Dancoup M, Sobrevega EE, Rosales R, Gamez G, Pacioles O, Perez M, Fahn S. Molecular genetic analysis of lubag. In: Fahn S, Marsden CD, DeLong MR, eds. Dystonia 3. Adv Neurol 1998;78:349-358. Philadelphia;Lippincott-Raven Pub.
376. Fahn S. Professor C. David Marsden - Obituary. Arch Neurol 1999;56:119-120.
377. Saunders-Pullman R, Gordon-Elliott J, Parides M, Fahn S, Saunders HR, Bressman S. The effect of estrogen replacement on early Parkinson's disease. Neurology 1999;52:1417-1421.
378. Klein C, Brin MF, Kramer P, Sena-Esteves M, de Leon D, Doheny D, Bressman S, Fahn S, Breakefield XO, Ozelius LJ. Association of a missense change in the D2 dopamine receptor with myoclonus dystonia. Proc Nat Acad Sci USA 1999;96:5173-5176.
379. Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S. Falling asleep at the wheel: Motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 1999;52:1908-1910.
380. Fahn S. Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Arch Neurol 1999;56:529-535.
381. Schwid SR, Kieburtz K, Nutt J, McDermott M, Kayson E, Chase T, Fahn S, Greenamyre T, Lang A, Penney J, Shoulson I. The impact of remacemide hydrochloride on levodopa concentrations in Parkinson's disease. Clin Neuropharmacol 1999;22:220-225.
382. Frucht S, Fahn S, Ford B, Gelb M. A geste antagoniste device to treat jaw-closing dystonia. Mov Disord 1999;14:883-886.
383. Frucht S, Fahn S. Paroxysmal kinesigenic dyskinesia in infancy. Mov Disord 1999;14:694-695.
384. Frucht S, Fahn S, Shannon KM, Waters CH. Clinical Grand Rounds: A 32-year-old man with progressive spasticity and parkinsonism. Mov Disord 1999;14:350-357.
385. Frucht S, Fahn S, Ford B. French horn embouchure dystonia. Mov Disord 1999;14:171-173.
386. Agid Y, Ahlskog E, Albanese A, Calne D, Chase T, De Yebenes J, Factor S, Fahn S, Gershanik O, Goetz C, Koller W, Kurth M, Lang A, Lees A, LeWitt P, Marsden D, Melamed E, Michel PP, Mizuno Y, Obeso J, Oertel W, Olanow W, Poewe W, Pollak P, Przedzorski S, Quinn N, Raisman-Vozari R, Rajput A, Stocchi F, Tolosa E. Levodopa in the treatment of Parkinson's disease: A consensus meeting. Mov Disord 1999;14:911-913.
387. Ozelius LJ, Page CE, Klein C, Hewett JW, Mineta M, Leung J, Shalish C, Bressman SB, de Leon D, Brin MF, Fahn S, Corey DP, Breakefield XO. The TOR1A (DYT1) gene family and its role in early onset torsion dystonia. Genomics 1999;62:377-384.
388. Shetty N, Friedman JH, Kieburtz K, Marshall FJ, Oakes D, Parkinson Study Group. The placebo response in Parkinson's disease. Clin Neuropharmacol 1999;22:207-212.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 83
389. Holloway R, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, McDermott M, Seibyl J, Weiner W, Welsh M, Kamp C, Day D, Pahwa R, Smith D, McGuire D, Barclay L, Sutherland L, Hildebrand K, Hubble J, Weeks C, LeWitt P, Mistura K, Bloomfield W, Miyasaki J, Duff J, Sime E, Suchowersky O, Argatoff P, Andreas Y, Kurth M, Brewer M, Russell D, Fussell B, Ford B, Dillon S, Hammerstad J, Stone C, Riley D, Rainey P, Standaert D, Tennis M, Wooten F, Rost-Ruffner E, Factor S, Brown D, Jankovic J, Beach J, Kurlan R, Gardiner I, et al. A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: Design and methods of the CALM-PD study. Clin Neuropharmacol 2000;23:34-44.
390. Furukawa Y, Hornykiewicz O, Fahn S, Kish SJ. Striatal dopamine in early-onset primary torsion dystonia with the DYT1 mutation. Neurology 2000;54:1193-1195.
391. Frucht S, Fahn S, Chin S, Dhawan V, Eidelberg D. Levodopa-induced dyskinesias in autopsy-proven cortical-basal ganglionic degeneration. Mov Disord 2000;15:340-343.
392. Frucht S, Fahn S, Ford B. Focal task-specific dystonia induced by peripheral trauma. Mov Disord 2000;15:348-350.
393. Shoulson I, Greenamyre T, Kieburtz K, Schwid S, McDermott M, Kayson E, Chase T, Fahn S, Lang A, Penney J, Hauser R, Gauger L, Kumar R, Keable L, Sime E, Siemers E, Belden J, Pappert EJ, Janko K, Trugman JM, Rost-Ruffner E, Kurlan R, Pearson N, Carter J, Nutt J, Stone C, Perlmutter JS, McGee- Minnich L, Freeman A, Duddleston C, Stacy M, Brewer M, Locke B, Stern M, Matthews M, Friedman J, Davies R, Lannon M, Grimes D, Gray P, Shults C, Fontaine D, O’Brien C, et al. Parkinson Study Group. A multicenter randomized controlled trial of remacemide hydrochloride as monotherapy for PD. Neurology 2000;54:1583-1588.
394. Fahn S. The spectrum of levodopa-induced dyskinesias. Ann Neurol 2000;47 (Suppl 1):S2-S11.
395. Olanow CW and The Tasmar Advisory Panel. Tolcapone and hepatotoxic effects. Arch Neurol 2000 57:263-267.
396. Bressman SB, Sabatti C, Raymond D, de Leon D, Klein C, Kramer PL, Brin MF, Fahn S, Breakefield X, Ozelius LJ, Risch NJ. The DYT1 phenotype and guidelines for diagnostic testing. Neurology 2000;54:1746- 1752.
397. Parkinson Study Group. Pramipexole versus levodopa as the initial treatment for Parkinson’s disease: a randomized controlled trial. JAMA 2000 284:1931-1938.
398. Thyagarajan D, Bressman S, Bruno C, Przedborski S, Shanske S, Lynch T, Fahn S, DiMauro S. A novel mitochondrial 12SrRNA point mutation in parkinsonism, deafness, and neuropathy. Ann. Neurol. 2000;48:730-736.
399. Klein C, Schilling K, Saunders-Pullman RJ, Garrels J, Breakfield XO, Brin MF, DeLeon D, Doheny D, Fahn S, Fink S, Forsgren L, Friedman J, Frucht S, Harris J, Holmgren G, Kis B, Kurlan R, Kyllerman M, Lang AE, Leung J, Raymond D, Robishaw JD, Sanner G, Schwinger E, Tabamo RE, Tagliati M, Vieregge P, Wahlstrom J, Wendt KJ, Kramer P, Bressman S, Ozelius LJ. A major locus for myoclonus-dystonia maps to chromosome 7q in eight families. Amer J Hum Genet 2000;67:1314-1319.
400. Freed CR, Greene PE, Breeze RE, Tsai W-Y, DuMouchel W, Kao R, Dillon S, Winfield H, Culver S, Trojanowski JQ, Eidelberg D, Fahn S. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001;344:710-719.
401. Parkinson Study Group. A randomized, controlled trial of remacemide for motor fluctuations in Parkinson's disease. Neurology 2001;56:455-462.
402. Giladi N, McDermott MP, Fahn S, Przedborski S, Jankovic J, Stern M, Tanner C. Freezing of gait in PD: Prospective assessment in the DATATOP cohort. Neurology. 2001;56:1712-1721.
403. Louis ED, Winfield L, Fahn S, Ford B. Speech dysfluency exacerbated by levodopa in Parkinson's disease.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 84
Mov Disord 2001;16:562-565.
404. Nakamura T, Dhawan V, Chaly T, Fukuda M, Ma YL, Breeze R, Greene P, Fahn S, Freed C, Eidelberg D. Blinded positron emission tomography study of dopamine cell implantation for Parkinson's disease. Ann Neurol 2001;50:181-187.
405. Frucht SJ, Louis ED, Chuang C, Fahn S. A pilot tolerability and efficacy study of levetiracetam in patients with chronic myoclonus. Neurology 2001;57:1112-1114.
406. Louis ED, Levy G, Cote LJ, Mejia H, Fahn S, Marder K. Clinical correlates of action tremor in Parkinson disease. Arch Neurol 2001;58:1630-1634.
407. Shoulson I, Lang A, Fahn S, McDermott M, Kieburtz K, et al. Parkinson Study Group. Evaluation of dyskinesias in a pilot, randomized, placebo-controlled trial of remacemide in advanced Parkinson disease. Arch Neurol 2001;58:1660-1668.
408. Frucht SJ, Fahn S, Greene PE, O’Brien C, Gelb M, Truong DD, Welsh J, Factor S, Ford B. The natural history of embouchure dystonia. Mov Disord 2001;16:899-906.
409. Frucht SJ, Leurgans SE, Hallett M, Fahn S, The Unified Myoclonus Rating Scale. Adv Neurol. 2002;89:361-376.
410. Chuang C, Fahn S, Frucht SJ. The natural history and treatment of acquired hemidystonia: report of 33 cases and review of the literature. J Neurol Neurosurg Psychiat 2002;72:59-67.
411. Marek K, Seibyl J, Shoulson I, Holloway R, Kieburtz K, McDermott M, Kamp C, Shinaman A, Fahn S, Lang A, Weiner W, Welsh M. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. J Am Med Assn 2002;287:1653-1661.
412. Shoulson I, Oakes D, Fahn S, Lang A, Langston JW, LeWitt P, Olanow CW, Penney JB, Tanner C, Kieburtz K, Rudolph A, Parkinson Study Group. Impact of sustained deprenyl (selegiline) in levodopa- treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol 2002;51(5):604-612.
413. Hedrich K, Marder K, Harris J, Kann M, Lynch T, Meija-Santana H, Pramstaller PP, Schwinger E, Bressman SB, Fahn S, Klein C. Evaluation of 50 probands with early-onset Parkinson's disease for Parkin mutations. Neurology 2002;58:1239-1246.
414. Ma Y, Feigin A, Dhawan V, Fukuda M, Shi Q, Greene P, Breeze R, Fahn S, Freed C, Eidelberg D. Dyskinesia after fetal cell transplantation for parkinsonism: A PET study. Ann Neurol, 2002;52:628-634.
415. Bressman SB, Raymond D, Wendt K, Saunders-Pullman R, deLeon D, Fahn S, Ozelius L, Risch N. Diagnostic criteria for dystonia in DYT1 families. Neurology 2002;59(11):1780-1782.
416. Siderowf A, Stern M, Shoulson I, Kieburtz K, Oakes D, Day D, Shinaman A, Plumb S, Fahn S, et al. A controlled trial of rasagiline in early Parkinson disease - The TEMPO study. Arch Neurol 2002;59(12):1937- 1943.
417. Louis ED, Levy G, Cote LJ, Mejia H, Fahn S, Marder K. Diagnosing Parkinson's disease using videotaped neurological examinations: Validity and factors that contribute to incorrect diagnoses. Mov Disord 2002;17(3):513-517.
418. Gordon PH, Pullman SL, Louis ED, Frucht SJ, Fahn S. Mirtazapine in Parkinsonian tremor and essential tremor. An exploratory study. Parkinson Rel Disord 2002;9:125-126.
419. Goetz CG, Leurgans S, Raman R, Parkinson Study Group. Placebo-associated improvements in motor function: comparison of subjective and objective sections of the UPDRS in early Parkinson's disease. Mov Disord 2002;17:283-288.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 85
420. Siderowf A, McDermott MP, Kieburtz K, Blindauer K, Plumb S, Shoulson I, Parkinson Study Group. Test- retest reliability of the Unified Parkinson’s Disease Rating Scale: results from a multicenter clinical trial. Mov Disord 2002;17(4):758-763.
421. Chatterjee A, Fahn S. Methylphenidate treats apathy in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 2002;14(4):461-462.
422. McRae C, Cherin E, Diem G, Vo AH, Ellgring JH, Russell D, Fahn S, Freed C. Does personality change as a result of fetal tissue transplantation in the brain? J Neurol. 2003 Mar;250(3):282-286.
423. Welsh M, McDermott MP, Holloway RG, Plumb S, Pfeiffer R, Hubble Hubble J, Parkinson Study Group. Development and testing of the Parkinson’s disease quality of life scale: the PDQUALIF. Mov Disord 2003;18(6):637-645.
424. Lyons KE, Pahwa R, Comella CL, Eisa MS, Elble RJ, Fahn S, Jankovic J, Juncos JL, Koller WC, Ondo WG, Sethi KD, Stern MB, Tanner CM, Tintner R, Watts RL. Benefits and risks of pharmacological treatments for essential tremor. Drug Safety 2003;26 (7):461-481.
425. Trott CT, Fahn S, Greene P, Dillon S, Winfield H, Winfield L, Kao R, Eidelberg D, Freed CR, Breeze RE, Stern Y. Cognition following bilateral implants of embryonic dopamine neurons in PD: a double blind study. Neurology. 2003; Jun 24;60(12):1938-1943.
426. Marder K, Levy G, Louis ED, Mejia-Santana H, Cote L, Andrews H, Harris J, Waters C, Ford B, Frucht S, Fahn S, Ottman R. Accuracy of family history data on Parkinson's disease. Neurology. 2003; Jul 8;61(1):18-23.
427. Louis ED, Levy G, Mejia-Santana H, Cote L, Andrews H, Harris J, Waters C, Ford B, Frucht S, Fahn S, Ottman R, Marder K. Risk of action tremor in relatives of tremor-dominant and postural instability gait disorder PD. Neurology. 2003; Oct 14;61(7):931-936.
428. Marder K, Levy G, Louis ED, Mejia-Santana H, Cote L, Andrews H, Harris J, Waters C, Ford B, Frucht S, Fahn S, Ottman R. Familial aggregation of early- and late-onset Parkinson's disease. Ann Neurol. 2003; Oct;54(4):507-513. (Erratum in: Ann Neurol. 2003; Nov; 54(5):693.)
429. Cohen O, Fahn S, Frucht SJ. Severe cervical dystonia in pathologically proven Parkinson's disease and dementia. Mov Disord. 2003; Nov;18(11):1381-1382.
430. Parkinson Study Group. A controlled trial of rotigotine monotherapy in early Parkinson's disease. Arch Neurol. 2003; Dec; 60(12):1721-1728.
431. Munhoz RP, Li JY, Kurtinecz M, Piboolnurak P, Constantino A, Fahn S, Lang AE. Evaluation of the pull test technique in assessing postural instability in Parkinson's disease. Neurology. 2004; Jan 13;62(1):125-127.
432. Noyes K, Dick A, Holloway RC, Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson’s disease. Med Decis Making 2004;24:472-485.
433. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004 Apr; 61(4):561-566.
434. McRae C, Cherin E, Yamazaki TG, Diem G, Vo AH, Russell D, Ellgring JH, Fahn S, Greene P, Dillon S, Winfield H, Bjugstad KB, Freed CR. Effects of perceived treatment on quality of life and medical outcomes in a double-blind placebo surgery trial. Arch Gen Psychiatry 2004 Apr ;61(4):412-420. (Erratum in: Arch Gen Psychiatry. 2004 Jun; 61(6):627)
435. Agarwal P, Fahn S, Frucht SJ. Diagnosis and management of pergolide-induced fibrosis. Mov Disord 2004 Jun;19(6):699-704.
436. Gordon PH, Yu Q, Qualls C, Winfield H, Dillon S, Greene PE, Fahn S, Breeze RE, Freed CR, Pullman SL.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 86
Reaction time and movement time after embryonic cell implantation in Parkinson disease. Arch Neurol. 2004 Jun; 61(6):858-861.
437. Schwid S, Shoulson I, Marek K, Oakes D, Kieburtz K, Gorbold E, Fahn S, Goetz C, Rudolph A, Shinaman A. The safety and tolerability of a mixed lineage kinase inhibitor (CEP- 1347) in PD. Neurology 2004;62(2):330-332.
438. Levy G, Louis ED, Mejia-Santana H, Cote L, Andrews H, Harris J, Waters C, Ford B, Frucht S, Fahn S, Ottman R, Marder K. Lack of familial aggregation of Parkinson disease and Alzheimer disease. Arch Neurol 2004;61(7):1033-1039.
439. Holloway RG, Shoulson I, Kieburtz K, McDermott M, Shinaman A, Kamp C, Fahn S, Lang A, Marek K, Seibyl J, Welsh M, Pahwa R, Montgomery A, Barclay L, Sutherland L, Hubble J, Weeks C, LeWitt P, DeAngelis M, Miyasaki J, Sime E, Suchowersky O, Wood S, Pantella C, Stacy M, Harrigan M, Russell DS, Fussell B, Ford B, Dillon S, Hammerstad J, AlexanderBrown B, Riley D, Rainey P, Standaert D, Tennis M, Wooten F, Rost-Ruffner E, Factor S, Brown D, Evans S, Jankovic J, Atassi F, Kurlan R, Berry D, Panisset M, Hall J, Rajput A, Shirley T, et.al. Pramipexole vs levodopa as initial treatment for Parkinson disease - A 4-year randomized controlled trial. Arch Neurol 2004;61(7):1044-1053.
440. Clark LN, Afridi S, Mejia-Santana H, Harris J, Louis ED, Cote LJ, Andrews H, Singleton A, DeVrieze FW, Hardy J, Mayeux R, Fahn S, Waters C, Ford B, Frucht S, Ottman R, Marder K. Analysis of an early-onset Parkinson's disease cohort for DJ-1 mutations. Mov Disord 2004;19(7):796-800.
441. Ford B, Winfield L, Pullman SL, Frucht SJ, Du Y, Greene P, Cheringal JH, Yu Q, Cote LJ, Fahn S, McKhann GM, Goodman RR. Subthalamic nucleus stimulation in advanced Parkinson's disease: blinded assessments at one year follow up. J Neurol Neurosurg Psychiat 2004;75(9):1255-1259.
442. Gordon PH, Fahn S, Chin S, Golbe LI, Lynch T, Eidelberg D. What Is It? Woman with a 26-year history of parkinsonism, supranuclear ophthalmoplegia, and loss of postural reflexes. Mov Disord. 2004 Aug;19(8):950-961.
443. Fahn S. ALS lessons learned from other neurological diseases. Parkinson's disease. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004 Sep;5 (Suppl 1):26-30.
444. Margolis RL, Holmes SE, Rosenblatt A, Gourley L, O'Hearn E, Ross CA, Seltzer WK, Walker RH, Ashizawa T, Rasmussen A, Hayden M, Almqvist EW, Harris J, Fahn S, MacDonald ME, Mysore J, Shimohata T, Tsuji S, Potter N, Nakaso K, Adachi Y, Nakashima K, Bird T, Krause A, Greenstein P. Huntington's Disease-like 2 (HDL2) in North America and Japan. Ann Neurol. 2004 Nov;56(5):670-674.
445. Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K; Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004 Dec 9;351(24):2498-2508.
446. Clark LN, Nicolai A, Afridi S, Harris J, Mejia-Santana H, Strug L, Cote LJ, Louis ED, Andrews H, Waters C, Ford B, Frucht S, Fahn S, Mayeux R, Ottman R, Marder K. Pilot association study of the beta- glucocerebrosidase N370S allele and Parkinson's disease in subjects of Jewish ethnicity. Mov Disord. 2005 Jan;20(1):100-103.
447. Marras C, McDermott MP, Rochon PA, Tanner CM, Naglie G, Rudolph A, Lang AE; Parkinson Study Group. Survival in Parkinson disease: thirteen-year follow-up of the DATATOP cohort. Neurology. 2005 Jan 11;64(1):87-93.
448. Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol. 2005 Feb;62(2):241-8.
449. Levy G, Louis ED, Cote L, Perez M, Mejia-Santana H, Andrews H, Harris J, Waters C, Ford B, Frucht S, Fahn S, Marder K. Contribution of aging to the severity of different motor signs in Parkinson disease. Arch Neurol. 2005 Mar;62(3):467-472.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 87
450. Fahn S, Parkinson Study Group. Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol 2005;252 [Suppl 4]:IV/37-IV/42.
451. Blindauer K, Shoulson I, Oakes D, Kieburtz K, Schwid S, Fahn S, Stern M, Goetz C, Nutt J, Goren S, Sayag N, Scolnik M, Levy R, Eyal E, Salzman P, Pagano M; Parkinson Study Group. A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations. Arch Neurol. 2006 Feb;63(2):210-216.
452. Portera-Cailliau C, Victor D, Frucht SJ, Fahn S. Movement disorders fellowship training program at Columbia University Medical Center in 2001-2002. Mov Disord 2006 Apr;21(4):479-485.
453. Clark LN, Afridi S, Karlins E, Wang Y, Mejia-Santana H, Harris J, Louis ED, Cote LJ, Andrews H, Fahn S, Waters C, Ford B, Frucht S, Ottman R, Marder K. Case-control study of the parkin gene in early-onset Parkinson disease. Arch Neurol. 2006 Apr;63(4):548-552.
454. Goetz CG, Schwid SR, Eberly SW, Oakes D, Shoulson I; Parkinson Study Group TEMPO and PRESTO Investigators. Safety of rasagiline in elderly patients with Parkinson disease. Neurology. 2006 May 9;66(9):1427-1429.
455. Biglan KM, Schwid S, Eberly S, Blindauer K, Fahn S, Goren T, Kieburtz K, Oakes D, Plumb S, Siderowf A, Stern M, Shoulson I. Rasagiline improves quality of life in patients with early Parkinson's disease. Mov Disord. 2006 May;21(5):616-623.
456. Holford NH, Chan PL, Nutt JG, Kieburtz K, Shoulson I; Parkinson Study Group. Disease progression and pharmacodynamics in Parkinson disease - evidence for functional protection with levodopa and other treatments. J Pharmacokinet Pharmacodyn. 2006 Jun;33(3):281-311.
457. Elmer L, Schwid S, Eberly S, Goetz C, Fahn S, Kieburtz K, Oakes D, Blindauer K, Salzman P, Oren S, Prisco UL, Stern M, Shoulson I; Parkinson Study Group TEMPO and PRESTO Investigators. Rasagiline- associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms. J Neurol Sci 2006 Oct 25;248(1-2):78-83.
458. Holford NHG, Chan PLS, Nutt JG, Kieburtz K., Shoulson I. Parkinson Study Group. Disease progression and pharmacodynamics in Parkinson’s disease: evidence for functional protection with levodopa and other treatments. J Pharmacokinet Pharmacodyn 2006;33:281-311.
459. deMarcaida JA, Schwid SR, White WB, Blindauer K, Fahn S, Kieburtz K, Stern M, Shoulson I. Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline. Mov Disord 2006 2006 Oct;21(10):1716-1721.
460. Fahn S. A new look at levodopa based on the ELLDOPA study. J Neural Transm 2006;Suppl 70:419-426.
461. Clark LN, Wang Y, Karlins E, Saito L, Mejia-Santana H, Harris J, Louis ED, Cote LJ, Andrews H, Fahn S, Waters C, Ford B, Frucht S, Ottman R, Marder K. Frequency of LRRK2 mutations in early- and late-onset Parkinson disease. Neurology. 2006 Nov 28;67(10):1786-1791.
462. Elble RJ, Pullman SL, Matsumoto JY, Raethjen J, Deuschl G, Tintner R, Tremor Research Group. Tremor amplitude is logarithmically related to 4- and 5-point tremor rating scales. Brain 2006;129:2660–2666.
463. Huntington Study Group: Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 2006;66:366-372.
464. Goetz CG, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stebbins GT, Stern MB, Tilley BC, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, Lewitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, Van Hilten JJ, Lapelle N. Movement Disorder Society- sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord. 2007 Jan;22(1):41-47.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 88
465. Nirenberg MJ, Libien J, Vonsattel JP, Fahn S. Multiple system atrophy in a patient with the spinocerebellar ataxia 3 gene mutation. Mov Disord. 2007 Jan15;22(2):251-253.
466. Lippa CF, Duda JE, Grossman M, Hurtig HI, Aarsland D, Boeve BF, Brooks DJ, Dickson DW, Dubois B, Emre M, Fahn S, Farmer JM, Galasko D, Galvin JE, Goetz CG, Growdon JH, Gwinn-Hardy KA, Hardy J, Heutink P, Iwatsubo T, Kosaka K, Lee VM, Leverenz JB, Masliah E, McKeith IG, Nussbaum RL, Olanow CW, Ravina BM, Singleton AB, Tanner CM, Trojanowski JQ, Wszolek ZK; DLB/PDD Working Group. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 2007 Mar 13;68(11):812-819.
467. Parkinson Study Group. Pramipexole in levodopa-treated Parkinson disease patients of African, Asian, and Hispanic heritage. Clin Neuropharmacol. 2007 Mar-Apr;30(2):72-85.
468. Constantinescu R, Romer M, Kieburtz K; DATATOP Investigators of the Parkinson Study Group. Malignant melanoma in early Parkinson's disease: the DATATOP trial. Mov Disord. 2007 Apr 15;22(5):720-732.
469. Clark LN, Haamer E, Mejia-Santana H, Harris J, Lesage S, Durr A, Bs SJ, Hedrich K, Louis ED, Cote LJ, Andrews H, Fahn S, Waters C, Ford B, Frucht S, Scott W, Klein C, Brice A, Roomere H, Ottman R, Marder K. Construction and validation of a Parkinson's disease mutation genotyping array for the Parkin gene. Mov Disord. 2007; May 15;22(7):932-937.
470. Constantinescu R, Romer M, McDermott MP, Kamp C, Kieburtz K; CALM-PD Investigators of the Parkinson Study Group. Impact of pramipexole on the onset of levodopa-related dyskinesias. Mov Disord. 2007 Jul 15;22(9):1317-1319.
471. Sanotsky Y, Lesyk R, Fedoryshyn L, Komnatska I, Matviyenko Y, Fahn S. Manganic encephalopathy due to "ephedrone" abuse. Mov Disord. 2007 Jul 15;22(9):1337-1343.
472. Biglan KM, Holloway RG Jr, McDermott MP, Richard IH; Parkinson Study Group CALM-PD Investigators. Risk factors for somnolence, edema, and hallucinations in early Parkinson disease. Neurology 2007 Jul 10;69(2):187-195.
473. Clark LN, Ross BM, Wang Y, Mejia-Santana H, Harris J, Louis ED, Cote LJ, Andrews H, Fahn S, Waters C, Ford B, Frucht S, Ottman R, Marder K. Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease. Neurology 2007 Sep 18;69(12):1270-1277.
474 Parkinson Study Group PRECEPT Investigators. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology 2007 Oct 9;69(15):1480-1490.
475. McClelland S 3rd, Vonsattel JP, Garcia RE, Amaya MD, Winfield LM, Pullman SL, Yu Q, Fahn S, Ford B, Goodman RR. Relationship of clinical efficacy to postmortem-determined anatomic subthalamic stimulation in Parkinson syndrome. Clin Neuropathol 2007 Nov-Dec;26(6):267-275.
476. Goetz CG, Wuu J, McDermott MP, Adler CH, Fahn S, Freed CR, Hauser RA, Olanow WC, Shoulson I, Tandon PK, Leurgans S; Parkinson Study Group. Placebo response in Parkinson's disease: Comparisons among 11 trials covering medical and surgical interventions. Mov Disord 2008 Apr 15;23(5):690-699. 477. Marras C, McDermott MP, Rochon PA, Tanner CM, Naglie G, Lang AE; Parkinson Study Group DATATOP Investigators. Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trial. Mov Disord 2008 Apr 15;23(5):653-659.
478. Schwarzschild MA, Schwid SR, Marek K, Watts A, Lang AE, Oakes D, Shoulson I, Ascherio A; Parkinson Study Group PRECEPT Investigators, Hyson C, Gorbold E, Rudolph A, Kieburtz K, Fahn S, Gauger L, Goetz C, Seibyl J, Forrest M, Ondrasik J. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol 2008 Jun;65(6):716-723.
479. Wang Y, Clark LN, Louis ED, Mejia-Santana H, Harris J, Cote LJ, Waters C, Andrews H, Ford B, Frucht S, Fahn S, Ottman R, Rabinowitz D, Marder K. Risk of Parkinson disease in carriers of parkin mutations:
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 89
estimation using the kin-cohort method. Arch Neurol 2008 Apr;65(4):467-474.
480. Frank S, Ondo W, Fahn S, Hunter C, Oakes D, Plumb S, Marshall F, Shoulson I, Eberly S, Walker F, Factor S, Hunt V, Shinaman A, Jankovic J. A study of chorea after tetrabenazine withdrawal in patients with Huntington disease. Clin Neuropharmacol 2008 May-Jun;31(3):127-133.
481. Schifitto G, Friedman JH, Oakes D, Shulman L, Comella CL, Marek K, Fahn S; Parkinson Study Group ELLDOPA Investigators. Fatigue in levodopa-naive subjects with Parkinson disease. Neurology 2008 Aug 12;71(7):481-485.
482. White WB, Salzman P, Schwid SR; Parkinson's Rasagiline: Efficacy and Safety in the Treatment of “Off” Parkinson Study Group. Transtelephonic home blood pressure to assess the monoamine oxidase-B inhibitor rasagiline in Parkinson disease. Hypertension 2008 Sep;52(3):587-593.
483. Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, Lewitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, van Hilten JJ, Lapelle N; for the Movement Disorder Society UPDRS Revision Task Force. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. Mov Disord 2008 Nov 15;23(15):2129-2170.
484. Clark LN, Kartsaklis LA, Wolf Gilbert R, Dorado B, Ross BM, Kisselev S, Verbitsky M, Mejia-Santana H, Cote LJ, Andrews H, Vonsattel JP, Fahn S, Mayeux R, Honig LS, Marder K. Association of glucocerebrosidase mutations with dementia with lewy bodies. Arch Neurol. 2009 May;66(5):578-583.
485. Parkinson Study Group CALM Cohort Investigators. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Arch Neurol. 2009 May;66(5):563-570.
486. Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, Bar-Shira A, Berg D, Bras J, Brice A, Chen CM, Clark LN, Condroyer C, De Marco EV, Dürr A, Eblan MJ, Fahn S, Farrer MJ, Fung HC, Gan-Or Z, Gasser T, Gershoni-Baruch R, Giladi N, Griffith A, Gurevich T, Januario C, Kropp P, Lang AE, Lee-Chen GJ, Lesage S, Marder K, Mata IF, Mirelman A, Mitsui J, Mizuta I, Nicoletti G, Oliveira C, Ottman R, Orr-Urtreger A, Pereira LV, Quattrone A, Rogaeva E, Rolfs A, Rosenbaum H, Rozenberg R, Samii A, Samaddar T, Schulte C, Sharma M, Singleton A, Spitz M, Tan EK, Tayebi N, Toda T, Troiano AR, Tsuji S, Wittstock M, Wolfsberg TG, Wu YR, Zabetian CP, Zhao Y, Ziegler SG. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med. 2009 Oct 22;361(17):1651-1661.
487. Ravina B, Tanner C, Dieuliis D, Eberly S, Flagg E, Galpern WR, Fahn S, Goetz CG, Grate S, Kurlan R, Lang AE, Marek K, Kieburtz K, Oakes D, Elliott R, Shoulson I; The Parkinson Study Group LABS-PD Investigators. A longitudinal program for biomarker development in Parkinson's disease: A feasibility study. Mov Disord. 2009 Oct 30;24(14):2081-2090.
488. Uc EY, McDermott MP, Marder KS, Anderson SW, Litvan I, Como PG, Auinger P, Chou KL, Growdon JC; Parkinson Study Group DATATOP Investigators. Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort. Neurology. 2009 Nov 3;73(18):1469-1477.
489. Hauser RA, Auinger P, Oakes D; on behalf of the Parkinson Study Group. Levodopa response in early Parkinson's disease. Mov Disord. 2009 Nov 11;24(16):2328-2336.
490 Marras C, Lang AE, Eberly SW, Oakes D, Fahn S, Schwid SR, Hyson C, Shoulson I, Parkinson Study Group DATATOP and PRECEPT investigators. A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts. Mov Disord.2009 Dec 15;24(16):2370-2378.
491. Ascherio A, LeWitt PA, Xu K, Eberly S, Watts A, Matson WR, Marras C, Kieburtz K, Rudolph A, Bogdanov MB, Schwid SR, Tennis M, Tanner CM, Beal MF, Lang AE, Oakes D, Fahn S, Shoulson I, Schwarzschild MA; Parkinson Study Group DATATOP Investigators. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol. 2009 Dec;66(12):1460-1468.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 90
492. Alcalay RN, Mejia-Santana H, Tang MX, Rosado L, Verbitsky M, Kisselev S, Ross BM, Louis ED, Comella CL, Colcher A, Jennings D, Nance MA, Bressman S, Scott WK, Tanner C, Mickel SF, Andrews HF, Waters CH, Fahn S, Cote LJ, Frucht SJ, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer R, Marsh L, Hiner B, Siderowf A, Caccappolo E, Ottman R, Clark LN, Marder KS. Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson disease. Arch Neurol. 2009 Dec;66(12):1517-1522. 493. Frank S. Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators. BMC Neurol. 2009 Dec 18;9:62. 494. Ma Y, Tang C, Chaly T, Greene P, Breeze R, Fahn S, Freed C, Dhawan V, Eidelberg D. Dopamine cell implantation in Parkinson's disease: Long-term clinical and 18F-FDOPA PET outcomes. J Nucl Med. 2010 Jan;51(1):7-15.
495. Tang CC, Poston KL, Eckert T, Feigin A, Frucht S, Gudesblatt M, Dhawan V, Lesser M, Vonsattel JP, Fahn S, Eidelberg D. Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis. Lancet Neurol. 2010 Feb;9(2):149-158.
496. Alcalay RN, Mejia-Santana H, Tang MX, Rakitin B, Rosado L, Ross B, Verbitsky M, Kisselev S, Louis ED, Comella CL, Colcher A, Jennings D, Nance MA, Bressman S, Scott WK, Tanner C, Mickel SF, Andrews HF, Waters CH, Fahn S, Cote LJ, Frucht SJ, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer R, Marsh L, Hiner B, Siderowf A, Ottman R, Clark LN, Marder KS, Caccappolo E. Self-report of cognitive impairment and mini-mental state examination performance in PRKN, LRRK2, and GBA carriers with early onset Parkinson's disease. J Clin Exp Neuropsychol. 2010 Feb 24:1-5.
497. Marder KS, Tang MX, Mejia-Santana H, Rosado L, Louis ED, Comella CL, Colcher A, Siderowf AD, Jennings D, Nance MA, Bressman S, Scott WK, Tanner CM, Mickel SF, Andrews HF, Waters C, Fahn S, Ross BM, Cote LJ, Frucht S, Ford B, Alcalay RN, Rezak M, Novak K, Friedman JH, Pfeiffer RF, Marsh L, Hiner B, Neils GD, Verbitsky M, Kisselev S, Caccappolo E, Ottman R, Clark LN. Predictors of parkin mutations in early-onset Parkinson disease: the consortium on risk for early-onset Parkinson disease study. Arch Neurol. 2010 Jun;67(6):731-738.
498. Goetz CG, Stebbins GT, Chmura TA, Fahn S, Poewe W, Tanner CM. Teaching program for the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale: (MDS-UPDRS). Mov Disord. 2010 Jul 15;25(9):1190-1194.
499. Gilbert RM, Fahn S, Mitsumoto H, Rowland LP. Parkinsonism and motor neuron diseases: Twenty-seven patients with diverse overlap syndromes. Mov Disord. 2010 Sep 15;25(12):1868-75
500. Alcalay RN, Caccappolo E, Mejia-Santana H, Tang MX, Rosado L, Ross BM, Verbitsky M, Kisselev S, Louis ED, Comella C, Colcher A, Jennings D, Nance MA, Bressman SB, Scott WK, Tanner C, Mickel S, Andrews H, Waters C, Fahn S, Cote L, Frucht S, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer R, Marsh L, Hiner B, Siderowf A, Ottman R, Marder K, Clark LN. Frequency of known mutations in early-onset Parkinson disease: implication for genetic counseling: the consortium on risk for early onset Parkinson disease study. Arch Neurol. 2010 Sep;67(9):1116-22.
501. Schwid SR, Bausch J, Oakes D, Schuchter L, Tanner C, Forrest M, Lang AE, Shoulson I; PSG PRECEPT Investigators, Shoulson I, Hyson C, Oakes D, Flagg E, Rudolph A, Kieburtz K, Lang A, Fahn S, Gauger L, Goetz C. Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease. Mov Disord. 2010 Sep 15;25(12):1801-8.
502. Caccappolo E, Alcalay RN, Mejia-Santana H, Tang MX, Rakitin B, Rosado L, Louis ED, Comella CL, Colcher A, Jennings D, Nance MA, Bressman S, Scott WK, Tanner CM, Mickel SF, Andrews HF, Waters C, Fahn S, Cote LJ, Frucht S, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer RF, Marsh L, Hiner B, Siderowf AD, Ross BM, Verbitsky M, Kisselev S, Ottman R, Clark LN, Marder KS. Neuropsychological profile of Parkin mutation carriers with and without Parkinson disease: The CORE-PD Study. J Int Neuropsychol Soc. 2011 Jan;17(1):91-100
503. Alcalay RN, Siderowf A, Ottman R, Caccappolo E, Mejia-Santana H, Tang MX, Rosado L, Louis E, Ruiz D, Waters C, Fahn S, Cote L, Frucht S, Ford B, Orbe-Reilly M, Ross B, Verbitsky M, Kisselev S, Comella C,
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 91
Colcher A, Jennings D, Nance M, Bressman S, Scott WK, Tanner C, Mickel S, Rezak M, Novak KE, Friedman JH, Pfeiffer R, Marsh L, Hiner B, Clark LN, Marder K. Olfaction in Parkin heterozygotes and compound heterozygotes: The CORE-PD study. Neurology. 2011 Jan 25;76(4):319-26.
504. Marras C, McDermott MP, Marek K, Rochon P, Naglie G, Tanner CM, Rudolph A, Shoulson I, Lang AE; on behalf of the Parkinson Study Group DATATOP and PRECEPT investigators. Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts. Mov Disord. 2011 Mar;26(4):608-613.
505. Donovan S, Lim C, Diaz N, Browner N, Rose P, Sudarsky LR, Tarsy D, Fahn S, Simon DK. LaserLight cues for gait freezing in Parkinson's disease: An open-label study. Parkinsonism Relat Disord. 2011 May;17(4):240-5
506. Liu X, Cheng R, Verbitsky M, Kisselev S, Browne A, Mejia-Sanatana H, Louis ED, Cote LJ, Andrews H, Waters C, Ford B, Frucht S, Fahn S, Marder K, Clark LN, Lee JH. Genome-Wide association study identifies candidate genes for Parkinson's disease in an Ashkenazi Jewish population. BMC Med Genet. 2011 Aug 3;12:104.
507: Schwarzschild MA, Marek K, Eberly S, Oakes D, Shoulson I, Jennings D, Seibyl J, Ascherio A; Parkinson Study Group PRECEPT Investigators. Serum urate and probability of dopaminergic deficit in early "Parkinson's disease". Mov Disord. 2011 Aug 15;26(10):1864-8.
508. Srivastava A, Tang MX, Mejia-Santana H, Rosado L, Louis ED, Caccappolo E, Comella C, Colcher A, Siderowf A, Jennings D, Nance M, Bressman S, Scott WK, Tanner C, Mickel S, Andrews H, Waters C, Fahn S, Cote L, Frucht S, Ford B, Alcalay RN, Ross B, Orbe Reilly M, Rezak M, Novak K, Friedman JH, Pfeiffer RD, Marsh L, Hiner B, Merle D, Ottman R, Clark LN, Marder K. The relation between depression and parkin genotype: The CORE-PD study. Parkinsonism Relat Disord. 2011 Dec;17(10):740-4.
509. Ma JF, Xin XY, Liang L, Liu LH, Fang R, Zhang YJ, Wang DY, Fahn S, Tang HD, Chen SD. Restless legs syndrome in Chinese elderly people of an urban suburb in Shanghai: A community-based survey. Parkinsonism Relat Disord. 2012 Mar;18(3):294-8.
510. Lees A, Fahn S, Eggert KM, Jankovic J, Lang A, Micheli F, Maral Mouradian M, Oertel WH, Olanow CW, Poewe W, Rascol O, Tolosa E, Squillacote D, Kumar D. Perampanel, an AMPA antagonist, Found to have no benefit in reducing "Off" time in Parkinson's disease. Mov Disord. 2012 Feb;27(2):284-8.
511: Pankratz N, Beecham GW, DeStefano AL, Dawson TM, Doheny KF, Factor SA, Hamza TH, Hung AY, Hyman BT, Ivinson AJ, Krainc D, Latourelle JC, Clark LN, Marder K, Martin ER, Mayeux R, Ross OA, Scherzer CR, Simon DK, Tanner C, Vance JM, Wszolek ZK, Zabetian CP, Myers RH, Payami H, Scott WK, Foroud T; PD GWAS Consortium. Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2. Ann Neurol. 2012 Mar;71(3):370-84.
512. Kang UJ, Auinger P; Parkinson Study Group ELLDOPA Investigators. Activity enhances dopaminergic long-duration response in Parkinson disease. Neurology. 2012 Apr 10;78(15):1146-9.
513. Poston KL, Tang CC, Eckert T, Dhawan V, Frucht S, Vonsattel JP, Fahn S, Eidelberg D. Network correlates of disease severity in multiple system atrophy. Neurology. 2012 Apr 17;78(16):1237-44.
514. Alcalay RN, Caccappolo E, Mejia-Santana H, Tang M-, Rosado L, Orbe Reilly M, Ruiz D, Ross B, Verbitsky M, Kisselev S, Louis E, Comella C, Colcher A, Jennings D, Nance M, Bressman S, Scott WK, Tanner C, Mickel S, Andrews H, Waters C, Fahn S, Cote L, Frucht S, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer R, Marsh L, Hiner B, Siderowf A, Payami H, Molho E, Factor S, Ottman R, Clark LN, Marder K. Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study. Neurology. 2012 May 1;78(18):1434-40.
515. Poulopoulos M, Cortes E, Vonsattel JP, Fahn S, Waters C, Cote LJ, Moskowitz C, Honig LS, Clark LN, Marder KS, Alcalay RN. Clinical and pathological characteristics of LRRK2 G2019S patients with PD. J Mol Neurosci. 2012 May;47(1):139-43.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 92
516. Barrett MJ, Bressman SB, Levy OA, Fahn S, O'Dell MW. Functional electrical stimulation for the treatment of lower extremity dystonia. Parkinsonism Relat Disord. 2012 Jun;18(5):660-1.
517. Elble R, Comella C, Fahn S, Hallett M, Jankovic J, Juncos JL, Lewitt P, Lyons K, Ondo W, Pahwa R, Sethi K, Stover N, Tarsy D, Testa C, Tintner R, Watts R, Zesiewicz T. Reliability of a new scale for essential tremor. Mov Disord. 2012 Oct;27(12):1567-9.
518. Elm JJ; NINDS NET-PD Investigators. Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1. Mov Disord. 2012 Oct;27(12):1513-21.
519: Kuo SH, Xie T, Fahn S. Anticholinergic responsive cyclic myoclonus. Mov Disord. 2013 Mar;28(3):401-2.
520. Klein C, Fahn S. Translation of Oppenheim's 1911 paper on dystonia. Mov Disord. 2013 Jun 15;28(7):851- 62.
521. Albanese A, Bhatia K, Bressman SB, Delong MR, Fahn S, Fung VS, Hallett M, Jankovic J, Jinnah HA, Klein C, Lang AE, Mink JW, Teller JK. Phenomenology and classification of dystonia: A consensus update. Mov Disord. 2013 Jun 15;28(7):863-73.
522. Liu X, Cheng R, Ye X, Verbitsky M, Kisselev S, Mejia-Santana H, Louis E, Cote L, Andrews H, Waters C, Ford B, Fahn S, Marder K, Lee J, Clark L. Increased Rate of Sporadic and Recurrent Rare Genic Copy Number Variants in Parkinson's Disease Among Ashkenazi Jews. Mol Genet Genomic Med. 2013 Sep;1(3):142-154.
523. Marder K, Gu Y, Eberly S, Tanner CM, Scarmeas N, Oakes D, Shoulson I; Huntington Study Group PHAROS Investigators. Relationship of Mediterranean diet and caloric intake to phenoconversion in Huntington disease. JAMA Neurol. 2013 Nov;70(11):1382-8.
524. Alcalay RN, Mirelman A, Saunders-Pullman R, Tang MX, Mejia Santana H, Raymond D, Roos E, Orbe- Reilly M, Gurevich T, Bar Shira A, Gana Weisz M, Yasinovsky K, Zalis M, Thaler A, Deik A, Barrett MJ, Cabassa J, Groves M, Hunt AL, Lubarr N, San Luciano M, Miravite J, Palmese C, Sachdev R, Sarva H, Severt L, Shanker V, Swan MC, Soto-Valencia J, Johannes B, Ortega R, Fahn S, Cote L, Waters C, Mazzoni P, Ford B, Louis E, Levy O, Rosado L, Ruiz D, Dorovski T, Pauciulo M, Nichols W, Orr-Urtreger A, Ozelius L, Clark L, Giladi N, Bressman S, Marder KS. Parkinson disease phenotype in Ashkenazi jews with and without LRRK2 G2019S mutations. Mov Disord. 2013 Dec;28(14):1966-71
525. Alcalay RN, Caccappolo E, Mejia-Santana H, Tang MX, Rosado L, Orbe Reilly M, Ruiz D, Louis ED, Comella CL, Nance MA, Bressman SB, Scott WK, Tanner CM, Mickel SF, Waters CH, Fahn S, Cote LJ, Frucht SJ, Ford B, Rezak M, Novak KE, Friedman JH, Pfeiffer RF, Marsh L, Hiner B, Payami H, Molho E, Factor SA, Nutt JG, Serrano C, Arroyo M, Ottman R, Pauciulo MW, Nichols WC, Clark LN, Marder KS. Cognitive and Motor Function in Long-Duration PARKIN-Associated Parkinson Disease. JAMA Neurol. 2014 Jan 1;71(1):62-7.
526. Galpern WR, Coffey CS, Albanese A, Cheung K, Comella CL, Ecklund DJ, Fahn S, Jankovic J, Kieburtz K, Lang AE, McDermott MP, Shefner JM, Teller JK, Thompson JL, Yeatts SD, Jinnah HA. Designing Clinical Trials for Dystonia. Neurotherapeutics. 2014 Jan;11(1):117-27.
527. Pahwa R, Lyons KE, Hauser RA, Fahn S, Jankovic J, Pourcher E, Hsu A, O'Connell M, Kell S, Gupta S; APEX-PD Investigators. Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease. Parkinsonism Relat Disord. 2014 Feb;20(2):142-8.
528. Arkadir D, Bergman H, Fahn S. Redundant dopaminergic activity may enable compensatory axonal sprouting in Parkinson disease. Neurology. 2014 Mar 25;82(12):1093-8.
529. Tanner CM, Meng CC, Ravina B, Lang A, Kurlan R, Marek K, Oakes D, Seibyl J, Flagg E, Gauger L, Guest DD, Goetz CG, Kieburtz K, Dieuliis D, Fahn S, Elliott RA, Shoulson I. A practical approach to remote longitudinal follow-up of Parkinson's disease: The FOUND study. Mov Disord. 2014 May;29(6):743-9.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 93
530. Alcalay RN, Dinur T, Quinn T, Sakanaka K, Levy O, Waters C, Fahn S, Dorovski T, Chung WK, Pauciulo M, Nichols W, Rana HQ, Balwani M, Bier L, Elstein D, Zimran A. Comparison of Parkinson Risk in Ashkenazi Jewish Patients With Gaucher Disease and GBA Heterozygotes. JAMA Neurol. 2014 Jun;71(6):752-7.
531. Fahn S, Olanow CW. "Psychogenic Movement Disorders": They Are What They Are. Mov Disord. 2014 Jun;29(7):853-6.
532. Fahn S, Olanow CW. Reply to: psychogenic movement disorders: what's in a name? Mov Disord. 2014 Nov;29(13):1699-701.
533. Simon KC, Eberly S, Gao X, Oakes D, Tanner CM, Shoulson I, Fahn S, Schwarzschild MA, Ascherio A; Parkinson Study Group. Mendelian randomization of serum urate and parkinson disease progression. Ann Neurol. 2014 Dec;76(6):862-8.
534. Jennings D, Eberly S, Oakes D, Seibyl J, Marek K, Shoulson I; Parkinson Study Group PRECEPT Investigators. Impact of disclosure of individual imaging results in a multi-center Parkinson clinical trial. J Parkinsons Dis. 2014;4(4):629-38.
535. Fahn S. The medical treatment of Parkinson disease from James Parkinson to George Cotzias. Mov Disord. 2015 Jan;30(1):4-18.
536. Fowler JS, Logan J, Volkow ND, Shumay E, McCall-Perez F, Jayne M, Wang GJ, Alexoff DL, Apelskog- Torres K, Hubbard B, Carter P, King P, Fahn S, Gilmor M, Telang F, Shea C, Xu Y, Muench L. Evidence that formulations of the selective MAO-B inhibitor, selegiline, which bypass first-pass metabolism, also inhibit MAO-A in the human brain. Neuropsychopharmacology. 2015 Feb;40(3):650-7.
537. Sharp ME, Caccappolo E, Mejia-Santana H, Tang MX, Rosado L, Orbe Reilly M, Ruiz D, Louis ED, Comella C, Nance M, Bressman S, Scott WK, Tanner C, Waters C, Fahn S, Cote L, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer R, Payami H, Molho E, Factor SA, Nutt J, Serrano C, Arroyo M, Pauciulo MW, Nichols WC, Clark LN, Alcalay RN, Marder KS. The relationship between obsessive-compulsive symptoms and PARKIN genotype: The CORE-PD study. Mov Disord. 2015 Feb;30(2):278-83.
538. Writing Group for the NINDS Exploratory Trials in Parkinson Disease (NET-PD) Investigators, Kieburtz K, Tilley BC, Elm JJ, Babcock D, Hauser R, et al. Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. JAMA. 2015 Feb 10;313(6):584-93.
539. Hall DA, Birch RC, Anheim M, Jønch AE, Pintado E, O'Keefe JA, Trollor JN, Stebbins GT, Hagerman RJ, Fahn S, Berry-Kravis E, Leehey MA. Emerging topics in FXTAS. J Neurodev Disord. 2015;7(1):13.
540. Clark LN, Chan R, Cheng R, Liu X, Park N, Parmalee N, Kisselev S, Cortes E, Torres PA, Pastores GM, Vonsattel JP, Alcalay R, Marder K, Honig LL, Fahn S, Mayeux R, Shelanski M, Di Paolo G, Lee JH. Gene- wise association of variants in four lysosomal storage disorder genes in neuropathologically confirmed lewy body disease. PLoS One. 2015 May 1;10(5):e0125204.
541. Gan-Or Z, Alcalay RN, Bar-Shira A, Leblond CS, Postuma RB, Ben-Shachar S, Waters C, Johnson A, Levy O, Mirelman A, Gana-Weisz M, Dupré N, Montplaisir J, Giladi N, Fahn S, Xiong L, Dion PA, Orr-Urtreger A, Rouleau GA. Genetic markers of Restless Legs Syndrome in Parkinson disease. Parkinsonism Relat Disord. 2015 Jun;21(6):582-5.
542. Nomura Y, Fahn S. Obituary: Masaya Segawa, MD, PhD, 1936-2014. Mov Disord. 2015 Jun;30(7):883-5.
543. Marder K, Wang Y, Alcalay RN, Mejia-Santana H, Tang MX, Lee A, Raymond D, Mirelman A, Saunders- Pullman R, Clark L, Ozelius L, Orr-Urtreger A, Giladi N, Bressman S; LRRK2 Ashkenazi Jewish Consortium. Age-specific penetrance of LRRK2 G2019S in the Michael J. Fox Ashkenazi Jewish LRRK2 Consortium. Neurology. 2015 Jul 7;85(1):89-95.
544. Alcalay RN, Levy OA, Waters CC, Fahn S, Ford B, Kuo SH, Mazzoni P, Pauciulo MW, Nichols WC, Gan-Or
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 94
Z, Rouleau GA, Chung WK, Wolf P, Oliva P, Keutzer J, Marder K, Zhang X. Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations. Brain. 2015 Sep;138(Pt 9):2648-58. PMID: 26117366.
545. McCarthy A, Lonergan R, Olszewska DA, O'Dowd S, Cummins G, Magennis B, Fallon EM, Pender N, Huey ED, Cosentino S, O'Rourke K, Kelly BD, O'Connell M, Delon I, Farrell M, Spillantini MG, Rowland LP, Fahn S, Craig P, Hutton M, Lynch T. Closing the tau loop: the missing tau mutation. Brain. 2015 Oct;138(Pt 10):3100-9. PMID: 26297556.
546. Saunders-Pullman R, Alcalay RN, Mirelman A, Wang C, Luciano MS, Ortega RA, Glickman A, Raymond D, Mejia-Santana H, Doan N, Johannes B, Yasinovsky K, Ozelius L, Clark L, Orr-Utreger A, Marder K, Giladi N, Bressman SB; AJ LRRK2 Consortium. REM sleep behavior disorder, as assessed by questionnaire, in G2019S LRRK2 mutation PD and carriers. Mov Disord. 2015 Nov;30(13):1834-9. doi: 10.1002/mds.26413. PubMed PMID: 26366513.
547. Virmani T, Moskowitz CB, Vonsattel JP, Fahn S. Clinicopathological characteristics of freezing of gait in autopsy-confirmed Parkinson's disease. Mov Disord. 2015 Dec;30(14):1874-84. doi: 10.1002/mds.26346. PMID: 26234730.
548. Robakis D, Fahn S, Kestenbaum M. Essential tips for videotaping a movement disorders patient encounter. Mov Disord Clin Pract 2015 Jun 30. doi: 10.1002/mdc3.12204.
549. Huntington Study Group PHAROS Investigators, et al. Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials. JAMA Neurol. 2016 Jan 1;73(1):102-10. doi: 10.1001/jamaneurol.2015.2736. PMID: 26569098
550. LeWitt PA, Fahn S. Levodopa therapy for Parkinson disease: A look backward and forward. Neurology. 2016 Apr 5;86(14 Suppl 1):S3-S12. doi: 10.1212/WNL.0000000000002509. Epub 2016 Apr 4. PubMed PMID: 27044648.
551. Fahn S. Obituary: Oliver Sacks, MD, 1933-2015. Mov Disord. 2016 Apr;31(4):493-6. doi: 10.1002/mds.26602. PubMed PMID: 27079682.
552. Alcalay RN, Levy OA, Wolf P, Oliva P, Zhang XK, Waters CH, Fahn S, Kang U, Liong C, Ford B, Mazzoni P, Kuo S, Johnson A, Xiong L, Rouleau GA, Chung W, Marder KS, Gan-Or Z. SCARB2 variants and glucocerebrosidase activity in Parkinson's disease. NPJ Parkinsons Dis. 2016;2. pii: 16004. Epub 2016 Mar 10. PubMed PMID: 27110593. PubMed Central PMCID: PMC4838276.
553. Sampson JB, Michaeli TH, Wright BA, Goldman JE, Vonsattel J-P, Fahn S. Basal ganglia gliosis in a case of rapid-onset dystonia-parkinsonism (DYT12) with a novel mutation in ATPase 1A3 (ATP1A3). Mov Disord Clin Pract, 2016;3:618–620. DOI: 10.1002/mdc3.12354. http://dx.doi.org/10.1002/mdc3.12354
554. LeWitt PA, Li J, Lu M, Guo L, Auinger P; Parkinson Study Group–DATATOP Investigators.. Metabolomic biomarkers as strong correlates of Parkinson disease progression. Neurology. 2017 Feb 8. pii: 10.1212/WNL.0000000000003663. doi: 10.1212/WNL.0000000000003663. [Epub ahead of print] PubMed PMID: 28179471.
555. Fahn S. Personal reflections about Lewis P. (Bud) Rowland (1925-2017). Neurology. 2017 May 30;88(22):2078-2079. doi: 10.1212/WNL.0000000000004050. PubMed PMID: 28554897.
556. Rodríguez-Violante M, Cervantes-Arriaga A, Fahn S, Tolosa E. Two-hundred Years Later: Is Parkinson's Disease a Single Defined Entity? Rev Invest Clin. 2017 Nov-Dec;69(6):308-313. doi: 10.24875/RIC.17002291. PubMed PMID: 29265118.
557. Martelli D, Luo L, Kang J, Kang UJ, Fahn S, Agrawal SK. Adaptation of Stability during Perturbed Walking in Parkinson's Disease. Sci Rep. 2017 Dec19;7(1):17875. doi: 10.1038/s41598-017-18075-6. PubMed PMID: 29259237; PubMed Central PMCID: PMC5736588.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 95
558. Schobel SA, Palermo G, Auinger P, Long JD, Ma S, Khwaja OS, Trundell D, Cudkowicz M, Hersch S, Sampaio C, Dorsey ER, Leavitt BR, Kieburtz KD, Sevigny JJ, Langbehn DR, Tabrizi SJ; TRACK-HD, COHORT, CARE-HD, and 2CARE Huntington Study Group Investigators. Motor, cognitive, and functional declines contribute to a single progressive factor in early HD. Neurology. 2017 Dec 12;89(24):2495- 2502.doi: 10.1212/WNL.0000000000004743. Epub 2017 Nov 15. PubMed PMID: 29142089; PubMed Central PMCID: PMC5729794.
559. Alcalay RN, Wolf P, Levy OA, Kang UJ, Waters C, Fahn S, Ford B, Kuo SH, Vanegas N, Shah H, Liong C, Narayan S, Pauciulo MW, Nichols WC, Gan-Or Z, Rouleau GA, Chung WK, Oliva P, Keutzer J, Marder K, Zhang XK. Alpha galactosidase A activity in Parkinson's disease. Neurobiol Dis. 2018 Apr;112:85-90. doi: 10.1016/j.nbd.2018.01.012. Epub 2018 Feb 2. PubMed PMID: 29369793; PubMed Central PMCID: PMC5811339.
560. Frei K, Truong DD, Fahn S, Jankovic J, Hauser RA. The nosology of tardive syndromes. J Neurol Sci. 2018 Jun 15;389:10-16. doi: 10.1016/j.jns.2018.02.008. Epub 2018 Feb 6. PMID: 29433810
561. Bhidayasiri R, Jitkritsadakul O, Friedman JH, Fahn S. Updating the recommendations for treatment of tardive syndromes: A systematic review of new evidence and practical treatment algorithm. J Neurol Sci. 2018 Jun 15;389:67-75. doi: 10.1016/j.jns.2018.02.010. Epub 2018 Feb 5. Review. PMID: 29454493
562. Kim R, Lee J, Kim Y, Kim A, Jang M, Kim HJ, Jeon B, Kang UJ, Fahn S. Presynaptic striatal dopaminergic depletion predicts the later development of freezing of gait in de novo Parkinson's disease: An analysis of the PPMI cohort. Parkinsonism Relat Disord. 2018 Feb 28. pii: S1353-8020(18)30113-5. doi: 10.1016/j.parkreldis.2018.02.047. [Epub ahead of print] PubMed PMID: 29523394.
563. Isaacson SH, Fahn S, Pahwa R, Tanner CM, Espay AJ, Trenkwalder C, Adler CH, Patni R, Johnson R. Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open-label ADS- 5102. Mov Disord Clin Pract. 2018 Mar-Apr;5(2):183-190. doi: 10.1002/mdc3.12595. Epub 2018 Feb 23. PubMed PMID: 29780852; PubMed Central PMCID: PMC5947645.
564. Sulzer D, Cassidy C, Horga G, Kang UJ, Fahn S, Casella L, Pezzoli G, Langley J, Hu XP, Zucca FA, Isaias IU, Zecca L. Neuromelanin detection by magnetic resonance imaging (MRI) and its promise as a biomarker for Parkinson's disease. NPJ Parkinsons Dis. 2018 Apr 10;4:11. doi: 10.1038/s41531-018-0047-3. eCollection 2018. Review. PubMed PMID: 29644335; PubMed Central PMCID: PMC5893576.
565. Gupta DK, Fahn S, Tatsuoka C, Kang UJ. Hoehn and Yahr stage 3 and postural stability item in the movement disorder society-unified Parkinson's disease rating scale. Mov Disord. 2018 Jul;33(7):1188- 1189. doi: 10.1002/mds.27453. PubMed PMID: 30153396.
566. Shah H, Liong C, Levy OA, Waters C, Fahn S, Marder K, Kang UJ, Wolf P, Oliva P, Zhang K, Alcalay RN, Gutierrez J. Association of Low Lysosomal Enzymes Activity With Brain Arterial Dilatation. Stroke. 2018 Aug;49(8):1977-1980. doi: 10.1161/STROKEAHA.118.021964. PubMed PMID: 29986930; PubMed Central PMCID: PMC6202241.
567. Merchant SH, Vial F, Leodori G, Fahn S, Pullman SL, Hallett M. A novel exaggerated "spino-bulbo-spinal like" reflex of lower brainstem origin. Parkinsonism Relat Disord. 2018 Oct 6. pii: S1353-8020(18)30435-8. doi: 10.1016/j.parkreldis.2018.10.007. [Epub ahead of print] PubMed PMID: 30316728. 30316728; PubMed Central PMCID: PMC6451678.
568. McRae C, Caspari J, Russell D, Ellgring H, Bezzant C, Greene P, Fahn S. Video Review of Baseline Performance on Global Ratings in a Double-Blind Placebo Surgery Trial. Mov Disord Clin Pract. 2018 Oct 4;5(6):597-602. doi: 10.1002/mdc3.12666. eCollection 2018 Nov-Dec. PubMed PMID: 30637279; PubMed Central PMCID: PMC6277360.
569. Rudakou U, Ouled Amar Bencheikh B, Ruskey JA, Krohn L, Laurent SB, Spiegelman D, Liong C, Fahn S, Waters C, Monchi O, Fon EA, Dauvilliers Y, Alcalay RN, Dupré N, Gan-Or Z. Common and rare GCH1 variants are associated with Parkinson's disease. Neurobiol Aging. 2019 Jan;73:231.e1-231.e6. doi: 10.1016/j.neurobiolaging.2018.09.008. Epub 2018 Sep 15. PubMed PMID: 30314816; PubMed Central
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 96
PMCID: PMC6251729.
570. Fahn S, Sulzer D, Kang UJ, Bressman S. In memoriam: Robert E. Burke, MD, 1949-2018. Mov Disord. 2019 Jan;34(1):35-40. doi: 10.1002/mds.27612. PubMed PMID: 30653722.
571. Ruskey JA, Greenbaum L, Roncière L, Alam A, Spiegelman D, Liong C, Levy OA, Waters C, Fahn S, Marder KS, Chung W, Yahalom G, Israeli-Korn S, Livneh V, Fay-Karmon T, Alcalay RN, Hassin-Baer S, Gan-Or Z. Increased yield of full GBA sequencing in Ashkenazi Jews with Parkinson's disease. Eur J Med Genet. 2019 Jan;62(1):65-69. doi: 10.1016/j.ejmg.2018.05.005. Epub 2018 May 26. PubMed PMID: 29842932; PubMed Central PMCID: PMC6261782.
572. Alcalay RN, Mallett V, Vanderperre B, Tavassoly O, Dauvilliers Y, Wu RYJ, Ruskey JA, Leblond CS, Ambalavanan A, Laurent SB, Spiegelman D, Dionne-Laporte A, Liong C, Levy OA, Fahn S, Waters C, Kuo SH, Chung WK, Ford B, Marder KS, Kang UJ, Hassin-Baer S, Greenbaum L, Trempe JF, Wolf P, Oliva P, Zhang XK, Clark LN, Langlois M, Dion PA, Fon EA, Dupre N, Rouleau GA, Gan-Or Z. SMPD1 mutations, activity, and α-synuclein accumulation in Parkinson's disease. Mov Disord. 2019 Apr;34(4):526-535. doi: 10.1002/mds.27642. Epub 2019 Feb 20. PubMed PMID: 30788890.
BOOKS PUBLISHED
1. Fahn S, Michels R. Medical Examination Review Book: Psychiatry and Neurology. 1961-1962 Journal Review. Med Exam Publ Co. Inc., Flushing, NY, 1963.
2. Eldridge R, Fahn S, eds: Dystonia, Adv Neurol, vol 14, New York, Raven Press, 1976.
3. Fahn S, Davis JN, Rowland LP, eds. Cerebral Hypoxia and Its Consequences. Adv Neurol, vol. 26. New York, Raven Press, 1979.
4. Marsden CD, Fahn S, editors: Movement Disorders. Butterworth's International Medical Reviews: Neurology 2. London, Butterworth Scientific, 1982.
5. Fahn S, Calne DB, Shoulson I: Editors, Experimental Therapeutics of Movement Disorders. Advances in Neurology, Vol 37, New York, Raven Press, 1983.
6. Fahn S, Marsden CD, Jenner P, Teychenne P, eds: Recent Developments in Parkinsonism. New York, Raven Press, 1986.
7. Fahn S, Marsden CD, Van Woert MH, eds: Myoclonus. Adv Neurol, New York, Raven Press, 1986.
8. Marsden CD, Fahn S, editors: Movement Disorders 2. Butterworth's International Medical Reviews. London:Butterworths, 1987.
9. Fahn S, Marsden CD, Calne DB, Goldstein M, eds: Recent Developments in Parkinson's Disease, vol. 2. Florham Park, NJ: Macmillan Healthcare, 1987.
10. Fahn S, Marsden CD, Calne DB, eds: Dystonia 2. Adv Neurol. vol. 50, Raven Press, New York, 1988.
11. Marsden CD, Fahn S, eds. The Assessment and Therapy of Parkinsonism. New Trends in Clinical Neurology. Parthenon Publishing, Carnforth, UK, 1991.
12. Blitzer A, Brin MF, Sasaki CT, Fahn S, Harris KS, eds: Neurologic Disorders of the Larnyx. New York, Thieme Medical Pub. Inc., 1992.
13. Marsden CD, Fahn S, editors: Movement Disorders 3. Oxford, Butterworth-Heinemann, 1994.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 97
14. Fahn S, Hallett M, Lueders HO, Marsden CD, eds. Negative Motor Phenomena. Adv Neurol, vol. 67, 1995; Philadelphia:Lippincott-Raven.
15. Fahn S, Greene PE, Ford B, Bressman SB. Handbook of Movement Disorders. Philadelphia: Current Science, 1998;1-200.
16. Fahn S, Marsden CD, DeLong MR, eds. Dystonia 3. Adv Neurol, Vol. 78. Lippincott-Raven Pub, Philadelphia, 1998.
17. Fahn S, Frucht SJ, Hallett M, Truong DD, eds. Myoclonus and Paroxysmal Dyskinesias. Adv Neurol, Vol. 89. Lippincott Williams & Wilkins, Philadelphia, 2002.
18. Bedard M-A, Agid Y, Chouinard S, Fahn S, Korczyn AD, Lesperance P. Mental and Behavioral Dysfunction in Movement Disorders. Totowa, NJ, Humana Press, 2003.
19. Federoff HJ Burke RE, Fahn S, Fiskum G, eds. Parkinson’s Disease: The Life Cycle of the Dopamine Neuron. Annals of the New York Academy of Sciences, Vol. 991, 2003.
20. Fahn S, Hallett M, DeLong MR, eds. Dystonia 4. Adv Neurol, Vol. 94. Lippincott Williams & Wilkins, Philadelphia, 2004.
21. Frucht SJ, Fahn S, eds. Movement Disorder Emergencies: Diagnosis and Treatment, Humana Press, Totowa, New Jersey, 2005.
22. Hallett M, Fahn S, Jankovic J, Lang AE, Cloninger CR, Yudofsky SC, eds. Psychogenic Movement Disorders – Neurology and Neuropsychiatry, Lippincott Williams & Wilkins, Philadelphia, 2006
23. Fahn S, Jankovic J. Principles and Practice of Movement Disorders. Philadelphia, Churchill Livingstone Elsevier, 2007.
24. Schapira AHV, Lang AET, Fahn S, editors: Movement Disorders 4. Philadelphia, Saunders-Elsevier, 2010.
25. Fahn S, Jankovic J. Hallett M. Principles and Practice of Movement Disorders, 2nd ed. Edinburgh, Saunders Elsevier, 2011.
26. Hallett M, Lang AE, Jankovic J, Fahn S, Halligan PW, Voon V, Cloninger CR, eds. Psychogenic Movement Disorders and Other Conversion Disorders, Cambridge University Press, Cambridge, 2011
CHAPTERS AND REVIEWS PUBLISHED
1. Fahn S: Regional distribution studies of GABA and other putative neurotransmitters and their enzymes. In Roberts E, Chase TN, Tower DB, eds: GABA in Nervous System Function. New York, Raven Press, 1976. pp 169-186.
2. Fahn S: Biochemistry of the basal ganglia. Adv Neurol 1976;14:59-88.
3. Fahn S: Gamma-aminobutyric acid, glycine and other putative amino acid neurotransmitters. In Vinken PJ, Bruyn GW, eds: Handbook of Clinical Neurology, Vol. 29., Metabolic and deficiency disease of the Nervous System, Amsterdam, North-Holland Publishing Co., 1977, pp 485-527.
4. Fahn S, Duffy P: Parkinson's disease. In Goldensohn ES, Appel SH, eds: Scientific Approaches to Clinical Neurology, Philadelphia, Lea & Febiger, 1977. pp 1119-1158.
5. Fahn S: Secondary parkinsonism. In Goldensohn ES, Appel SH, eds: Scientific Approaches to Clinical
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 98
Neurology, Philadelphia, Lea & Febiger, 1977. pp 1159-1189.
6. Fahn S: Posthypoxic action myoclonus: Review of the literature and report of two new cases with response to valproate and estrogen. In: Fahn S, Davis JN, Rowland LP: eds, Cerebral Hypoxia and Its Consquences, New York; Raven Press. Adv Neurol 1979;26:49-84.
7. Ghez C, Fahn S. The cerebellum. In Principles of Neural Sciences, Kandel E. ed. Amsterdam, Elsevier- North-Holland, 1981.
8. Burke RE, Fahn S. Movement Disorders. In Current Neurology, Vol. 3. Appel SH, ed. John Wiley and Sons, New York, 1981;92-137.
9. Fahn S. The extrapyramidal disorders. In Cecil Textbook of Medicine, 16th edition. Wyngaarden JB, Smith LH Jr., eds. Philadelphia, Saunders, 1982;2022-2034.
10, Marsden CD, Fahn S: Problems in Parkinson's disease. In: Movement Disorders. Marsden CD, Fahn S: eds, London, Butterworth Scientific, 1982. pp 1-7.
11. Fahn S: Fluctuations of disability in Parkinson's disease: Pathophysiological aspects. In: Movement Disorders. Marsden CD, Fahn S: eds, London, Butterworth Scientific, 1982. pp 123-145.
12. Marsden CD, Fahn S: Problems in dyskinesias. In: Movement Disorders. Marsden CD, Fahn S: eds. London, Butterworth Scientific, 1982. pp 191-195.
13. Marsden CD, Hallett M, Fahn S: The nosology and pathophysiology of myoclonus. In: Movement Disorders. Marsden CD, Fahn S: eds. London, Butterworth Scientific, 1982. pp 196-248.
14. Marsden CD, Fahn S: Surgical approaches to the dyskinesias: foreword. In: Movement Disorders. Marsden CD, Fahn S: eds. London, Butterworth Scientific, 1982. p 291.
15. Marsden CD, Fahn S: Surgical approaches to the dyskinesias: afterword. In: Movement Disorders. Marsden CD, Fahn S: eds. London, Butterworth Scientific, 1982. p 345-347.
16. Fahn S: editor. Management of Parkinson's disease at different stages of the illness. Clin Neuropharmacol 5: S1-S43, 1982.
17. Burke RE, Fahn S: Movement disorders. In: Current Neurology, Vol 4. Appel SH, ed. New York, John Wiley and Sons, 1982. pp 55-87.
18. Fahn S: Extrapyramidal system. In: Frohlich ED, ed: Pathophysiology, 3rd edition, Philadelphia, J. B. Lippincott Co., 1984. pp. 771-788.
19. Fahn S: Dystonia. In: Hung TP, Lee TK, Hung CC, Munsat TL, eds: Topics in contemparary Neurology, Excerpta Medica, Asia Pacific Congress Series No. 23. pp.22-28, 1984.
20. Fahn S: Myoclonus. In: Hung TP, Lee TK, Hung CC, Munsat TL, eds: Topics in contemparary Neurology, Excerpta Medica, Asia Pacific Congress Series No. 23. pp.74-81, 1984.
21. Fahn S: Involuntary movements. In: Rowland LP, ed: Merritt's Textbook of Neurology, 7th Ed., Philadelphia, Lea & Febiger, 1984. pp. 38-41.
22. Fahn S: Huntington disease and other forms of chorea. In: Rowland LP, ed: Merritt's Textbook of Neurology, 7th Ed., Philadelphia, Lea & Febiger, 1984. pp. 517-521.
23. Fahn S: Myoclonus. In: Rowland LP, ed: Merritt's Textbook of Neurology, 7th Ed., Philadelphia, Lea & Febiger, 1984. p. 521.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 99
24. Fahn S: Gilles de la Tourette syndrome. In: Rowland LP, ed: Merritt's Textbook of Neurology, 7th Ed., Philadelphia, Lea & Febiger, 1984. p. 522.
25. Fahn S: Dystonia. In: Rowland LP, ed: Merritt's Textbook of Neurology, 7th Ed., Philadelphia, Lea & Febiger, 1984. p. 522- 525.
26. Fahn S: Tardive dyskinesia. In: Rowland LP, ed: Merritt's Textbook of Neurology, 7th Ed., Philadelphia, Lea & Febiger, 1984. p. 539-541.
27. Fahn S: Dystonia. In: Taylor RB, ed: Difficult Diagnosis., Philadelphia, Saunders, 1984. pp. 123-129.
28. Fahn S: Pharmacological differentiation of tremor. In: Findley LJ, Capiledeo R, eds: Movement Disorders: Tremor., New York, Oxford University Press, 1984; 85-93.
29. Fahn S: The tardive dyskinesias. In: Matthews WB, Glaser GH, eds: Recent Advances in Clinical Neurology, Vol 4, Edinburgh, Churchill Livingstone, 1984, pp 229-260.
30. Fahn S: The extrapyramidal disorders. In: Wyngaarden JB, Smith LH Jr, eds: Cecil Textbook of Medicine, 17th edition, Philadelphia, Saunders, 1985, pp 2069-2079.
31. Ghez C, Fahn S: The Cerebellum. In: Kandel ER, Schwartz JH, eds: Principles of Neural Science, 2nd ed. Elsevier/North-Holland, 1985, pp 502-522.
32. Fahn S, Marsden CD, Van Woert MH: Definition and clinical classification of myoclonus. In: Fahn S, Marsden CD, Van Woert MH, eds: Myoclonus. Adv Neurol, New York, Raven Press, 1986;43:1-5.
33. Fahn S: Posthypoxic action myoclonus: Literature review update. In: Fahn S, Marsden CD, Van Woert MH, eds: Myoclonus. Adv Neurol, New York, Raven Press, 1986. pp 157-169.
34. Jankovic J, Fahn S: The phenomenology of tics. Mov Disord 1986;1:17-26.
35. Fahn S: Parkinson's disease and other basal ganglion disorders. In Asbury AK, McKhann GM, McDonald WI, eds: Diseases_of_the Nervous_System. Clinical Neurobiology, Philadelphia, Ardmore Medical Books, 1986. pp. 1217-1228.
36. Marsden CD, Fahn S: Problems in Parkinson's disease and other akinetic- rigid syndromes. In Marsden CD, Fahn S, eds: Movement Disorders 2. London:Butterworths, 1987. pp 65-72.
37. Marsden CD, Fahn S: Problems in the dyskinesias. In Marsden CD, Fahn S, eds: Movement Disorders 2. London:Butterworths, 1987. pp 305-312.
38. Fahn S, Marsden CD, Calne DB: Classification and investigation of dystonia. In Marsden CD, Fahn S, eds: Movement Disorders 2. London:Butterworths, 1987. pp 332-358.
39. Fahn S, Marsden CD: The treatment of dystonia. In Marsden CD, Fahn S, eds: Movement Disorders 2. London:Butterworths, 1987. pp 359-382.
40. Hallett M, Marsden CD, Fahn S: Myoclonus. In Vinken PJ, Bruyn GW, Klawans HL, eds. Handbook of Clinical Neurology, Vol. 49, Extrapyramidal Disorders, Amsterdam, Elsevier, 1987. pp. 609- 625.
41. Fahn S: Drug treatment of hyperkinetic movement disorders. Seminars in Neurology 7:192-208, 1987.
42. Fahn S: Systemic therapy of dystonia. Can J Neurol Sci 14:528-532, 1987.
43. Fahn S: Clinical aspects and treatment of rigidity and dystonia. In Benecke R, Conrad B, Marsden C.D., eds: Motor Disturbances I. London:Academic Press, 1987. pp 101-110.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 100
44. Bressman S, Fahn S: Parkinson's disease (Part 1). Hospital Med pp. 82-96, Dec. 1987.
45. Bressman S, Fahn S: Parkinson's disease (Part 2). Hospital Med pp. 55-63, Jan. 1988.
46. Fahn S: The extrapyramidal disorders. In: Wyngaarden JB, Smith LH Jr, eds: Cecil Textbook of Medicine, 18th edition, Philadelphia, Saunders, 1988. pp 2143-2152.
47. Fahn S. Concept and classification of dystonia. In Fahn S, Marsden CD, Calne DB, eds. Dystonia 2. Adv Neurol 1988;50:1-8.
48. Fahn S, Erenberg G: Differential diagnosis of tic phenomena: A neurologic perspective. In Cohen DJ, Bruun RD, Leckman JF, eds: Tourette's Syndrome and Tic Disorders: Clinical Understanding and Treatment. New York: John Wiley and Sons, 1988;41-54.
49. Fahn S: Parkinson's disease. In Hurst JW, ed: Medicine for the Practicing Physician, 2nd edition, Boston: Butterworths, 1988:1519-1522.
50. Fahn S: Disorders with parkinsonian features. In Hurst JW, ed: Medicine for the Practicing Physician, 2nd edition, Boston: Butterworths, 1988:1522-1525.
51. Fahn S, Jankovic J, eds: Extrapyramidal, developmental and inherited CNS disease. Current Opinion in Neurol Neurosurg 1988;1:269-369.
52. Fahn S, Jankovic J. Extrapyramidal, developmental and inherited CNS disease: Overview. Current Opinion in Neurol Neurosurg 1988;1:269-270.
53. Nygaard TG, Fahn S. Treatment strategies for idiopathic dystonia. Current Opinion in Neurol Neurosurg 1988;1:307-309.
54. Brin MF, de Yebenes J, Fahn S. Neuroacanthocytosis (Levine syndrome). Current Opinion in Neurol Neurosurg 1988;1:332-334.
55. Fahn S. Essential tremor. Current Opinion in Neurol Neurosurg 1988;1:338-340.
56. Shoulson I, Fahn S, Langston JW. Conference Report: Symposium on the etiology, pathogenesis and prevention of Parkinson's disease. Arch Neurol 1988;45:807-811.
57. Jankovic J, Fahn S. Dystonic syndromes. In Jankovic J, Tolosa E, eds: Parkinson's Disease and Movement Disorders. Baltimore: Urban and Schwarzenberg;1988:283-314.
58. Fahn S. Failure of levo-3,4,-dihydroxyphenylalanine therapy in Parkinson's disease. In Progress in Catecholamine Research. Part C. Clinical Aspects. New York: Alan R. Liss;1988:35-41.
59. Fahn S. Whither Parkinson's disease? In Stern MB, Hurtig HI, eds: The Comprehensive Management of Parkinson's Disease. New York: PMA Publishing; 1988:187-191.
60. Kang UJ, Fahn S. Management of tardive dyskinesia. Rational Drug Therapy 1988;22:No. 8:1-7.
61. Fahn S, Mayeux R, editors. Supplement on Parkinson's disease. Movement Disorders 1989;4:supplement 1.
62. Fahn S. The history of parkinsonism. Movement Disorders 1989;4:S2-S10.
63. Fahn S. Assessment of the primary dystonias. In Munsat TL, ed: Quantification of Neurologic Deficit. Boston: Butterworths; 1989:241-270.
64. Lang AET, Fahn S. Assessment of Parkinson's disease. In Munsat TL, ed: Quantification of Neurologic
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 101
Deficit. Boston: Butterworths; 1989:283-309.
65. Fahn S. Involuntary movements. In: Rowland LP, ed: Merritt's Textbook of Neurology, 8th Ed., Philadelphia, Lea & Febiger, 1989. pp. 48-50.
66. Fahn S. Huntington disease and other forms of chorea. In: Rowland LP, ed: Merritt's Textbook of Neurology, 9th Ed., Philadelphia, Lea & Febiger, 1989. pp. 647-652.
67. Fahn S. Myoclonus. In: Rowland LP, ed: Merritt's Textbook of Neurology, 8th Ed., Philadelphia, Lea & Febiger, 1989. p. 652.
68. Fahn S. Gilles de la Tourette syndrome. In: Rowland LP, ed: Merritt's Textbook of Neurology, 8th Ed., Philadelphia, Lea & Febiger, 1989. p. 653.
69. Fahn S. Dystonia. In: Rowland LP, ed: Merritt's Textbook of Neurology, 8th Ed., Philadelphia, Lea & Febiger;1989:653-656.
70. Fahn S. Tardive dyskinesia. In: Rowland LP, ed: Merritt's Textbook of Neurology, 8th Ed., Philadelphia, Lea & Febiger, 1989. p. 673-676.
71. Fahn S, Jankovic J, eds: Extrapyramidal, developmental and inherited CNS disease. Current Opinion in Neurol Neurosurg 1989;2:303-352.
72. Fahn S, Jankovic J. Extrapyramidal, developmental and inherited CNS disease: Editorial overview. Current Opinion in Neurol Neurosurg 1989;2:303-304.
73. Fahn S. Choreic disorders. Current Opinion in Neurol Neurosurg 1989;2:319-323.
74. Fahn S: Parkinson's disease. In Hurst JW, ed: Criteria for Diagnosis, Stoneham: Butterworths, 1989:524-525.
75. Fahn S: Disorders with parkinsonian features. In Hurst JW, ed: Criteria for Diagnosis, Stoneham: Butterworths, 1989:525-526.
76. Fahn S. Adverse effects of levodopa in Parkinson's disease. In Calne DB, ed; Drugs for the Treatment of Parkinson's Disease. Berlin: Springer-Verlag, Handbook of Experimental Pharmacology 1989;88:385-409.
77. Fahn S. The medical treatment of movement disorders. In Crossman A, Sambrook MA, eds: Neural Mechanisms in Disorders of Movement. London, John Libbey & Co;1989:249-267.
78. Kang UJ, Fahn S. Tardive Dyskinesia. In Rowland LP, ed: Merritt's Textbook of Neurology 1989;Update 3:1-16.
79. Fahn S. Dystonia: Where next? In Quinn NP, Jenner PG, eds: Disorders of Movement: Clinical, Pharmacological and Physiological Aspects, London: Academic Press;1989:349-357.
80. Mena AM, de Yebenes JG, Steinert R, Dwork A, Goodman R, Jamrosik Z, Latov N, Fahn S, Herbert J. Trasplantes neuronales con celulas diferenciadas procedentes de neuroblastomas humanos en modelos experimentales de enfermedad de Parkinson. In Gimenez-Roldan S, ed: Nuevas Estrategias Terapeuticas en la Enfermedad de Parkinson. Madrid:Jarpyo Editores, 1989;63-79.
81. Pezzoli G, Silani V, Motti EDF, Ferrante C, Buscaglia M, Zecchinelli A, Pizzuti A, Goodman R, Dwork A, Truong DD, de Yebenez JG, Jackson-Lewis V, Cadet JL, Popilskis S, Fahn S. L'Impianto di cellule midollari surrenali fetali riduce il parkinsonismo sperimentale indotto nel primate. In Agnoli A, Battistin L, eds: Morbo di Parkinson: Neuromodulatori, Fattori Trofici, Trapianti Cellulari, Roma: D. Guanella, 1989;53-59.
82. Pezzoli G, Fahn S, Dwork A, Truong DD, de Yebenez JG, Jackson-Lewis V, Cadet JL, Herbert J,
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 102
Zecchinelli A, Motti E. Il trapianto intraventricolare di tessuto cromaffine con infusione intraventricolare di NGF riduce il parkinsonismo indotto nel ratto. In Agnoli A, Battistin L, eds: Morbo di Parkinson: Neuromodulatori, Fattori Trofici, Trapianti Cellulari, Roma: D. Guanella, 1989;75-82.
83. Greene P, Fahn S. Dystonia. In Johnson R, ed: Current Therapy in Neurologic Disease - 3. Philadelphia: B. C. Decker;1990:267-270.
84. Fahn S, Greene P. Hemifacial spasm. In Johnson R, ed: Current Therapy in Neurologic Disease - 3. Philadelphia: B. C. Decker, 1990:275-275.
85. Fahn S. Akinesia. In Berardelli A, Benecke R, Manfredi M, Marsden CD, eds: Motor Disturbances II. London: Academic Press. 1990:141-150.
86. Shale HM, Fahn S. Parkinson's disease. In Taylor RB, ed: Difficult Medical Management. Philadelphia, W. B. Saunders, 1990;497-504.
87. Fahn S. Recent concepts in the diagnosis and treatment of dystonias. In Chokroverty S, ed: Movement Disorders. Costa Mesa, CA; PMA Publishing Corp.;1990:237-258.
88. de Yebenes JG, Fahn S, Goodman R, Jamrosik Z, Pezzoli G, Popalski S. Intracerebroventricular infusion of (+)-4-propyl-9-hydroxy-naphthoxacine in monkeys with MPTP-induced akinesia. Adv Neurol;1990;53:231-238.
89. Fahn S, Burke R, Stern Y. Antimuscarinic drugs in the treatment of movement disorders. Prog Brain Res 1990;84:389-397.
90. American Academy of Neurology, Therapeutics and Technology Assessment Subcommittee. Assessment: The clinical usefulness of botulinum toxin-A in treating neurologic disorders. Neurology 1990;40:1332-1336.
91. Fahn S. Diagnostico diferencial de las anomalias del movimiento. Jano Medicina y Humanidades 1990;39:81-90.
92. Fahn S. What are the basal ganglia diseases? Reviews in the Neurosciences 1990;2:165-172.
93. Fahn S. Current trends in the treatment of basal ganglia diseases. Reviews in the Neurosciences. 1990;2:173-180.
94. Fahn S, Shale HM. Parkinsonism. In Rakel RE, ed. Conn's Current Therapy. Philadelphia: W. B. Saunders, 1990;841-847.
95. Fahn S. Tics, myoclonus, and miscellaneous movement disorders. Current Opinions in Neurology & Neurosurgery 1991;4:337-342.
96. Fahn S. The DATATOP study. In Rinne UK, Nagatsu T, Horowski R: eds. International Workshop Berlin Parkinson's Disease. Bussum, The Netherlands: Medicom Europe, 1991;308-311.
97. Fahn S. Conclusions. In Rinne UK, Nagatsu T, Horowski R: eds. International Workshop Berlin Parkinson's Disease. Bussum, The Netherlands: Medicom Europe, 1991;368-371.
98. Fahn S. Parkinson's disease: Clinical features, etiology, and treatment. New Issues in Neurosciences Basic and Clinical Approaches.Basal Ganglia and Movement Disorders. 1991;3:305-311.
99. Fahn S. Dystonia: phenomenology, classification, etiology, genetics & pathology. Medical Problems of Performing Artists 1991;6:110-115.
100. Fahn S. The genetics of idiopathic torsion dystonia. Int J Neurol. 1991-1992;25-26:70-80.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 103
101. Fahn S: Parkinson's disease and other basal ganglion disorders. In Asbury AK, McKhann GM, McDonald WI, eds: Diseases of the Nervous System. Clinical Neurobiology, 2nd Ed., Philadelphia, W. B. Saunders Co., 1992; 1144-1158.
102. Brin MF, Blitzer A, Stewart C, Fahn S. Treatment of spasmodic dysphonia (laryngeal dystonia) with local injections of botulinum toxin: Review and technical aspects. In Blitzer A, Brin MF, Sasaki CT, Fahn S, Harris KS, eds: Neurologic Disorders of the Larnyx. New York, Thieme Medical Pub. Inc., 1992;214-228.
103. Brin MF, Fahn S, Blitzer A, Ramig LO, Stewart C. Movement disorders of the larynx. In Blitzer A, Brin MF, Sasaki CT, Fahn S, Harris KS, eds: Neurologic Disorders of the Larnyx. New York, Thieme Medical Pub. Inc., 1992;248-278.
104. Langston JW, Widner H, Brooks D, Fahn S, Freeman T, Goetz CG, Watts R. Core assessment program for intracerebral transplantations (CAPIT). In Lindvall O, Bjorklund A, Widner H, eds: Intracerebral Transplantaion in Movement Disorders. Restorative Neurol 1991;4:227-241.
105. Fahn S, Breakefield XO, Dystonic Genetics Research Group. Idiopathic torsion dystonia in Ashkenazi Jews: Autosomal dominant inheritance pattern of gene located on chromosome 9q32-34. In Bonne-Tamir B, Adam A, eds: Genetic Diversity Among Jews. Diseases and Markers at the DNA Level. New York:Oxford University Press, 1992;202-219.
106. Fahn S. Adverse effects of levodopa. In Olanow CW, Lieberman AN, eds: The Scientific Basis for the Treatment of Parkinson's Disease. Carnforth, England; Parthenon Publishing Group. 1992;89-112.
107. Gasser T, Fahn S, Breakefield XO. The autosomal dominant dystonias. Brain Pathol 1992;2:297-308.
108. Fahn S, Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol 1992;32:804-812.
109. Epstein CJ, Chan PH, Cadet JL, Carlson E, Chen S, Chu L, Fahn S, Jackson-Lewis V, Kinouchi H, Kostic V, Kujirai, Mizui A, Naini BA, Przedborski S, Yang G. Resistance of SOD-transgenic mice to oxidative stress. In: Gage FH, Christen Y (eds.): Gene Transfer and Therapy in the Nervous System. Springer-Verlag, Berlin, 1992, pp. 106-117.
110. Fahn S. Tardive dystonia. In: Joseph AB, Young RR, eds: Movement Disorders in Neurology and Neuropsychiatry. Boston: Blackwell Scientific Publications;1992:123-124.
111. Fahn S. Idiopathic torsion dystonia. In: Joseph AB, Young RR, eds: Movement Disorders in Neurology and Neuropsychiatry. Boston: Blackwell Scientific Publications;1992:569-574.
112. Fahn S. Motor and vocal tics. In: Kurlan R, ed:Handbook of Tourette's Syndrome and Related Tic and Behavioral Disorders. New York:Marcel Dekker;1993:3-16.
113. Nygaard TG, Snow BJ, Fahn S, Calne DB. Dopa-responsive dystonia: clinical characteristics and definition. In: Segawa M, ed. :Hereditary Progressive Dystonia with Marked Diurnal Fluctuation. Lancs, UK:Parthenon Publishing Group;1993:21-35.
114. Jankovic J, Fahn S. Dystonic disorders. In: Jankovic J, Tolosa E, eds: Parkinson's Disease and Movement Disorders, 2nd ed. Baltimore: Williams and Wilkins;1993:337-374.
115. Fahn S. Future strategies for the treatment of Parkinson's disease. Adv Neurol 1993;60:636-640.
116. Shale H, Fahn S. Pharmacotherapy for essential tremor. In Therapeutic Considerations for Trembling - Focus on Essential Tremor. Tokyo: Churchill Livingstone Japan, 1993;156-165.
117. Fahn S. Future strategies for the treatment of Parkinson's disease. In Gandevia SC, Burke D, Anthony M: eds. Science and Practice in Clinical Neurology. Cambridge, Cambridge University Press, 1993:130-138.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 104
118. Fahn S. Understanding the genetics of classical idiopathic torsion dystonia. In: Gandevia SC, Burke D, Anthony M: eds. Science and Practice in Clinical Neurology. Cambridge, Cambridge University Press, 1993:139-153.
119. Tourette Syndrome Classification Study Group. [Fahn S, Bruun RD, Caine E, Cohen DJ, Comings DE, Como PG, Conneally PM, Gancher ST, Goetz C, Golden GS, Jankovic J, Kurlan R, LeWitt P, Pauls D, Riddle MA, Shapiro AK, Singer HS.] Definitions and classification of tic disorders. Arch Neurol 1993;50:1013-1016.
120. Fahn S, Editor. Therapy of Parkinson's disease: Four critical issues. Neurology 1994;44 (Suppl 1), S1-S20.
121. Rogers JD, Fahn S. Movement disorders and pregnancy. In: Devinsky O, Feldmann E, Hainline B, eds. Neurological Complications of Pregnancy. New York: Raven Press, 1994:163-178.
122. Fahn S. Idiopathic torsion dystonia. In: Calne DB, ed: Neurodegenerative Diseases. Philadelphia:W.B.Saunders, 1994;705-715.
123. Fahn S. Dystonia. In: Jankovic J, Hallett M, eds: Therapy with Botulinum Toxin. New York:Marcel Dekker, 1994;173-189.
124. Marsden CD, Fahn S. Problems in Parkinson's disease and other akinetic-rigid syndromes. In: Marsden CD, Fahn S, eds: Movement Disorders 3. Oxford:Butterworth-Heinemann, 1994;117-123.
125. Fahn S, Marsden CD. Problems in the dyskinesias. In: Marsden CD, Fahn S, eds: Movement Disorders 3. Oxford:Butterworth-Heinemann, 1994;303-309.
126. Fahn S. Paroxysmal dyskinesias. In: Marsden CD, Fahn S, eds: Movement Disorders 3. Oxford:Butterworth-Heinemann, 1994;310-345.
127. Fahn S. Psychogenic movement disorders. In: Marsden CD, Fahn S, eds: Movement Disorders 3. Oxford:Butterworth-Heinemann, 1994;359-372.
128. Greene P, Fahn S, Brin MF, Blitzer A. Botulinum toxin therapy. In: Fahn S, Marsden CD, eds: Movement Disorders 3. Oxford:Butterworth-Heinemann, 1994;477-502.
129. Shale H, Fahn S. Parkinson's disease in the elderly patient. In Albert ML, Knoefel JE, eds: Clinical Neurology of Aging, 2nd ed. New York:Oxford University Press, 1994;493-501.
130. Williams DT, Ford B, Fahn S. Phenomenology and psychopathology related to psychogenic movement disorders. Adv Neurol 1995;65:231-257.
131. Ford B, Williams DT, Fahn S. Treatment of psychogenic movement disorders. In Kurlan R, ed: Treatment of Movement Disorders. Philadelphia, J.B. Lippincott, 1995;475-485.
132. Fahn S. Involuntary movements. In Rowland LP, ed: Merritt's Textbook of Neurology, 9th Edition, Baltimore, Williams & Wilkins, 1995;45-47.
133. Fahn S. Huntington disease. In Rowland LP, ed: Merritt's Textbook of Neurology, 9th Edition, Baltimore, Williams & Wilkins, 1995;695-699.
134. Fahn S. Sydenham and other forms of chorea. In Rowland LP, ed: Merritt's Textbook of Neurology, 9th Edition, Baltimore, Williams & Wilkins, 1995;699-703.
135. Fahn S. Myoclonus. In Rowland LP, ed: Merritt's Textbook of Neurology, 9th Edition, Baltimore, Williams & Wilkins, 1995;703-704.
136. Fahn S. Gilles de la Tourette syndrome. In Rowland LP, ed: Merritt's Textbook of Neurology, 9th Edition,
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 105
Baltimore, Williams & Wilkins, 1995;704-705.
137. Fahn S, Bressman SB, Brin MF. Dystonia. In Rowland LP, ed: Merritt's Textbook of Neurology, 9th Edition, Baltimore, Williams & Wilkins, 1995;705-712.
138. Fahn S. Parkinsonism. In Rowland LP, ed: Merritt's Textbook of Neurology, 9th Edition, Baltimore, Williams & Wilkins, 1995;713-730.
139. Fahn S, Burke RE. Tardive dyskinesia and other neuroleptic-induced syndromes. In Rowland LP, ed: Merritt's Textbook of Neurology, 9th Edition, Baltimore, Williams & Wilkins, 1995;733-736.
140. Kramer PL, Bressman SB, Fahn S, Ozelius L, Breakefield XO. The genetics of dystonia. In: Tsui JJCT, Calne DB, eds: Handbook of Dystonia. New York:Marcel Dekker, 1995;43-58.
141. Fahn S. Generalized dystonia. In: Tsui JJCT, Calne DB, eds: Handbook of Dystonia. New York:Marcel Dekker, 1995;193-211.
142. Fahn S. Medical treatment of dystonia. In: Tsui JJCT, Calne DB, eds: Handbook of Dystonia. New York:Marcel Dekker;1995;317-328.
143. Ozelius LJ, Bressman SB, Kramer PL, Risch N, de Leon D, Fahn S, Breakefield XO. Early-onset, generalized dystonia caused by DYT1 gene on chromosome 9q34. In: Segawa M, Nomura Y, eds: Age-Related Dopamine Dependent Disorders. Basel:Karger, 1995;126-132.
144. Fahn S. The freezing phenomenon in parkinsonism. Adv Neurol 1995;67:53-63.
145. Fahn S. Controversies in the therapy of Parkinson's disease. Adv Neurol 1996;69:477-486.
146. Ford B, Fahn S. Agents for treating Parkinson's disease and other movement disorders. In Rowland LP, Klein DF, eds. Current Neurologic Drugs. Philadelphia:Current Medicine, 1996;309-327.
147. Fahn S. Is levodopa toxic? Neurology 1996;47:S184-S195.
148. Bressman SB, Fahn S. Childhood dystonia. In Watts RL, Koller WC, eds. Movement Disorders: Neurologic Principles and Practice. New York:McGraw-Hill, 1997;419-428.
149. Fahn S. An overview of novel therapies for Parkinson's disease. Exp Neurol 1997;144:21-23.
150. Fahn S. Third International Dystonia Symposium - Miami, Florida, USA -October 9-11, 1996 - Introduction. Mov Disord 1997 (May);12:A1-A2.
151. Fahn S. Movement disorders. In Engel J Jr., Pedley TA, eds. Epilepsy. A Comprehensive Textbook. Philadelphia: Lippincott-Raven, 1997;2725-2738.
152. Fahn S. Levodopa-induced neurotoxicity: Does it represent a problem for the treatment of Parkinson's disease? CNS Drugs 1997;8:376-393.
153. Fahn S, Greene PE, Ford B, Bressman SB. Movement disorders. In Rosenberg RN, ed. Atlas of Clinical Neurology. Boston: Butterworth-Heinemann, 1998;9.1-9.40.
154. Fahn S. Parkinsonism. In Rakel RE, ed. Conn's Current Therapy. Philadelphia: W. B. Saunders, 1998;944-953.
155. Ford B, Fahn S. Agents for treating Parkinson's disease and other movement disorders. In Rowland LP, ed. Current Neurologic Drugs, 2nd ed. Philadelphia:Current Medicine, 1998;332-358.
156. Jankovic J, Fahn S. Dystonic disorders. In: Jankovic J, Tolosa E, eds: Parkinson's Disease and
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 106
Movement Disorders, 3rd ed. Baltimore: Williams and Wilkins;1998:513-551.
157. Dauer WT, Burke RE, Greene P, Fahn S. Current concepts on the clinical features, aetiology and management of idiopathic cervical dystonia. Brain 1998;121:547-560.
158. Fahn S, Elliott R. Highlights of the Parkinson's Disease Foundation. Mov Disord 1998;13:2-6.
159. Fahn S, Clarence-Smith KE, Chase TN. Parkinson's disease: Neurodegenerative mechanisms and neuroprotective interventions - Report of a workshop. Mov Disord 1998;13:759-767.
160. Giladi N, Fahn S. Freezing phenomenon, the fifth cardinal sign of parkinsonism. In Fisher A, Hanin I, Yoshida M, eds. Progress in Alzheimer's and Parkinson's Diseases. New York, Plenum Press; 1998:329-335.
161. Marsden CD, Fahn S. Dystonia Symposium: Summary and conclusions. In: Fahn S, Marsden CD, DeLong MR, eds. Dystonia 3. Adv Neurol. Lippincott-Raven Pub, 1998:359-364.
162. Fahn S, Burke RE, Mayeux R, Przedborski S, eds. Frontiers in Parkinson's Disease. The Proceedings of the Symposium Celebrating the 40th Anniversary of the Parkinson's Disease Foundation. Mov Disord 1998;13 (Suppl 1).
163. Tabbal S, Fahn S, Frucht S. Fetal tissue transplantation in Parkinson's disease. Curr Opin Neurol 1998;11:341-349.
164. Fahn S. Medical treatment of Parkinson's disease. J Neurol 1998;245:P15-P24.
165. Dauer WT, Fahn S, Burke RE. The diagnosis and treatment of tardive disorders. Med Update Psychiat 1998;3:119-125.
166. Fahn S. Hypokinesia and hyperkinesia. In: Goetz CG, Pappert EJ, eds: Textbook of Clinical Neurology. Philadelphia, W.B. Saunders Co. 1999:267-284.
167. Fahn S. Tardive dystonia. In: Joseph AB, Young RR, eds: Movement Disorders in Neurology and Neuropsychiatry, 2nd Ed. Malden, MA: Blackwell Science;1999:104-105.
168. Fahn S. Primary torsion dystonia. In: Joseph AB, Young RR, eds: Movement Disorders in Neurology and Neuropsychiatry, 2nd Ed. Malden, MA: Blackwell Science;1999:526-530.
169. Frucht S, Fahn S. The clinical spectrum of posthypoxic myoclonus. Mov Disord 2000;15 (Suppl 1):2-7.
170. Ford B, Fahn S. Agents for treating Parkinson's disease and other movement disorders. In Rowland LP, ed. Current Neurologic Drugs. Philadelphia:Lippincott Williams & Wilkins, 2000;330-356.
171. Fahn S. Involuntary movements. In Rowland LP, ed: Merritt's Neurology, 10th Edition, Philadelphia, Lippincott Williams & Wilkins, 2000;38-41.
172. Fahn S. Huntington disease. In Rowland LP, ed: Merritt's Neurology, 10th Edition, Philadelphia, Lippincott Williams & Wilkins, 2000;659-662.
173. Fahn S. Sydenham and other forms of chorea. In Rowland LP, ed: Merritt's Neurology, 10th Edition, Philadelphia, Lippincott Williams & Wilkins, 2000;662-666.
174. Fahn S. Myoclonus. In Rowland LP, ed: Merritt's Neurology, 10th Edition, Philadelphia, Lippincott Williams & Wilkins, 2000;666-668.
175. Fahn S. Gilles de la Tourette syndrome. In Rowland LP, ed: Merritt's Neurology, 10th Edition, Philadelphia, Lippincott Williams & Wilkins, 2000;668-669.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 107
176. Fahn S, Bressman SB. Dystonia. In Rowland LP, ed: Merritt's Merritt's Neurology, 10th Edition, Philadelphia, Lippincott Williams & Wilkins, 2000;669-677.
177. Fahn S, Przedborski S. Parkinsonism. In Rowland LP, ed: Merritt's Neurology, 10th Edition, Philadelphia, Lippincott Williams & Wilkins, 2000;679-693.
178. Fahn S, Burke RE. Tardive dyskinesia and other neuroleptic-induced syndromes. In Rowland LP, ed: Merritt's Neurology, 10th Edition, Philadelphia, Lippincott Williams & Wilkins, 2000;696-699.
179. Frucht SJ, Greene PE, Fahn S. Sleep episodes in Parkinson’s disease: a wake-up call. Mov Disord 2000;15:601-603.
180. Gordon PH, Frucht SJ, Fahn S. Parkinson’s disease: identification, management and new treatment options. Progress in Neurology 2000;2:3-21.
181. Fahn S. Parkinson’s disease. In: Edlich RF, ed.. Advances in Medicine. ABI Professional Publications, Arlington, Virginia, 2000;304-320.
182. Frucht SJ, Fahn S. A 23-year-old man with arm and vocal tremor. A case of Wilson’s disease. In Schapira AHV, Rowland LP, eds. Clinical Cases in Neurology. Oxford, Butterworth-Heinemann, 2001; 89-97.
183. Frucht SJ, Fahn S. A 32-year-old man with progressive spasticity and parkinsonism. A case of Huntington’s disease. In Schapira AHV, Rowland LP, eds. Clinical Cases in Neurology. Oxford, Butterworth-Heinemann, 2001; 127-133.
184. Frucht SJ, Fahn S. Chapter 25: A 26-year-old woman with fatigue and cramping of the foot. A case of dopa-responsive dystonia. In: Clinical cases in Neurology, Schapira AHV, Rowland LP, eds. Butterworth Heinemann, Oxford, 2001.
185. Fahn S. Overview, history and classification of myoclonus. Adv Neurol 2002;89:13-17.
186. Fahn S. The early history of paroxysmal dyskinesias. Adv Neurol 2002;89:377-385.
187. Jankovic J, Fahn S. Dystonic disorders. In: Jankovic J, Tolosa E, eds: Parkinson's Disease and Movement Disorders, 4th ed. Philadelphia: Lippincott Williams & Wilkins;2002:331-357.
188. Greene PE, Fahn S. Status of fetal tissue transplantation for the treatment of advanced Parkinson disease. Neurosurg Focus. 2002 Nov 15;13(5):e3.
189. Fahn S. Dystonia, spasms, and cramps. In: Bloom FE, Beal MF, Kupfer DJ, eds. The Dana Guide to Brain Health. New York: The Dana Press, 2003;494-496.
190. Fahn S, Greene PE, Ford B, Bressman SB. Movement disorders. In Rosenberg RN, ed. Atlas of Clinical Neurology, 2nd ed. Philadelphia: Current Medicine, 2003;313-356.
191. Fahn S. Hypokinesia and hyperkinesia. In: Goetz CG, ed: Textbook of Clinical Neurology, 2nd edition. Philadelphia, W.B. Saunders Co, 2003:279-297.
192. Lyons K, Pahwa R, Comella C, Eisa M, Elble R, Fahn S, Jankovic J, Juncos J, Koller W, Ondo W, Sethi K, Stern M, Tanner C, Tintner R, Watts R.Benefits and risks of pharmacological treatments for essential tremor. Drug Safety 2003;26(7):461-481.
193. Fahn S. Overview of movement disorders. In Noseworthy JH, ed. Neurological Therapeutics: Principles and Practice. London, Martin Dunitz, 2003;2421-2446.
194. Fahn S, Ford B. Medical treatment of Parkinson’s disease and its complications. In Noseworthy JH, ed. Neurological Therapeutics: Principles and Practice. London, Martin Dunitz, 2003;2447-2482.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 108
195. Fahn S. Tardive dyskinesia and related disorders. In Noseworthy JH, ed. Neurological Therapeutics: Principles and Practice. London, Martin Dunitz, 2003;2600-2622.
196. Fahn S. Paroxysmal dyskinesias. In Noseworthy JH, ed. Neurological Therapeutics: Principles and Practice. London, Martin Dunitz, 2003;2633-2647.
197. Fahn S, Williams D, Ford B. Psychogenic movement disorders. In Noseworthy JH, ed. Neurological Therapeutics: Principles and Practice. London, Martin Dunitz, 2003;2677-2687.
198. Fahn S. Description of Parkinson’s disease as a clinical syndrome. In Federoff HJ Burke RE, Fahn S, Fiskum G, eds. Parkinson’s Disease: The Life Cycle of the Dopamine Neuron. Annals of the New York Academy of Sciences 2003;991:1-14.
199. Fahn S. Parkinson’s disease and related disorders. In Hazzard WR, Blass JP, Halter JB, Ouslander JG, Tinnetti ME, eds. Principles of Geriatric Medicine & Gerontology. New York, McGraw-Hill, 2003;1401-1408.
200. Harris JM, Fahn S. Genetics of movement disorders. In: Rosenberg RN, Prusiner SB, DiMauro S, Barchi RL, Nestler EJ, eds: The Molecular and Genetic Basis of Neurologic and Psychiatric Disease, 3rd edition. Philadelphia, Butterworth-Heinemann, 2003:351-368.
201. Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins GT, Fahn S, Lang AE, Martinez-Martin P, Tilley B, Van Hilten B, Kleczka C, Seidl L. The Unified Parkinson's Disease Rating Scale (UPDRS): Status and recommendations. Mov Disord 2003;18(7):738-750.
202. Fahn S, Sulzer D. Neurodegeneration and neuroprotection in Parkinson disease. NeuroRx 2004;1:139-154.
203. Fahn S. Lessons learned from other neurological diseases: Parkinson’s disease. Amyotrophic Lateral Scleosis and Other Motor Neuron Disorders. 2004;5 (Suppl 1):26-30.
204. Ravina B, Eidelberg D, Ahlskog JE, Albin RL, Brooks DJ, Carbon M, Dhawan V, Feigin A, Fahn S, Guttman M, Gwinn-Hardy K, McFarland H, Innis R, Katz RG, Kieburtz K, Kish SJ, Lange N, Langston JW, Marek K, Morin L, Moy C, Murphy D, Oertel WH, Oliver G, Palesch Y, Powers W, Seibyl J, Sethi KD, Shults CW, Sheehy P, Stoessl AJ, Holloway R. The role of radiotracer imaging in Parkinson disease. Neurology. 2005 Jan 25;64(2):208-215.
205. Fahn S. Motor and vocal tics. In: Kurlan R, ed:Handbook of Tourette's Syndrome and Related Tic and Behavioral Disorders, 2nd Ed. New York:Marcel Dekker; 2005:1-14.
206. Fahn S. Involuntary movements. In Rowland LP, ed: Merritt's Neurology, 11th Edition, Philadelphia, Lippincott Williams & Wilkins, 2005;48-52.
207. Fahn S. Huntington disease. In Rowland LP, ed: Merritt's Neurology, 11th Edition, Philadelphia, Lippincott Williams & Wilkins, 2005;803-807.
208. Fahn S. Sydenham and other forms of chorea. In Rowland LP, ed: Merritt's Neurology, 11th Edition, Philadelphia, Lippincott Williams & Wilkins, 2005;807-812.
209. Fahn S. Myoclonus. In Rowland LP, ed: Merritt's Neurology, 11th Edition, Philadelphia, Lippincott Williams & Wilkins, 2005;812-814.
210. Fahn S. Gilles de la Tourette syndrome. In Rowland LP, ed: Merritt's Neurology, 11th Edition, Philadelphia, Lippincott Williams & Wilkins, 2005;815-816.
211. Fahn S, Bressman SB. Dystonia. In Rowland LP, ed: Merritt's Merritt's Neurology, 11th Edition, Philadelphia, Lippincott Williams & Wilkins, 2005;816-826.
212. Fahn S, Przedborski S. Parkinsonism. In Rowland LP, ed: Merritt's Neurology, 11th Edition, Philadelphia, Lippincott Williams & Wilkins, 2005;828-846.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 109
213. Fahn S, Burke RE. Tardive dyskinesia and other neuroleptic-induced syndromes. In Rowland LP, ed: Merritt's Neurology, 11th Edition, Philadelphia, Lippincott Williams & Wilkins, 2005;849-852.
214. Siderowf A, Fahn S. The role and design of clinical trials for Parkinson’s disease. In Ebadi M, Pfeiffer RF, eds. Parkinson’s Disease. Boca Raton:CRC Press, 2005;961-973.
215. Bordelon YM, Fahn S. Gender differences in movement disorders. In Kaplan PW, ed. Neurologic Disease in Women, New York, Demos Medical Publishing, 2005;349-354.
216. Nirenberg MJ, Fahn S. The role of levodopa and catichol-O-methyltransferase inhibitors. In Schapira AHV, Olanow CW, eds. Principles of Treatment in Parkinson’s Disease, Philadelphia, Elsevier, 2005;3-24.
217. Fahn S. The history of psychogenic movement disorders. In Hallett M, Fahn S, Jankovic J, Lang JE, Cloninger CR, Yudofsky SC, eds. Psychogenic Movement Disorders – Neurology and Neuropsychiatry, Philadelphia, Lippincott Williams & Wilkins, 2006;24-31.
218. Fahn S. The role of anesthesia in the diagnosis and treatment of psychogenic movement disorders. In Hallett M, Fahn S, Jankovic J, Lang JE, Cloninger CR, Yudofsky SC, eds. Psychogenic Movement Disorders – Neurology and Neuropsychiatry, Philadelphia, Lippincott Williams & Wilkins, 2006;256-261.
219. Williams DT, Ford B, Fahn S, Williams M. Natural history of psychogenic movement disorders. In Hallett M, Fahn S, Jankovic J, Lang JE, Cloninger CR, Yudofsky SC, eds. Psychogenic Movement Disorders – Neurology and Neuropsychiatry, Philadelphia, Lippincott Williams & Wilkins, 2006;274-286.
220. Jankovic J, Cloninger CR, Fahn S, Hallett M, Lang AE, Williams DT. Therapeutic approaches to psychogenic movement disorders. In Hallett M, Fahn S, Jankovic J, Lang JE, Cloninger CR, Yudofsky SC, eds. Psychogenic Movement Disorders – Neurology and Neuropsychiatry, Philadelphia, Lippincott Williams & Wilkins, 2006;323-328.
221. Williams DT, Ford B, Fahn S. Treatment issues in psychogenic-neuropsychiatric movement disorders. Adv Neurol 2005;96:350-363.
222. Fahn S. Overview of movement disorders. In Noseworthy JH, ed. Neurological Therapeutics: Principles and Practice, 2nd Ed. Milton Park, Abingdon, Oxon, Informa Healthcare, 2006;2741-2765.
223. Fahn S, Ford B. Medical treatment of Parkinson’s disease and its complications. In Noseworthy JH, ed. Neurological Therapeutics: Principles and Practice, 2nd Ed. Milton Park, Abingdon, Oxon, Informa Healthcare, 2006;2766-2802.
224. Fahn S, Ford B. Tardive dyskinesia and related disorders. In Noseworthy JH, ed. Neurological Therapeutics: Principles and Practice, 2nd Ed. Milton Park, Abingdon, Oxon, Informa Healthcare, 2006;2927-2942.
225. Fahn S. Paroxysmal dyskinesias. In Noseworthy JH, ed. Neurological Therapeutics: Principles and Practice, 2nd Ed. Milton Park, Abingdon, Oxon, Informa Healthcare, 2006;2952-2966.
226. Fahn S, Williams DT, Ford B. Psychogenic movement disorders. In Noseworthy JH, ed. Neurological Therapeutics: Principles and Practice. 2nd Ed. Milton Park, Abingdon, Oxon, Informa Healthcare, 2006;2999-3010.
227. Fahn S. Levodopa in the treatment of Parkinson’s disease. J Neural Transm 2006;Suppl 71:1-15.
228. Fahn S. Dystonia, spasms, and cramps. In: Bloom FE, Beal MF, Kupfer DJ, eds. The Dana Guide to Brain Health. New York: The Dana Press, 2006;494-496.
229. Olanow CW. and Fahn S. Fetal Nigral Transplantation as a Therapy for Parkinson’s Disease. In Brundin P, and Olanow CW., eds. Restorative Therapies in Parkinson’s Disease. Springer, 2006.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 110
230. Fahn S. Psychogenic movement disorders. In: Jankovic J, Tolosa E, eds: Parkinson's Disease and Movement Disorders, 5th ed. Philadelphia: Lippincott Williams & Wilkins;2007:562-566.
231. Elble RJ, Tremor Research Group. Report From a U.S. Conference on Essential Tremor. Mov Disord 2006,21 (12):2052–2061.
232. Fahn S. Hypokinesia and hyperkinesia. In: Goetz CG, ed: Textbook of Clinical Neurology, 3rd edition. Philadelphia, Saunders Elsevier, 2007:289-306.
233. Fahn S. Treatment of Parkinson’s disease. In: Dawson TD, ed. Parkinson’s Disease: Genetics and Pathogenesis, New York, Informa Healthcare, 2007:53-73.
234. Harris JM, Frazier J, Fahn S. Genetics of movement disorders. In: Rosenberg RN, DiMauro S, Paulson HL, Ptacek L, Nestler EJ, eds: The Molecular and Genetic Basis of Neurologic and Psychiatric Disease, 4th edition. Philadelphia, Lippincott Williams & Wilkins, 2007:339-357.
235. Fahn S, Frucht SJ. Movement disorders. In Engel J Jr., Pedley TA, eds. Epilepsy. A Comprehensive Textbook, 2nd Edition. Philadelphia: Lippincott-Raven, 2008;2721-2778.
236. Fahn S. The history of dopamine and levodopa in the treatment of Parkinson's disease. Mov Disord 2008;23 Suppl 3:S497-508.
237. Fahn S. How do you treat motor complications in Parkinson's disease: Medicine, surgery, or both? Ann Neurol. 2008 Dec;64 Suppl 2:S56-64.
238. Bordelon YM, Fahn S. Weakness, ataxia, and myoclonus in a 68-year-old woman. In: Reich S, ed. Movement Disorders: 100 Instructive Cases. London, Informa Healthcare, 2008;75-78.
239 Jain S, Fahn S. Parkinson’s gait: when falls become pitfalls. In: Reich S, ed. Movement Disorders: 100 Instructive Cases. London, Informa Healthcare, 2008;183-185.
240 Grewal AK, Fahn S. A 70-year-old man with tremor, ataxia and bright middle cerebellar peduncles. In: Reich S, ed. Movement Disorders: 100 Instructive Cases. London, Informa Healthcare, 2008;187-189.
241. Merchant KM, Chesselet M-F, Hu S-C, Fahn S. Animal models of Parkinson’s disease to aid drug discovery and development In McArthur RA, Borsini F, eds. Animal and Translational Models for CNS Drug Discovery. Vol. II. Neurological Disorders. Burlington, MA, Academic Press, 2008;159-205.
242. Fahn S.Clinical aspects of Parkinson disease. In: Nass R, Przedborski SL eds. Parkinson’s Disease: Molecular and Therapeutic Insights From Model systems. New York: Academic Press, 2008:3-8..
243. Fahn S. Restless legs syndrome as a movement disorder. In Hening WA, Allen RP, Chokroverty S, Earley CJ, eds. Restless Legs Syndrome. Philadelphia, Saunders, 2009;9-10.
244. Fahn S. Parkinson’s disease and related disorders. In Halter JB, Ouslander JG, Tinnetti ME, Studenski S, High KP, Asthana S, eds. Hazzard’s Geriatric Medicine and Gerontology. New York, McGraw-Hill, 2009;813-821.
245. Fahn S. Diagnosis and medical management of dystonia. In Lozano AM, Gildenberg PL, Tasker RR, eds. Textbook of Stereotactic and Functional Neurosurgery, Second Edition. Berlin, Springer-Verlag, 2009;1767-1778.
246. Fahn S. Parkinson's disease: 10 years of progress, 1997-2007. Mov Disord. 2010;25 Suppl 1:S2-14.
247. Fahn S, Marder K, Côté L, Reich SG, Editors. Frontiers of science and clinical advances in quality of life in Parkinson's disease. Mov Disord. 2010;25 Suppl 1:S1-S179.
248. Fahn S.Movement disorders: Introduction. In: Kompoliti K, and Verhagen Metman L (eds) Encyclopedia of
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 111
Movement Disorders. Oxford: Academic Press, 2010.
249. Fahn S. Involuntary movements. In Rowland LP, Pedley TA, eds: Merritt's Neurology,12th Edition, Philadelphia, Lippincott Williams & Wilkins, 2010;50-53.
250. Fahn S, Jankovic J. Huntington disease. In Rowland LP, Pedley TA, eds: Merritt's Neurology,12th Edition, Philadelphia, Lippincott Williams & Wilkins, 2010;723-726.
251. Jankovic J. Fahn S. Choreas. In Rowland LP, Pedley TA, eds: Merritt's Neurology,12th Edition, Philadelphia, Lippincott Williams & Wilkins, 2010;727-731.
252. Fahn S, Frucht S. Myoclonus. In Rowland LP, Pedley TA, eds: Merritt's Neurology,12th Edition, Philadelphia, Lippincott Williams & Wilkins, 2010;732-734.
253. Fahn S, Ford B, Peterson B. Gilles de la Tourette syndrome. In Rowland LP, Pedley TA, eds: Merritt's Neurology,12th Edition, Philadelphia, Lippincott Williams & Wilkins, 2010;735-737.
254. Fahn S, Bressman SB. Dystonia. In Rowland LP, Pedley TA, eds: Merritt's Neurology,12th Edition, Philadelphia, Lippincott Williams & Wilkins, 2010;738-748.
255. Fahn S, Przedborski S. Parkinson Disease. In Rowland LP, Pedley TA, eds: Merritt's Neurology,12th Edition, Philadelphia, Lippincott Williams & Wilkins, 2010;751-769.
256. Fahn S. Paroxysmal dyskinesias. In Rowland LP, Pedley TA, eds: Merritt's Neurology,12th Edition, Philadelphia, Lippincott Williams & Wilkins, 2010;775-777.
257 Fahn S, Burke RE.Tardive dyskinesia and other neuroleptic-induced syndromes. In Rowland LP, Pedley TA, eds: Merritt's Neurology,12th Edition, Philadelphia, Lippincott Williams & Wilkins, 2010;778-781.
258. Fahn S, Halliday GM. Lesions associated with the classic triad of parkinsonian motor features. In Halliday 7GM, Barker RA, Rowe DB, eds. Non-dopamine Lesions in Parkinson’s Disease. Oxford, Oxford University Press, 2011;3-17.
259. Fahn S. Parkinson’s Disease. In Albert ML, Knoefel JE, eds. Clinical Neurology of Aging, 3rd edition. Oxford, Oxford University Press, 2011:251-260.
260. Fahn S. Classification of movement disorders. Mov Disord. 2011 May;26(6):947-57.
261. Williams DT, Dyakina N, Fisher P, Graber J, Fahn S. Inpatient therapy: trying to transcend pathological dissociation, dependence, and disability. In Hallett M, Lang AE, Jankovic J, Fahn S, Halligan PW, Voon V, Cloninger CR, eds. Psychogenic Movement Disorders and Other Conversion Disorders, Cambridge University Press, Cambridge, 2011;302-309.
262: Fahn S. Psychogenic movement disorders. In Albanese A, Jankovic J, eds. Hyperkinetic Movement Disorders. Differential diagnosis and treatment. Wiley-Blackwell, Oxford. 2012;375-384.
263: Thenganatt MA, Fahn S. Botulinum toxin for the treatment of movement disorders. Curr Neurol Neurosci Rep. 2012 Aug;12(4):399-409.
264. Bhidayasiri R, Fahn S, Weiner WJ, Gronseth GS, Sullivan KL, Zesiewicz TA. Evidence-based guideline: Treatment of tardive syndromes: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013 Jul 30;81(5):463-469.
265. Hall DA, Birch RC, Anheim M, Jønch AE, Pintado E, O'Keefe J, Trollor JN, Stebbins GT, Hagerman RJ, Fahn S, Berry-Kravis E, Leehey MA. Emerging topics in FXTAS. J Neurodev Disord. 2014;6(1):31.
266. Kestenbaum M, Fahn S. Safety of IPX066 , an extended release carbidopa-levodopa formulation, for the
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 112
treatment of Parkinson's disease. Expert Opin Drug Saf. 2015 Feb 19:1-7.
267. Robakis D, Fahn S. Defining the Role of the Monoamine Oxidase-B Inhibitors for Parkinson's Disease. CNS Drugs. 2015 Jun;29(6):433-41.
268. Goldman JS, Fahn S. Genetics of Parkinson disease and related disorders. In: Rosenberg RN, Pascual JM, eds: Rosenberg’s Molecular and Genetic Basis of Neurologic and Psychiatric Disease, 5th edition. Amsterdam, Academic Press, 2015;769-778.
269. Fahn S, Goldman JS. Non-parkinsonian movement disorders. In: Rosenberg RN, Pascual JM, eds: Rosenberg’s Molecular and Genetic Basis of Neurologic and Psychiatric Disease, 5th edition. Amsterdam, Academic Press, 2015;869-890.
269. Fahn S, Robakis D. Tics and Tourette syndrome. In Louis ED, Mayer SA, Rowland LP, eds: Merritt's Neurology,13th Edition, Philadelphia, Wolters Kluwer, 2016;636-639.
271. Fahn S. Dystonia. In Louis ED, Mayer SA, Rowland LP, eds: Merritt's Neurology,13th Edition, Philadelphia, Wolters Kluwer, 2016;644-656.
272 Kang UJ, Burke RE, Fahn S.Tardive dyskinesia and other neuroleptic-induced syndromes. In Louis ED, Mayer SA, Rowland LP, eds: Merritt's Neurology,13th Edition, Philadelphia, Wolters Kluwer, 2016;686-690.
273. Jankovic J. Fahn S. Choreas. In Louis ED, Mayer SA, Rowland LP, eds: Merritt's Neurology,13th Edition, Philadelphia, Wolters Kluwer, 2016;691-697.
274. Fahn S, Kang UJ. Parkinson Disease. In Louis ED, Mayer SA, Rowland LP, eds: Merritt's Neurology,13th Edition, Philadelphia, Wolters Kluwer, 2016;704-721.
275. LeWitt PA, Fahn S. Levodopa therapy for Parkinson disease: A look backward and forward. Neurology. 2016 Apr 5;86(14 Suppl 1):S3-S12. doi:10.1212/WNL.0000000000002509. Epub 2016 Apr 4. PubMed PMID: 27044648.
276. Williams DT, LaFaver K, Carson A, Fahn S. Inpatient treatment for functional neurologic disorders. In Hallett M, Stone J, Carson A, eds. Functional Neurologic Disorders. Handbook of Clinical Neruology 2016;139:631-641. doi: 10.1016/B978-0-12-801772-2.00051-5. PubMed PMID: 27719878. http://dx.doi.org/10.1016/B978-0-12-801772-2.00051-5
277. Obeso JA, Stamelou M, Goetz CG, Poewe W, Lang AE, Weintraub D, Burn D, Halliday GM, Bezard E, Przedborski S, Lehericy S, Brooks DJ, Rothwell JC, Hallett M, DeLong MR, Marras C, Tanner CM, Ross GW, Langston JW, Klein C, Bonifati V, Jankovic J, Lozano AM, Deuschl G, Bergman H, Tolosa E, Rodriguez-Violante M, Fahn S, Postuma RB, Berg D, Marek K, Standaert DG, Surmeier DJ, Olanow CW, Kordower JH, Calabresi P, Schapira AHV, Stoessl AJ. Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy. Mov Disord. 2017 Sep;32(9):1264-1310. doi: 10.1002/mds.27115. Review. PubMed PMID: 28887905.
278. Fahn S. The 200-year journey of Parkinson disease: Reflecting on the past and looking towards the future. Parkinsonism Relat Disord. 2018 Jan; 46 Suppl 1:S1-S5. doi: 10.1016/j.parkreldis.2017.07.020. Epub 2017 Aug 1. PubMed PMID: 28784297.
279. Fahn S. Development of the concept of dystonia as a disease, a syndrome and movement phenomenology. In Dressler D, Aletenmüller, Krauss JK, eds. Treatment of Dystonia. Cambridge, Cambridge University Press, 2018;1-5.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 113
ABSTRACTS, LETTERS, REPORTS AND COMMENTARIES PUBLISHED
1. Morton D, Fahn S. Acceleration of maturation of newborn rats by thyroxin. Anat Record 1955;121:410.
2. Fahn S, Schotland DL, Rowland LP. McArdle’s disease: Hereditary myopathy due to absence of muscle phosphorylase. Trans Am Neurol Assn 1963;88:145-147.
3. Fahn S, Albers RW, Koval GJ. Phosphorylated intermediate of Na+-K+ activated ATPase. Fed Proc 1963;22:213.
4. Fahn S, Albers RW, Koval GJ.Sodium-activated high-energy phosphorylated intermediate of Na+-K+- activated ATPase. Fed Proc 1965;24:670.
5. Fahn S, Coté LJ. Regional and subcellular distribution of tyrosine hydroxylase. Neurology 1968;18:193- 294.
6. Coté LJ, Fahn S. Properties of tyrosine hydroxylase in brain and its distribution in Rhesus monkey brain. Fed Proc 1968;27:752.
7. Coté LJ, Fahn S. Biochemical aspects of tyrosine hydroxylase in human brain. Trans Am Soc Neurochem 1971;2:63.
8. Fahn S. Topographic distribution of monoamines in human neostriatum: Normals and Parkinson’s disease.. Neurology 1971;21:420.
9. Earnest MP, Fahn S, Rowland LP, Gambetti P. Normal pressure hydrocephalus syndrome with cerebrovascular disease. Trans Am Neurol Assn 1971;97:268-270.
10. Brait K, Fahn S, Schwarz GA. The association of parkinsonism and motor neuron disease. Neurology 1972;22:443-444.
11. Fahn S. L-Dopa effect in Huntington’s chorea. N Engl J Med 1972;287:467-468.
12. Prasad ALN, Fahn S. A simplified method for the simultaneous determination of the biogenic monoamines, their precursors and metabolites. Trans Am Soc Neurochem 1973;4:105.
13. Fahn S. Discussion of catalase and peroxidase in human brain. Trans Am Neurol Assn 1973;98:9-10.
14. Prasad ALN, Fahn S. A new semi-automated method for the determination of dopamine. Trans Am Soc 10. Neurochem 1974;5:82.
15. Johnson WG, Fahn S. Treatment of vascular hemichorea and hemiballism with perphenazine. Trans Am Neurol Assn 1974;99:222-224.
16. Prasad ALN, Snider S, Fahn S. Determination of 5-hydroxyindoles by an improved semi-automated fluorometric procedure. Trans Am Soc Neurochem 1975;6:153.
17. Kremzner LT, Fahn S, Coté LJ. Human brain glutamic acid decarboxylase methods of assay, purification and characterization. Trans Am Soc Neurochem 1975;6:168.
18. Snider S, Fahn S, Isgreen WP, Coté LJ. Pain, paresthesia and parkinsonism. N Engl J Med 1975;293:200.
19. Prasad ALN, Sahar DI, Snider SR, Fahn S. Effect of ACTH on stress induced changes in adrenal dopamine and catecholamines. Trans Am Soc Neurochem 1976;7:123.
20. Prasad ALN, Snider SR, Fahn S. Short-term changes in adrenal dopamine and catecholamines induced by morphine. Fed Proc 1976;33:384-385.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 114
21. Isgreen WP, Chutorian AM, Fahn S. Sequential parkinsonism and chorea following “mild” influenza. Arch Neurol 1976;33:384-385.
22. Fahn S, Snider SR. Effect of bromocriptine on the levodopa/carbidopa induced changes in serotonin metabolism. Soc Neurosci Abstracts 1976;2:601.
23. Fahn S, Glowinski J. A radiochemical assay for GABA. Trans Am Soc Neurochem 1977;8:251.
24. Fahn S. Episodic failure of absorption of levodopa: a factor in the control of clinical fluctuations in the treatment of parkinsonsonism. Neurology 1977;27:390.
25. Fahn S. Report on Huntington’s disease workshop. Biomedicine 1977;26:105-106.
26. Prasad ALN, Fahn S. Measurement of γ-aminobutyric acid (GABA) in cerebrospinal fluid by high performance liquid chromatography. Proc Internat Soc Neurochem 1977;6:604.
27. Lesser RP, Fahn S, Snider S, Coté LJ, Barrett RE, Isgreen WP. Analysis of the clinical problems in parkinsonism and of the complications of long-term levodopa therapy. Neurology 1978;28:342.
28. Fahn S, Coté LJ, Snider S, Barrett RE, Isgreen WP. Efficacy and toxicity of bromocriptine in the treatment of parkinsonism. Neurology 1978;28:343.
29. Fahn S. Tardive dyskinesia and akathisia. N Engl J Med 1978;299:202-203.
30. Fahn S. Postanoxic action myoclonus: improvement with valproic acid. N Engl J Med 1978;299:313-314.
31. Fahn S. Treatment of tardive dyskinesia with combined reserpine and alpha-methyltyrosine. Ann Neurol 1978;4:169.
32. Fahn S. Treatment of dystonia with high-dosage anticholinergic medication. Neurology 1979;29:605.
33. Forrest DV, Fahn S. Tardive dysphrenia and subjective akathisia. J Clin Psychiat 1979;40:206.
34. Fahn S, Barrett RE. Increase in parkinsonian symptoms as a manifestation of levodopa toxicity. Canad J Neurol Sci 1979;6:78.
35. Snider SR, Snider RS, Fahn S. Anterior cerebellum and catcholaminergic nuclei: Anatomical and biochemical evidence for direct interconnections.. Canad J Neurol Sci 1979;6:89.
36. Fahn S, Prasad ALN. The effects of orally administered U-0521, an inhibitor of catechol-O- methyltransferase. Soc Neurosci Abstracts 1979;5:402.
37. Prasad ALN, Fahn S.GABA levels in cerebrospinal fluid of neurological patients. Soc Neurosci Abstracts 1979;5:414.
38. Jackson V, Miller C, Prasad ALN, Snider S, Fahn S. Behavioral hypersensitivity with apomorphine: prevention by L-DOPA. Soc Neurosci Abstracts 1979;5:561
39. Sharma JN, Fahn S. Microiontophoretic studies with L-DOPA and some putative neurotransmitters in the neurons of caudate nucleus of rat. Soc Neurosci Abstracts 1979;5:599.
40. Fahn S. Treatment of tardive dyskinesia with combined reserpine and alpha-methyltyrosine. Trans Am Neurol Assoc 1978;103:100-103.
41. Fahn S, Prasad ALN. Sequestration of levedopa into erythrocytes: Implication for therapy of parkinsonism. . Neurology 1980;30:364.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 115
42. Floud A, Fahn S. Kinetics of L-DOPA uptake by human erythrocytes. Neurology 1980;30:364-365.
43. Mayeux R, Fahn S. Paroxysmal dystonic choreoathetosis in two brothers with cerebellar ataxia, successfully treated with acetazolamide. Neurology 1980;30:380.
44. Burke RE, Fahn S, Gold AP. Delayed-onset dystonia in 'static' encephalopathy. Neurology 1980;30:382
45. Fahn S, Singh N.Segmental tremor vs. rhythmic myoclonus: Successful treatment with serotonin precursors. Neurology 1980;30:383-384.
46. Singh N, Fahn S.Electrophysiologic studies in Shy-Drager syndrome. Neurology 1980;30:394.
47. Mayeux R, Hunter S, Fahn S. More on myoclonus in Alzheimer disease. Ann Neurol 1980; 8:300.
48. Fahn S. Levodopa provocative test for Huntington's disease. New Engl J Med 1980;303:884..
49. Mauro AJ, Fahn S, Russman B. Hemidystonia following 'minor' head trauma. Ann Neurol 1980; 8:108.
50. Singh N, Fahn S. 'Late' electromyographic responses to ankle displacement in hemiplegia and basal ganglion diseases. Ann Neurol 1980;8:109-110.
51. Jackson V, Reches A, Fahn S, Prasad ALN. COMT inhibitor, U-0521, does not interfere with brain uptake of L-DOPA. Trans Am Soc Neurochem 1981;12:194.
52. Reches A, Jackson V, Jiang D, Prasad ALN, Fahn S. Simultaneous assay for COMT and its competitive inhibitor U-0521. Trans Am Soc Neurochem 1981;12:185.
53. Gollomp S, Ilson J, Burke R, Reches A, Fahn S. Meige syndrome: A review of 31 cases. Neurology 1981;31(No. 4, pt. 2):78.
54. Burke RE, Fahn S, Jankovic J, Ilson J, Gollomp S. Tardive dystonia: A persistent dystonia due to antipsychotic drugs. Neurology 1981;31(No. 4, pt. 2):79.
55. Barrett RE, Singh N, Fahn S. The syndrome of painful legs and moving toes. Neurology 1981;31(No. 4, pt. 2):79.
56. Fahn S, Singh N. An oscillating form of essential myoclonus. Neurology 1981;31(No. 4, pt. 2):80.
57. Reches A, Fahn S. O-Methyldopa interferes with striatal utilization of levodopa. Ann Neurol 1981;10:94-95.
58. Jackson V, Reches A, Prasad ALN, Fahn S. Time course and distribution patterns in rat tissues after L- DOPA administration. Soc Neurosci Abstracts 1981;7:936.
59. Burke RE, Wagner HR, Fahn S. Barrel rotation in rats induced by intraventricular chlorpromazine methiodide: an antimuscarinic effect. Soc Neurosci Abstracts 1981;7:736.
60. Jiang D, Reches A, Wagner HR, Fahn S: Attenuation of dopamine agonist effects of chronic pergolide administration. Soc Neurosci Abstracts 1981;7:206.
61. Jiang D, Reches A, Wagner HR, Fahn S. Attenuation of dopamine agonist effects of chronic pergolide administration. Soc Neurosci Abstracts 1981;7:206.
62. Fahn S, Allen AH Jr, Rubenstein P. Genetic evidence for a case of spontaneous mutation of 'presumed' Huntington's disease. 12th World Congress of Neurology Abstracts, Excerpta Medica International Congress Series 548, Amsterdam, 1981. p 67.
63. Fahn S. Neuropharmacology of Parkinson's disease. 12th World Congress of Neurology Abstracts,
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 116
Excerpta Medica International Congress Series 548, Amsterdam, 1981. pp 181-182,
64. Reches A, Fahn S. O-Methyldopa interferes with striatal utilization of levodopa. Trans Amer Neurol Assn 106: 251-252, 1981.
65. Mauro AJ, Fahn S, Russman B. Hemidystonia following 'minor' head trauma. Trans Am Neurol Assoc 105: 229-231, 1980.
66. Reches A, Burke RE, Hassan M, Jackson V, Fahn S. Tetrabenazine may interact with dopamine receptors in rat brain. Trans Am Soc Neurochem 13:274, 1982.
67. Burke RE, Fahn S. Double-blind evaluation of high-dosage trihexyphenidyl treatment of torsion dystonia. Neurology 32: A112, 1982.
68. Ilson J, Parrish M, Fahn S, Cote LJ: Familial Shy-Drager syndrome: Clinical, biochemical and pathologic findings. Neurology 32: A160, 1982.
69. Reches A, Wagner HR, Jackson V, Jiang D, Fahn S: Chronic dopamine agonist treatment in an animal model of tardive dyskinesia: Differential effect on pre- and postsynaptic receptor sensitivity. Neurology 32: A161, 1982.
70. Ilson J, Fahn S, Mayeux R, Cote LJ: Pergolide treatment in parkinsonism. Neurology 32: A181, 1982.
71. Hallett M, Marsden CD, Fahn S: Origins of the term myoclonus. Neurology 32: A231, 1982.
72. Reches A, Fahn S: Chronic dopa feeding of mice. Neurology 32: 684-685, 1982.
73. Reches A, Wagner HR, Jackson V, Fahn S: Dopamine receptor supersensitivity and tolerance induced by haloperidol is not inhibited by prophylactic lithium administration. Ann Neurol 12: 93-94, 1982.
74. Reches A, Burke RE, Kuhn C, Hassan M, Jackson V, Fahn S: Tetrabenazine blocks dopaminergic receptors in rat brain. Ann Neurol 12: 94, 1982.
75. Burke RE, Fahn S: Pharmacokinetics of trihexyphenidyl after acute and chronic administration. Ann Neurol 12: 94, 1982.
76. Wagner HR, Yablonskaya-Alter E, Reches A, Fahn S: 3H-Spiperone binding is increased in striatal membranes of adult male rats. Soc Neurosci Abstracts 8: 485, 1982.
77. Kordower JH, Bodnar RJ, Reches A, Simone DA, Wallace MM, Fahn S: Reduction of morphine analgesia and basal nociception following central parachlorophenylalanine treatment. Soc Neurosci Abstracts 8: 511, 1982.
78. Simone DA, Bodnar RJ, Reches A, Kordower JH, Fahn S: Tail pinch hyperalgesia: Dopamine and opioid modulation. Soc Neurosci Abstracts 8: 511, 1982.
79. Reches A, Burke RE, Jiang D-H, Wagner HR, Fahn S: Neurotensin increases dopamine turnover in rat brain. Soc Neurosci Abstracts 8: 581, 1982.
80. Jiang D-H, Wagner HR, Yablonskaya-Alter E, Reches A, Fahn S: Presynaptic regulation of endogenous dopamine release from rat striatal synaptosomes. Soc Neurosci Abstracts 8:655,1982.
81. Burke RE, Fahn S: Antimuscarinic and somatostatin-induced barrel rotation are elicited by microinjection of vestibular nuclear complex. Soc Neurosci Abstracts 8: 698, 1982.
82. Hassan M, Wagner HR, Jackson V, Crider AM, Fahn S: Attenuation of dopamine agonist effects of chronic pergolide administration. Neurology 32:A65,1982.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 117
83. Reches A, Burke RE, Jiang D-H, Wagner HR, Fahn S: The effect of neurotensin on dopaminergic neurons in rat brain. Ann NY Acad Sci 400: 420-421, 1982.
84. Reches A, Liu K, Karpiak S, Tamir H, Fahn S: 5-HT depletion by reserpine is inhibited by chronic administration of lithium. Trans Am Soc Neurochem 14: 173, 1983.
85. Hassan MN, Reches A, Kuhn CM, Jackson-Lewis V, Lopez J, Fahn S: Metoclopramide blocks dopaminergic receptors in rat brain. Neurology 33 (Suppl 2): 90, 1983.
86. Reches A, Hassan MN, Jackson-Lewis V, Fahn S: Lithium antagonizes the dopamine-depleting effects of reserpine and tetra benazine but not that of alpha-methyl-P-tyrosine. Neurology 33 (Suppl 2): 91, 1983.
87. Burke RE, Fahn S, Bressman S: Studies of trihexyphenidyl serum levels in patients with dystonia. Neurology 33 (Suppl 2): 91, 1983.
88. Ilson J, Braun N, Fahn S: Respiratory fluctuations in Parkinson's disease. Neurology 33 (Supl 2): 113, 1983.
89. Fahn S: Recurrent intention tremor and peripheral neuropathy associated with repeated naphthalene intoxication. Neurology 33 (Suppl 2): 131, 1983.
90. Fahn S: Paroxysmal tremor. Neurology 33 (Suppl 2): 131, 1983.
91. Fahn S, Williams D, Reches A, Lesser RP, Jankovic J, Silberstein SD: Hysterical dystonia, a rare disorder: report of five documented cases. Neurology 33 (Suppl 2): 161, 1983.
92. Fahn S, Bressman S: sporadic paroxysmal dystonic choreoathetosis. Neurology 33 (Suppl 2): 161, 1983.
93. Fahn S: Natural history and treatment of dystonia. J Neurochem 41 (Suppl): S37, 1983.
94. Reches A, Wagner HR, Jackson V, Yablonskaya-Alter E, Fahn S: Changes in membrane binding of 3H-spiperone induced by denervation and receptor blockade, in the rat striatum, are additive. J Neurochem 41 (Suppl):S78, 1983.
95. Reches A, Fahn S: Lithium in the "on-off" phenomenon. Ann Neurol 14:91, 1983.
96. Bressman S, Fahn S, Eisenberg M, Maltese W: Adult-onset encephalopathy with myoclonus, ataxia, deafness, hemianopsia, and hemiparesis responsive to biotin. Ann Neurol 14 109-110, 1983.
97. Fahn S, Bressman S, Burke R, Hening W, Ilson J, Walters A: Treatment of blepharospasm with high-dose baclofen. Ann Neurol 14:112,1983.
98. Hening W, Walters A, Cote L, Fahn S: Opiate responsive myoclonus. Ann Neurol 14:112,1983.
99. Reches A, Burke RE, Fahn S, Ilson J: Tetrabenazine induces acute dystonic reactions. Ann Neurol 14: 134, 1983.
100. Reches A, Jackson-Lewis V, Fahn S: DL-Threo-dihydroxyphenylserine as a precursor of norepinephrine. Ann Neurol 14: 137, 1983.
101. Barkai AI, Kowalik S, Reches A, Fahn S: Electroconvulsive treatment attenuates haloperidol-induced increase of 3H-imipramine binding in rat brain. Soc Neurosci Abstracts 9: 229, 1983.
102. Wagner HR, Yablonskaya E, Reches A, Fahn S: Chronic clonazepam treatment increases the density of serotonin-1 and serotonin-2 binding sites in rat frontal cortex. Soc Neurosci Abstracts 9: 230, 1983.
103. Burke RE, Fahn S: The effect of selective lesion on vestibular nuclear complex (VNC) choline
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 118
acetyltransferase (CAT) activity in the rat. Soc Neurosci Abstracts 9:966,1983.
104. Reches A, Wagner HR, Barkai AI, Alter E, Jackson-Lewis V, Fahn S: Electroconvulsive treatment induces dopamine autoreceptors supersensitivity rat brain. Soc Neurosci Abstracts 9: 1109, 1983.
105. Hassan MN, Reches A, Kuhn C, Jackson-Lewis V, Fahn S: Behavioral and biochemical effects of the dopamine D1 agonist SK&F 38393-A. Soc Neurosci Abstracts 9: 1112, 1983.
106. Yablonskaya E, Wagner HR, Mayeux R, Fahn S: Alpha-1 and alpha-2 adrenergic binding sites in human frontal cortex. Soc Neurosci Abstracts 9:1117,1983.
107. Fahn S: Treatment of Parkinson's disease. JAMA 250:3106, 1983.
108. Reches A, Wagner HR, Jackson V, Yablonskaya-Alter E, Fahn S: Denervation induced dopamine receptor supersensitivity is different from that induced by chronic haloperidol or reserpine treatment. Neurology 34: suppl 1:104, 1984.
109. Reches A, Wagner HR, Jackson V, Yablonskaya-Alter E, Fahn S: Chronic levodopa or pergolide administration induces subsensitivity of dopamine receptors in denervated striatum. Neurology 34: suppl 1: 105, 1984.
110. Walters A, Hening W, Kavey N, Gidro-Frank S, Cote L, Fahn S: Restless legs syndrome: A pleomorphic sensorimotor disorder. Neurology 34: suppl 1:129,1984.
111. Hassan MN, Higgins D, Jackson-Lewis V, Fahn S: Pharmacologic characteristics of the presynaptic dopamine receptor. Neurology 34: suppl 1:218,1984.
112. Reches A, Jackson V, Fahn S: DL-threo-DOPS: Effective peripheral precursors of norepinephrine with no effect on brain levels of norepinephrine or dopamine. Neurology 34: suppl 1: 269, 1984.
113. Burke RE, Fahn S: The relative selectivity of anticholinergic antiparkinsonian drugs for M1 and M2 muscarinic receptor subtypes. Soc Neurosci Abstracts 10: 1189, 1984.
114. Brin MF, Bressman SB, Fahn S, Resor SR, Weitz J, Sagman DL: Chorea-acanthocytosis: clinical and laboratory features in five cases. Neurology 35: suppl 1:110,1985.
115. Traub M, Wagner HR, Hassan M, Jackson-Lewis V, Fahn S: Effects of chronic bromocriptine treatment on behavior and on dopamine receptor binding in the rat striatum. Neurology 35: suppl 1:118, 1985.
116. Hassan MN, Higgins D, Traub M, Fahn S: Chronic bromocriptine treatment induces behavioral supersensitivity. Neurology 35:suppl 1:158, 1985.
117. Reches A, Wagner HR, Jackson V, Fahn S: Presynaptic dopamine receptors in rat brain: effects of dopamine depletion and receptor blockade. Neurology 35: suppl 1:237-238, 1985.
118. Fahn S, List T, Moskowitz C, Brin M, Bressman S, Burke R, Scott A: Double-blind controlled study of botulinum toxin for blepharospasm. Neurology 35: suppl 1:271-272, 1985.
119. Friedman A, Fahn S: Spontaneous remissions in spasmodic torticollis (ST). Neurology 35: suppl 1:272, 1985.
120. Burke RE, Fahn S, Brin M, Bressman S, Moskowitz C: The clinical course of autosomal dominant torsion dystonia. Neurology 35: suppl 1:273, 1985.
121. Bressman SB, Fahn S: Clinical spectrum of essential myoclonus. Neurology 35: suppl 1:274, 1985.
122. Voulters L, Bressman SB, Fahn S: Treatment of tic disorders with clonazepam. Canad J Neurol Sci
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 119
12:172-173, 1985.
123. Hassan MN, Crider AM, Grimes JD, Fahn S: Pharmacological profile of suspected presynaptic dopamine receptor agonists. Canad J Neurol Sci 12:196, 1985.
124. Hassan MN, Fahn S: Correlation of behavioral and biochemical parameters of dopamine D1 and D2 receptor activation. J Neurology 232: 107, 1985.
125. Fahn S, Brin MF: Delayed-onset dystonia in adults following vascular insult. J Neurology 232: 220, 1985.
126. Walters A, Hening W, Chokroverty S, Fahn S: Opioid responsiveness of neuroleptic-induced akathisia. Ann Neurol 18: 137, 1985.
127. Kramer P, Breakefield X, Bressman S, Ozelius L, Moskowitz C, Tanzi R, Hobbs W, Kidd K, Fahn S, Gusella J: Linkage analysis in family with dominantly-inherited torsion dystonia: exclusion of pro-opiomelanocortin gene and regions of chromosomes 4 and 21. Am J Hum Genetics 37:A163, 1985.
128. Wagner HR, Traub M, Reches A, Nilaver G, Alter E, Lewis V, Fahn S, Zimmerman EA: Regulation of striatal D2 dopamine receptors. Soc Neurosci Abstracts 11:923, 1985.
129. Lange DJ, Warner C, Brin M, List T, Fahn S, Lovelace RE. Botulinum toxin therapy: distant effects on neuromuscular transmission. Muscle and Nerve 8:624-625, 1985.
130. Fahn S: Lack of benefit from cervical cord stimulation for dystonia. N Engl J Med 313:1229, 1985.
131. Burke RE, Fahn S, Gold A: Delayed onset dystonia. J Neurol Neurosurg Psychiat 48:1190-1191, 1985.
132. de Yebenes JG, Voulters L, Jackson-Lewis V, Lovelle S, Fahn S: Reversal of reserpine-induced akinesia by intraventricular infusion of dopamine. Neurology 36 (Suppl 1):77, 1986.
133. de Yebenes JG, Voulters L, Jackson-Lewis V, Alter E, Lovelle S, Fahn S: The effect of intraventricular dopamine infusion in 6-OH-DA lesioned rats on contralateral rotation, dopamine levels, and dopamine receptors in striatum. Neurology 36 (Suppl 1):77-78, 1986.
134. Shale HM, Truong DD, Fahn S: Tics in patients with other movement disorders. Neurology 36 (Suppl 1):118, 1986.
135. Brin MF, Fahn S, Bressman SB, Burke RE: Dystonia precipitated by peripheral trauma. Neurology 36 (Suppl 1):119, 1986.
136. Brin MF, Fahn S, Moskowitz CB, Blitzer A, Friedman A, Shale HM, Greene PE, List T, Lovelace RE: Injections of botulinum toxin for the treatment of focal dystonia. Neurology 36 (Suppl 1):120, 1986.
137. Kang UJ, Burke RE, Fahn S: Natural history and treatment of tardive dystonia. Neurology 36 (Suppl 1):121, 1986.
138. Fahn S, Marsden CD: Editorial: A new society, a new journal, and a new medium. Movement Disorders 1:1-2, 1986.
139. Fahn S: Dystonia - diagnosis, classification and therapy. Upsala J Med Sci Suppl 43:98,1986.
140. Mayeux R, Rosenstein R, Stern Y, Cote L, Fahn S: The prevalence and risk of dementia in idiopathic Parkinson's disease. Ann Neurol 20:128, 1986.
141. Truong DD, Pranzatelli MR, Jackson-Lewis V, Fahn S: Intracerebroventricular glycine blocks myoclonus induced by p,p'-DDT in the rat. Ann Neurol 20:149, 1986.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 120
142. Fahn S, Marsden CD: Editorial: The video medium creates new responsibilities and opportunities. Mov Disord 1:91-92, 1986.
143. Blitzer A, Brin MF, Fahn S, Lange D, Lovelace RE: Botulinum toxin (BOTOX) for the treatment of "spastic dysphonia" as part of a trial of toxin injections for the treatment of other cranial dystonias. Laryngoscope 96:1300-1301, 1986. Letter to the Editor.
144. de Leon D, Bressman SB, Brin MF, Fahn S, Risch N. Inheritance of idiopathic torsion dystonia in the Ashkenazim. Am J Human Genetics 39:(suppl 2):A58, 1986.
145. Brin MF, Ozelius L, DeLeon D, Seeley R, Amos J, Warburton D, Fahn S, Bressman SB, Wasmuth J, Kramer P, Kidd K, Gusella J, Breakefield XO. Dystonia symptoms in a female with 45,XX,-18,-21,+der t(18;21)(18q21q)mat and exclusion of regions of chromosome 18 in another family with autosomal dominant dystonia. Am J Human Genetics 39:(suppl 2):A190, 1986.
146. Fahn S: Paroxysmal myoclonic dystonia with vocalisations. J Neurol Neurosurg Psychiatry 50:117, 1987.
147. Fahn S, Marsden CD: Editorial: Introducing the "What Is It?" section. Movement Disorders 1:221, 1986.
148. Shale H, Fahn S. Response of essential tremor to treatment with primidone. Neurology 37 (Suppl 1):122-123, 1987.
149. Greene P, Shale H, Fahn S, Brin M, Friedman A. Treatment of torticollis with injections of botulinum toxin. Neurology 37 (Suppl 1):123, 1987.
150. Burke RE, Kang UJ, Fahn S. Tardive akathisia: motor phenomena and treatment. Neurology 37 (Suppl 1):124, 1987.
151. Brin MF, Bressman SB, Moskowitz CB, Fahn S, Burke RE, de Leon D. Autosomal dominant dystonia in a large North American family: clinical features. Neurology 37 (Suppl 1):137, 1987.
152. Bressman SB, de Leon D, Brin MF, Risch N, Shale H, Burke RE, Greene PE, Fahn S. Inheritance of primary torsion dystonia among Ashkenazi Jews. Neurology 37 (Suppl 1):187, 1987.
153. Philips PC, Brin MF, Fahn S, Greene PE, Sidtis JJ, Ragassa J, Krol G, Moeller, Sergi ML, Rottenberg DA. Abnormal regional cerebral glucose metabolism in choreo-acanthocytosis: An 18F-fluorodeoxglucose positron emission tomographic study. Neurology 37 (Suppl 1):211, 1987.
154. Kang UJ, Burke RE, Fahn S, Greene P. Adult-onset foot dystonia. Neurology 37 (Suppl 1): 258, 1987.
155. Greene P, Fahn S. Patterns of spread of dystonia in childhood onset dystonia. Neurology 37 (Suppl 1):269, 1987.
156. Parkinson Study Group: Shoulson I, Fahn S, Brin M, Burke R, Bressman S, et al. Correlates of clinical decline in early Parkinson's disease. Neurology 37 (Suppl 1):278, 1987.
157. Truong DD, Bressman SB, Shale H, Brin MF, Greene PE, Fahn S. Clonazepam, haloperidol, and clonidine in tic disorders. Neurology 37 (Suppl 1):279, 1987.
158. Truong DD, Pranzatelli, Jackson-Lewis V, Fahn S. DDT-induced myoclonus in rats: Effects of pharmacologic agents. Neurology 37 (Suppl 1):377, 1987.
159. de Yebenes JG, Fahn S, Jackson-Lewis V, Mena MA. Intracerebroventricular infusion of L-(+)-4-propyl-9-hydroxynaphthoxacine reverses behavioral effects of dopamine deficiency in rats. Ann Neurol 22:145, 1987.
160. Hening W, Fahn S, Saines N, Lovelace R. Prominence of negative myoclonus in the treatment-resistant
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 121
motor disturbances of postanoxic myoclonus. Ann Neurol 22:174, 1987.
161. Jackson-Lewis V, Cadet JL, Kuyatt B, Fahn S, de Souza E: Iminodipropionitrile causes downregulation of opiate mu receptors in rat brain. Soc Neurosci Abstracts 13:136, 1987.
162. Mena MA, de Yebenes JG, Dwork A, Latov N, Fahn S, Herbert J: Neuroblastoma cells as a possible donor for transplantation in animal models of Parkinson's disease. Soc Neurosci Abstracts 13:162, 1987.
163. Truong DD, Claude JJ, Pezzoli G, Fahn S: Effects of glycine and milacemide in DDT induced hyperthermia. Soc Neurosci Abstracts 13:733, 1987.
164. Fahn S. Is the thought disorder with oculogyric crisis a feature of tardive akathisia or tardive dysphrenia? Ann Neurol. 1988 Mar;23(3):313-4. PubMed PMID:2897825.
165. Bressman SB, de Leon D, Brin MF, Risch N, Shale H, Burke RE, Greene PE, Kang U, Fahn S: Clinical spectrum of dystonia in Ashkenazi Jewish families. Neurology 38 (Suppl 1):124, 1988.
166. de Yebenes JG, Mena MA, Dwork A, Latov N, Fahn S, Herbert J. Transplantation of human neuroblastoma cells in 6-OH-DA lesioned rats. Neurology 38 (Suppl 1):128-129, 1988.
167. Brin MF, Blitzer A, Fahn S, Lovelace RE: Laryngeal dystonia (LD) at the Dystonia Clinical Research Center (DCRC): Clinical & electromyographic (EMG) features in 110 cases. Neurology 38 (Suppl 1):129, 1988.
168. Saint-Hilaire M-H, Burke RE, Fahn S, Bressman SB. Delayed-onset dystonia following perinatal or childhood anoxia: Natural history and treatment. Neurology 38 (Suppl 1):130, 1988.
168. Greene P, Fahn S: Tardive complications in patients with idiopathic dystonia treated with dopamine blocking agents. Neurology 38 (Suppl 1):131, 1988.
170. de Yebenes JG, Russell N, Fahn S. Intracerebral infusion of norepinephrine produces dystonia in the rat. Neurology 38 (Suppl 1):207, 1988.
171. Cadet JL, Jackson-Lewis V, Clark CR, Fahn S. Differential effects of alpha-benzyl-N-methylphenethylamine, a methamphetamine analog, on catecholamine concentration in rat brain. Neurology 38 (Suppl 1):225, 1988.
172. Kang UJ, Greene P, Fahn S, Brin M, Moskowitz C, Burke RE, Lange DJ, Flaster E: Double-blind placebo-controlled study of botulinum toxin injections for torticollis. Neurology 38 (Suppl 1):244, 1988.
173. Brin MF, Blitzer A, Fahn S, Lovelace RE: Adductor laryngeal dystonia: Treatment with local injections of botulinum toxin (BOTOX). Neurology 38 (Suppl 1):244-245, 1988.
174. Shale H, Greene P, Fahn S: Analysis of failures of botulinum toxin injections in the treatment of blepharospasm. Neurology 38 (Suppl 1):245, 1988.
175. Stern Y, Mullen L, Fahn S: Long-term effects of high-dose anticholinergic medications. Neurology 38 (Suppl 1):248, 1988.
166. de Yebenes JG, Fahn S, Pezzoli G, Jamrosik Z, Goodman R, Popalski S. The effect of chronic intracerebral infusion of PHNO on MPTP-induced akinesia in monkeys. Neurology 38 (Suppl 1): 314, 1988.
177. Nygaard TG, Fahn S: Variability of symptoms in idiopathic dystonia. Neurology 38 (Suppl 1):419, 1988.
178. Eidelberg D, Sidtis JJ, Moeller JR, Dhawan V, Ginos J, Cedarbaum J, Greene P, Dahl C, Fahn S, Rottenberg DA: The metabolic anatomy of typical and atypical parkinsonism: Complementary 18F-fluoro-
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 122
deoxyglucose and 18F- fluorodopa positron emission tomographic studies. Ann Neurol 24:151, 1988.
179. Fahn S, Moskowitz C: X-Linked recessive dystonia and parkinsonism in Filipino males. Ann Neurol 24:179, 1988.
180. Jackson-Lewis V, Katz M, Clark CR, Fahn S, Cadet JL. Regional effects of alpha-benzyl-N-methylphenethylamine (ABNMP) on dopamine and serotonin metabolism in rat brain. Neurosci Abstracts 1988;14:423.
181. Cadet JL, Stennet R, Katz M, Jackson-Lewis V, Fahn S. Anisomycin causes exacerbation of the iminodipropionitrile (IDPN)-induced dyskinetic syndrome in rats. Neurosci Abstracts 1988;14:718.
182. Pezzoli G, Fahn S, Dwork A, de Yebenes J, Jackson-Lewis V, Cadet JL. Behavioral and biochemical effects of nerve growth factor in rats with 6-hydroxydopamine induced nigrostriatal denervation. Neurosci Abstracts 1988;14:1116.
183. Dwork AJ, Pezzoli G, Silani V, Fahn S, Hill R. Letter on transplantation of fetal substantia nigra and adrenal medulla to the caudate nucleus in two patients with Parkison's disease. N Engl J Med 1988;319:370-372.
184. Cadet JL, Klotz A, Jackson-Lewis V, Brin M, Fahn S. Vitamin E or vitamin C treatment attenuate apomorphine-induced rotations in rats after intrastriatal injection of 6-hydroxydopamine. Arch Neurol 1988;45:810.
185. Fahn S. High-dosage antioxidants in early Parkinson's disease. Arch Neurol 1988;45:810.
186. Fazzini E, Burke R, Cote L, Goodman R, Naini AB, Pezzoli G, Pullman S, Solomon R, Stern Y, Weber C, Fahn S. Stereotaxic implantation of autologous adrenal medulla into caudate nucleus in Parkinson's disease. Neurology 1989;39 (Suppl 1):125.
187. Eidelberg D, Moeller JR, Sidtis JJ, Dhawan V, Strother SC, Fahn S, Rottenberg DA. Corticodentatonigral degeneration: metabolic asymmetries studied with 18F-fluorodeoxyglucose and positron emission tomography. Neurology 1989;39 (Suppl 1):164.
188. Burke RE, Brin MF, de Leon D, Bressman S, Fahn S. Comparison of the clinical couse of the Jewish and non-Jewish, juvenile-onset, familial torsion dystonias. Neurology 1989;39 (Suppl 1):188.
189. Shale HM, Greene P, Fahn S. Tardive movement disorders in tic patients treated with dopamine receptor blocking agents. Neurology 1989;39 (Suppl 1):202.
190. Cadet JL, Jackson-Lewis V, Freeman S, Fahn S. Acute effects of beta-N-oxalylamino L-alanine (BOAA) on dopamine and serotonin in rat striatum. Neurology 1989;39 (Suppl 1):203.
191. Greene P, Kang UJ, Fahn S. Spread of idiopathic, adult-onset torsion dystonia. Neurology 1989;39 (Suppl 1):246.
192. Eidelberg D, Moeller JR, Sidtis JJ, Dhawan V, Strother SC, Ginos JZ, Cedarbaum J, Greene P, Fahn S, Rottenberg DA. The metabolic pathology of Parkinson's disease: complementary 18F-fluorodopa and 18F-fluorodeoxyglucose PET studies. Neurology 1989;39 (Suppl 1):273.
193. Brin MF, Blitzer A, Greene PE, Fahn S. Botulinum toxin for the treatment of oromandibulolingual (OMD) dystonia. Neurology 1989;39 (Suppl 1):294.
194. Fink ME, Klebanoff LM, Lennihan L, Fahn S. Acute respiratory failure during drug manipulation in patients with Parkinson's disease. Neurology 1989;39 (Suppl 1):348.
195. Perumal AS, Cooper TB, Fahn S, Cadet JL. Regional effects of 6-hydroxydopamine (6OHDA) and neuroleptic on free radical scavenging system in rat brain. Neurosci Abstracts 1989;15:139.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 123
196. Przedborski S, Wright M, Fahn S, Cadet JL. Quantitative autoradiography of 5-HT-1A serotonin receptors in iminodipropionitrile (IDPN)-induced dyskinetic rats. Neurosci Abstracts 1989;15:421.
197. Breakefield XO, Ozelius L, Kramer PL, Moskowitz CB, Kwiatkowski DJ, Brin MF, Bressman SB, Schuback DE, DeLeon D, Hau Y-PP, Craft C, Hu G, Haines J, Burke RE, Nygaard T, Raese J, Gusella JF, Fahn S. Human dystonia gene found on chromosome 9q32-q34. Neurosci Abstracts 1989;15:653.
198. Jackson-Lewis V, Cadet JL, Suber F, Fahn S. Regional effects of the chronic administration of the excitotoxin B-N-oxalylamino-L-amino (BOAA) on dopamine and serotonin metabolism in rat brain. Neurosci Abstracts 1989;15:765.
199. Cadet JL, Angulo J, Jackson-Lewis V, McEwen BS, Fahn S. NGF potentiates the effects of 6-OHDA-induced nigral lesions on striatal proenkephalin and protachykinin mRNA in rat brain. Neurosci Abstracts 1989;15:1011.
200. Brin MF, Moskowitz CB, Bressman SB, Burke RE, de Leon D, Risch N, Fahn S. Autosomal dominant dystonia in a large North American family: clinical features. Am J Hum Genet (Suppl) 1989;45:A41.
201. Risch N, Bressman SB, de Leon D, Brin MF, Burke RE, Greene PE, Shale H, Claus EB, Cupples LA, Fahn S. Autosomal dominant inheritance of idiopathic torsion dystonia in Ashkenazi Jews. Am J Hum Genet (Suppl) 1989;45:A60.
202. de Leon D, Bressman S, Brin M, Burke R, Fahn S. Genetic counseling for dystonia. Am J Hum Genet (Suppl) 1989;45:A120.
203. Kramer PL, Ozelius L, Risch N, de Leon D, Bressman S, Brin M, Schuback D, Gusella J, Breakefield XO, Fahn S. Gene for dystonia in Ashkenazi Jewish population located on chromosome 9q. Am J Hum Genet (Suppl) 1989;45:A147.
204. Ozelius L, Kramer PL, Moskowitz CB, Kwiatkowski DJ, Brin MF, Bressman SB, Schuback DE, de Leon D, Hsu Y -PP, Craft C, Hu G, Haines J, Burke RE, Raese J, Gusella JF, Fahn S, Breakefield XO. Human dystonia gene found on chromosome 9q32-q34. Am J Hum Genet (Suppl) 1989;45:A211.
205. Blitzer A, Brin MF, Fahn S. Botulinum toxin therapy for recurrent laryngeal nerve section failure for adductor laryngeal dystonia. Trans Am Laryngol Assoc 1989;110:206.
206. de Yebenes JG, Casarejos MJ, Pardo B, Mena MA, Herraiz MV, Fahn S. Neurotoxicity of levodopa on catecholamine neurons is prevented by deprenyl. Mov Disord 1990;5 (Suppl 1):54.
207. Gordon MF, Brin MF, Giladi N, Hunt A, Fahn S. Dystonia precipitated by peripheral trauma. Mov Disord 1990;5 (Suppl 1):67.
208. Penafiel N, Magarinos C, Jorge P, Mena MA, Casarejos MJ, Pardo B, de Yebenes JG, Fahn S. Intracerebroventricular infusion of PHNO in MPTP treated monkeys. Mov Disord 1990;5 (Suppl 1):77.
209. Mena MA, Casarejos MJ, Pardo B, de Yebenes JG, Latov N, Fahn S. Neurobiology of dopamine neurons "in vitro". I. The effect of aging and neurotoxins. Mov Disord 1990;5 (Suppl 1):87.
210. Mena MA, Casarejos MJ, Pardo B, de Yebenes JG, Latov N, Fahn S. Neurobiology of dopamine neurons "in vitro". II. The effect of neurotrophic factors. Mov Disord 1990;5 (Suppl 1):87.
211. Jackson-Lewis V, Przedborski S, Kostic V, Suber F, Fahn S, Cadet JL. Effects of chronic fluphenazine plus alphatocopherol on regional monoamine metabolism in rat brain. Mov Disord 1990;5 (Suppl 1):89.
212. Giladi N, Fahn S, Cadet JL. Benztropine is toxic to LA-N-5 human neuroblastoma cells in vitro. Mov Disord 1990;5 (Suppl 1):90.
213. Przedborski S, Wright M, Fahn S, Cadet JL. Quantitative autoradiography of 5-HT-1 serotonin receptors in
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 124
iminodipropionitrile (IDPN)-induced dyskinetic rats. Mov Disord 1990;5 (Suppl 1):91.
214. Pullman S, Uncini A, Kujirai T, Gluck B, Fahn S. Unique issues in the physiology of orthostatic tremor. Neurology 1990;40 (Suppl 1):125.
215. de Leon D, Brin MF, Blitzer A, Heiman G, Fahn S. Genetic factors in spastic dysphonia. Neurology 1990;40 (Suppl 1):142.
216. Greene P, Fahn S. Treatment of idiopathic dystonia in children with baclofen. Neurology 1990;40 (Suppl 1):143.
217. Bressman SB, de Leon D, Brin MF, Moskowitz CB, Kramer PL, Risch N, Ozelius L, Schuback D, Kwiatkowski DJ, Jaines J, Gusella JF, Breakefield XO, Falk C, Shale H, Burke RE, Fahn S. Dystonia gene located on chromosome 9q. Neurology 1990;40 (Suppl 1):144.
218. Hunt A, Gordon M, Greene P, Giladi N, Fazzini R, Fahn S. Treatment of tardive dyskinesia with dopamine depleting agents. Neurology 1990;40 (Suppl 1):147.
219. Shoulson I, Parkinson Study Group. Deprenyl in early Parkinson's disease: symptomatic versus protective efficacy? Neurology 1990;40 (Suppl 1):153.
220. Fazzini R, Fleming J, Fahn S. Cerebrospinal fluid antibodies to coronaviruses in patients with Parkinson's disease. Neurology 1990;40 (Suppl 1):169.
221. Giladi N, Burke RE, Kostic V, Przedborski S, Gordon M, Hunt A, Fahn S. Hemiparkinsonism and body hemiatrophy. Radiologic findings and prognosis. Neurology 1990;40 (Suppl 1):224.
222. Oakes D, Parkinson Study Group. Progression of early Parkinson's disease until levodopa therapy is required. Neurology 1990;40 (Suppl 1):370.
223. Brin MF, Blitzer A, Stewart C, Fahn S. Botulinum toxin: Now for abductor laryngeal dystonia. Neurology 1990;40 (Suppl 1):381.
224. Eidelberg D, Dhawan V, Cedarbaum J, Greene P, Fahn S. Contralateral basal ganglia hypermetabolism in primary unilateral limb dystonia. Neurology 1990;40 (Suppl 1):399.
225. Cadet JL, Przedborski S, Wright M, Fahn S. Quantitative receptor autoradiography of 2nd-messenger systems in the iminodipropionitrile model of persistent dyskinesias in rat brain. Neurology 1990;40 (Suppl 1):399-400.
226. Hermanowicz N, Nigro M, Fahn S, Truong DD. Grisel's syndrome as a cause of torticollis: report of 2 cases. Neurology 1990;40 (Suppl 1):445.
227. Shoulson I, Fahn S, Oakes D, Lang A, Langston JW, LeWitt P, Olanow W, Penney JB, Tanner C. Deprenyl for the treatment of early Parkinson's disease. N Engl J Med 1990;322:1527-1528.
228. Kwiatkowski DJ, Ozelius L, Kramer PL, Haines J, Schuback DE, Perman S, Bylani B, Jewel C, Francomano, Puffenberger E, Short P, Amos J, Fahn S, Breakefield XO. Highly informative (GT)n polymorphisms from 9q32-q34 permit creation of a high resolution map and delineation of a region likely to contain genes for torsion dystonia (DYT1), tuberous sclerosis (TSC1), and nail-patella syndrome (NPS1). Am J Hum Genet (Suppl) 1990;47:A187.
229. Hall WJ, Oakes, D, Parkinson Study Group. Statistical issues in monitoring a 2 X 2 factorial clinical trial. Cont Clin Trials 1990;11:264.
230. Oakes, D, McDermott M, Eberly S, Plumb S, Watts A, Shoulson I, Parkinson Study Group. Investigator effects in a multicenter trial for Parkinson's disease. Cont Clin Trials 1990;11:284.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 125
231. Pelusio RM, Rudolph A, Orme C, Evans P, Plumb S, Oakes D, Shoulson I, Parkinson Study Group. DATATOP: managing an accelerated trial. Cont Clin Trials 1990;11:304.
232. Tryon WW, Brin MF, Fahn S, Guillory S, Winfield L, Bressman. Validating accelerometric measures of parkinsonism: Technical aspects and preliminary results. Ann Neurol 1990;28:297.
233. Kujirai K, Przedborski S, Kostic V, Jackson-Lewis, Fahn S, Cadet JL. Quantitative autoradiography of dopamine receptors in the spontaneously hypertensive rat. Soc Neurosci Abstracts 1990;16:80.
234. Zecchinelli A, Pezzoli G, Ricciardi S, Burke RE, Fahn S, Fusi R, Mariani CB, Scarloto G, Carenzi A. Epidermal growth factor (EGF) enhances, in rats, dopaminergic pathway "in vivo": an immunohistochemical study. Soc Neurosci Abstracts 1990;16:999.
235. Lang A, Fahn S. Movement disorder of RSD. Neurology 1990;40:1476-1477.
236. Przedborski S, Kostic V, Jackson-Lewis V, Carlson E, Epstein CJ, Fahn S, Cadet JL. Transgenic mice with increased activity of superoxide dismutase are resistant to MPTP-induced toxicity. Neurology 1991;41 (Suppl 1):175.
237. Wilhelmsen KC, Defendini R, Dooneief G, Bell K, Marder K, Sano M, Fahn S, Mayeux R. Identification of a kindred with autosomal dominant thalamic dementia. Neurology 1991;41 (Suppl 1):176.
238. Pullman SL, Gordon MF, Fahn S, Gluck B, McDonald TD. Interneuronal abnormalities in stiff-man syndrome. Neurology 1991;41 (Suppl 1):223.
239. Gordon MF, Pullman S, McDonald TD, Fahn S. Plasmapheresis in the treatment of stiff-man syndrome. Neurology 1991;41 (Suppl 1):223.
240. Brin MF, Blitzer A, Braun N, Stewart C, Fahn S. Respiratory and obstructive laryngeal dystonia: treatment with botulinum toxin (botox). Neurology 1991;41 (Suppl 1):291.
241. Hunt AL, Giladi N, Bressman S, Fahn S. L-Dopa treatment in idiopathic torsion dystonia. Neurology 1991;41 (Suppl 1):293.
242. Cadet JL, Jujirai K, Berger K, Fahn S. Differential effects of three clones of the human neuroblastoma, SKN-SH, after transplantation in the rat model of hemiparkinosnism. Neurology 1991;41 (Suppl 1):325.
243. Giladi N, Kostic V, Przedborski S, Flaster E, Guillory S, Fahn S. Motor blocks ("freezing") in Parkinson's disease. Neurology 1991;41 (Suppl 1):343.
244. Greene P, Przedborski S, Kostic V, Giladi N, Eidelberg D, Fahn S. Cortical-basal ganglionic degeneration: survey of 18 clinically diagnosed patients. Neurology 1991;41 (Suppl 1):344.
245. Ozelius L, Kramer P, de Leon D, Bressman S, Risch N, Schuback D, Brin M, Kwaitkowski DJ, Burke R, Gusella JF, Fahn S, Breakefield XO. Strong allele association between the torsion dystonia gene and loci on chromosome 9q32-q34 in Ashkenazic Jews. Am J Hum Genet (Suppl) 1991;48:A414.
246. Greene PE, Fahn S. Baclofen in the treatment of idiopathic dystonia in children. Mov Disord 1991;6:273.
247. de Leon D, Brin MF, Murphy P, Bressman SB, Ozelius L, Cardon N, Reich S, Breakefield XO, Fahn S. Genetic counseling for idiopathic torsion dystonia: First use of DNA based carrier detection in Ashkenazic Jews. Mov Disord 1991;6:273-274.
248. Levivier M, Przedborski S, Kostic V, Jackson-Lewis V, Gash DM, Fahn S, Cadet JL. Grafting surgery protects against 6-hydroxydopamine-induced dopaminergic toxicity in rats: behavioral and morphological evidence. Soc Neurosci Abstracts 1991;17:770.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 126
249. Kujirai K, Jackson-Lewis V, Fahn S, Carlson E, Epstein CJ, Cadet JL. Comparative quantitataive autoradiographic distribution of µ opioid receptors in the brains of superoxide dismutase-transgenic (SOD-Tg) mice and of their non-transgenic (Non-Tg) littermates: age effects. Soc Neurosci Abstracts 1991;17:812.
250. Jackson-Lewis V, Naini A, Przedborski S, Simonetti S, Fahn S, Cadet JL. Catecholamines inhibit mitochondrial Complex I activity in rat brain. Soc Neurosci Abstracts 1991;17:1276.
251. Blitzer A, Brin MF, Fahn S. Botulinum toxin injections for lingual dystonia. Laryngoscope 1991;101:799.
252. Gordon MF, Franklin M, de Leon D, Warburton D, Seely R, Phillips P, Asaikar S, Maccabee P, Lazar R, Sinha K, Yeboa K, Pearl M, Fahn S, Brin MF. Dystonia in two patients with deletion of 18p. Neurology 1992;(Suppl 3):239.
253. Eidelberg D, Dhawan V, Takikawa S, Mandel F, Reddington K, Chaly T, Robeson W, Spetsieris P, Greene P, Fahn S. Cerebral metabolic determinants of drug responsiveness in parkinsonism. Neurology 1992;42 (Suppl 3):297.
254. Takikawa S, Dhawan V, Reddington K, Chaly T, Robeson W, Spetsieris P, Fazzini E, Greene P, Fahn S, Eidelberg D. Cerebral hypometabolism in presumed striatonigral degeneration. Neurology 1992;42 (Suppl 3):321.
255. Giladi N, Dhawan V, Takikawa S, Reddington K, Chaly T, Robeson W, Spetsieris P, Fahn S, Eidelberg D. Metabolic asymmetries in hemiparkinsonism-hemiatrophy syndrome. Neurology 1992;42 (Suppl 3):322.
256. Bressman SB, de Leon D, Ozelius L, Kramer P, Gusella JF, Brin MF, Burke RE, Fahn S, Breakefield XO, Risch N. Linkage disequilibrium of idiopathic torsion dystonia (ITD) in Ashkenazim: a single mutation and its phenotype. Neurology 1992;42 (Suppl 3):393.
257. Waters CH, Shubin R, Takahashi H, Snow, Calne DB, Wilhelmsen KC, Nygaard TG, Moskowitz CB, Fahn S, Warburton D. Clinical expression of lubag (X-linked dystonia-parkinsonism) in two women. Neurology 1992;42 (Suppl 3):424.
258. Takahashi H, Snow, Waters CH, Shubin R, Warburton D, Nygaard TG, Wilhelmsen KC, Moskowitz CB, Fahn S, Calne DB. Evidence for nigrostriatal lesions in lubag (X-linked dystonia-parkinsonism in the Philippines). Neurology 1992;42 (Suppl 3):441.
259. Pullman S, Fahn S, Rueda J. Physiologic characterization of dystonic and essential tremors. Neurology 1992;42 (Suppl 3):471.
260. Fahn S. The tardive syndromes: phenomenology concepts on pathophysiology, & treatment. Mov Disord 1992;7 (Suppl 1):7.
261. Giladi N, Lo B, Gross B, Fahn S, Cadet JL. The trophic effect of antimuscarinic agents on SK-N-SH human neuroblastoma cell line, in vitro. Mov Disord 1992;7 (Suppl 1):61.
262. Jackson-Lewis V, Naini A, Przedborski S, Fahn S, Cadet JL. Inhibition of mitochondrial respiration by dopamine-related compounds. Mov Disord 1992;7 (Suppl 1):71.
263. Gordon MF, Brin MF, de Leon D, Warburton KA, Bressman S, Fahn S. Dystonia in a patient with deletion of 18q. Mov Disord 1992;7(Suppl 1):25.
264. Lang A, Koller W, Fahn S. Psychogenic parkinsonism (PP). Mov Disord 1992;7 (Suppl 1):82.
265. Brin M, Blitzer A, Stewart C, Viswanath N, Beardsley A, Rosenfield D, Fahn S. Laryngeal botulinum toxin (botox) injections in 431 patients with laryngeal movement disorders: spasmodic dysphonia, adult stuttering and essential voice tremor. Mov Disord 1992;7 (Suppl 1):130.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 127
266. Greene P, Fahn S. Development of antibodies to botulinum toxin type A in torticollis patients treated with botulinum toxin injections. Mov Disord 1992;7 (Suppl 1):134.
267. Greene P, Fahn S. Treatment of torticollis patients treated with injections of botulinum toxin type F in patients with antibodies to botulinum toxin type A. Mov Disord 1992;7 (Suppl 1):134.
268. Eidelberg D, Dhawan V, Takikawa S, Mandel F, Reddington K, Greene P, Fahn S. Cerebral metabolic determinants of drug responsiveness in parkinsonism. Mov Disord 1992;7 (Suppl 1):142.
269. Eidelberg D, Moeller JR, Dhawan V, Takikawa S, Reddington K, Greene P, Fahn S. Regional metabolic covariation in idiopathic torsion dystonia: [18]F-fluorodeoxyglucose PET studies. Mov Disord 1992;7 (Suppl 1):144.
270. Parkinson Study Group. Assessment of the short-term tolerability of lazabemide (Ro 19-6327) in untreated Parkinson's disease. Mov Disord 1992;7:293-294.
271. Stewart C, Winfield, Hunt A, Ciecierski K, Bressman S, Fahn S, Brin MF. Speech dysfunction in early Parkinson's disease. Mov Disord 1992;7:294.
272. de Leon D, Bressman S, Brin M, Risch N, Fahn S. Torsion dystonia in Ashkenazi Jews: Is there evidence for an imprinted gene? Mov Disord 1992;7:297.
273. Eidelberg D, Dhawan V, Takikawa S, Redington K, Chaly T, Greene P, Fahn S. Regional metabolic covariation in idiopathic torsion dystonia: [18F]flurodeoxyglucose PET studies. Mov Disord 1992;7:297.
274. Eidelberg D, Dhawan V, Takikawa S, Chaly T, Greene P, Nygaard T, Fahn S. Positron emission tomographic (PET) findings in Filipino X-linked dystonia-parkinsonism. Mov Disord 1992;7:298.
275. Waters CH, Powers J, Vinters H, Moskowitz C, Hunt AL, Fahn S. The neuropathology of lubag. Mov Disord 1992;7:298.
276. Lew MF, Shindo M, Moskowitz C, Fahn S, Waters CH. Adductor laryngeal "breathing dystonia" in a case of X-linked dystonia-parkinsonism syndrome. Mov Disord 1992;7:301.
277. Walters A, Johnson W, Lehner T, Coccagna G, Ehrenberg B, lazzarini A, Stenroos E, Lugaresi C, Gold B, Brin M, Fazzini E, McCormack C, Fahn S, Ott J, Chokroverty S. Linkage analysis of autosomal-dominant restless legs syndrome. Mov Disord 1992;7:301-302.
278. Lang A, Quinn N, Marsden CD, Findley L, Koller W, Brin M, Fahn S. Essential tremor. Neurology 1992;42:1432-1433.
279. Jackson-Lewis V, Przedborski S, Jiang H, Fahn S. Effect of neuroleptics on the mitochondrial electron transport chain. Soc Neurosci Abstracts 1992;18:1103.
280. Przedborski S, Jackson-Lewis V, Jiang H, Naini AB, Fahn S. Effect of L-dopa on the mitochondrial electron transport chain. Soc Neurosci Abstracts 1992;18:1103.
281. Bressman SB, de Leon D, Ozelius L, Kramer P, Brin MF, Burke RE, Fahn S, Gusella JF, Breakefield XO. Idiopathic torsion dystonia in Ashkenazim: A distinct phenotype of a single mutation. Am J Hum Genet 1992;51(4) Suppl:A209.
282. Ozelius LJ, Teitz SS, Buckler A, Hewitt J, Gasser T, de Leon D, Kramer PL, Risch N, Bressman SB, Housman D, Fahn S, Gusella JF, Breakefield XO. Fine mapping of the human dystonia gene (DYT1) on 9q34 and evlauation of a candidate cDNA. Am J Hum Genet 1992;51(4) Suppl:A224.
283. Fahn S. Editorial: Fetal-tissue transplants in Parkinson's disease. N Engl J Med 1992;327:1589-1590.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 128
284. Wilhelmsen KC, Weeks DE, Neystat M, Nygaard TG, Fahn S. Linkage disequilibrium mapping of lubag (X-linked dystonia-parkinsonism) using simple sequence repeats. Am J Human Gen 1992;51:A204.
285. Jackson-Lewis V, Muthane U, Ramsay KA, Jiang H, Fahn S, Przedborski S. Biodisposition of MPP+ in the cerebellum of mice. Neurology 1993;43 (Suppl):A153-154.
286. Muthane U, Ramsay KA, Jackson-Lewis V, Jiang H, Fahn S, Przedborski S. Is the differential sensitivity to MPTP in various mouse strains dependent on calbindin? Neurology 1993;43 (Suppl):A154.
287. Jiang H, Jackson-Lewis V, Muthane U, Parson B, Fahn S, Przedborski S. Potentiation of antiparkinsonian effects of dopamine agonists by adenosine antagonists in 6-hydroxydopamine-lesioned rats. Neurology 1993;43 (Suppl):A154.
288. Ford B, Fahn S. Effect of antioxidants on prevention of dopa-induced complications of Parkinson's disease. Neurology 1993;43 (Suppl):A156.
289. Wilhelmsen KC, Perez M, Gamez G, Pasciles O, Sobrevega EE, Rosales R, Moskowitz C, Neystat M, Nygaard T, Fahn S. Identification of pre-symptomatic carriers of Lubag (X-linked dystonia-parkinsonism). Neurology 1993;43 (Suppl):A210.
290. Przedborski S, Takikawa S, Dhawan V, Chaly T, Greene P, Fahn S, Eidelberg D. Quantitative FDG/PET imaging in hemiparkinsonism. Neurology 1993;43 (Suppl):A269.
291. Eidelberg D, Moeller JR, Takikawa S, Dhawan V, Chaly T, Robeson W, Fazzini E, Fahn S. Brain metabolic topography in parkinsonism. Neurology 1993;43 (Suppl):A270.
292. Bressman SB, Heiman G, Hunt A, Ozelius L, Nygaard T, Brin M, Moskowitz C, de Leon D, Burke RE, Fahn S, Risch N, Breakefield XO, Kramer P. Evidence for genetic heterogeneity in idiopathic torsion dystonia (ITD). Neurology 1993;43 (Suppl):A330.
293. Dhawan V, Takikawa S, Chaly T, Robeson W, Spetsieris P, Fahn S, Eidelberg D. Does striatal F-dopa uptake decrease with age? Neurology 1993;43 (Suppl):A380.
294. Moeller JR, Takikawa S, Dhawan V, Chaly T, Greene P, Fahn S, Eidelberg D. Brain metabolic topography in idiopathic torsion dystonia. Neurology 1993;43 (Suppl):A408.
295. Lange DJ, Brin MF, Greene P, Lovelace RE, Fahn S. Distant effects of locally injected botulinum toxin - A double-blind study of single fiber EMG changes: A reply. Muscle Nerve 1993;16:677.
296. Fahn S. Postvaccinal parkinsonism. Reply. Mov Disord 1993;8:253.
297. Ozelius LJ, Bressman SB, Gasser T, deLeon D, Hewitt J, Heiman G, Hunt A, Nygaard TN, Moskowitz CB, Brin MF, Fahn S, Breakefield XO, Kramer PL. Most early onset cases of dystonia are caused by the DYT1 gene on chromosome 9q34. Am J Hum Genet 1993;53:840.
298. Parkinson Study Group. The DATATOP study: cerebrospinal fluid homovanillic acid changes in patients with mild, early parkinsonism. Mov Disord 1993;8:410-411.
299. Parkinson Study Group. Controlled trial of lazabemide in lovodopa-treated Parkinson's disease. Mov Disord 1993;8:411.
300. Penney JB, Parkinson Study Group. Effects of sustained deprenyl and tocopherol therapy in levodopa-treated parkinsonian patients. Ann Neurol 1993;34:247.
301. Parkinson Study Group. The impact of extended deprenyl treatment in Parkinson's disease patients not requiring levodopa therapy. Ann Neurol 1993;34:263.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 129
302. de Leon D, Kramer P, Ozelius L, Breakefield X, Fahn S, Bressman SB. Phenotypic expression of the DYT1 gene: who is the carrier? Ann Neurol 1993;34:301.
303. Muthane U, Perez E, Ford B, Fahn S. Does slow release levodopa/carbidopa benefit complications due to regular levodopa/carbidopa in Parkinson's disease? Can J Neurol Sci 1993;20 (Suppl 4):S155.
304. Brin MF, Ozelius L, Risch N, Ivanova-Smolenskaye IA, Markova ED, Limborska SA, Kramer P, de Leon D, Bressman SB, Hewett J, Fahn S, Breakefield X. Analysis of the dystonia gene (DYT1) in Russia. Can J Neurol Sci 1993;20 (Suppl 4):S235.
305. Louis ED, Fahn S. Extrapyramidal features of twelve autopsy-proven cases of diffuse Lewy body disease. New Trends in Clinical Neuropharmacology 1994;8:58-59.
306. Ford B, Elibol B, Fahn S, Pullman S. The electromyographic silent period in dystonia. Neurology 1994;44 (Suppl 2):A234.
307. Lynch T, Bell K, Sano M, Marder K, Nygaard TG, Keohane C, Defendini R, Fahn S, Mayeux R, Wilhelmsen K. The clinical and pathologic presentation of Moynihan's disease: familial dementia-parkinsonism-amyotrophy complex. Neurology 1994;44 (Suppl 2):A260-A261.
308. Ishikawa T, Moeller JR, Dhawan V, Fahn S, Eidelberg D. FDG/PET predicts clinical disability in Parkinson's disease. Neurology 1994;44 (Suppl 2):A280.
309. Nygaard TG, Barclay CL, Segawa M, Fletcher NA, Duff J, Nomura Y, Harding AE, Lang AE, Wilhelmsen KC, St. George-Hyslop PH, Tsuji S, Fahn S, Risch NJ, Weeks DE. Genetic linkage mapping of dopa-responsive dystonia (DRD). Neurology 1994;44 (Suppl 2):A293.
310. Brin MF, Sadiq S, Goodman R, Ford B, Perez E, Fahn S. Intrathecal baclofen (IT-B) for dystonia. Neurology 1994;44 (Suppl 2):A338.
311. Eidelberg D, Moeller JR, Dhawan V, Ishikawa T, Przedborski S, Fahn S. Detection of early Parkinson's disease with [18]F-fluorodeoxyglucose and positron emission tomography. Neurology 1994;44 (Suppl 2):A352.
312. Goetz CG, Stebbens GT, Chmura T, Fahn S, Klawans HL, Marsden CD. UPDRS teaching tape. Neurology 1994;44 (Suppl 2):A368.
313. Louis ED, Lynch T, Bressman SB, Greene PE, Nygaard TG, Fahn S. Gender differences in dopa-responsive dystonia. Neurology 1994;44 (Suppl 2):A368-A369.
314. Lynch T, Burke RE, Fahn S. Progress in psychiatry. N Engl J Med 1994;330:285-286.
315. Ford B, Fahn S. Intrathecal baclofen. Neurology 1994;44:1367-1368.
316. Breakefield XO, Ozelius LJ, Cox G, Hewett J, Shalish C, Bressman SB, Kramer PL, Risch N, Fahn S, Kunkel LM, Dystonia Research Group. Candidate genes for torsion dystonia. Soc Neurosci Abstracts 1994;20:169.
317. de Leon D, Naini A, Brown S, Fahn S, Bressman SB, Wilhelmsen K. DNA testing for idiopathic torsion dystonia in Ashkenazi Jews based on allelic association. Am J Hum Genetics 1994;55:A347.
318. LeWitt P, Oakes D, Cui L, Parkinson Study Group. Endpoints for the study of Parkinson's disease progression. Mov Disord 1994;9:480.
319. LeWitt P, Aizenman E, Newcomer T, Loeffler D, Parkinson Study Group. The search for an endogenous neurotoxin in Parkinson's disease: TOPA and TOPA-quinone. Mov Disord 1994;9:482.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 130
320. Trifiletti PR, Bolan EA, Lynch T, Lovelace RE, Cote L, Pullman S, Fahn S. Quantitative stochastic analysis of myoclonic movements in a patient with Whipple's disease. Mov Disord 1994;9:489.
321. Lynch T, Odel J, Nagle K, Pullman S, Markowitz DD, Lovelace RE, Fahn S, Cote L. CNS Whipple mimicking "hemifacial spasm". Mov Disord 1994;9:489.
322. Fahn S, Mayeux R, Rowland LP. A new eponym: Wilhelmsen-Lynch disease. Neurology 1994;44:1980.
323. Brin MF, de Leon D, Busenbark K, Pahwa R, Marjama J, Petzinger G, Bentivoglio A, Lynch T, Winfield L, Rasnick H, Boinoff J, Bressman SB, Diamond B, Giladi N, Ford B, Fahn S, Koller W. Essential tremor: clinical characteristics of 5 large North American kindreds. Mov Disord 1994;9 (Suppl 1):31.
324. Wilhelmsen KC, Neystat M, Weeks DE, Moskowitz CB, Fahn S, Nygaard TG. Progress in positional cloning of the gene responsible for Lubag: implications for presymptomatic diagnosis. Mov Disord 1994;9 (Suppl 1):32.
325. Przedborski S, Jiang H, Jackson-Lewis V, Parson B, Togasaki D, Fahn S. Antiparkinson-like effects of adenosine in 6-hydroxydopamine lesioned rats. Mov Disord 1994;9 (Suppl 1):107.
326. Przedborski S, Jackson-Lewis V, Fahn S. Effects of chronic levodopa administration on mitochondrial respiration in rats. Mov Disord 1994;9 (Suppl 1):109.
327. Petzinger G, Perez E, Fahn S. Motor features of normal pressure hydrocephalus. Mov Disord 1994;9 (Suppl 1):126.
328. Wilhelmsen KC, Nygaard TG, Weeks DE, Przuntek H, Kraus P, Klotz P, Quinn NP, Sjaastad O, Fahn S. Progress in genetic localization of the gene for hereditary essential myoclonus. Mov Disord 1994;9 (Suppl 1):133.
329. Pullman SL, Wang Y, Pedersen SF, Fahn S. Computerized spiral analysis in patients with movement disorders. Neurology 1995;45(Suppl 4):A218.
330. Kieburtz K, Parkinson Study Group. Effect of lazabemide on the progression of disability of early Parkinson's disease. Neurology 1995;45(Suppl 4):A291.
331. Jackson-Lewis V, Muthane U, Fahn S, Przedborski S. Effects of antiparkinsonian drugs on mitochondrial function. Neurology 1995;45(Suppl 4):A291-A292.
332. Lee TC, Pullman SL, Yao YL, Wang Y, Fahn S, Pedersen SF. Evaluating patients with Parkinson disease, essential tremor and dystonia with artificial neural network paradigms. Neurology 1995;45(Suppl 4):A340.
333. Naini A, Nygaard TG, Hirsch O, Moskowitz CB, Levine RA, Fahn S, Przedborski S. Cerebrospinal fluid biopterin in disorders causing juvenile dystonia-parkinsonism. Neurology 1995;45(Suppl 4):A430.
334. Risch N, de Leon D, Fahn S, Bressman S, Ozelius L, Breakefield X, Kramer P, Almasy L, Singer B. ITD in Ashkenazi Jews - Genetic drift or selection? Reply. Nat Genet 1995;11:14-15.
335. Levivier M, Gash DM, Brotchi J, Fahn S, Przedborski S. Time course of the protective effect of intracerebral transplantation in an experimental model of Huntington's. J Neurosurgery 1995;82:A362-A362.
336. Ozelius L, Hewett J, Shalish C, Smith E, Bressman S, de Leon D, Kramer P, Fahn S, Buckler AJ, McCormick MK, Gusella JF, Breakefield XO. Isolation of candidate genes from the torsion dystonia region of human chromosome 9q34. Am J Hum Genet 1995;57(Suppl):A222.
337. Parkinson Study Group. Dose-ranging study of the safety and efficacy of the dopamine agonist pramipexole in early Parkinson's disease. Mov Disord 1995;10:691.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 131
338. Salgado M, Tan A, Jackson S, Louis E, Ford B, Greene P, Fahn S. Predictors and clinical outcome in hemifacial spasm. Mov Disord 1995;10:702.
339. Ford B, Fahn S, Greene P. Tardive pain. Neurology 1995;45:2114
340. Ford B, Fahn S. 78-Year old woman with tremors, parkinsonism, and dementia. Mov Disord 1996;11:355.
341. Ford B, Greene P, Fahn S. 60-Year old woman with parkinsonism and unilateral dystonia. Mov Disord 1996;11:355-356.
342. Dhawan V, Ishikawa T, Kazumata K, Chaly T, Neumeyer J, Porter J, Fahn S, Eidelberg D. Comparative studies of [123]I-ßCIT-FP/SPECT and [18]F-fluorodopa/PET in normal aging. Neurology 1996;46 (Suppl):A135.
343. Ford B, Greene, Fahn S. Outcome of cervical ramisectomy for intractable torticollis. Neurology 1996;46 (Suppl):A273.
344. Giladi N, McDermott M, Fahn S, Parkinson Study Group. Freezing of gait in Parkinsons's disease. Neurology 1996;46 (Suppl):A377.
345. Petzinger G, Tan A, Kao R, Salgado M, Fahn S. Tremor predominance defines a subtype of Parkinsons's disease patients. Neurology 1996;46 (Suppl):A379.
346. Fahn S. Genetics of dystonia. Mov Disord 1996;11(suppl 1):7.
347. Lynch T, Lendon C, Busfield F, Morris JC, Craddock N, Fahn S, Wilhelmsen KC, Goate A. Hereditary dysphasic dementia (HDD) and disinhibition-dementia-parkinsonism-amyotrophy complex (DDPAC) are linked to the wld locus on chromosome 17g21-22. Mov Disord 1996;11(suppl 1):86.
348. Tan A, Chouinard S, Petzinger G, Fahn S. The clinical spectrum of dystonia in untreated Parkinson's disease. Mov Disord 1996;11(suppl 1):115.
349. Louis ED, Klatka LA, Fahn S. Antemortem diagnosis of diffuse Lewy body disease (DLBD): differences in the parkinsonism of DLBD and PD. Mov Disord 1996;11(suppl 1):133.
350. Winfield L, Bressman S, Brin M, Kao R, Fahn S. The psychosocial impact of the progression of Parkinson's disease. Mov Disord 1996;11(suppl 1):159.
351. Giladi N, McDermott M, Fahn S, Przedborski S, Parkinson Study Group. Freezing of gait in Parkinson's disease. Mov Disord 1996;11(suppl 1):167.
352. Petzinger GM, Stewart C, Khandji AG, Brin M, Greene P, Bressman S, Fahn S. Thalamotomies and speech impairment in idiopathic torsion dystonia (ITD). Mov Disord 1996;11(suppl 1):229.
353. Chouinard S, Louis ED, Tan A, Fahn S. Agreement among movement disorders specialists on definition and diagnosis of essential tremor. Mov Disord 1996;11(suppl 1):253.
354. Fahn S, Rudolph A, Parkinson Study Group. Neurologists' treatment patterns for Parkinson's disease (PD). Mov Disord 1996;11:595.
355. Parkinson Study Group, Nordic Study Group. The COMT inhibitor entacaone increases "on" time in levodopa-treated PD patients with motor fluctuations: report of two randomized placebo-controlled trials. Mov Disord 1996;11:595.
356. Shults CW, Tanner CM, Chan P, Fink s, Kurth M, Marek K, Elmer L, Parkinson Study Group. Parkinson Study Group DNA repository. Mov Disord 1996;11:600.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 132
357. Fahn S, Kao R, DuMouchel W, Winfield L, Dillon S, Winfield H, Greene P. Validation of a new daily diary to quantify fluctuations and dyskinesias in Parkinson's disease. Mov Disord 1996;11:602.
358. Erenberg G, Fahn S. Tourette syndrome. Arch Neurol 1996;53:588
359. Louis ED, Lynch T, Ford B, Bressman SB, Fahn S. Postraumatic-delayed cerebellar syndrome - Reply. Arch Neurol 1996;53:1214-1215.
360. Mena MA, Sulzer D, Khan U, Epstein CJ, Fahn S, Przedborski S. Increased superoxide dismutase activity promotes neuronal survival and protects against L-dopa-induced toxicity. Mov Disord 1997;12 (Suppl 1):36.
361. Fahn S. Clinical consequences of long-term levodopa therapy and modes of overcoming them. Mov Disord 1997;12 (Suppl 1):140.
362. Eidelberg D, Moeller JR, Antonini A, Kazumata K, Brin MF, Bressman S, Fahn S. Abnormal metabolic brain networks in DYT-1 dystonia. Neurology 1997;48 (Suppl 3):A62.
363. Dauer WT, Burke RE, Fahn S. Clinical characteristics of patients with tardive dystonia. Neurology 1997;48 (Suppl 3):A118.
364. Almasy L, Bressman SB, de Leon D, Greene PE, Heiman GA, Ford BA, Raymond D, Jones AC, Shen H, Kramer PL, Fahn S, Risch NJ, Nygaard TG. Idiopathic torsion dystonia linked to chromosome 8 markers in a family of German Mennonite origin. Neurology 1997;48 (Suppl 3):A395.
365. Chouinard S, Fahn S, Ford B. Adult-onset tic disorders. Neurology 1997;48 (Suppl 3):A398.
366. Thyagarajan D, Bressman S, Shanske S, DiMauro S, Fahn S. A novel T1095C mutation in the mitochondrial 12S ribosomal RNA gene. Neurology 1997;48 (Suppl 3):A444.
367. Fahn S, Bressman S, Marsden CD. Classification of dystonia. Mov Disord 1997;12:(3:Suppl):A3-A5.
368. Breakefield XO, Ozelius L, Bressman S, Hewett J, Kramer P, Page C, de Leon D, Sims K, McCormick MK, Buckler AJ, Brin M, Risch N, Gusella J, Fahn S. Role of the DYT1 gene in dystonia. Mov Disord 1997;12:(3:Suppl):A16.
369. Bressman S, de Leon D, Raymond D, Greene PE, Brin M, Fahn S, Ozelius L, Breakefield XO, Kramer P, Risch N. The role of the DYT1 gene in secondary dystonia. Mov Disord 1997;12:(3:Suppl):A18.
370. Ford B, Greene P, Louis ED, Petzinger G, Bressman SB, Goodman R, Brin MF, Sadiq S, Fahn S. Intrathecal baclofen in dystonia. Mov Disord 1997;12:(3:Suppl):A30.
371. Wilhelmsen KC, Clark LN, Neystat N, Moskowitz C, Fahn S. Progress in the positional cloning of lubag: X-linked dystonia-parkinsonism. Mov Disord 1997;12:(3:Suppl):A44.
372. Louis ED, Lynch T, Fahn S, Odel J. Treatment guidelines in central nervous system Whipple's disease. Ann Neurol 1997;41:A562
373. Freed CR, Trojanowski JQ, Galvin JE, Rosenstein JM, Breeze RE, Greene PE, DuMouchel W, Eidelberg D, Rubinstein JM, Bell KP, Fahn S. Embryonic dopamine cells cultured as strands show long term survival without immunosuppression in a patient with advanced Parkinson's disease. Soc Neurosci Abstracts 1997;23:1682.
374. Yu OP, Pullman SL, Fahn S, Pedersen SF. Homonymous hemi-spiral abnormalities in patients with Parkinson's disease. Soc Neurosci Abstracts 1997;23:1898.
375. Breakefield XO, Hewett J, Page C, Shalish C, Bressman S, Kramer P, Buckler AJ, Brin M, Fahn S, Risch N, Corey DP, Gusella J, Ozelius L. Early onset torsion dystonia caused by domnant defect in ATP-binding
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 133
protein. Soc Neurosci Abstracts 1997;23:1962.
376. Fahn S. Etiologic classification of dystonia based on genetic data. Rev Neurol Argentina 1997;22 (Suppl 1):38.
377. Parkinson Study Group. DOPASCAN and SPECT is a sensitive and specific diagnostic tool for parkinsonism. Mov Disord 1997;12:835.
378. Panisset M, Siderowf A, McDermott M, Kieburtz K, Friedman J, Growdon J, Parkinson Study Group. Baseline predictors of subsequent dementia in the DATATOP cohort. Mov Disord 1997;12:836.
379. Lynch T, Marquinez A, Fahn S. Steroid responsive encephalomyelitis with rigidity (spinal interneuronitis). Mov Disord 1997;12:838.
380. Parkinson Study Group. Clinical outcome following placebo-controlled withdrawal of deprenyl (selegiline) among levodopa-treated DATATOP subjects. Mov Disord 1997;12:838.
381. Lynch T, Al-Shahi R, Louis ED, Ford B, Greene P, Bressman SB, Fahn S. Delayed-onset cerebellar syndrome. Ann Neurol 1997;42:407.
382. Louis ED, Lynch T, Kaufmann P, Fahn S, Odel J. Diagnostic guidelines in central nervous system Whipple's disease. Ann Neurol 1997;41:561-562.
383. Lynch T, Fahn S, Louis ED, Odel JG. Oculofacial-skeletal myorhythmia in Whipple's disease. Mov Disord 1997;12:625-626.
384. Lynch T, Neystat M, Orvis L, Mejia H, Fahn S, Bressman S, Marder KS. Normal alpha-synuclein gene sequence in 21 autosomal dominant Parkinson's disease families. Neurology 1998;50 (Suppl 4):A197-A198.
385. Saunders-Pullman RJ, Gordon-Elliott JS, Fahn S, Saunders HR, Bressman SB. The effect of hormone replacement therapy on early Parkinson's disease. Neurology 1998;50 (Suppl 4):A329-A330.
386. Fahn S. Videotapes of motor complications of encephalitis lethargica. Mov Disord 1998;13:752
387. Fahn S. Welcome news about levodopa, but uncertainty remains. Ann Neurol 1998;43:551-554.
388. Kao R, Fahn S, Tsai W, Greene P. Smoking and Parkinson's disease: a case-spouse control study. Mov Disord 1998;13 (Suppl 2):50.
389. Sue CM, Krishna S, Tanji K, Andreu AL, Bruno C, Hadjigeorgiou GM, Chin S, Fahn S, Bonilla E, DiMauro S. Is cytochrome c oxidase (Complex IV) deficiency in corticobasal ganglionic degeneration region-specific? Mov Disord 1998;13 (Suppl 2):56.
390. Chang H, Healton ED, Brust JCM, Fahn S, Lynch T. "Presumably Azorean Disease in a presumably non-Portuguese Family" is due to a MJD/SCA3 Trinucleotide expansion. Mov Disord 1998;13 (Suppl 2):83.
391. Frucht S, Lynch T, Ford B, Eidelberg D, Fahn S. Clinical features of multiple system atrophy. Mov Disord 1998;13 (Suppl 2):125.
392. Fahn S, Togasaki D, Chouinard S. MAO-A and -B inhibition with tranylcypromine in early Parkinson's disease: clinical and CSF effects. Mov Disord 1998 (Suppl 2);13:148.
393. Chang H, Orvis LJ, Naini AB, Fahn S, Lynch T. Homozygous inheritance of the GAG deletion in DYT1 does not cause juvenile Parkinsonism. Mov Disord 1998;13 (Suppl 2):232.
394. Orvis LJ, Fahn S, Chang H, Moskowitz C, Marder K, Lynch T. Clinical genetic study of five families with
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 134
autosomal dominant Parkinson's disease. Mov Disord 1998;13 (Suppl 2):233.
395. Hunt AL, Sethi KD, Fahn S. The use of the pull test by movement disorder specialists. Mov Disord 1998;13 (Suppl 2):296.
396. Moskowitz CB, Kapisyzi M, Petrela M, Fahn S. Parkinson's disease in Albania (1995-1996). Mov Disord 1998;13 (Suppl 2):298.
397. Raymond D, Bressman SB, Sabatti C, de Leon D, Klein C, Fahn S, Saunders-Pullman R, Brin MF, Kramer PL, Breakefield XO, Ozelius LJ, Risch NJ. The DYT1 phenotype. Neurology 1999;52 (Suppl 2):A117-A118.
398. Parkinson Study Group. The glutamate antagonist remacemide improves motor performance in levodopa-treated Parkinson's disease. Neurology 1999;52 (Suppl 2):A262.
399. Klein C, Brin MF, Kramer P, Sena Esteves M, de Leon D, Doheny D, Bressman S, Fahn S, Breakefield XO, Ozelius LJ. Mutation in the D2 dopamine receptor associated with myoclonus-dystonia in a large family of British-German origin. Neurology 1999;52 (Suppl 2):A376.
400. Freed CR, Breeze RE, Greene PE, Tsai W-Y, Eidelberg D, Trojanowski JQ, Rosenstein JM, Fahn S. Double-blind controlled trial of human embryonic dopamine cell transplants in advanced Parkinson's disease: Study design, surgical strategy, patient demographics and pathological outcome. Neurology 1999;52 (Suppl 2):A272-A273.
401. Fahn S, Greene PE, Tsai W-Y, Eidelberg D, Winfield H, Dillon S, Kao R, Winfield L, Breeze RE, Freed CR. Double-blind controlled trial of human embryonic dopaminergic tissue transplants in advanced Parkinson's disease: Clinical outcomes. Neurology 1999;52 (Suppl 2):A405.
402. Greene PE, Fahn S, Tsai WY, Winfield H, Dillon S, Kao R, Winfield L, Eidelberg D, Breeze RE, Freed CR. Double-blind controlled trial of human embryonic dopaminergic tissue transplants in advanced Parkinson's disease: Long-term unblinded follow-up phase. Neurology 1999;52 (Suppl 2):A405.
403. Dhawan V, Nakamura T, Margouleff C, Freed CR, Breeze RE, Fahn S, Greene PE, Tsai WY, Kao R, Eidelberg D. Double-blind controlled trial of human embryonic dopaminergic tissue transplants in advanced Parkinson's disease: Fluorodopa PET imaging. Neurology 1999;52 (Suppl 2):A405-A406.
404. Frucht SJ, Rogers J, Greene PE, Gordon MF, Fahn S. Falling asleep at the wheel: a serious side effect of pramipexole and ropinirole. Neurology 1999;52 (Suppl 2):A409.
405. Frucht S, Fahn S. Commentary on "The genetics of Parkinson's disease." Neurol Network Commentary 1999;3:78-80.
406. McRae C, Cherin E, Diem G, Vo a, Yamazaki G, Ellgring H, Russell D, Fahn S, Greene P, Dillon S, Winfield H, Freed C. Evidence of the placebo effect on medical outcomes in neural implantation. Mov Disord 1999;14:899-900.
407. Greene PE, Fahn S, Tsai WY, Breeze RE, Eidelberg D, Winfield H, Dillon S, Kao R, Winfield L, Breeze CR. Severe spontaneous dyskinesias: a disabling complication of embryonic dopaminergic tissue implants in a subset of transplanted patients with advanced Parkinson's disease. Mov Disord 1999;14:904.
408. Holloway R, McDermott M, Kieburtz K, Penney J, Fahn S, Lang AE, Shoulson S, Parkinson Study Group. Estimating the incidence of motor complications in patients starting levodopa: Implications for clinical trials. Mov Disord 1999;14:905.
409. Frucht S, Rogers JD, Greene PE, Fahn S, Gordon MF. Falling asleep at the wheel: Motor vehicle mishaps in people taking pramipexole and ropinirole - Reply. Neurology 2000;54:276-277
410. Freed CR, Breeze RE, Fahn S. Placebo surgery in trials of therapy for Parkinson's disease. N Engl J Med 2000;342:353-354.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 135
411. Pullman SL, Gordon PH, Fahn S, Yu Q. Computerized analysis of reaction and movement times after fetal cell tissue transplantation in Parkinson disease patients. Neurology 2000;54(Suppl 3):A49.
412. Holloway R, Parkinson Study Group. Pramipexole versus levodopa in early Parkinson’s disease: A randomized clinical trial. Neurology 2000;54(Suppl 3):A89.
413. Marek K and the Parkinson Study Group. β-CIT/SPECT assessment of progression of Parkinson=s disease in subjects participating in the CALM-PD study. Neurology 2000; 54 (suppl 3):A90.
414. Ma Y, Dhawan V, Mentis MJ, Greene P, Fahn S, Freed C, Eidelberg D. Embryonic dopamine cell transplantation for Parkinson's disease: Voxel-based analysis of data from a double-blind placebo- controlled PET study. Neurology 2000;54(Suppl 3):A115.
415. Bressman SB, Raymond D, de Leon D, Fahn S, Burke RE, Brin MF, Saunders-Pullman RJ, Wendt KJ, Kramer PL, Breakefield XO, Ozelius LJ, Risch NJ. Validity of definite, probable, and possible dystonia as diagnostic categories. Neurology 2000;54(Suppl 3):A118.
416. Petzinger GM, Figueroa KP, Jakowec MW, Fahn S, Pulst SM. Double mutants for Huntington and spinocerebellar ataxia type 2 (SCA2) in a large pedigree segregating both mutations. Neurology 2000;54(Suppl 3):A192.
417. Frucht SJ, Fahn S, Greene PE, Welsh JP, O'Brien CF, Truong D, Gelb M, Ford B. The natural history of embouchure dystonia, a focal task-specific dystonia of the lower cranial muscles in professional brass and woodwind players. Neurology 2000;54(Suppl 3):A197.
418. Ford B, Winfield L, Frucht S, Louis ED, Greene PE, Fahn S, Pullman SL, Goodman RR. Treatment of severe generalized dystonia using stereotactic pallidotomy. Neurology 2000;54(Suppl 3):A219.
419. Chuang C, Fahn S, Frucht S. The natural history and treatment of hemidystonia: Report of 33 patients and review of the literature. Neurology 2000;54(Suppl 3):A220.
420. Fahn S. Double-blind controlled trial of embryonic dopaminergic tissue transplants in advanced Parkinson's disease. Biological Psychiatry 2000;47:1138.
421. Fahn S. The earlier vs. later Levodopa (ELLDOPA) study: a clinical trial to evaluate levodopa’s effect on the natural history of Parkinson’s disease. Mov Disord 2000;15 (Suppl 3):5.
422. Fahn S. Double-blind controlled trial of embryonic dopaminergic tissue transplants in advanced Parkinson’s disease. Mov Disord 2000;15 (Suppl 3):7-8.
423. Frucht S, Leurgans S, Hallett M, Fahn S. The Unified Myoclonus Rating Scale (UMRS): a statistically valid clinical rating instrument for evaluating patients with myoclonus. Mov Disord 2000;15 (Suppl 3):107.
424. Saunders-Pullman R, Giladi N, Ozelius L, Fahn S, de Leon D, Bressman S. Peripheral trauma exacerbating DYT1 dystonia. Mov Disord 2000;15 (Suppl 3):161.
425. Frucht S, Fahn S, Hallett M. Posthypoxic myoclonus. Mov Disord 2000;15 (Suppl 1):1.
426. McRae C, Cherin E, Diem G, Yamazaki TG, Russell D, Ellgring H, Fahn S, Greene P, Dillon S, Winfield H, Freed C. Changes in quality of life among persons receiving fetal transplant surgery for the treatment of Parkinson's disease: Caregivers' perspectives. Mov Disord 2000;15:1039-1040.
427. Goetz CG, Leurgans S, Raman R, Parkinson Study Group. Placebo-related improvements in motor function in early Parkinson's disease. Ann Neurol 2000;48:433.
428. McRae C, Cherin E, Vo A, Diem G, Russell D, Ellgring H, Fahn S, Greene P, Freed C. Quality of life in a double-blind surgical placebo trial for the treatment of Parkinson's disease: Caregivers' perspectives. Ann Neurol 2000;48:487-488.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 136
429. Parkinson Study Group.A controlled trial of rasagiline in early Parkinson's disease. Ann Neurol 2000;48:489.
430. Freed CR, Breeze RE, Greene PE, Tsai WY, Trojanowski JO, Eidelberg D, Fahn S. Double-blind placebo- controlled human embryonic dopamine cell transplants in advanced Parkinson's disease – Long-term unblended followup. Soc Neurosci Abstracts 2000;26:553.
431. Liu T, Hilton HJ, Cooper LA, DiMauro A, Fahn S, Greene PE, Freed CR. Implicit and explicit memory for novel visual objects in Parkinson’s patients following fetal nigral transplant surgery. Soc Neurosci Abstracts 2000;26:747.
432. Dauer WT, Kumar P, Ozelius LJ, Breakefield XO, Fahn S, Hen R. Characterization of the motor phenotype of DYT1 mutant mice. Soc Neurosci Abstracts 2000;26:1536
433. Gordon PH, Pullman SL, Louis ED, Frucht SJ, Fahn S. Mirtazapine in parkinsonian tremor and essential tremor. Neurology 2001;56 (Suppl 3):A25.
434. Marek K, Parkinson Study Group. Comparison of imaging and clinical endpoints in subjects participating in the CALM-PD study. Neurology 2001;56 (Suppl 3):A73.
435. Marder KS, Levy G, Mejia-Santana H, Ramirez R, Amud M, Perez M, Rodriguez A, Cote L, Fahn S, Bressman S, Ottman R. Assessing reliability of a family history interview for PD among first-degree relatives. Neurology 2001;56 (Suppl 3):A116.
436. Hedrich K, Klein C, Harris J, Kann M, Lynch T, Santana HM, Schwinger E, Pramstaller PP, Vieregge P, Bressman S, Fahn S, Marder. Evaluation of a large patient cohort with early-onset Parkinson’s disease for mutations in the parkin gene. Neurology 2001;56 (Suppl 3):A224.
437. Dhawan V, Ma Y, Fukuda M, Breeze R, Greene P, Fahn S, Freed C, Eidelberg D. PET imaging two years following embryonic dopamine cell transplantation for Parkinson's disease. Neurology 2001;56 (Suppl 3):A270-271.
438. Blindauer K, Parkinson Study Group. Tyramine challenge to assess the safety of rasagiline monotherapy in a placebo-controlled multicenter trial for early Parkinson’s disease (the TEMPO study). Neurology 2001;56 (Suppl 3):A345.
439. Comella CL, Dystonia Study Group. Rating Scales for Dystonia: A Multicenter Assessment of Three Dystonia Rating Scales: The Unified Dystonia Rating Scale (UDRS), the Burke-Fahn Marsden (BFM) and the Global Dystonia Rating Scale (GDS). Neurology 2001;56 (Suppl 3):A387.
440. Mir P, Greene P, Fahn S. Sporadic parkinsonism and motor neuron disease. J Neurol Sci 2001;187 (Suppl 1):S304.
441. Fahn S, Parkinson Study Group. Rotigotine transdermal system (SPM-962) is safe and effective as monotherapy in early Parkinson’s disease (PD). Parkinsonism & Related Disorders 2001;7 (Suppl):S55.
442. Kieburtz K, Parkinson Study Group. Efficacy and safety of rasagiline in early Parkinson’s disease. Parkinsonism & Related Disorders 2001;7 (Suppl):S60.
443. Bressman SB, Fahn S, Ozelius LJ, Kramer PL, Risch NJ. The DYT1 mutation and nonfamilial primary torsion dystonia. Arch Neurol 2001; 58:681-682.
444. Ma Y, Dhawan V, Fukuda M, Smith G, Greene P, Breeze RE, Fahn S, Freed CR, Eidelberg D. Dyskinesias following dopamine cell implantation for Parkinson's disease are related to increases in putamen FDOPA uptake. Soc Neurosci Abstracts 2001;27:9.1
445. Freed CR, Breeze RE, Greene P, Tsai W-Y, Bjugstad KB, Trojanowski JQ, Eidelberg D, Fahn S. In double- blind trial, l-dopa responsiveness and not age predicts outcome of human embryonic dopamine cell
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 137
transplants for Parkinson’s disease. Soc Neurosci Abstracts 2001;27:887.1
446. Goodchild RE, Zhang L, Browne SE, Narr6 S, DiMauro6 J-PP, Ozelius LJ, Breakefield XO, Fahn S, Hen R; Dauer WT. Relevance of subcellular distribution of mutant torsinA to the pathophysiology of DYT1 dystonia. Soc Neurosci Abstracts 2001;27:993.7
447. Parkinson Study Group. Earlier treatment with rasagiline may attenuate (UPDRS) progression of PD. Mov Disord 2001;16:981.
448. Parkinson Study Group. Defining responder status in a clinical trial of the rotigotine transdermal system (SPM-962) in early Parkinson’s disease. Mov Disord 2001;16:981-982.
449. Freed CR, Bjugstad K, Breeze RE, Greene PE, Tsai W-Y, Kao R, Eidelberg D, Fahn S. Changes in motor performance after human embryonic dopamine cell transplantation is predicted by pre-operative levodopa response. Mov Disord 2001;16:983.
450. Huntington Study Group. Willingness to consent for future genetic testing by individuals at risk for or with Huntington’s disease. Mov Disord 2001;16:987.
451. McRae C, Cherin E, Diem G, Yamazaki TG, Vo A, Russell D, Ellgring H, Fahn S, Greene PE, Dillon S, Wionfield H, Winfield L, Freed CR. Long-term effects n quality of life among persons receiving fetal transplant surgery for treatment of Parkinson’s disease. Mov Disord 2001;16:987-988.
452. Noyes K, Zwanziger J, Dick AW, Holloway R, Parkinson Study Group. Do dopaminergic complications predict quality of life in Parkinson’s disease?. Mov Disord 2001;16:988.
453. DeMarcaida JA, Schwid S, Blindauer, Fahn S, Kieburtz K, Marek K, Oakes D, Stern M, Shoulson I, Parkinson Study Group. Current opinions on appropriate endpoints in Parkinson’s disease. Mov Disord 2001;16:989-990.
454. Reider CR, Halter CA, foroud T, Oakes D, Parkinson Study Group. Reliability of self-reporting age of onset for Parkinson’s disease. Mov Disord 2001;16:991-992.
455. Chuang C, Fahn S. Dramatic benefit with clonazepam treatment of intractable anxiety and panic attacks in Parkinson’s disease. Mov Disord 2001;16(suppl 1):S35.
456. Yahr MD and World Federation of Neurology Research Committee. Pharmacological agents in Parkinson's disease treatment of Parkinsonism and related disorders. Parkinsonism and Related Disorders. 2001;7:79- 80.
457. Fahn S. Foreword to book: American Academy of Neurology and American Association of Neuroscience Nurses. Neuro-Triage Telephone Advice. Butterworth-Heinemann, Boston, 2002.
458. Fahn S. Foreword to book:: Factor SA, Weiner WJ, eds. Parkinson’s Disease. Diagnosis and Clinical Management. Demos, New York, 2002.
459. Ford B, Goodman RR, Winfield L, Pullman SL, Frucht SJ, Greene P, Cheringal JH, McKhann GM, Hamberger M, Yu Q, Cote LJ, Fahn S. Subthalamic nucleus stimulation for advanced Parkinson's disease: Blinded evaluations at one-year follow-up. Neurology 2002;58 (Suppl 3):A61.
460. Parkinson Study Group, Holloway RG. Pramipexole versus levodopa as initial treatment for Parkinson disease: A 4-year randomized controlled trial. Neurology 2002;58 (Suppl 3):A81-A82.
461. Parkinson Study Group. Pramipexole versus levodopa: Effects on Parkinson disease progression assessed by dopamine transporter imaging. Neurology 2002;58 (Suppl 3):A82.
462. Kayson EP, Huntington Study Group/PHAROS Investigators. Safety and feasibility of the prospective Huntington at risk observational study (PHAROS): A preliminary report. Neurology 2002;58 (Suppl 3):A334.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 138
463. Pillai V, Ma Y, Dhawan V, Greene P, Fahn S, Breeze R, Freed C, Eidelberg D. PET imaging in Parkinson's disease four years following embryonic dopamine cell transplantation. Neurology 2002;58 (Suppl 3):A341- A342.
464. Freed CR, Breeze RE, DeMasters BK, Galvin J, Trojanowski JQ, Greene P, Eidelberg D, Fahn S. Transplants of embryonic dopamine cells show progressive histologic maturation for at least 8 years and improve signs of Parkinsons up to the maximum benefit of L-DOPA preoperatively. Neurology 2002;58 (Suppl 3):A342.
465. Ozelius L, Liu L, Kock N, de Carvalho Aguiar P, Mueller B, Raymond D, Harris J, Doheny D, Frucht S, Ford B, Lynch T, deLeon D, Garrels J, Schwinger E, Brin M, Kurlan R, Lang A, Fahn S, Saunders-Pullman R, Klein C, Bressman S. Mutation analysis of the epsilon-sarcoglycan (SGCE) gene in ten families with myoclonus-dystonia. Neurology 2002;58 (Suppl 3):A392.
466. Levy G, Coté LJ, Louis ED, Waters C, Perez M, Meja H, Fahn S, Marder K. Differential contribution of aging to motor signs in Parkinson’s disease. Mov Disord 2002;17:1112.
467. Freed CR, Bjugstad KB, Breeze RE, Greene P, Tsai WY, Kao R, Eidelberg D, Fahn S. Human embryonic dopamine cell transplant patients show stable clinical outcome for at least five years after surgery. Soc Neurosci Abstracts 2002;28:326.5.
468. Cohen OS, Tieu K, Jackson-Lewis V, Vila M, Marks D, Fahn S, Przedborski S. An accurate and reproducible method for quantifying SNpc dopaminergic neurons in the MPTP mouse model of Parkinson's disease. Soc Neurosci Abstracts 2002;28:505.1.
469. Fahn S. Results of the ELLDOPA (Earlier vs. Later Levodopa) study. Mov Disord 2002;17 (Suppl 5): S13.
470. Schwid SR, Parkinson Study Group. CEP-1347 in Parkinson's disease: a pilot study. Mov Disord 2002;17 (Suppl 5):S91.
471. Schwid SR, Parkinson Study Group. Rasagiline improves quality of life in patients with early Parkinson's disease. Mov Disord 2002;17 (Suppl 5):S92.
472. Chan PLS, Holford NHG, Nutt JG, Parkinson Study Group. Application of clinical trial simulation to evaluate the ELLDOPA trial design. Mov Disord 2002;17 (Suppl 5):S111-S112.
473. Biglan KM, Holloway RG, Shoulson I, Parkinson Study Group. An item analysis of the Unified Parkinson Disease rating scale (UPDRS) in individuals with early Parkinson's disease (PD) treated initially with pramipexole or levodopa: A sub analysis of the 4-year CALM-PD trial. Mov Disord 2002;17 (Suppl 5):S114.
474. Munhoz RP, Li J-Y, Piboolnurak P, Constantino A, Fahn S, Lang AE. An evaluation of pull test technique in assessing postural instability in Parkinson’s disease. Mov Disord 2002;17 (Suppl 5):S143.
475. Parkinson Study Group. Assessment of CEP-1347 interaction with beta-CIT striatal uptake in Parkinson disease. Mov Disord 2002;17 (Suppl 5):S167.
476. Freed CR, Bjugstad KB, Breeze RE, Greene P, Eidelberg D, Fahn S. Stable outcome 5 years after embryonic dopamine celll transplantation for Parkinson’s disease is compatible with ongoing transplant development or lack of disease progression. Mov Disord 2002;17 (Suppl 5): S216.
477. Biglan KM, Holloway RG, Shoulson I, Parkinson Study Group. An item analysis of the Mental Unified Parkinson Disease rating scale (UPDRS) in individuals with early Parkinson's disease (PD) treated initially with pramipexole or levodopa: A sub analysis of the 4-year CALM-PD trial. Mov Disord 2002;17:1107.
478. Kock N, Muller B, Vieregge P, Pramstaller PP, Marder K, Abbruzzese G, Martinelli P, Lang AE, Jacobs H, Hagenah J, Harris J, Meija-Santana H, Fahn S, Hedrich K, Kann M, Gehlken U, Culjkovic B, Schwinger E, Wszolek ZK, Zuhlke C, Klein C. Role of SCA2 mutations in early- and late-onset dopa-responsive parkinsonism. Ann Neurol 2002;52(2):257-258.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 139
479. Marek K, Seibyl J, McDermott M, Fahn S, Lang A. Brain imaging to assess the effects of dopamine agonists on progression of Parkinson disease. J Am Med Assn 2002;288(3):312-313.
480. Fahn S, Hallett M, DeLong M. Fourth International Dystonia Symposium - Introduction - Report on the Fourth International Dystonia Symposium. Mov Disord 2002;17(5):1115-1116.
481. Pedley TA, Swift TR, Miller A, Fahn S. Pharmaceutical industry support of the AAN Annual Meeting - Policies and violation. Neurology 2002;58(4):519-521.
482. Greene PE, Fahn S. Status of fetal tissue transplantation for the treatment of advanced Parkinson disease. Neurosurg Focus. 2002 Nov 15;13(5):e3.
483. Fahn S, Parkinson Study Group. Does levodopa slow or hasten the rate of progression of Parkinson disease? The results of the ELLDOPA trial. Neurology 2003;60 (Suppl 1):A80-A81.
484. Blindauer K, Parkinson Study Group. Delayed response to levodopa and response failures account for a large percentage of daily off time in advanced Parkinson’s disease patients with motor fluctuations. Neurology 2003;60 (Suppl 1):A81-A82.
485. Marek K, Seibyl J, Parkinson Study Group. β-CIT Scans without evidence of dopaminergic deficit (SWEDD) in the ELLDOPA-CIT and CALM-CIT study: long-term imaging assessment Neurology 2003;60 (Suppl 1):A298.
486. Marek K, Seibyl J, Jennings D, Parkinson Study Group. Pramipexole versus levodopa: 5-year follow-up of Parkinson disease progression assessed by dopamine transporter imaging in the CALM-CIT study. Neurology 2003;60 (Suppl 1):A298.
487. Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins GT, Fahn S, Lang AE, Martinez-Martin P, Tilley BC, Van Hilten B. Movement Disorder Society Task Force critique of the Unified Parkinson s Disease Rating Scale: status and recommendations. Neurology 2003;60 (Suppl 1):A403.
488. Fahn S. Foreward. In: Pulst S-M, ed. Genetics of Movement Disorders. San Diego, Academic Press, 2003;xix.
489. Munhoz RP, Li JY, Piboolnurak P, Constantino A, Fahn S, Lang AE. An evaluation of pull technique in assessing postural instability in Parkinson s disease. Neurology 2003;60 (Suppl 1):A403.
490. Marder KS, Levy G, Louis ED, Mejia-Santana H, Harris J, Cote L, Waters C, Greene P, Ford B, Frucht S, Andrews H, Fahn S, Ottman T. Clinical phenotypes associated with a genetic susceptibility to PD. Neurology 2003;60 (Suppl 1):A437.
491. Parkinson Study Group. Pilot study to develop a method for long term follow-up of persons with neurologic diseases (FOUND). Mov Disord 2003;18(9):1082.
492. Fahn S, Parkinson Study Group. Evaluation of the long-duration benefit from levodopa: results from the ELLDOPA (Earlier vs. Later LevoDOPA) Study. Mov Disord 2003;18(9):1085-1086.
493. Parkinson Study Group, Stern M. A controlled trial of rasagiline in Parkinson’s disease patients with levodopa-related motor fluctuations (PRESTO Study). Ann Neurol 2003;54(7):S27.
494. Clark LN, Nicolai A, Harris J, Mejia-Santana H, Cote LJ, Louis ED, Fahn S, Marder K. Frequency of the Glucocerebrosidase N370S mutation and Susceptibilty to Parkinson's Disease in a cohort of Ashkenazi Jewish Ethnicity. Amer J Hum Genet 2003;S73:1999.
495. Harris J, Afridi S, Greene P, Fahn S, Marder K, Clark LN. Parkin mutations cause late-onset slowly progressing Parkinson's disease. Amer J Hum Genet 2003;S73:2008.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 140
496. Freed CR, Breeze RE, Zawada M, Jones S., Ellison K, Greene PE, Fahn S, Eidelberg D. human embryonic dopamine neurons transplanted into parkinson's patients accumulate neuromelanin pigment over many years in parallel with normal human development. Soc Neurosci Abstr 2003;20:233.2.
497. Rosenberg RN, Pedley TA, Baringer JR, Fahn S, Lisak RP, Mayeux RP, Olson SF, Ringel SP, Rowland LP, Selzer ME. At jeopardy: the NIH as we know it. Arch Neurol. 2003 Sep;60(9):1191-1192.
498. Pulst S-M, Editor. Genetics of Movement Disorders. San Diego, Academic Press, 2003.
499. Furukawa Y, Kish SJ, Fahn S. Dopa-responsive dystonia due to mild tyrosine hydroxylase deficiency. Ann Neurol. 2004 Jan;55(1):147-148.
500. Portera-Cailliau C, Victor D, Frucht SJ, Fahn S. Designing the ideal movement disorders fellowship training program: The Columbia University experience 2001-2002. Neurology 2004;62 (Suppl 5):A80.
501. Freed CR, Breeze RE, Zawada M, Jones S, Ellison K, DeMasters BK, Bjugstad KB, Greene PE, Fahn S, Eidelberg D. Dopamine neurons transplanted into putamen of Parkinson patients develop neuritis ad accumulate neuromelanin over many years suggesting that the Parkinson putamen has neurotrophic activity similar to normal developing brain. Neurology 2004;62 (Suppl 5):A105.
502. Freed CR, Breeze RE, Fahn S, Eidelberg D. Preoperative response to levodopa is the best predictor of transplant outcome. Ann Neurol 2004 Jun;55(6):896; author reply 896-897.
503. Biglan KM, Holloway RG, McDermott MP, Richard IH, Parkinson Study Group. Predicting incident non- motor complications of dopaminergic therapy in patients with early Parkinson’s disease: A secondary analysis of the CALM-PD trial. Mov Disord 2004;19 (Suppl 9):S205.
504. Marras C, Lang AE, Oakes D, McDermott MP, Kieburtz K, Shoulson I, Tanner CM, Fahn S. High-dosage vitamin E supplementation and all-cause mortality. Ann Intern Med. 2005 Jul 19;143(2):152-3
505. Dodel RC. Dubois B, Fahn S, Goetz CG, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees AJ, Leurgans S, LeWitt PA, Martinez-Martin P, Nyenhuis D, Olanow CW, Poewe W, Rascol O, Sampaio C, Schrag A, Stebbins GT, Stern MB, Teresi J, Tilley BC, Van Hilten B. Addressing non–motor Impairments in Parkinson's disease: the new version of the UPDRS. Mov Disord 2005;20 (Suppl 10):S83.
506. Goetz CG, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stebbins G, Stern MB, Tilley B, Dodel RC, Dubois B, Holloway RG, Jankovic J, Kulisevsky J, Lang AE, Lees AJ, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi J, Van Hilten B. New Version of the UPDRS: Development Methods and Working Document for Field Testing. Neurology 2005;64 (Suppl 1):A395-A395.
507. Frucht SJ , Agarwal P, Fahn S. Reply: Diagnosis and management of pergolide-induced fibrosis. Mov Disord 2005 Apr;20(4):513.
508 Elmer LW, Parkinson Study Group. Rasagiline is effective and wll tolerated in the treatment of Parkinson’s disease patients with levodopa-related motor fluctuations receiving concomitant dopamine agonists (DA) theerapy. Ann Neurol 2005;58 (Suppl 90):S54.
509 Reich SG, Verhagen-Metman L, Karp BI, Bara-Jimenez W, Greene P, Eidelberg D, Fahn S, Breeze RE, Freed CR. Persistent Dyskinesias Following Fetal Dopamine Neuron Implantation for Parkinson’s Disease: A Case Report with 9-Year Follow-Up. Ann Neurol 2005;58 (Suppl 90):S56.
510 Schwid SR, Parkinson Study Group. Safety of rasagiline in combination with serotonin reuptake inhibitors. Ann Neurol 2005;58 (Suppl 90):S56.
511 Parkinson Study Group. A randomized controlled trial of etilevodopa in Parkinson’s disease patients with motor fluctuations. Mov Disord 2005;20;1237.
512. Frank S, Ondo W, Hunter C, Marshall F, Walker F, Eberly S, Factor S, Fahn S, Hunt V, Oakes D, Plumb S,
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 141
Shinaman A, Shoulson I, Zhao H, Jankovic J. A randomized double-blind, placebo-controlled, staggered withdrawal study in patients with Huntington’s disease treated with tetrabenazine. Mov Disord 2005;20;1244.
513. Fahn S, Clinical assessment and recognition of subtypes of Parkinson disease. J Neurol Sci 2005;238 (Suppl 1) S26.
514. Fahn S, Clinical skills - Dystonia. J Neurol Sci 2005;238 (Suppl 1) S36.
515. Fahn S. Overview of PD; clinical features, natural history, diagnosis, imaging, and treatment. Mov Disord 2006;21 (Suppl 13):S1.
516. Leegwater-Kim J, Ozelius L, Fraser J, Frucht S, Dauer W, Fahn S. A case of sporadic rapid-onset dystonia- parkinsonism associated with mutations in the ATP1A3 gene. Mov Disord 2006;21 (Suppl 13):S87.
517. Schifitto G, Friedman JH, Oakes D, Shulman LM, C. Comella L, Fahn S. Fatigue in levodopa-naive subjects with early PD. Mov Disord 2006;21 (Suppl 13):S97-S98.
518. Fahn S, Mazzoni P. Survey of levodopa treatment patterns by clinical practitioners. Mov Disord 2006;21 (Suppl 13):S109-S110.
519. Kieburtz K, Romer M, McDermott M, Kamp C, the CALM-PD Parkinson Study Group Investigators. Impact of pramipexole on the onset of levodopa-related dyskinesias. Mov Disord 2006;21 (Suppl 13):S122
520 Parkinson Study Group, Tanner CM presenter. Follow-Up of persons with Neurologic Diseases (FOUND): Up to 46 months follow-up. Mov Disord 2006;21 (Suppl 13):S127.
521 Clark LN, Wang Y, Fahn S, Ottman R, Marder K. Mutations in th glucocerebrosidase gene and Parkinson’s disease. Neurology 2005;66 (Suppl 2):A143.
522 Mazzoni P, Fahn S. Impact of ELLDOPA study on levodopa treatment considerations for Parkinson’s disease. Neurology 2005;66 (Suppl 2):A294.
523 Shoulson I, Parkinson Study Group (PSG), PRECEPT investigators. CEP-1347 treatment fails to favorably modify the progression of Parkinson’s disease (PRECEPT) study. Neurology 2006;67:185.
524 Conti AM, Frucht SJ , Fahn S. A new variant of paroxysmal exercise-induced dyskinesia. Mov Disord 2006;21(Suppl 15):S388-S389.
525 Severt WL, Olarte M, Fahn S. A case of “jumpy stumps” responsive to zolpidem. Mov Disord 2006;21(Suppl 15):S440.
526 Hu S, Lo SE, Fahn S. “Diphasic offs”: a new pattern of levodopa-induced motor fluctuations in Parkinson’s diseae. Mov Disord 2006;21(Suppl 15):S472.
527 Marshall FJ, Fahn S, Clarence-Smith K. Tetrabenazine as antichorea therapy in Huntington disease: A randomized controlled trial. [letter] Neurology 2007;68;797.
528 Browner NM, Fahn S. Unusual presentation of progressive supranuclear palsy with palatal and diaphragmal myoclonus: A case report. Mov Disord 2007;22 (Suppl 16):S258-259.
529 Goetz CG, Tilley BC, Schaftman S, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol OO, Schrag A, Teresi J, van Hilten JJ. Clinimetric testing of the new UPDRS (MDS-UPDRS) vs iriginal version. Mov Disord. 2007;22 (Suppl 16):S6.
530. Marder K, Clark L, Mejia-Santana H, Louis E, Comella C, Colcher A, Jennings D, Nance M, Bressman S,
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 142
Scott W, Tanner C, Mickel S, Andrews A, Waters C, Fahn S, Fraser J, Rosada L, Cote L, Caccappolo E, Frucht S, Ford B, Novak K, Friedman J, Pfeiffer R, Tang M-X, Ottman R. Features associated with parkin mutation status in probands in the Core-PD study. Ann Neurol 2007;62 (Suppl 11):S38.
531. McRae CA, Caspari J, Fazio E, Hartsock G, Russell D, Winfield LM, Greene P, Fahn S. Fetal transplant surgery: Effect on global ratings by reviewing baseline video taken 12 months earlier. Ann Neurol 2007;62 (Suppl 11):S39.
532. McRae CA, Fazio E, Hartsock G, Chavez E, Russell D, Winfield LM, Greene P, Fahn S. Predictors of the placebo effect at 12 months in a double-blind sham surgery controlled trial. Ann Neurol 2007;62 (Suppl 11):S39.
533. Fahn S. Advances in Parkinson disease (PD). Hong Kong Med J 2007;13 (Suppl 6):30.
534. Goetz CG, Tilley BC, Shaftman SR, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern M, Dodel, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang A, Lees A, Leurgans S, LeWitt P, Nyenhuis D, Olanow C, Rascol O, Schrag A, Teresi J, van Hilten JJ, Stebbins GT. New version of the UPDRS (MDS- UPDRS): Factor Analysis. Neurology 2008;70 (Suppl 1):A55-A56.
535. Kartsaklis LA, Wolf R, Dorado B, Consattel JP, Ross BM, Fahn S, Honig L, Marder K, Clark L. Glucocerebrosidase mutations are associated with ‘purer’ forms of Lewy Body disorders. Neurology 2008;70 (Suppl 1):A106.
536. Alcalay RN, Caccappolo E, Maroof D, Clark L, Mejia-Santana H, Louis E, Comella C, Colcher A, Jennings D, Nance M, Bressman S, Scott W, Tanner C, Mickel S, Andrews H, Waters C, Fahn S, Rosado L, Cote L, Frucht S, Ford B, Novak K, Rezak M, Siderowf A, Friedman JH, Pfeiffer R, Tang M.-X, Marsh L, Ottman R, Marder K. Performance on the mini-mental state exam in carriers and non-carriers of parkin mutations. Mov Disord 2008;23 (Suppl 1):S97-S98.
537. Elble R, Comella C, Fahn S, Hallett M, Jankovic J, Juncos J, Louis E, Lyons K, Ondo W, Pahwa R, Sethi K, Stern M, Tanner C, Tarsy D, Tintner R, Watts R, Tremor Research Group. The essential tremor rating assessment scale (TETRAS). Mov Disord 2008;23 (Suppl 1):S357.
538. McRae CA, Fazio E, Hartsock G, Pinarowicz J, Colarossi D, Russell D, Winfield L, Greene P, Fahn S. Does the placebo effect extend to caregivers? Mov Disord 2008;23:1629-1630.
539 McRae CA, Fazio E, Pinarowicz J, Colarossi D, Russell D, Winfield L, Greene P, Fahn S. Predictors of the placebo effect at 4, 8, and 12 months in the double-blind sham surgery trial for the treatment of Parkinson’s disease. Mov Disord 2008;23:1637.
540. Uc EY, McDermott MP, Growdon JC, Marder KS, Anderson SW, Litvan I, Como P, Chou KL, Parkinson Study Group. Incidence and predictors of dementia in early Parkinson’s disease: Results from the DATATOP study. Ann Neurol 2008;64 (Issue S12): 541. Lang AE, Angel M, Bhatia K, Chen R, Fahn S, Hallett M, Schrag A, Thompson P. Myoclonus in complex regional pain syndrome. Mov Disord. 2009 Jan 30;24(2):314-316.
542. Alcalay RN, Clark L, Mejia-Santana H, Tang M, Rosado LE, Louis E, Comella C, Colcher A, Jennings D, Nance M, Bressman S, Scott WK, Tanner C, Mickel S, Andrews H, Waters C, Fahn S, Ross BM, Cote LJ, Frucht S, Rezak M, Ford B, Novak K, Friedman J, Pfeiffer R, Marsh L, Caccappolo EA, Hiner B, Siderowf A, Ottman R, Marder K. Demographic and clinical characteristics of LRRK2 G2019S carriers in early onset PD. Neurology 2009;72 (Suppl 3):A389.
543. Pearson T, Rotstein M, Pons R, Fahn S. Juvenile Parkinsonism: Clinical aspects of parkinsonism in children and adolescents. Ann Neurol 2009;66 (Suppl 1):S117.
544. Fahn S. Genetic alterations in Parkinson disease – clues to its pathogenesis. J Korean Neurol Assoc. 2009 Oct;27 (Suppl 1):6.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 143
545. Alcalay RN, Caccappolo E, Mejia-Santana H, Tang MX, Rosado L, Verbitsky M, Ross B, Kisselev S, Louis E, Comella C, Colcher A, Jennings D, Nance M, Bressman S, Scott W, Tanner C, Mickel S, Andrews H, Waters C, Fahn S, Cote L, Frucht S, Ford B, Rezak M, Novak K, Friedman J, Pfeiffer R, Marsh L, Hiner B, Siderowf A, Ottman R, Marder K, Clark L. Frequency and phenotypic characteristics of PRKN, LRRK2, GBA, PINK1 and DJ1 mutation carriers in early onset PD: The CORE-PD study. Neurology 2010;74 (Suppl):A2.
546. Tanner CM, Meng CC, Shoulson I, Ravina B, Lang A, Kurlan R, Marek K, Oakes D, Seibyl J, Flagg E, Gauger L, Goetz C, Kieburtz, K DiEuliis D, Fahn S, Elliott RA. Follow-Up of persons with Neurologic Diseases (FOUND): Remote follow-up – A practical approach to maintain continuous contact. Neurology 2010;74 (Suppl):A60-A61.
547. Srivastava A, Tang M, Louis E, Mejia-Santana H, Ottman R, RosadoL, Marder K, Comella C, Bressman B, Nance M, Siderowf A, Jennings D, Colcher A, Scott W, Waters C, Cote L, Andrews H, Tanner C, Mickel S, Fahn S, Ross B, Frucht S, Verbitsky M, Ford B, Kisselev S, Alcalay R, Rezak M, Novak K, Neils , Friedman J, Pfeiffer R, Marsh L, Hiner B, Clark LN, Caccappolo EA. Depression among carriers and non carriers of Parkin mutations. Neurology 2010;74 (Suppl):A114-A115.
548. Rotstein M, Pearson T, Greene PE, Fahn S. Tardive syndromes in children and adolescents. Mov Disord 2010;25 (Suppl):S225.
549. Schneider D, Fahn S. Tardive akathisia successfully treated with electro-convulsive therapy (ECT). Mov Disord 2010;25 (Suppl):S225.
550. Hanspal EK, Fahn S. An unusual presentation of dystonia in Lubag’s Syndrome. Mov Disord 2010;25 (Suppl):S237.
551. Alcalay RN, Caccappolo E, Mejia-Santana H, Tang MX, Rosado L, Ross B, Verbitsky M, Kisselev S, Louis E, Comella C, Colcher A, Jennings D, Nance M, Bressman S, Scott WK, Tanner C, Mickel S, Andrews H, Waters C, Fahn S, Cote L, Frucht S, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer R, Marsh L, Hiner B, Siderowf A, Ottman R, Clark LN, Marder KS. Neuropsychologica performance of early onset PD cases with and without GBA mutations: The Core-PD study. Mov Disord 2010;25 (Suppl):S312. 552. Poston K, Tang C, Eckert T, Frucht S, Vonsattel J-P, Fahn S, Eidelberg D. Metabolic and network correlates of disease severity in multiple system atrophy. Mov Disord 2010;25 (Suppl):S390-391. 553. Fahn S, Marder K, Côté L. Frontiers of science and clinical advances in quality of life in Parkinson's disease. Preface. Mov Disord. 2010;25 Suppl 1:S1. 554. Fahn S. What is PD? Mov Disord. 2010;25 Suppl 3:S572. 555. Fahn S, McCall-Perez F, JHammond J, Telang F, Logan J, Wang G-J, Fowler JS. The effect of high dose orally disintegrated tablet selegiline (ODT-S: Zelapar®), a selective monoamine oxidase B inhibitor (MAO- B), on monoamine oxidase A (MAO-A), and compared to EMSAM® (transdermal formulation of selegiline). Neurology. 2011 Mar 1;76(9) Suppl 4:A275 556. Alcalay RN, Rosado L, Siderowf A, Ottman R, Caccappolo E, Mejia-Santana H, Tang MX, Louis E, Ruiz D, Andrews H, Waters C, Fahn S, Cote L, Frucht S, Ford B, Orbe-Reilly M, Ross B, Verbitsky M, Kisselev S, Comella C, Colcher A, Jennings D, Nance M, Bressman S, Scott WK, Tanner C, Mickel S, Rezak M, Novak KE, Friedman JH, Pfeiffer R, Marsh L, Hiner B, Clark LN, Marder K. Olfaction in glucocerebrosidase mutation carriers with and without PD. Neurology. 2011 Mar 1;76(9) Suppl 4:A490. 557. Pahwa R, Ellenbogen A, Jankovic J, Hauser R, Fahn S, Clinical Team at Impax, Efficacy and safety of IPX066, a new carbidopa-levodopa (CD-LD) extended-release formulation, in LD-naïve early Parkinson's disease (APEX-PD trial). Mov Disord 2011;26 (Suppl): Abstract # 407 558 Fahn S. McCall-Perez, F, Hammond J, Telang F, Logan J, Want G.-J, Fowler J. The effect of high dose orally disintegrated tablet selegiline, a selective monoamine oxidase B inhibitor (MAO-B), on monoamine oxidase A (MAO-A), and compared to transdermal formulation of selegiline. Mov Disord 2011;26 (Suppl): Abstract # 832
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 144
559. McRae C, McNevin C, Greene P, Fahn S. Longitudinal study of neural tissue implantation for treatment of Parkinson's disease: Effects on quality of life. Mov Disord 2011;26 (Suppl): Abstract # 881 560. Poulopoulos M, Cortes E, Vonsattel JPG, Fahn S, Waters C, Cote L., Moskowitz C, Honig LS, Clark LN, Marder KS, Alcalay R. Clinical and pathological findings in three cases of LRRK2 G2019S mutation carries with PD. Mov Disord 2011;26 (Suppl): Abstract # 947 561. Xie T, Marder K, Tang Y, Levey A, Santella R, Tang M, Wang Q, Cubells J, Duan W, Clark L, Fahn S. Functional polymorphisms of dopamine pathway genes (COMT, MAOB and DBH) in the development of Parkinson's disease: A study with multiple stratifications and risk factor adjustments. Mov Disord 2011;26 (Suppl): Abstract # 955 562. Browner NM, Vonsattel JP, Greene P, Frucht S, Fahn S. Square wave jerks in progressive supranuclear palsy and corticobasal degeneration: A clinicopathological study. Mov Disord 2011;26 (Suppl): Abstract # 997 563. Schneider D, Haberfeld E, Fahn S. Treating the patient, not the scan: Two patients with psychogenic parkinsonism in spite of abnormal PET scans. Mov Disord 2011;26 (Suppl): Abstract # 1035 564. Fahn S, Hsu A, O’Connell M, Kell S, Gupta S. Comparison of immediate release (IR) and extended release (ER) carbidopa-levodopa preparations in patients with early Parkinson disease (PD). Mov Disord 2012; 27 (Suppl. 1):S117. (Abstract 364) 565. Tazen S, Goldman J, Fahn S. Cerebellar ataxia in adult-onset Sandhoff disease: A case report. Mov Disord 2012; 27 (Suppl. 1):S195. (Abstract 604) 566. Di Biasio F, Pullman SL, Cortes JC, Yu QP, Hess C, Fahn S. Long term history of orthostatic tremor: A review of 50 patients. Mov Disord 2012; 27 (Suppl. 1):S409. (Abstract 1239)
567. Fahn S. Foreward in Bhidayasiri R, Tarsy D. Movement Disorders: A Video Atlas. Springer New York, 2012.
5688. Virmani T, Vonsattel J-P, Fahn S. Clinical characteristics of pathologically confirmed Parkinson disease patients with freezing of gait. Neurology 2013; February 14;80:P06.099
569. Martinez R, Fahn S. Severe echolalia, palilalia and palipraxia in a patient with Progressive Supranuclear Palsy syndrome. J Parkinsons Dis 2013 Jan 1;3(0):92. P12.21 570. Sharp ME, Alcalay RN, Caccappolo E, Mejia-Santana H, Tang M –X, Rosado L, Orbe Reilly M, Ruiz D, Louis ED, Comella C, Nance M, Bressman S, Scott WK, Tanner C MD, Mickel S, Waters C, Fahn S, Cote L, Frucht S, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer R, Marsh L, Hiner B, Siderowf A, Payami H, Molho E, Factor S, Nutt J, Serrano C, Arroyo M, Ottman R, Pauciulo M, Nichols W, Clark LN, Marder K. The relation between bsessive-compulsive behaviors and PARKIN genotype. J Parkinsons Dis 2013 Jan 1;3(0):101-102. P14.05 571. Freed CR, Breeze RE, Zawada WM, Fahn S, Eidelberg D, Jones S, Zhou W. Human embryonic dopamine neurons transplanted into putamen of Parkinson patients survive for at least 22 years without immunosuppression. Society for Neuroscience Abstracts 2013; 526.28/J15 572. Bhidayasiri R, Fahn S, Gronseth GS, Sullivan KL, Zesiewicz TA. Author response. Neurology. 2013 Nov 26;81(22):1967. 573. Dinur T, Quinn T, Sakanaka T, Levy O, Marder KS, Waters C, Fahn S, Dorovski T, Pauciulo M, Nichols W, Rana HQ, Balwani M, Bier L, Elstein D, Zimran A, Alcalay RN. Parkinson disease penetrance in patients with Gaucher disease and glucocerebrosidase mutation carriers. 10th Annual WORLD Symposium San Diego, CA – USA. 2014. 574. Lerner V, Miodownik C, Sheva B, Bhidayasiri R, Fahn S, Gronseth GS, Sullivan KL, Zesiewicz TA. Evidence-based guideline: Treatment of tardive syndromes: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014 Feb 18;82(7):643. doi: 0.1212/WNL.0000000000000075. PubMed PMID: 24536064. 575. Bhidayasiri R, Fahn S, Gronseth GS, Sullivan KL, Zesiewicz TA. Author response. Neurology. 2014 Feb 18;82(7):643.
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 145
576. Albanese A, Bhatia K, Bressman SB, Delong MR, Fahn S, Fung VS, Hallett M, Jankovic J, Jinnah HA, Klein C, Lang AE, Mink JW, Teller JK. Reply: Dystonia after severe head injuries. Mov Disord. 2014 Apr;29(4):578-9. 577. Alcalay R, Dinur T, Quinn T, Sakanaka K, Levy O, Waters C, Fahn S, Dorovski T, Chung T, Pauciulo M, Nichols W, Rana H, Balwani M, Bier L, Elstein D, Zimran A. Parkinson Risk in Ashkenazi Jewish Gaucher Patients and GBA Heterozygotes: Is There a Gene Dose Effect? e-poster P1.015, American Academy of Neurology meeting. 2014 578. Berlyand Y, Alcalay R, Swanson C, Fahn S, Waters C, Levy O, Schwartz S, Chen-Plotkin S. Statin Use, Apolipoprotein A1, and Parkinson’s Disease. Poster P2.055. American Academy of Neurology meeting. 2014 579. Rydz D, Sharp M, Fahn S. Case Study: First Reported Case of Interferon-alpha Induced Postural and Action Tremor. Poster P4.074. American Academy of Neurology meeting. 2014 580. Xie T, Kang UJ, Kuo S.-H, Greene P, Fahn S. Natural history of pathologically confirmed PSP and MSA cases followed at a tertiary center [abstract]. Mov Disord 2014;29 Suppl 1:341. 581. McRae C, Fazio E, Kuhne J, Ellgring H, Russell D, Hultgren K, Greene P, Fahn S. Longitudinal study of neural tissue implantation for treatment of Parkinson's disease: Effects on quality of life [abstract]. Mov Disord 2014;29 Suppl 1:1208. 582. Shaath HY, Fahn S. Case report: Sporadic progressive ataxia with oculopalatal myoclonus [abstract]. Mov Disord 2014;29 Suppl 1:1312; 583. Wright BA, Sampson JB, Vonsattel CP, Goldman JE, Fahn S. Unique presentation of primary generalized dystonia with novel findings on post-mortem brain pathology [abstract]. Mov Disord 2014;29 Suppl 1:1452. 584. Fahn S. Prologue. In Micheli FE, LeWitt PA, eds. Chorea. Causes and Management. Springer, London. 2014; vii-ix. 585. Fahn S, Poewe W. Editorial: Levodopa: 50 years of a revolutionary drug for Parkinson disease. Mov Disord. 2015 Jan;30(1):1-3. 586. Sampson J, Michaeli T, Teed S, Wright B, Fahn S, Goldman J, Vonsattel JP. Unique astrocyte pathology in a case of rapid onset dystonia-parkinsonsm (DYT12) with novel mutation in ATP1A3. Poster P2.137. American Academy of Neurology meeting. 2015. 587. Alcalay RN, Levy OA, Waters C, Fahn S, Ford B, Kuo SH, Mazzoni P, Marder K, Pauciulo MW, Nichols WC, Gan-Or Z, Rouleau GA, Chung WK, Wolf P, Oliva P, Keutzer J, Zhang XK. Glucocerebrosidase activity in Parkinson’s disease with and without GBA mutations. Platform S7.003. American Academy of Neurology meeting. 2015. 588. Sulzer D, Chaudhuri KR, Fahn S. Introducion a new journal on Parkinson’s disease. npj Parkinson's Disease 2015;1:15006. 589. Fahn S. Reply: Oleh Hornykiewicz's contribution to the l-dopa story. Mov Disord. 2015 Jun;30(7):1008-9. 590. Albanese A, Bhatia K, DeLong MR, Fahn S, Fung VS, Hallett M, Jankovic J, Jinnah HA, Mink JW, Teller JK. "Complex" dystonia is not a category in the new 2013 consensus classification. Mov Disord. 2016 Nov;31(11):1758-1759. doi: 10.1002/mds.26764. PubMed PMID: 27612445. 591. Freed CR, Breeze RE, Symmes BA, Fahn S, Eidetberg D, Zhou W. Transplants of human fetal dopamine neurons into putamen of Parkinson patients survive for at least 27 years without immunosuppression. SfN Abstract 287.02: 2016. http://bit.ly/SFN-fetaltransplants 592. Alcalay R, Levy O, Waters C, Fahn S, Ford B, Kuo S-H, Vanegas-Arroyave N, Shah H, Liong C, Narayan S, Pauciulo M, Nichols W, Gan-Or Z, Rouleau G, Chung W, Wolf P, Oliva P, Keutzer J, Marder K, Zhang X. Alpha Galactosidase A activity in Parkinson disease. AAN Abstrat S45.005, 2018. https://issuu.com/americanacademyofneurology/docs/18am_scienceprogram_rev2_v920?e=26992184/598 61099 Abstract located in: https://submissions.mirasmart.com/Verify/AAN2018/submission/temp/rad2C7DB.pdf
Stanley Fahn, M.D. Curriculum Vitae and Bibliography Page 146